Document

0000944809-18-000035.txt : 20180807 0000944809-18-000035.hdr.sgml : 20180807 20180807161816 ACCESSION NUMBER: 0000944809-18-000035 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 79 CONFORMED PERIOD OF REPORT: 20180630 FILED AS OF DATE: 20180807 DATE AS OF CHANGE: 20180807 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Opko Health, Inc. CENTRAL INDEX KEY: 0000944809 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 752402409 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-33528 FILM NUMBER: 18998340 BUSINESS ADDRESS: STREET 1: 4400 BISCAYNE BLVD. CITY: MIAMI STATE: FL ZIP: 33137 BUSINESS PHONE: 305-575-4138 MAIL ADDRESS: STREET 1: 4400 BISCAYNE BLVD. CITY: MIAMI STATE: FL ZIP: 33137 FORMER COMPANY: FORMER CONFORMED NAME: eXegenics Inc DATE OF NAME CHANGE: 20040505 FORMER COMPANY: FORMER CONFORMED NAME: EXEGENICS INC DATE OF NAME CHANGE: 20011114 FORMER COMPANY: FORMER CONFORMED NAME: CYTOCLONAL PHARMACEUTICS INC /DE DATE OF NAME CHANGE: 19950503 10-Q 1 opk-6302018x10q.htm 10-Q Document

Table of Contents

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 10-Q

(Mark One)



ý	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2018.



¨	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to .

Commission file number 001-33528

OPKO Health, Inc.

(Exact Name of Registrant as Specified in Its Charter)



Delaware		75-2402409
(State or Other Jurisdiction of Incorporation or Organization)		(I.R.S. Employer Identification No.)

4400 Biscayne Blvd.
Miami, FL 33137
(Address of Principal Executive Offices) (Zip Code)

(305) 575-4100
(Registrant’s Telephone Number, Including Area Code)

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. ý YES ¨ NO

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Website, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). ý YES ¨ NO

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company”

(in Rule 12b-2 of the Exchange Act) (Check one):



Large accelerated filer	x	Accelerated filer	¨
Non-accelerated filer	¨ (Do not check if a smaller reporting company)	Smaller reporting company	¨
		Emerging growth company	¨

Table of Contents

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act): ¨ YES ý NO

As of August 1, 2018, the registrant had 559,770,995 shares of Common Stock outstanding.

Table of Contents

TABLE OF CONTENTS



PART I. FINANCIAL INFORMATION		Page
Item 1.	Financial Statements
Condensed Consolidated Balance Sheets as of June 30, 2018 and December 31, 2017 (unaudited)		6
Condensed Consolidated Statements of Operations for the three and six months ended June 30, 2018 and 2017 (unaudited)		7
Condensed Consolidated Statements of Comprehensive Loss for the three and six months ended June 30, 2018 and 2017 (unaudited)		8
Condensed Consolidated Statements of Cash Flows for the six months ended June 30, 2018 and 2017 (unaudited)		9
Notes to Condensed Consolidated Financial Statements (unaudited)		10
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	40
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	59
Item 4.	Controls and Procedures	60
PART II. OTHER INFORMATION
Item 1.	Legal Proceedings	61
Item 1A.	Risk Factors	62
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	62
Item 3.	Defaults Upon Senior Securities	62
Item 4.	Mine Safety Disclosures	62
Item 5.	Other Information	62
Item 6.	Exhibits	63
Signatures		64

Table of Contents

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q contains “forward-looking statements,” as that term is defined under the Private Securities Litigation Reform Act of 1995 (“PSLRA”), Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Securities Act”). Forward-looking statements include statements about our expectations, beliefs or intentions regarding our product development efforts, business, financial condition, results of operations, strategies or prospects. You can identify forward-looking statements by the fact that these statements do not relate strictly to historical or current matters. Rather, forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause our actual results to differ materially from any future results expressed or implied by the forward-looking statements. Many factors could cause our actual activities or results to differ materially from the activities and results anticipated in forward-looking statements. These factors include those described below and in “Item 1A-Risk Factors” of our Annual Report on Form 10-K for the year ended December 31, 2017, and described from time to time in our other reports filed with the Securities and Exchange Commission. We do not undertake an obligation to update forward-looking statements. We intend that all forward-looking statements be subject to the safe-harbor provisions of the PSLRA. These forward-looking statements are only predictions and reflect our views as of the date they are made with respect to future events and financial performance.

Risks and uncertainties, the occurrence of which could adversely affect our business, include the following:


•	we have a history of losses and may not generate sustained positive cash flow sufficient to fund our operations and research and development programs;


•	the risks inherent in developing, obtaining regulatory approvals for and commercializing new, commercially viable and competitive products and treatments;


•	our research and development activities may not result in commercially viable products;


•	that earlier clinical results of effectiveness and safety may not be reproducible or indicative of future results;


•	that we may fail to obtain regulatory approval for hGH-CTP or successfully commercialize Rayaldee and hGH-CTP;


•	that we may not generate profits or cash flow from our laboratory operations or substantial revenue from our pharmaceutical and diagnostic products;


•	that currently available over-the-counter and prescription products, as well as products under development by others, may prove to be as or more effective than our products for the indications being studied;


•	our ability to build a successful pharmaceutical sales and marketing infrastructure;


•	our ability and our distribution and marketing partners’ ability to comply with regulatory requirements regarding the sales, marketing and manufacturing of our products and product candidates and the operation of our laboratories;


•	the performance of our third-party distribution partners, licensees and manufacturers over which we have limited control;


•	our success is dependent on the involvement and continued efforts of our Chairman and Chief Executive Officer;


•	integration challenges for Transition Therapeutics, BioReference, EirGen and other acquired businesses;


•	changes in regulation and policies in the United States and other countries, including increasing downward pressure on healthcare reimbursement;


•	our ability to manage our growth and our expanded operations;


•	increased competition, including price competition;


•	changing relationships with payers, including the various state and multi-state Blues programs, suppliers and strategic partners;


•	efforts by third-party payors to reduce utilization and reimbursement for clinical testing services;


•	failure to timely or accurately bill and collect for our services;


•	failure in our information technology systems, including cybersecurity attacks or other data security or privacy incidents;


•	failure to obtain and retain new clients and business partners, or a reduction in tests ordered or specimens submitted by existing clients;


•	failure to establish, and perform to, appropriate quality standards to assure that the highest level of quality is observed in the performance of our testing services;


•	failure to maintain the security of patient-related information;


•	our ability to obtain and maintain intellectual property protection for our products;


•	our ability to defend our intellectual property rights with respect to our products;


•	our ability to operate our business without infringing the intellectual property rights of others;


•	our ability to attract and retain key scientific and management personnel;


•	our need for, and ability to obtain, additional financing;


•	adverse results in material litigation matters or governmental inquiries;

Table of Contents


•	failure to obtain and maintain regulatory approval outside the U.S.;


•	legal, economic, political, regulatory, currency exchange, and other risks associated with international operations; and


•	our ability to finance and successfully complete construction of a research, development and manufacturing center in Waterford, Ireland.

Table of Contents

PART I. FINANCIAL INFORMATION

Unless the context otherwise requires, all references in this Quarterly Report on Form 10-Q to the “Company”, “OPKO”, “we”, “our”, “ours”, and “us” refer to OPKO Health, Inc., a Delaware corporation, including our wholly-owned subsidiaries.

Item 1. Financial Statements

OPKO Health, Inc. and Subsidiaries

CONDENSED CONSOLIDATED BALANCE SHEETS

(Unaudited)

(In thousands, except share and per share data)



	June 30, 2018			December 31, 2017
ASSETS
Current assets:
Cash and cash equivalents	$	80,381		$	91,499
Accounts receivable, net	152,777			165,516
Inventory, net	46,753			49,333
Other current assets and prepaid expenses	41,651			42,513
Total current assets	321,562			348,861
Property, plant and equipment, net	150,156			146,557
Intangible assets, net	648,541			683,835
In-process research and development	645,714			647,347
Goodwill	714,234			717,099
Investments	45,497			40,642
Other assets	5,246			5,615
Total assets	$	2,530,950		$	2,589,956
LIABILITIES AND EQUITY
Current liabilities:
Accounts payable	$	69,061		$	74,307
Accrued expenses	200,992			230,301
Current portion of 2033 Senior Notes	30,343			—
Current portion of lines of credit and notes payable	6,465			11,926
Total current liabilities	306,861			316,534
2023 Convertible Notes and 2033 Senior Notes	55,894			29,160
Deferred tax liabilities, net	148,255			148,729
Other long-term liabilities, principally contract liabilities, contingent consideration and line of credit	209,444			239,955
Total long-term liabilities	413,593			417,844
Total liabilities	720,454			734,378
Equity:
Common Stock - $0.01 par value, 750,000,000 shares authorized; 560,169,422 and 560,023,745 shares issued at June 30, 2018 and December 31, 2017, respectively	5,602			5,600
Treasury Stock - 549,907 and 549,907 shares at June 30, 2018 and December 31, 2017, respectively	(1,791		)	(1,791		)
Additional paid-in capital	2,901,086			2,889,256
Accumulated other comprehensive loss	(13,004		)	(528		)
Accumulated deficit	(1,081,397		)	(1,036,959		)
Total shareholders’ equity	1,810,496			1,855,578
Total liabilities and equity	$	2,530,950		$	2,589,956

The accompanying unaudited Notes to Condensed Consolidated Financial Statements are an integral part of these statements.

Table of Contents

OPKO Health, Inc. and Subsidiaries

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

(In thousands, except share and per share data)



	For the three months ended June 30,						For the six months ended June 30,
	2018			2017			2018			2017
Revenues:
Revenue from services	$	216,055		$	233,912		$	427,369		$	462,456
Revenue from products	28,523			28,966			56,374			51,197
Revenue from transfer of intellectual property and other	19,107			29,723			34,855			45,328
Total revenues	263,685			292,601			518,598			558,981
Costs and expenses:
Cost of service revenue	134,408			143,901			273,849			283,867
Cost of product revenue	15,652			13,505			30,300			28,334
Selling, general and administrative	87,653			105,579			179,172			215,523
Research and development	29,211			33,128			62,097			59,685
Contingent consideration	(15,358		)	4,366			(13,599		)	6,738
Amortization of intangible assets	17,227			17,953			34,498			35,881
Total costs and expenses	268,793			318,432			566,317			630,028
Operating loss	(5,108		)	(25,831		)	(47,719		)	(71,047		)
Other income and (expense), net:
Interest income	27			136			67			385
Interest expense	(2,722		)	(1,502		)	(4,989		)	(2,931		)
Fair value changes of derivative instruments, net	2,248			5,482			3,644			9,519
Other income (expense), net	8,584			(533		)	10,477			2,509
Other income and (expense), net	8,137			3,583			9,199			9,482
Income (loss) before income taxes and investment losses	3,029			(22,248		)	(38,520		)	(61,565		)
Income tax benefit (provision)	(2,017		)	10,960			(1,126		)	17,904
Net income (loss) before investment losses	1,012			(11,288		)	(39,646		)	(43,661		)
Loss from investments in investees	(7,213		)	(5,628		)	(9,669		)	(7,758		)
Net loss	$	(6,201	)	$	(16,916	)	$	(49,315	)	$	(51,419	)
Loss per share:
Loss per share, basic	$	(0.01	)	$	(0.03	)	$	(0.09	)	$	(0.09	)
Loss per share, diluted	$	(0.01	)	$	(0.04	)	$	(0.09	)	$	(0.11	)
Weighted average common shares outstanding, basic	559,541,253			559,347,540			559,507,732			558,892,375
Weighted average common shares outstanding, diluted	559,541,253			564,163,808			559,507,732			563,617,274

The accompanying unaudited Notes to Condensed Consolidated Financial Statements are an integral part of these statements.

Table of Contents

OPKO Health, Inc. and Subsidiaries

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS

(Unaudited)

(In thousands)



	For the three months ended June 30,						For the six months ended June 30,
	2018			2017			2018			2017
Net loss	$	(6,201	)	$	(16,916	)	$	(49,315	)	$	(51,419	)
Other comprehensive income (loss), net of tax:
Change in foreign currency translation and other comprehensive income (loss)	(12,465		)	10,495			(7,600		)	13,088
Investments:
Change in unrealized loss, net of tax	—			(206		)	—			(743		)
Reclassification adjustment due to adoption of ASU 2016-01	—			—			(4,876		)	—
Reclassification adjustments for losses included in net loss, net of tax	—			594			—			594
Comprehensive loss	$	(18,666	)	$	(6,033	)	$	(61,791	)	$	(38,480	)

The accompanying unaudited Notes to Condensed Consolidated Financial Statements are an integral part of these statements.

Table of Contents

OPKO Health, Inc. and Subsidiaries

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

(In thousands)



	For the six months ended June 30,
	2018			2017
Cash flows from operating activities:
Net loss	$	(49,315	)	$	(51,419	)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Depreciation and amortization	49,518			51,281
Non-cash interest	2,198			1,294
Amortization of deferred financing costs	99			112
Losses from investments in investees	9,669			7,758
Equity-based compensation – employees and non-employees	11,514			15,844
Gain on disposal of fixed assets	(495		)	(2,473		)
Change in fair value of equity securities and derivative instruments	(14,819		)	(9,519		)
Change in fair value of contingent consideration	(13,599		)	6,738
Deferred income tax benefit	(2,026		)	(23,039		)
Changes in assets and liabilities, net of the effects of acquisitions:
Accounts receivable, net	12,440			(30,865		)
Inventory, net	894			(443		)
Other current assets and prepaid expenses	(3,730		)	3,692
Other assets	(146		)	(254		)
Accounts payable	(8,092		)	9,439
Foreign currency measurement	(77		)	230
Contract liabilities	(30,812		)	(31,122		)
Accrued expenses and other liabilities	(15,820		)	(3,837		)
Net cash used in operating activities	(52,599		)	(56,583		)
Cash flows from investing activities:
Investments in investees	(1,000		)	(3,000		)
Proceeds from sale of equity securities	1,286			—
Purchase of marketable securities	—			(5		)
Proceeds from the sale of property, plant and equipment	840			3,398
Capital expenditures	(12,792		)	(16,805		)
Net cash used in investing activities	(11,666		)	(16,412		)
Cash flows from financing activities:
Issuance of 2033 Senior Notes, including to related parties	55,000			—
Proceeds from the exercise of Common Stock options and warrants	318			1,916
Borrowings on lines of credit	18,817			45,524
Repayments of lines of credit	(20,924		)	(13,525		)
Net cash provided by financing activities	53,211			33,915
Effect of exchange rate changes on cash and cash equivalents	(64		)	877
Net decrease in cash and cash equivalents	(11,118		)	(38,203		)
Cash and cash equivalents at beginning of period	91,499			168,733
Cash and cash equivalents at end of period	$	80,381		$	130,530
SUPPLEMENTAL INFORMATION:
Interest paid	$	785		$	748
Income taxes paid, net of refunds	$	5,251		$	4,321
Non-cash financing:
Shares issued upon the conversion of:
Common Stock options and warrants, surrendered in net exercise	$	806		$	1,546
Issuance of capital stock for contingent consideration settlement:
OPKO Health Europe	$	—		$	303

The accompanying unaudited Notes to Condensed Consolidated Financial Statements are an integral part of these statements.

Table of Contents

OPKO Health, Inc. and Subsidiaries

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (unaudited)

NOTE 1 BUSINESS AND ORGANIZATION

We are a diversified healthcare company that seeks to establish industry-leading positions in large and rapidly growing medical markets. Our diagnostics business includes BioReference Laboratories, Inc. (“BioReference”), the nation’s third-largest clinical laboratory with a core genetic testing business and an almost 400-person sales and marketing team to drive growth and leverage new products, including the 4Kscore prostate cancer test and the Claros 1 in-office immunoassay platform (in development). Our pharmaceutical business features Rayaldee, an FDA-approved treatment for secondary hyperparathyroidism (“SHPT”) in adults with stage 3 or 4 chronic kidney disease (“CKD”) and vitamin D insufficiency (launched in November 2016), OPK88004, a selective androgen receptor modulator being developed for benign prostatic hyperplasia, OPK88003, a once or twice weekly oxyntomodulin for type 2 diabetes and obesity which is a clinically advanced drug candidate among the new class of GLP-1 glucagon receptor dual agonists (Phase 2b), and 88002, an NK-1 antagonist to treat pruritis (itching) in dialysis patients. Our pharmaceutical business also features hGH-CTP, a once-weekly human growth hormone injection (in Phase 3 and partnered with Pfizer). We are incorporated in Delaware and our principal executive offices are located in leased offices in Miami, Florida.

Through BioReference, we provide laboratory testing services, primarily to customers in the larger metropolitan areas across New York, New Jersey, Maryland, Pennsylvania, Delaware, Washington, DC, Florida, California, Texas, Illinois and Massachusetts as well as to customers in a number of other states. We offer a comprehensive test menu of clinical diagnostics for blood, urine, and tissue analysis. This includes hematology, clinical chemistry, immunoassay, infectious diseases, serology, hormones, and toxicology assays, as well as Pap smear, anatomic pathology (biopsies) and other types of tissue analysis. We market our laboratory testing services directly to physicians, geneticists, hospitals, clinics, correctional and other health facilities.

We operate established pharmaceutical platforms in Ireland, Chile, Spain, and Mexico, which are generating revenue and which we expect to facilitate future market entry for our products currently in development. In addition, we have a development and commercial supply pharmaceutical company and a global supply chain operation and holding company in Ireland. We own a specialty active pharmaceutical ingredients (“APIs”) manufacturer in Israel, which we expect will facilitate the development of our pipeline of molecules and compounds for our molecular diagnostic and therapeutic products.

Our research and development activities are primarily performed at facilities in Miramar, FL, Woburn, MA, Waterford, Ireland, Kiryat Gat, Israel, and Barcelona, Spain.

Table of Contents

NOTE 2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of presentation. The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all information and notes required by GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of only normal recurring adjustments or otherwise disclosed herein) considered necessary to present fairly the Company’s results of operations, financial position and cash flows have been made. The results of operations and cash flows for the three and six months ended June 30, 2018, are not necessarily indicative of the results of operations and cash flows that may be reported for the remainder of 2018 or any future periods. The unaudited Condensed Consolidated Financial Statements should be read in conjunction with the Consolidated Financial Statements and the Notes to Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended December 31, 2017.

Principles of consolidation. The accompanying unaudited Condensed Consolidated Financial Statements include the accounts of OPKO Health, Inc. and of our wholly-owned subsidiaries. All intercompany accounts and transactions are eliminated in consolidation.

Use of estimates. The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ significantly from these estimates.

Cash and cash equivalents. Cash and cash equivalents include short-term, interest-bearing instruments with original maturities of 90 days or less at the date of purchase. We also consider all highly liquid investments with original maturities at the date of purchase of 90 days or less as cash equivalents. These investments include money markets, bank deposits, certificates of deposit and U.S. treasury securities.

Inventories. Inventories are valued at the lower of cost and net realizable value. Cost is determined by the first-in, first-out method. We consider such factors as the amount of inventory on hand, estimated time required to sell such inventories, remaining shelf-life, and current market conditions to determine whether inventories are stated at the lower of cost and net realizable value. Inventories at our diagnostics segment consist primarily of purchased laboratory supplies, which is used in our testing laboratories. Inventory obsolescence expense for the six months ended June 30, 2018 and 2017 was $1.2 million and $4.8 million, respectively.

Pre-launch inventories. We may accumulate commercial quantities of certain product candidates prior to the date we anticipate that such products will receive final U.S. FDA approval. The accumulation of such pre-launch inventories involves the risk that such products may not be approved for marketing by the FDA on a timely basis, or ever. This risk notwithstanding, we may accumulate pre-launch inventories of certain products when such action is appropriate in relation to the commercial value of the product launch opportunity. In accordance with our policy, this pre-launch inventory is expensed.

Goodwill and intangible assets. Goodwill represents the difference between the purchase price and the estimated fair value of the net assets acquired accounted for by the acquisition method of accounting and arose from our acquisitions. Refer to Note 4. Goodwill, in-process research and development (“IPR&D”) and other intangible assets acquired in business combinations, licensing and other transactions at both June 30, 2018 and December 31, 2017 was $2.0 billion.

Goodwill is tested at least annually for impairment, or when events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable, by assessing qualitative factors or performing a quantitative analysis in determining whether it is more likely than not that its fair value exceeds the carrying value.

Intangible assets are tested for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable, although IPR&D is required to be tested at least annually until the project is completed or abandoned. Upon obtaining regulatory approval, the IPR&D asset is then accounted for as a finite-lived intangible asset and amortized on a straight-line basis over its estimated useful life. If the project is abandoned, the IPR&D asset is charged to expense.

Table of Contents

benefits of our intangible assets are consumed or otherwise used up. Amortization expense was $34.5 million and $35.9 million for the six months ended June 30, 2018 and 2017, respectively.

Fair value measurements. The carrying amounts of our cash and cash equivalents, accounts receivable, accounts payable and short-term debt approximate their fair value due to the short-term maturities of these instruments. Investments that are considered equity securities as of June 30, 2018 and December 31, 2017 are carried at fair value. Our debt under the credit agreement with JPMorgan Chase Bank, N.A. approximates fair value due to the variable rate of interest.

In evaluating the fair value information, considerable judgment is required to interpret the market data used to develop the estimates. The use of different market assumptions and/or different valuation techniques may have a material effect on the estimated fair value amounts. Accordingly, the estimates of fair value presented herein may not be indicative of the amounts that could be realized in a current market exchange. Refer to Note 8.

Contingent consideration. Each period we revalue the contingent consideration obligations associated with certain prior acquisitions to their fair value and record increases in the fair value as contingent consideration expense and decreases in the fair value as a reduction in contingent consideration expense. Changes in contingent consideration result from changes in the assumptions regarding probabilities of successful achievement of related milestones, the estimated timing in which the milestones are achieved and the discount rate used to estimate the fair value of the liability. Contingent consideration may change significantly as our development programs progress, revenue estimates evolve and additional data is obtained, impacting our assumptions. The assumptions used in estimating fair value require significant judgment. The use of different assumptions and judgments could result in a materially different estimate of fair value which may have a material impact on our results from operations and financial position.

Derivative financial instruments. We record derivative financial instruments on our Condensed Consolidated Balance Sheet at their fair value and recognize the changes in the fair value in our Condensed Consolidated Statement of Operations when they occur, the only exception being derivatives that qualify as hedges. For the derivative instrument to qualify as a hedge, we are required to meet strict hedge effectiveness and contemporaneous documentation requirements at the initiation of the hedge and assess the hedge effectiveness on an ongoing basis over the life of the hedge. At June 30, 2018 and December 31, 2017, our foreign currency forward contracts held to economically hedge inventory purchases did not meet the documentation requirements to be designated as hedges. Accordingly, we recognize all changes in the fair values of our derivatives instruments, net, in our Condensed Consolidated Statements of Operations. Refer to Note 9.

Property, plant and equipment. Property, plant and equipment are recorded at cost. Depreciation is provided using the straight-line method over the estimated useful lives of the assets and includes amortization expense for assets capitalized under capital leases. The estimated useful lives by asset class are as follows: software - 3 years, machinery, medical and other equipment - 5-8 years, furniture and fixtures - 5-12 years, leasehold improvements - the lesser of their useful life or the lease term, buildings and improvements - 10-40 years, automobiles - 3-5 years. Expenditures for repairs and maintenance are charged to expense as incurred. Depreciation expense was $15.0 million and $15.4 million for the six months ended June 30, 2018 and 2017, respectively. Assets held under capital leases are included within Property, plant and equipment, net in our Condensed Consolidated Balance Sheet and are amortized over the shorter of their useful lives or the expected term of their related leases.

Impairment of long-lived assets. Long-lived assets, such as property and equipment, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated future cash flows, then an impairment charge is recognized for the amount by which the carrying amount of the asset exceeds the fair value of the asset.

Income taxes. Income taxes are accounted for under the asset-and-liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and the respective tax bases and for operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period that includes the enactment date. We periodically evaluate the realizability of our net deferred tax assets. Our tax accruals are analyzed periodically and adjustments are made as events occur to warrant such adjustment. Valuation allowances on certain U.S. deferred tax assets and non-U.S. deferred tax assets are established, because realization of these tax benefits through future taxable income does not meet the more-likely-than-not threshold.

Table of Contents

January 1, 2018, and a one-time mandatory transition tax on accumulated foreign earnings, among others. We are required to recognize the effect of the tax law changes in the period of enactment, such as remeasuring our U.S. deferred tax assets and liabilities, as well as reassessing the net realizability of our deferred tax assets and liabilities. In December 2017, the SEC staff issued Staff Accounting Bulletin No. 118, Income Tax Accounting Implications of the Tax Act (“SAB 118”), which allows us to record provisional amounts during a measurement period not to extend beyond one year of the enactment date. Through June 30, 2018, we did not have any significant adjustments to our provisional amounts. As we continue to perform our analysis of the Tax Act, and interpret any additional accounting guidance issued by the FASB, the U.S. Department of the Treasury and the IRS, we may make adjustments to these provisional amounts.

Effective January 1, 2018, the Tax Act provides for a new global intangible low-taxed income (GILTI) provision. Under the GILTI provision, certain foreign subsidiary earnings in excess of an allowable return on the foreign subsidiary’s tangible assets are included in U.S. taxable income. We are now subject to GILTI but have not triggered an income inclusion as of June 30, 2018. Any future inclusion is expected to be offset by net operating loss carry forwards in the U.S. We are still evaluating, pending further interpretive guidance, whether to make a policy election to treat the GILTI tax as a period expense or to provide U.S. deferred taxes on foreign temporary differences that are expected to generate GILTI income when they reverse in future years.

We anticipate future impacts at a U.S. state and local tax level related to the Tax Act; however, the limited amount of statutory and interpretive guidance available from applicable state and local tax authorities is not sufficient to reasonably estimate the impact. Consequently, for those jurisdictions, we have not recorded provisional amounts and have continued to apply ASC 740 based on the provisions of the tax laws that were in effect immediately prior to Tax Act enactment.

We operate in various countries and tax jurisdictions globally. For interim reporting purposes, we record income taxes based on the expected effective income tax rate taking into consideration year to date and global forecasted tax results. For the three and six months ended June 30, 2018, the tax rate differed from the U.S. federal statutory rate of 21% primarily due to the valuation allowance against certain U.S. and non-U.S. deferred tax assets, the relative mix in earnings and losses in the U.S. versus foreign tax jurisdictions, and the impact of certain discrete tax events and operating results in tax jurisdictions which do not result in a tax benefit.

Revenue recognition. Effective January 1, 2018, we adopted Accounting Standards Codification Topic 606, Revenue from Contracts with Customers (“Topic 606”). We recognize revenue when a customer obtains control of promised goods or services. The amount of revenue that is recorded reflects the consideration that we expect to receive in exchange for those goods or services. We apply the following five-step model in order to determine this amount: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) we satisfy a performance obligation.

We only apply the five-step model to contracts when it is probable that we will collect the consideration we are entitled to in exchange for the goods or services we transfer to the customer. At contract inception, once the contract is determined to be within the scope of Topic 606, we review the contract to determine which performance obligations we must deliver and which of these performance obligations are distinct. We recognize as revenue the amount of the transaction price that is allocated to the respective performance obligation when the performance obligation is satisfied or as it is satisfied. For a complete discussion of accounting for Revenues from services, Revenues from products and Revenue from transfer of intellectual property and other, see Note 12, “Revenue Recognition.”

Concentration of credit risk and allowance for doubtful accounts. Financial instruments that potentially subject us to concentrations of credit risk consist primarily of accounts receivable. Substantially all of our accounts receivable are with either companies in the healthcare industry or patients. However, credit risk is limited due to the number of our clients as well as their dispersion across many different geographic regions.

While we have receivables due from federal and state governmental agencies, we do not believe that such receivables represent a credit risk since the related healthcare programs are funded by federal and state governments, and payment is primarily dependent upon submitting appropriate documentation. At June 30, 2018 and December 31, 2017, receivable balances (net of contractual adjustments) from Medicare and Medicaid were 17.4% and 15.8%, respectively, of our consolidated Accounts receivable, net.

The portion of our accounts receivable due from individual patients comprises the largest portion of credit risk. At June 30, 2018 and December 31, 2017, receivables due from patients represent approximately 2.6% and 3.2%, respectively, of our consolidated Accounts receivable, net.

Table of Contents

We assess the collectability of accounts receivable balances by considering factors such as historical collection experience, customer credit worthiness, the age of accounts receivable balances, regulatory changes and current economic conditions and trends that may affect a customer’s ability to pay. Actual results could differ from those estimates. Our reported net income (loss) is directly affected by our estimate of the collectability of accounts receivable. The allowance for doubtful accounts was $1.5 million and $1.4 million at June 30, 2018 and December 31, 2017, respectively. The provision for bad debts for the six months ended June 30, 2018 and 2017 was $0.2 million and $0.5 million, respectively.

Research and development expenses. Research and development expenses include external and internal expenses. External expenses include clinical and non-clinical activities performed by contract research organizations, lab services, purchases of drug and diagnostic product materials and manufacturing development costs. Research and development employee-related expenses include salaries, benefits and equity-based compensation expense. Other internal research and development expenses are incurred to support overall research and development activities and include expenses related to general overhead and facilities. We expense these costs in the period in which they are incurred. We estimate our liabilities for research and development expenses in order to match the recognition of expenses to the period in which the actual services are received. As such, accrued liabilities related to third party research and development activities are recognized based upon our estimate of services received and degree of completion of the services in accordance with the specific third party contract.

Research and development expense includes costs for in-process research and development projects acquired in asset acquisitions which have not reached technological feasibility and which have no alternative future use. For in-process research and development projects acquired in business combinations, the in-process research and development project is capitalized and evaluated for impairment until the development process has been completed. Once the development process has been completed the asset will be amortized over its remaining useful life.

Segment reporting. Our chief operating decision-maker (“CODM”) is Phillip Frost, M.D., our Chairman and Chief Executive Officer. Our CODM reviews our operating results and operating plans and makes resource allocation decisions on a Company-wide or aggregate basis. We manage our operations in two reportable segments, pharmaceutical and diagnostics. The pharmaceutical segment consists of our pharmaceutical operations we acquired in Chile, Mexico, Ireland, Israel and Spain and our pharmaceutical research and development. The diagnostics segment primarily consists of clinical laboratory operations we acquired through the acquisition of BioReference and point-of-care operations. There are no significant inter-segment sales. We evaluate the performance of each segment based on operating profit or loss. There is no inter-segment allocation of interest expense and income taxes. Refer to Note 14.

Shipping and handling costs. We do not charge customers for shipping and handling costs. Shipping and handling costs are classified as Cost of revenues in the Condensed Consolidated Statement of Operations.

Foreign currency translation. The financial statements of certain of our foreign operations are measured using the local currency as the functional currency. The local currency assets and liabilities are generally translated at the rate of exchange to the United States (“U.S.”) dollar on the balance sheet date and the local currency revenues and expenses are translated at average rates of exchange to the U.S. dollar during the reporting periods. Foreign currency transaction gains (losses) have been reflected as a component of Other income (expense), net within the Condensed Consolidated Statement of Operations and foreign currency translation gains (losses) have been included as a component of the Condensed Consolidated Statement of Comprehensive Loss.

Variable interest entities. The consolidation of a variable interest entity (“VIE”) is required when an enterprise has a controlling financial interest. A controlling financial interest in a VIE will have both of the following characteristics: (a) the power to direct the activities of a VIE that most significantly impact the VIE’s economic performance and (b) the obligation to absorb losses of the VIE that could potentially be significant to the VIE. Refer to Note 5.

Table of Contents

Statements of Operations. Refer to Note 5. For investments classified as equity securities, we record changes in their fair value as Other income (expense) in our Condensed Consolidated Statements of Operations based on their closing price per share at the end of each reporting period unless the equity security does not have a readily determinable fair value. Refer to Note 5.

Recently adopted accounting pronouncements.

In May 2014, the Financial Accounting Standards Board (the “FASB”) issued Accounting Standards Update (“ASU”) No. 2014-09, “Revenue from Contracts with Customers.” ASU 2014-09, as amended and codified into Topic 606, clarifies the principles for recognizing revenue and develops a common revenue standard for GAAP that removes inconsistencies and weaknesses in revenue requirements, provides a more robust framework for addressing revenue issues, improves comparability of revenue recognition practices across entities, industries, jurisdictions, and capital markets, provides more useful information to users of financial statements through improved disclosure requirements and simplifies the preparation of financial statements by reducing the number of requirements to which an entity must refer. As required, we adopted ASU 2014-09 on January 1, 2018 using the full retrospective approach, and have elected to use the following practical expedients that are permitted under the rules of the adoption, which have been applied consistently to all contracts within all reporting periods presented:


•	For all reporting periods presented before January 1, 2018, we have not restated revenue from contracts that begin and are completed within the same annual reporting period.


•	For all reporting periods presented before January 1, 2018, we have not disclosed the amount of the transaction price allocated to the remaining performance obligations or an explanation of when we expect to recognize that amount as revenue.


•	We have applied the practical expedient provided for by Topic 606 by not adjusting the transaction price for significant financing components for periods less than one year.

As a result of adopting ASU 2014-09 on January 1, 2018 using the full retrospective approach, we revised our comparative financial statements for the prior years as if Topic 606 had been effective for those periods. As a result, the following financial statement line items for 2017 were affected:

Condensed Consolidated Statement of Operations



	For the three months ended June 30, 2017 (in thousands)
	As adjusted under Topic 606		As originally reported		Effect of change
Revenue from services	$	233,912	$	256,671	$	(22,759	)
Revenue from transfer of intellectual property and other	29,723		28,576		1,147
Selling, general and administrative	105,579		128,338		(22,759		)
Research and development	33,128		32,593		535



	For the six months ended June 30, 2017 (in thousands)
	As adjusted under Topic 606		As originally reported		Effect of change
Revenue from services	$	462,456	$	511,956	$	(49,500	)
Revenue from transfer of intellectual property and other	45,328		47,154		(1,826		)
Selling, general and administrative	215,523		265,023		(49,500		)
Research and development	59,685		58,615		1,070

Table of Contents

Condensed Consolidated Balance Sheet



	December 31, 2017 (in thousands)
	As adjusted under Topic 606			As originally reported			Effect of change
Other current assets and prepaid expenses	$	42,513		$	37,113		$	5,400
Accrued expenses	230,301			215,102			15,199
Other long-term liabilities, principally contract liabilities, contingent consideration and line of credit	239,955			219,954			20,001
Accumulated deficit	(1,036,959		)	(1,007,159		)	(29,800		)

Condensed Consolidated Statement of Cash Flows



	For the six months ended June 30, 2017 (in thousands)
	As adjusted under Topic 606			As originally reported			Effect of change
Net loss	$	(51,419	)	$	(48,523	)	$	(2,896	)
Contract liabilities	(31,122		)	(34,018		)	2,896

The most significant change above relates to amounts in our clinical laboratory operations that were historically classified as provision for bad debts, primarily related to patient responsibility, which are considered an element of variable consideration as an implicit price concession in determining revenues under Topic 606. Accordingly, we report uncollectible balances associated with individual patients as a reduction of the transaction price and therefore as a reduction in Revenue from services when historically these amounts were classified as provision for bad debts within Selling, general and administrative expenses.

In addition, under Topic 606, the upfront consideration received for a license and contract services combined performance obligation is recognized as revenue to the extent of costs incurred based on the length of the expected performance period and the subjectivity in estimating progress towards satisfaction of the performance obligation. Under previous accounting, we recognized revenue over the expected performance period. The adoption of Topic 606 resulted in a cumulative revenue reduction of $29.8 million and an increase of our accumulated deficit balance as of December 31, 2017; with a corresponding increase in our contract liabilities. For the six months ended June 30, 2017, Revenue from the transfer of intellectual property and other was reduced by $2.9 million for the change in accounting. For a further discussion of the adoption of Topic 606, see Note 12, “Revenue Recognition.”

In January 2016, the FASB issued ASU No. 2016-01, “Financial Instruments - Overall (Subtopic 825-10),” which addresses certain aspects of recognition, measurement, presentation, and disclosure of financial instruments. The ASU requires equity investments (except those accounted for under the equity method of accounting or those that result in consolidation of the investee) to be measured at fair value with changes in fair value recognized in net income. As a result of the required adoption of ASU 2016-01 on January 1, 2018, we recorded a cumulative-effect adjustment to reclassify our net unrealized gains on our equity securities of $4.9 million as of January 1, 2018 from Accumulated other comprehensive loss to Accumulated deficit in our Condensed Consolidated Balance Sheet. Changes in the fair value of our equity securities subsequent to the adoption of ASU 2016-01 on January 1, 2018 will be recognized in net income.

In August 2016, the FASB issued ASU No. 2016-15, “Statement of Cash Flows (Topic 230),” which addresses the classification of eight specific cash flow issues with the objective of reducing the existing diversity in practice. The required adoption of ASU 2016-15 in the first quarter of 2018 did not have a significant impact on our Condensed Consolidated Financial Statements.

In January 2017, the FASB issued ASU No. 2017-01, “Business Combinations (Topic 805),” which clarifies the definition of a business to assist entities in evaluating whether transactions should be accounted for acquisitions (or disposals) of assets or businesses. The required adoption of ASU 2017-01 in the first quarter of 2018 did not have a significant impact on our Condensed Consolidated Financial Statements.

Table of Contents

Pending accounting pronouncements.

In February 2016, the FASB issued ASU No. 2016-02, “Leases (Topic 842),” which will require organizations that lease assets with lease terms of more than 12 months to recognize assets and liabilities for the rights and obligations created by those leases on their balance sheets. The ASU will also require new qualitative and quantitative disclosures to help investors and other financial statement users better understand the amount, timing, and uncertainty of cash flows arising from leases. ASU 2016-02 will be effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years, with early adoption permitted. We have begun a process to identify a complete population of our leases. Such process includes reviewing various contracts to identify whether such arrangements convey the right to control the use of an identified asset. The determination of the impact of this new guidance is ongoing and, as such, we are not able to reasonably estimate the effect the adoption of this new standard will have on our financial statements. Based on our preliminary assessment of this ASU, we believe the new standard will have a significant impact on our Condensed Consolidated Balance Sheet, which has not yet been quantified.

In January 2017, the FASB issued ASU No. 2017-04, “Intangibles - Goodwill and Other (Topic 350),” which simplifies how an entity is required to test for goodwill impairment. ASU 2017-04 will be effective for annual or interim goodwill impairment tests in fiscal years beginning after December 15, 2019, with early adoption permitted after January 1, 2017. We are currently evaluating the impact of this new guidance on our Condensed Consolidated Financial Statements.

In June 2018, the FASB issued ASU No. 2018-07, “Compensation - Stock Compensation (Topic 718),” which expands the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from nonemployees. ASU 2018-07 will be effective for public business entities for fiscal years beginning after December 15, 2018, including interim periods within that fiscal year, with early adoption permitted. We are currently evaluating the impact of this new guidance on our Condensed Consolidated Financial Statements.

Table of Contents

NOTE 3 EARNINGS (LOSS) PER SHARE

Basic loss per share is computed by dividing our net loss by the weighted average number of shares outstanding during the period. For diluted earnings per share, the dilutive impact of stock options and warrants is determined by applying the “treasury stock” method. The dilutive impact of the 2033 Senior Notes and 2023 Convertible Notes (each, as defined herein) has been considered using the “if converted” method. In the periods in which their effect would be antidilutive, no effect has been given to outstanding options, warrants or the potentially dilutive shares issuable pursuant to the 2033 Senior Notes and 2023 Convertible Notes (discussed in Note 6) in the dilutive computation. The following table sets forth the computation of basic and diluted loss per share:



	For the three months ended June 30,						For the six months ended June 30,
(In thousands, except per share data)	2018			2017			2018			2017
Numerator
Net loss, basic	$	(6,201	)	$	(16,916	)	$	(49,315	)	$	(51,419	)
Add: Interest on 2033 Senior Notes	—			652			—			1,291
Change in FV of embedded derivative income	—			(5,069		)	—			(10,014		)
Net loss, diluted	$	(6,201	)	$	(21,333	)	$	(49,315	)	$	(60,142	)

Denominator
(Shares in thousands)
Weighted average common shares outstanding, basic	559,541			559,348			559,508			558,892
Effect of dilutive securities:
Stock options	—			—			—			—
Warrants	—			—			—			—
2033 Senior Notes	—			4,816			—			4,725
Dilutive potential shares	—			4,816			—			4,725
Weighted average common shares outstanding, diluted	559,541			564,164			559,508			563,617

Loss per share, basic	$	(0.01	)	$	(0.03	)	$	(0.09	)	$	(0.09	)
Loss per share, diluted	$	(0.01	)	$	(0.04	)	$	(0.09	)	$	(0.11	)

A total of 16,520,314 and 16,545,495 potential shares of Common Stock have been excluded from the calculation of diluted net loss per share for three and six months ended June 30, 2018, respectively, because their inclusion would be antidilutive.

During the three months ended June 30, 2018, 332,000 Common Stock options and Common Stock warrants to purchase shares of our Common Stock were exercised, resulting in the issuance of 145,677 shares of Common Stock. Of the 332,000 Common Stock options and Common Stock warrants exercised, 186,323 shares of Common Stock were surrendered in lieu of a cash payment via the net exercise feature of the agreements.

During the six months ended June 30, 2018, 332,000 Common Stock options and Common Stock warrants to purchase shares of our Common Stock were exercised, resulting in the issuance of 145,677 shares of Common Stock. Of the 332,000 Common Stock options and Common Stock warrants exercised, 186,323 shares of Common Stock were surrendered in lieu of a cash payment via the net exercise feature of the agreements.

During the three months ended June 30, 2017, 539,500 Common Stock options and Common Stock warrants to purchase shares of our Common Stock were exercised, resulting in the issuance of 351,625 shares of Common Stock. Of the 539,500 Common Stock options and Common Stock warrants exercised, 187,875 shares of Common Stock were surrendered in lieu of a cash payment via the net exercise feature of the agreements.

During the six months ended June 30, 2017, 1,646,372 Common Stock options and Common Stock warrants to purchase shares of our Common Stock were exercised, resulting in the issuance of 1,373,515 shares of Common Stock. Of the 1,646,372 Common Stock options and Common Stock warrants exercised, 272,857 shares of Common Stock were surrendered in lieu of a cash payment via the net exercise feature of the agreements.

Table of Contents

NOTE 4 COMPOSITION OF CERTAIN FINANCIAL STATEMENT CAPTIONS



(In thousands)	June 30, 2018			December 31, 2017
Accounts receivable, net:
Accounts receivable	$	154,269		$	166,962
Less: allowance for doubtful accounts	(1,492		)	(1,446		)
	$	152,777		$	165,516
Inventories, net:
Consumable supplies	$	24,986		$	21,546
Finished products	16,783			21,012
Work in-process	3,910			5,873
Raw materials	5,800			7,467
Less: inventory reserve	(4,726		)	(6,565		)
	$	46,753		$	49,333
Other current assets and prepaid expenses:
Taxes recoverable	21,319			18,138
Other receivables	2,031			8,798
Prepaid supplies	10,278			8,207
Prepaid insurance	3,259			3,532
Other	4,764			3,838
	$	41,651		$	42,513
Intangible assets, net:
Customer relationships	$	447,225		$	448,345
Technologies	340,815			340,921
Trade names	50,494			50,553
Licenses	10,246			10,305
Covenants not to compete	16,367			16,372
Product registrations	9,694			10,475
Other	5,696			5,799
Less: accumulated amortization	(231,996		)	(198,935		)
	$	648,541		$	683,835
Accrued expenses:
Contract liabilities	$	61,846		$	61,388
Employee benefits	46,621			50,377
Clinical trials	11,598			12,191
Taxes payable	3,604			4,609
Contingent consideration	2,042			11,750
Capital leases short-term	3,166			3,399
Milestone payment	4,967			4,868
Professional fees	1,727			2,355
Other	65,421			79,364
	$	200,992		$	230,301

Table of Contents



(In thousands)	June 30, 2018		December 31, 2017
Other long-term liabilities:
Contract liabilities	$	47,720	$	78,990
Line of credit	105,539		104,152
Contingent consideration	25,712		29,603
Mortgages and other debts payable	1,704		1,567
Capital leases long-term	6,638		7,786
Other	22,131		17,857
	$	209,444	$	239,955

All of the intangible assets and goodwill acquired relate to our acquisitions of principally OPKO Renal, OPKO Biologics, EirGen Pharma Limited (“EirGen”) and BioReference. We do not anticipate capitalizing the cost of product registration renewals, rather we expect to expense these costs, as incurred. Our goodwill is not tax deductible for income tax purposes in any jurisdiction we operate in.

The changes in value of the intangible assets and goodwill during the six months ended June 30, 2018 are primarily due to foreign currency fluctuations between the Chilean Peso, the Euro and the Shekel against the U.S. dollar.

The following table summarizes the changes in Goodwill during the six months ended June 30, 2018.



	2018
(In thousands)	Balance at January 1		Foreign exchange and other			Balance at June 30th
Pharmaceuticals
CURNA	$	4,827	$	—		$	4,827
EirGen	89,226		(2,201		)	87,025
FineTech	11,698		—			11,698
OPKO Chile	5,203		(307		)	4,896
OPKO Biologics	139,784		—			139,784
OPKO Health Europe	7,898		(197		)	7,701
OPKO Renal	2,069		—			2,069
Transition Therapeutics	3,608		(160		)	3,448

Diagnostics
BioReference	401,821		—			401,821
OPKO Diagnostics	17,977		—			17,977
OPKO Lab	32,988		—			32,988
	$	717,099	$	(2,865	)	$	714,234

Table of Contents

NOTE 5 ACQUISITIONS, INVESTMENTS AND LICENSES

Investments

The following table reflects the accounting method, carrying value and underlying equity in net assets of our unconsolidated investments as of June 30, 2018:



(in thousands)
Investment type	Investment Carrying Value		Underlying Equity in Net Assets
Equity method investments	$	19,703	$	15,547
Variable interest entity, equity method	706		—
Equity securities	22,350
Equity securities with no readily determinable fair value	939
Warrants and options	1,799
Total carrying value of investments	$	45,497

Equity method investments

Our equity method investments consist of investments in Pharmsynthez (ownership 9%), Cocrystal Pharma, Inc. (“COCP”) (9%), Non-Invasive Monitoring Systems, Inc. (“NIMS”) (1%), Neovasc, Inc. (“Neovasc”) (6%), VBI Vaccines Inc. (“VBI”) (10%), InCellDx, Inc. (29%), BioCardia, Inc. (“BioCardia”) (5%), and Xenetic Biosciences, Inc. (“Xenetic”) (5%). The total assets, liabilities, and net losses of our equity method investees as of and for the six months ended June 30, 2018 were $363.3 million, $174.6 million, and $143.5 million, respectively. We have determined that we and/or our related parties can significantly influence the success of our equity method investments through our board representation and/or voting power. Accordingly, we account for our investment in these entities under the equity method and record our proportionate share of their losses in Loss from investments in investees in our Condensed Consolidated Statements of Operations. The aggregate value of our equity method investments based on the quoted market price of their common stock and the number of shares held by us as of June 30, 2018 is $40.1 million.

Equity Securities

Our equity securities consist of investments in RXi Pharmaceuticals Corporation (“RXi”) (ownership 1%), ChromaDex Corporation (0%), MabVax Therapeutics Holdings, Inc. (“MabVax”) (2%), and Eloxx Pharmaceuticals, Inc. (“Eloxx”) (4%). We have determined that our ownership, along with that of our related parties, does not provide us with significant influence over the operations of these investments. Accordingly, we account for our investment in these entities as equity securities, and we record changes in the fair value of these investments in Other income (expense) each reporting period when they have readily determinable fair value. Equity securities without a readily determinable fair value are adjusted to fair value when an observable price change can be identified. Net gains and losses on our equity securities for the six months ended June 30, 2018 are as follows:



(in thousands)
Equity Securities	For the six months ended June 30, 2018
Net gains recognized during the period on equity securities	$	11,289
Less: Net losses realized during the period on equity securities sold during the period	(113		)
Unrealized net gains and losses recognized during the period on equity securities still held at the reporting date	$	11,402

Sales of investments

Gains (losses) included in earnings from sales of our investments are recorded in Other income (expense), net in our Condensed Consolidated Statements of Operations. We did not have significant sales activity during the six months ended June 30, 2018 and 2017. The cost of securities sold is based on the specific identification method.

Warrants and options

Table of Contents

the changes in the fair value of the options and warrants in Fair value changes of derivative instruments, net in our Condensed Consolidated Statements of Operations. We also recorded the fair value of the options and warrants in Investments, net in our Condensed Consolidated Balance Sheets. See further discussion of the Company’s options and warrants in Note 8 and Note 9.

Investments in variable interest entities

We have determined that we hold variable interests in Zebra Biologics, Inc. (“Zebra”). We made this determination as a result of our assessment that Zebra does not have sufficient resources to carry out its principal activities without additional financial support.

We own 1,260,000 shares of Zebra Series A-2 Preferred Stock and 900,000 shares of Zebra restricted common stock (ownership 29% at June 30, 2018). Zebra is a privately held biotechnology company focused on the discovery and development of biosuperior antibody therapeutics and complex drugs. Dr. Richard Lerner, M.D., a member of our Board of Directors, is a founder of Zebra and, along with Dr. Frost, serves as a member of Zebra’s Board of Directors.

In order to determine the primary beneficiary of Zebra, we evaluated our investment and our related parties’ investment, as well as our investment combined with the related party group’s investment to identify if we had the power to direct the activities that most significantly impact the economic performance of Zebra. Based on the capital structure, governing documents and overall business operations of Zebra, we determined that, while a VIE, we do not have the power to direct the activities that most significantly impact Zebra’s economic performance and have no obligation to fund expected losses. We did determine, however, that we can significantly influence the success of Zebra through our board representation and voting power. Therefore, we have the ability to exercise significant influence over Zebra’s operations and account for our investment in Zebra under the equity method.

Table of Contents

NOTE 6 DEBT

In February 2018, we issued a series of 5% Convertible Promissory Notes (the “2023 Convertible Notes”) in the aggregate principal amount of $55.0 million. The 2023 Convertible Notes mature 5 years from the date of issuance. Each holder of a 2023 Convertible Note has the option, from time to time, to convert all or any portion of the outstanding principal balance of such 2023 Convertible Note, together with accrued and unpaid interest thereon, into shares of our Common Stock, par value $0.01 per share, at a conversion price of $5.00 per share of Common Stock (the “Shares”). We may redeem all or any part of the then issued and outstanding 2023 Convertible Notes, together with accrued and unpaid interest thereon, pro ratably among the holders, upon no fewer than 30 days, and no more than 60 days, notice to the holders. The 2023 Convertible Notes contain customary events of default and representations and warranties of OPKO.

Purchasers of the 2023 Convertible Notes include an affiliate of Dr. Phillip Frost, M.D., our Chairman and Chief Executive Officer, and Dr. Jane H. Hsiao, Ph.D., MBA, our Vice-Chairman and Chief Technical Officer.

In January 2013, we entered into note purchase agreements (the “2033 Senior Notes”) with qualified institutional buyers and accredited investors (collectively, the “Purchasers”) in a private placement in reliance on exemptions from registration under the Securities Act. The 2033 Senior Notes were issued on January 30, 2013. The 2033 Senior Notes, which totaled $175.0 million in original principal amount, bear interest at the rate of 3.00% per year, payable semiannually on February 1 and August 1 of each year. The 2033 Senior Notes will mature on February 1, 2033, unless earlier repurchased, redeemed or converted. Upon a fundamental change as defined in the Indenture, dated as of January 30, 2013, by and between the Company and Wells Fargo Bank N.A., as trustee, governing the 2033 Senior Notes (the “Indenture”), subject to certain exceptions, the holders may require us to repurchase all or any portion of their 2033 Senior Notes for cash at a repurchase price equal to 100% of the principal amount of the 2033 Senior Notes being repurchased, plus any accrued and unpaid interest to but not including the related fundamental change repurchase date.

The following table sets forth information related to the 2033 Senior Notes which is included in our Condensed Consolidated Balance Sheets as of December 31, 2017 and June 30, 2018:



(In thousands)	2033 Senior Notes		Discount			Debt Issuance Cost			Total
Balance at December 31, 2017	$	31,850	$	(2,565	)	$	(125	)	$	29,160
Amortization of debt discount and debt issuance costs	—		1,109			74			1,183
Balance at June 30, 2018	$	31,850	$	(1,456	)	$	(51	)	$	30,343

The 2033 Senior Notes will be convertible at any time on or after November 1, 2032, through the second scheduled trading day immediately preceding the maturity date, at the option of the holders. Additionally, holders may convert their 2033 Senior Notes prior to the close of business on the scheduled trading day immediately preceding November 1, 2032, under the following circumstances: (1) conversion based upon satisfaction of the trading price condition relating to the 2033 Senior Notes; (2) conversion based on the Common Stock price; (3) conversion based upon the occurrence of specified corporate events; or (4) if we call the 2033 Senior Notes for redemption. The 2033 Senior Notes will be convertible into cash, shares of our Common Stock, or a combination of cash and shares of Common Stock, at our election unless we have made an irrevocable election of net share settlement. The initial conversion rate for the 2033 Senior Notes will be 141.48 shares of Common Stock per $1,000 principal amount of 2033 Senior Notes (equivalent to an initial conversion price of approximately $7.07 per share of Common Stock), and will be subject to adjustment upon the occurrence of certain events. In addition, we will, in certain circumstances, increase the conversion rate for holders who convert their 2033 Senior Notes in connection with a make-whole fundamental change (as defined in the Indenture). Holders of the 2033 Senior Notes may require us to repurchase the 2033 Senior Notes for 100% of their principal amount, plus accrued and unpaid interest, on February 1, 2019, February 1, 2023 and February 1, 2028, or following the occurrence of a fundamental change as defined in the indenture governing the 2033 Senior Notes.

Table of Contents

accrued and unpaid interest to but not including the redemption date. On or after February 1, 2019, we may redeem for cash any or all of the 2033 Senior Notes at a redemption price of 100% of the principal amount of the 2033 Senior Notes to be redeemed, plus any accrued and unpaid interest up to but not including the redemption date.

The terms of the 2033 Senior Notes, include, among others: (i) rights to convert into shares of our Common Stock, including upon a fundamental change; and (ii) a coupon make-whole payment in the event of a conversion by the holders of the 2033 Senior Notes on or after February 1, 2017 but prior to February 1, 2019. We determined that these specific terms were considered to be embedded derivatives. Embedded derivatives are required to be separated from the host contract, the 2033 Senior Notes, and carried at fair value when: (a) the embedded derivative possesses economic characteristics that are not clearly and closely related to the economic characteristics of the host contract; and (b) a separate, stand-alone instrument with the same terms would qualify as a derivative instrument. We concluded that the embedded derivatives within the 2033 Senior Notes meet these criteria and, as such, were valued separate and apart from the 2033 Senior Notes and recorded at fair value each reporting period.

For accounting and financial reporting purposes, we combined these embedded derivatives and valued them together as one unit of accounting. In 2017, certain terms of the embedded derivatives expired pursuant to the original agreement and the embedded derivatives no longer met the criteria to be separated from the host contract and, as a result, the embedded derivatives are no longer required to be valued separate and apart from the 2033 Senior Notes and were reclassified to additional paid in capital. Accordingly, there was no derivative income (loss) for the six months ended June 30, 2018.

From 2013 to 2016, holders of the 2033 Senior Notes converted $143.2 million in aggregate principal amount into an aggregate of 21,539,873 shares of the Company’s Common Stock.

In April 2015, we initially announced that our 2033 Senior Notes were convertible through June 2015 by holders of such notes. This conversion right was triggered because the closing price per share of our Common Stock exceeded $9.19, or 130% of the initial conversion price of $7.07, for at least 20 of 30 consecutive trading days during the applicable measurement period. We have elected to satisfy our conversion obligation under the 2033 Senior Notes in shares of our Common Stock. Our 2033 Senior Notes continued to be convertible by holders of such notes for the remainder of 2015, 2016 and the first quarter of 2017. They may become convertible again if one or more of the conversion conditions specified in the Indenture is satisfied during future measurement periods. Pursuant to the Indenture, a holder who elects to convert the 2033 Senior Notes will receive 141.4827 shares of our Common Stock plus such number of additional shares as is applicable on the conversion date per $1,000 principal amount of 2033 Senior Notes based on the early conversion provisions in the Indenture.

In November 2015, BioReference and certain of its subsidiaries entered into a credit agreement with JPMorgan Chase Bank, N.A. (“CB”), as lender and administrative agent, as amended (the “Credit Agreement”). The Credit Agreement provides for a $175.0 million secured revolving credit facility and includes a $20.0 million sub-facility for swingline loans and a $20.0 million sub-facility for the issuance of letters of credit. BioReference may increase the credit facility to up to $275.0 million on a secured basis, subject to the satisfaction of specified conditions. The Credit Agreement matures on November 5, 2020 and is guaranteed by all of BioReference’s domestic subsidiaries. The Credit Agreement is also secured by substantially all assets of BioReference and its domestic subsidiaries, as well as a non-recourse pledge by us of our equity interest in BioReference. Availability under the Credit Agreement is based on a borrowing base comprised of eligible accounts receivables of BioReference and certain of its subsidiaries, as specified therein. As of June 30, 2018, no additional funds were available to be borrowed under the Credit Agreement. Principal under the Credit Agreement is due upon maturity on November 5, 2020.

At BioReference’s option, borrowings under the Credit Agreement (other than swingline loans) will bear interest at (i) the CB floating rate (defined as the higher of (a) the prime rate and (b) the LIBOR rate (adjusted for statutory reserve requirements for Eurocurrency liabilities) for an interest period of one month plus 2.50%) plus an applicable margin of 0.35% for the first 12 months and 0.50% thereafter or (ii) the LIBOR rate (adjusted for statutory reserve requirements for Eurocurrency liabilities) plus an applicable margin of 1.35% for the first 12 months and 1.50% thereafter. Swingline loans will bear interest at the CB floating rate plus the applicable margin. The Credit Agreement also calls for other customary fees and charges, including an unused commitment fee of 0.50% of the lending commitments.

In February 2018, BioReference and certain of its subsidiaries entered into Amendment No. 7 to the Credit Agreement, which amended the Credit Agreement to permit BioReference and its subsidiaries to use cash on hand, up to a maximum amount set forth in the amendment, to meet the availability requirements that otherwise would trigger (i) covenants that would require BioReference to maintain a minimum fixed charge coverage ratio and provide certain increased reporting under the Credit Agreement and (ii) CB’s right, as agent for the lenders under the Credit Agreement, to exercise sole dominion over funds held in certain accounts of BioReference. The other terms of the Credit Agreement remain unchanged.

Table of Contents

The Credit Agreement contains customary covenants and restrictions, including, without limitation, covenants that require BioReference and its subsidiaries to maintain a minimum fixed charge coverage ratio if availability under the new credit facility falls below a specified amount and to comply with laws and restrictions on the ability of BioReference and its subsidiaries to incur additional indebtedness or to pay dividends and make certain other distributions to the Company, subject to certain exceptions as specified therein. Failure to comply with these covenants would constitute an event of default under the Credit Agreement, notwithstanding the ability of BioReference to meet its debt service obligations. The Credit Agreement also includes various customary remedies for the lenders following an event of default, including the acceleration of repayment of outstanding amounts under the Credit Agreement and execution upon the collateral securing obligations under the Credit Agreement. Substantially all the assets of BioReference and its subsidiaries are restricted from sale, transfer, lease, disposal or distributions to the Company, subject to certain exceptions. BioReference and its subsidiaries net assets as of June 30, 2018 were approximately $1.0 billion, which includes goodwill of $401.8 million and intangible assets of $425.4 million.

In addition to the Credit Agreement with CB, we have line of credit agreements with eleven other financial institutions as of June 30, 2018 and December 31, 2017 in the United States, Chile and Spain. These lines of credit are used primarily as a source of working capital for inventory purchases.

The following table summarizes the amounts outstanding under the BioReference, Chilean and Spanish lines of credit:



(Dollars in thousands)				Balance Outstanding
Lender	Interest rate on borrowings at June 30, 2018	Credit line capacity		June 30, 2018		December 31, 2017
JPMorgan Chase	4.01%	$	175,000	$	105,539	$	104,152
Itau Bank	5.50%	1,810		1,179		446
Bank of Chile	6.60%	3,800		502		1,598
BICE Bank	5.50%	2,500		798		1,819
BBVA Bank	5.50%	3,250		250		1,665
Security Bank	5.50%	98		98		501
Estado Bank	5.50%	3,500		757		2,111
Santander Bank	5.50%	4,500		262		1,988
Scotiabank	5.00%	1,800		9		384
Banco Bilbao Vizcaya	2.90%	292		—		—
Santander Bank	2.67%	350		102		—
Total		$	196,900	$	109,496	$	114,664

At June 30, 2018 and December 31, 2017, the weighted average interest rate on our lines of credit was approximately 4.7% and 4.2%, respectively.

At June 30, 2018 and December 31, 2017, we had notes payable and other debt (excluding the 2033 Senior Notes, the 2023 Convertible Notes, the Credit Agreement and amounts outstanding under lines of credit) as follows:



(In thousands)	June 30, 2018		December 31, 2017
Current portion of notes payable	$	2,821	$	1,632
Other long-term liabilities	6,469		2,011
Total	$	9,290	$	3,643

The notes and other debt mature at various dates ranging from 2018 through 2024 bearing variable interest rates from 1.8% up to 6.3%. The weighted average interest rate on the notes and other debt at June 30, 2018 and December 31, 2017, was 3.0% and 3.0%, respectively. The notes are secured by our office space in Barcelona.

Table of Contents

NOTE 7 ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS)

For the six months ended June 30, 2018, changes in Accumulated other comprehensive income (loss), net of tax, were as follows:



(In thousands)	Foreign currency			Unrealized gain (loss) in Accumulated OCI			Total
Balance at December 31, 2017	$	(5,404	)	$	4,876		$	(528	)
Other comprehensive loss before reclassifications	(7,600		)	—			(7,600		)
Reclassification adjustment due to adoption of ASU 2016-01	—			(4,876		)	(4,876		)
Net other comprehensive loss	(7,600		)	(4,876		)	(12,476		)
Balance at June 30, 2018	$	(13,004	)	$	—		$	(13,004	)

NOTE 8 FAIR VALUE MEASUREMENTS

We record fair values at an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement determined based on assumptions that market participants would use in pricing an asset or liability. We utilize a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. These tiers include: Level 1, defined as observable inputs such as quoted prices in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions.

As of June 30, 2018, we have equity securities (refer to Note 5), forward foreign currency exchange contracts for inventory purchases (refer to Note 9) and contingent consideration related to the acquisitions of CURNA, OPKO Diagnostics and OPKO Renal that are required to be measured at fair value on a recurring basis. In addition, in connection with our investment and our consulting agreement with BioCardia, we record the related BioCardia options at fair value as well as the warrants from COCP, InCellDx, Inc., Xenetic, RXi and Neovasc.

Our financial assets and liabilities measured at fair value on a recurring basis are as follows:



	Fair value measurements as of June 30, 2018
(In thousands)	Quoted prices in active markets for identical assets (Level 1)		Significant other observable inputs (Level 2)		Significant unobservable inputs (Level 3)		Total
Assets:
Equity securities	22,350		—		—		22,350
Common stock options/warrants	—		1,799		—		1,799
Forward contracts	—		23		—		23
Total assets	$	22,350	$	1,822	$	—	$	24,172
Liabilities:
Contingent consideration	—		—		27,754		27,754
Total liabilities	$	—	$	—	$	27,754	$	27,754

Table of Contents



	Fair value measurements as of December 31, 2017
(In thousands)	Quoted prices in active markets for identical assets (Level 1)		Significant other observable inputs (Level 2)		Significant unobservable inputs (Level 3)		Total
Assets:
Money market funds	$	107	$	—	$	—	$	107
Equity securities	12,461		—		—		12,461
Common stock options/warrants	—		3,333		—		3,333
Total assets	$	12,568	$	3,333	$	—	$	15,901
Liabilities:
Forward contracts	—		317		—		317
Contingent consideration	—		—		41,353		41,353
Total liabilities	$	—	$	317	$	41,353	$	41,670

There have been no transfers between Level 1 and Level 2 and no transfers to or from Level 3 of the fair value hierarchy.

As of June 30, 2018 and December 31, 2017, the carrying value of our other financial instrument assets approximates their fair value due to their short-term nature or variable rate of interest.

The following table reconciles the beginning and ending balances of our Level 3 assets and liabilities as of June 30, 2018:



	June 30, 2018
(In thousands)	Contingent consideration
Balance at December 31, 2017	$	41,353
Change in fair value:
Included in results of operations	(13,599		)
Balance at June 30, 2018	$	27,754

The estimated fair values of our financial instruments have been determined by using available market information and what we believe to be appropriate valuation methodologies. We use the following methods and assumptions in estimating fair value:

Contingent consideration – We estimate the fair value of the contingent consideration utilizing a discounted cash flow model for the expected payments based on estimated timing and expected revenues. We use several discount rates depending on each type of contingent consideration related to OPKO Diagnostics, CURNA and OPKO Renal transactions. If estimated future sales were to decrease by 10%, the contingent consideration related to OPKO Renal, which represents the majority of our contingent consideration liability, would decrease by $1.7 million. As of June 30, 2018, of the $27.7 million of contingent consideration, $2.0 million is recorded in Accrued expenses and $25.7 million is recorded in Other long-term liabilities. As of December 31, 2017, of the $41.4 million of contingent consideration, $11.8 million is recorded in Accrued expenses and $29.6 million is recorded in Other long-term liabilities.

Table of Contents

NOTE 9 DERIVATIVE CONTRACTS

The following table summarizes the fair values and the presentation of our derivative assets (liabilities) in the Condensed Consolidated Balance Sheets:



(In thousands)	Balance Sheet Component	June 30, 2018		December 31, 2017
Derivative financial instruments:
Common Stock options/warrants	Investments, net	$	1,799	$	3,333
Forward contracts	Unrealized gains on forward contracts are recorded in Other current assets and prepaid expenses. Unrealized (losses) on forward contracts are recorded in Accrued expenses.	$	23	$	(317	)

We enter into foreign currency forward exchange contracts to cover the risk of exposure to exchange rate differences arising from inventory purchases on letters of credit. Under these forward contracts, for any rate above or below the fixed rate, we receive or pay the difference between the spot rate and the fixed rate for the given amount at the settlement date.

To qualify the derivative instrument as a hedge, we are required to meet strict hedge effectiveness and contemporaneous documentation requirements at the initiation of the hedge and assess the hedge effectiveness on an ongoing basis over the life of the hedge. At June 30, 2018 and December 31, 2017, our derivative financial instruments do not meet the documentation requirements to be designated as hedges. Accordingly, we recognize the changes in Fair value of derivative instruments, net in our Condensed Consolidated Statement of Operations. The following table summarizes the losses and gains recorded for the three and six months ended June 30, 2018 and 2017:



	Three months ended June 30,					Six months ended June 30,
(In thousands)	2018		2017			2018		2017
Derivative gain (loss):
Common Stock options/warrants	$	1,916	$	444		$	3,587	$	(512	)
2033 Senior Notes	—		5,069			—		10,014
Forward contracts	332		(31		)	57		17
Total	$	2,248	$	5,482		$	3,644	$	9,519

Table of Contents

NOTE 10 RELATED PARTY TRANSACTIONS

In February 2018, we issued the 2023 Convertible Notes in the aggregate principal amount of $55.0 million. Refer to Note 6. Purchasers of the 2023 Convertible Notes include an affiliate of Dr. Phillip Frost, M.D., our Chairman and Chief Executive Officer, and Dr. Jane H. Hsiao, Ph.D., MBA, our Vice-Chairman and Chief Technical Officer.

We hold investments in Zebra (ownership 29%), Neovasc (6%), ChromaDex Corporation (0%), MabVax (2%), COCP (9%), NIMS (1%) and BioCardia (5%). These investments were considered related party transactions as a result of our executive management’s ownership interests and/or board representation in these entities. See further discussion of our investments in Note 5.

In February 2018, we invested an additional $1.0 million in COCP for a convertible note, which was converted into 538,544 shares of its common stock in May 2018. In April 2017, we invested an additional $1.0 million in COCP for 138,889 shares of its common stock, and in August 2016, we had invested an additional $2.0 million in COCP for 162,602 shares of its common stock.

In November 2017, we invested an additional $3.0 million in Neovasc for 2,054,794 shares of its common stock, 2,054,794 Series A warrants, 2,054,794 Series B warrants and 822,192 Series C warrants. In April 2018, we exercised our Series B warrants in a cashless exercise and received 106,909,044 shares on Neovasc common stock.

In July 2017, we invested an additional $0.1 million in MabVax for 50,714 shares of common stock and in May 2017, we invested an additional $0.5 million in MabVax for 1,667 shares of Series L Preferred Stock and 107,607 shares of Series I Preferred Stock.

In November 2016, we entered into a Pledge Agreement with the Museum of Science, Inc. and the Museum of Science Endowment Fund, Inc. pursuant to which we will contribute an aggregate of $1.0 million over a four-year period for constructing, equipping and the general operation of the Frost Science Museum. Dr. Frost and Mr. Pfenniger serve on the Board of Trustees of the Frost Science Museum and Mr. Pfenniger is the Vice Chairman of the Board of Trustees.

We lease office space from Frost Real Estate Holdings, LLC (“Frost Holdings”) in Miami, Florida, where our principal executive offices are located. Effective January 1, 2017, we entered into an amendment to our lease agreement with Frost Holdings. The lease, as amended, is for approximately 29,500 square feet of space. The lease provides for payments of approximately $81 thousand per month in the first year increasing annually to $86 thousand per month in the third year, plus applicable sales tax. The rent is inclusive of operating expenses, property taxes and parking.

Our wholly-owned subsidiary, BioReference, purchases and uses certain products acquired from InCellDx, Inc., a company in which we hold a 29% minority interest.

We reimburse Dr. Frost for Company-related use by Dr. Frost and our other executives of an airplane owned by a company that is beneficially owned by Dr. Frost. We reimburse Dr. Frost for out-of-pocket operating costs for the use of the airplane by Dr. Frost or Company executives for Company-related business. We do not reimburse Dr. Frost for personal use of the airplane by Dr. Frost or any other executive. For the three and six months ended June 30, 2018, we recognized approximately $61 thousand and $140 thousand, respectively, for Company-related travel by Dr. Frost and other OPKO executives. For the three and six months ended June 30, 2017, we recognized $121 thousand and $141 thousand, respectively, for Company-related travel by Dr. Frost and other OPKO executives.

Table of Contents

NOTE 11 COMMITMENTS AND CONTINGENCIES

In connection with our acquisitions of CURNA, OPKO Diagnostics and OPKO Renal, we agreed to pay future consideration to the sellers upon the achievement of certain events. As a result, as of June 30, 2018, we have recorded $27.7 million as contingent consideration, with $2.0 million recorded within Accrued expenses and $25.7 million recorded within Other long-term liabilities in the accompanying Condensed Consolidated Balance Sheets. Refer to Note 4.

In August 2017, we entered into a Commitment Letter (the “Commitment Letter”) with Veterans Accountable Care Group, LLC (“VACG”) in connection with submission of a bid by its affiliate, the Veterans Accountable Care Organization, LLC (“VACO”) in response to a request for proposal (“RFP”) from the Veterans Health Administration (“VA”) regarding its Community Care Network. If VACO is successful in its bid, we will acquire a fifteen percent (15%) membership interest in VACO. In addition, BioReference, our wholly-owned subsidiary, will provide laboratory services for the Community Care Network, a region which currently includes approximately 2,133,000 veterans in the states of Massachusetts, Maine, New Hampshire, Vermont, New York, Pennsylvania, New Jersey, Rhode Island, Connecticut, Maryland, Virginia, West Virginia, and North Carolina.

Pursuant to the Commitment Letter, we committed to provide, or to arrange from a third party lender, a line of credit for VACG in the amount of $50.0 million (the “Facility”). Funds drawn under the Facility would be contributed by VACG to VACO in order to satisfy the financial stability requirement of VACO in connection with its submission of the RFP. VACG would not be permitted to draw down on the Facility unless and until the VHA awards a contract to VACO. The Facility would have a maturity of five years. Interest on the Facility would be payable at a rate equal to 6.5% per annum, payable quarterly in arrears. The Facility is subject to the negotiation of definitive documentation conditions customary for transactions of such type and otherwise acceptable to VACG and the lender under the Facility.

We currently anticipate that a decision by the VHA with respect to the RFP will occur during 2018, although there can be no assurance that a decision will be made by such time or that, if favorable, such decision will not be challenged by participants in the RFP process or otherwise.

We accrue a liability for legal contingencies when we believe that it is both probable that a liability has been incurred and that we can reasonably estimate the amount of the loss. We review established accruals and adjust them to reflect ongoing negotiations, settlements, rulings, advice of legal counsel and other relevant information. To the extent new information is obtained and our views on the probable outcomes of claims, suits, assessments, investigations or legal proceedings change, changes in our accrued liabilities would be recorded in the period in which such determination is made. For the matters referenced in the paragraph below, the amount of liability is not probable or the amount cannot be reasonably estimated; and, therefore, accruals have not been made. In addition, in accordance with the relevant authoritative guidance, for matters which the likelihood of material loss is at least reasonably possible, we provide disclosure of the possible loss or range of loss; however, if a reasonable estimate cannot be made, we will provide disclosure to that effect.

From time to time, we may receive inquiries, document requests, or subpoenas from the Department of Justice, the Office of Inspector General and Office for Civil Rights (“OCR”) of the Department of Health and Human Services, the Centers for Medicare and Medicaid Services, various payors and fiscal intermediaries, and other state and federal regulators regarding investigations, audits and reviews. In addition to the matters discussed in this note, we are currently responding to subpoenas or document requests for various matters relating to our laboratory operations. Some pending or threatened proceedings against us may involve potentially substantial amounts as well as the possibility of civil, criminal, or administrative fines, penalties, or other sanctions, which could be material. Settlements of suits involving the types of issues that we routinely confront may require monetary payments as well as corporate integrity agreements. Additionally, qui tam or “whistleblower” actions initiated under the civil False Claims Act may be pending but placed under seal by the court to comply with the False Claims Act’s requirements for filing such suits. Also, from time to time, we may detect issues of non-compliance with federal healthcare laws pertaining to claims submission and reimbursement practices and/or financial relationships with physicians, among other things. We may avail ourselves of various mechanisms to address these issues, including participation in voluntary disclosure protocols. Participating in voluntary disclosure protocols can have the potential for significant settlement obligations or even enforcement action. The Company generally has cooperated, and intends to continue to cooperate, with appropriate regulatory authorities as and when investigations, audits and inquiries arise.

We are a party to other litigation in the ordinary course of business. We do not believe that any such litigation will have a material adverse effect on our business, financial condition, results of operations or cash flows.

In April 2017, the Civil Division of the United States Attorney’s Office for the Southern District of New York (the “SDNY”) informed BioReference that it believes that, from 2006 to the present, BioReference had, in violation of the False Claims Act, improperly billed Medicare and TRICARE (both are federal government healthcare programs) for clinical laboratory services provided to hospital inpatient beneficiaries at certain hospitals. BioReference is reviewing and assessing

Table of Contents

the allegations made by the SDNY, and, at this point, BioReference has not determined whether there is any merit to the SDNY’s claims nor can it determine the extent of any potential liability. While management cannot predict the outcome of these matters at this time, the ultimate outcome could be material to our business, financial condition, results of operations, and cash flows.

We expect to continue to incur substantial research and development expenses, including expenses related to the hiring of personnel and additional clinical trials. We expect that selling, general and administrative expenses will also increase as we expand our sales, marketing and administrative staff and add infrastructure, particularly as it relates to the launch of Rayaldee. We do not anticipate that we will generate substantial revenue from the sale of proprietary pharmaceutical products or certain of our diagnostic products for some time and we have generated only limited revenue from our pharmaceutical operations in Chile, Mexico, Israel, Spain, and Ireland, and from sale of the 4Kscore test. If we acquire additional assets or companies, accelerate our product development programs or initiate additional clinical trials, we will need additional funds. If we are not able to secure additional funding when needed, we may have to delay, reduce the scope of, or eliminate one or more of our clinical trials or research and development programs or possible acquisitions.

At June 30, 2018, we were committed to make future purchases for inventory and other items in 2018 that occur in the ordinary course of business under various purchase arrangements with fixed purchase provisions aggregating $84.4 million.

NOTE 12 REVENUE RECOGNITION

Effective January 1, 2018, we adopted Accounting Standards Codification Topic 606, Revenue from Contracts with Customers. We generate revenues from services, products and intellectual property as follows:

Revenue from services

Revenue for laboratory services is recognized at the time test results are reported, which approximates when services are provided and the performance obligations are satisfied. Services are provided to patients covered by various third-party payor programs including various managed care organizations, as well as the Medicare and Medicaid programs. Billings for services are included in revenue net of allowances for contractual discounts, allowances for differences between the amounts billed and estimated program payment amounts, and implicit price concessions provided to uninsured patients which are all elements of variable consideration.

The following are descriptions of our payors for laboratory services:

Healthcare Insurers. Reimbursements from healthcare insurers are based on negotiated fee-for-service schedules. Revenues consist of amounts billed, net of contractual allowances for differences between amounts billed and the estimated consideration we expect to receive from such payers, which considers historical denial and collection experience and the terms of our contractual arrangements. Adjustments to the allowances, based on actual receipts from the third-party payers, are recorded upon settlement.

Government Payers. Reimbursements from government payers are based on fee-for-service schedules set by governmental authorities, including traditional Medicare and Medicaid. Revenues consist of amounts billed, net of contractual allowances for differences between amounts billed and the estimated consideration we expect to receive from such payers, which considers historical denial and collection experience and the terms of our contractual arrangements. Adjustments to the allowances, based on actual receipts from the government payers, are recorded upon settlement.

Client Payers. Client payers include physicians, hospitals, employers, and other institutions for which services are performed on a wholesale basis, and are billed and recognized as revenue based on negotiated fee schedules.

Patients. Uninsured patients are billed based on established patient fee schedules or fees negotiated with physicians on behalf of their patients. Insured patients (including amounts for coinsurance and deductible responsibilities) are billed based on fees negotiated with healthcare insurers. Collection of billings from patients is subject to credit risk and ability of the patients to pay. Revenues consist of amounts billed net of discounts provided to uninsured patients in accordance with our policies and implicit price concessions. Implicit price concessions represent differences between amounts billed and the estimated consideration that we expect to receive from patients, which considers historical collection experience and other factors including current market conditions. Adjustments to the estimated allowances, based on actual receipts from the patients, are recorded upon settlement.

Table of Contents

consideration in the recognition of revenue in the period the related services are rendered. Actual amounts are adjusted in the period those adjustments become known.

Third-party payers, including government programs, may decide to deny payment or recoup payments for testing they contend were improperly billed or not medically necessary, against their coverage determinations, or for which they believe they have otherwise overpaid (including as a result of their own error), and we may be required to refund payments already received. Our revenues may be subject to retroactive adjustment as a result of these factors among others, including without limitation, differing interpretations of billing and coding guidance and changes by government agencies and payors in interpretations, requirements, and “conditions of participation” in various programs. We have processed requests for recoupment from third-party payers in the ordinary course of our business, and it is likely that we will continue to do so in the future. If a third-party payer denies payment for testing or recoups money from us in a later period, reimbursement revenue for our testing could decline.

As an integral part of our billing compliance program, we periodically assess our billing and coding practices, respond to payor audits on a routine basis, and investigate reported failures or suspected failures to comply with federal and state healthcare reimbursement requirements, as well as overpayment claims which may arise from time to time without fault on the part of the Company. We may have an obligation to reimburse Medicare, Medicaid, and third-party payers for overpayments regardless of fault. We have periodically identified and reported overpayments, reimbursed payors for overpayments and taken appropriate corrective action.

Settlements with third-party payors for retroactive adjustments due to audits, reviews or investigations are also considered variable consideration and are included in the determination of the estimated transaction price for providing services. These settlements are estimated based on the terms of the payment agreement with the payor, correspondence from the payor and our historical settlement activity, including an assessment of the probability a significant reversal of cumulative revenue recognized will occur when the uncertainty is subsequently resolved. Estimated settlements are adjusted in future periods as adjustments become known (that is, new information becomes available), or as years are settled or are no longer subject to such audits, reviews, and investigations.

The composition of Revenue from services by payor for the three and six months ended June 30, 2018 and 2017 is as follow:



	Three months ended June 30,				Six months ended June 30,
(In thousands)	2018		2017		2018		2017
Healthcare insurers	$	92,033	$	104,366	$	192,986	$	217,062
Government payers	72,459		80,037		139,595		157,090
Client payers	45,828		42,961		83,357		76,900
Patients	5,735		6,548		11,431		11,404
Total	$	216,055	$	233,912	$	427,369	$	462,456

Revenue from products

We recognize revenue from product sales when a customer obtains control of promised goods or services. The amount of revenue that is recorded reflects the consideration that we expect to receive in exchange for those goods or services. Our estimates for sales returns and allowances are based upon the historical patterns of product returns and allowances taken, matched against the sales from which they originated, and our evaluation of specific factors that may increase or decrease the risk of product returns. Product revenues are recorded net of estimated rebates, chargebacks, discounts, co-pay assistance and other deductions (collectively, “Sales Deductions”) as well as estimated product returns which are all elements of variable consideration. Allowances are recorded as a reduction of revenue at the time product revenues are recognized. The actual amounts of consideration ultimately received may differ from our estimates. If actual results in the future vary from our estimates, we will adjust these estimates, which would affect Revenue from products in the period such variances become known.

We launched Rayaldee in the U.S. through our dedicated renal sales force in November 2016. Rayaldee is distributed in the U.S. principally through the retail pharmacy channel, which initiates with the largest wholesalers in the U.S. (collectively, “Rayaldee Customers”). In addition to distribution agreements with Rayaldee Customers, we have entered into arrangements with many healthcare providers and payers that provide for government-mandated and/or privately-negotiated rebates, chargebacks and discounts with respect to the purchase of Rayaldee.

Table of Contents

We recognize revenue for shipments of Rayaldee at the time of delivery to customers after estimating Sales Deductions and product returns as elements of variable consideration utilizing historical information and market research projections. For the three and six months ended June 30, 2018, we recognized $4.8 million and $8.5 million in net product revenue from sales of Rayaldee. Amounts shipped prior to June 30, 2017 were insignificant and no revenue was recognized from sales of Rayaldee for the three and six months ended June 30, 2017.

The following table presents an analysis of product sales allowances and accruals as contract liabilities for the six months ended June 30, 2018:



(In thousands)	Chargebacks, discounts, rebates and fees			Governmental			Returns			Total
Balance at December 31, 2017	$	233		$	348		$	437		$	1,018
Provision related to current period sales	2,188			2,936			—			5,124
Credits or payments made	(1,697		)	(2,557		)	(311		)	(4,565		)
Balance at June 30, 2018	$	724		$	727		$	126		$	1,577

Total gross Rayaldee sales										$	13,582
Provision for Rayaldee sales allowances and accruals as a percentage of gross Rayaldee sales										38		%

Taxes collected from customers related to revenues from services and revenues from products are excluded from revenues.

Revenue from intellectual property

We recognize revenues from the transfer of intellectual property generated through license, development, collaboration and/or commercialization agreements. The terms of these agreements typically include payment to us for one or more of the following: non-refundable, up-front license fees; development and commercialization milestone payments; funding of research and/or development activities; and royalties on sales of licensed products. Revenue is recognized upon satisfaction of a performance obligation by transferring control of a good or service to the customer.

For research, development and/or commercialization agreements that result in revenues, we identify all material performance obligations, which may include a license to intellectual property and know-how, and research and development activities. In order to determine the transaction price, in addition to any upfront payment, we estimate the amount of variable consideration at the outset of the contract either utilizing the expected value or most likely amount method, depending on the facts and circumstances relative to the contract. We constrain (reduce) our estimates of variable consideration such that it is probable that a significant reversal of previously recognized revenue will not occur throughout the life of the contract. When determining if variable consideration should be constrained, we consider whether there are factors outside of our control that could result in a significant reversal of revenue. In making these assessments, we consider the likelihood and magnitude of a potential reversal of revenue. These estimates are re-assessed each reporting period as required.

Upfront License Fees: If a license to our intellectual property is determined to be functional intellectual property distinct from the other performance obligations identified in the arrangement, we recognize revenue from nonrefundable, upfront license fees based on the relative value prescribed to the license compared to the total value of the arrangement. The revenue is recognized when the license is transferred to the customer and the customer is able to use and benefit from the license. For licenses that are not distinct from other obligations identified in the arrangement, we utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time. If the combined performance obligation is satisfied over time, we apply an appropriate method of measuring progress for purposes of recognizing revenue from nonrefundable, upfront license fees. We evaluate the measure of progress each reporting period and, if necessary, adjust the measure of performance and related revenue recognition.

Table of Contents

that have been fully constrained are not included in the transaction price to date. These milestones remain fully constrained until we conclude that achievement of the milestone is probable and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods. We re-evaluate the probability of achievement of such development milestones and any related constraint each reporting period. We adjust our estimate of the overall transaction price, including the amount of revenue recorded, if necessary.

Research and Development Activities: If we are entitled to reimbursement from our customers for specified research and development expenses, we account for them as separate performance obligations if distinct. We also determine whether the research and development funding would result in revenues or an offset to research and development expenses in accordance with provisions of gross or net revenue presentation. The corresponding revenues or offset to research and development expenses are recognized as the related performance obligations are satisfied.

Sales-based Milestone and Royalty Payments: Our customers may be required to pay us sales-based milestone payments or royalties on future sales of commercial products. We recognize revenues related to sales-based milestone and royalty payments upon the later to occur of (i) achievement of the customer’s underlying sales or (ii) satisfaction of any performance obligation(s) related to these sales, in each case assuming the license to our intellectual property is deemed to be the predominant item to which the sales-based milestones and/or royalties relate.

Other Potential Products and Services: Arrangements may include an option for license rights, future supply of drug substance or drug product for either clinical development or commercial supply at the licensee’s election. We assess if these options provide a material right to the licensee and if so, they are accounted for as separate performance obligations at the inception of the contract and revenue is recognized only if the option is exercised and products or services are subsequently delivered or when the rights expire. If the promise is based on market terms and not considered a material right, the option is accounted for if and when exercised. If we are entitled to additional payments when the licensee exercises these options, any additional payments are generally recorded in license or other revenues when the licensee obtains control of the goods, which is upon delivery.

For the three and six months ended June 30, 2018, revenue from transfer of intellectual property principally reflects $16.3 million and $31.0 million of revenue, respectively related to the Pfizer Transaction (as defined below). For the three and six months ended June 30, 2017, revenue from transfer of intellectual property principally reflects and $18.3 million and $32.4 million of revenue, respectively related to the Pfizer Transaction. Refer to Note 13. Total contract liabilities included in Accrued expenses and Other long-term liabilities was $109.6 million and $140.4 million at June 30, 2018 and December 31, 2017, respectively. The contract liability balance at June 30, 2018 relates primarily to the Pfizer Transaction.

NOTE 13 STRATEGIC ALLIANCES

Japan Tobacco Inc.

In connection with the license, OPKO received an initial upfront payment of $6 million. OPKO will receive another $6 million upon the initiation of OPKO’s planned phase 2 study for Rayaldee in dialysis patients in the U.S. OPKO is also eligible to receive up to an additional aggregate amount of $31 million upon the achievement of certain regulatory and development milestones by JT for Rayaldee in the JT Territory, and $75 million upon the achievement of certain sales based milestones by JT in the JT Territory. OPKO will also receive tiered, double digit royalty payments at rates ranging from low double digits to mid-teens on net sales of Rayaldee within the JT Territory. JT will, at its sole cost and expense, be responsible for performing all development activities necessary to obtain all regulatory approvals for Rayaldee in Japan and for all commercial activities pertaining to Rayaldee in Japan, except for certain preclinical expenses which OPKO has agreed to reimburse JT up to a capped amount.

The JT Agreement provides for the following: (1) an exclusive license in the JT Territory in the JT Field for the development and commercialization of Rayaldee; and (2) at JT’s option, EirGen will supply products to support the development, sale and commercialization of the products to JT in the JT Territory.

Table of Contents

The initial consideration primarily includes the non-refundable $6 million upfront payment and $6 million of probable variable consideration we will receive upon the initiation of our planned phase 2 study for Rayaldee in dialysis patients in the U.S. The initial consideration will be recognized over the performance period through 2021, when we anticipate completing the transfer of license materials specified in the JT Agreement and our performance obligation is complete.

We are also eligible to receive up to $31 million in regulatory and development milestones and $75 million in sales milestones. Payments received for regulatory, development and sales milestones are non-refundable. The milestones are payable if and when the associated milestone is achieved and will be recognized as revenue in the period in which the associated milestone is achieved, assuming all other revenue recognition criteria are met. To date, no revenue has been recognized related to these milestones.

Vifor Fresenius Medical Care Renal Pharma Ltd

In May 2016, EirGen, our wholly-owned subsidiary, and Vifor Fresenius Medical Care Renal Pharma Ltd (“VFMCRP”), entered into a Development and License Agreement (the “VFMCRP Agreement”) for the development and commercialization of Rayaldee (the “Product”) worldwide, except for (i) the United States, (ii) any country in Central America or South America (excluding Mexico), (iii) Russia, (iv) China, (v) Japan, (vi) Ukraine, (vii) Belorussia, (viii) Azerbaijan, (ix) Kazakhstan, and (x) Taiwan (the “VFMCRP Territory”). The license to VFMCRP potentially covers all therapeutic and prophylactic uses of the Product in human patients (the “VFMCRP Field”), provided that initially the license is for the use of the Product for the treatment or prevention of SHPT related to patients with stage 3 or 4 chronic kidney disease and vitamin D insufficiency/deficiency (the “VFMCRP Initial Indication”).

Under the terms of the VFMCRP Agreement, EirGen granted to VFMCRP an exclusive license in the VFMCRP Territory in the VFMCRP Field to use certain EirGen patents and technology to make, have made, use, sell, offer for sale, and import Products and to develop, commercialize, have commercialized, and otherwise exploit the Product. EirGen received a non-refundable and non-creditable initial payment of $50 million, which was recognized in Revenue from the transfer of intellectual property and other in our Condensed Consolidated Statement of Operations in 2016. EirGen is also eligible to receive up to an additional $37 million in regulatory milestones (“Regulatory Milestones”) and $195 million in launch and sales-based milestones (“Sales Milestones”), and will receive tiered royalties on sales of the product at percentage rates that range from the mid-teens to the mid-twenties or a minimum royalty, whichever is greater, upon the commencement of sales of the Product within the VFMCRP Territory and in the VFMCRP Field.

We plan to share responsibility with VFMCRP for the conduct of trials specified within an agreed-upon development plan, with each company leading certain activities within the plan. EirGen will lead the manufacturing activities within and outside the VFMCRP Territory and the commercialization activities outside the VFMCRP Territory and outside the VFMCRP Field in the VFMCRP Territory and VFMCRP will lead the commercialization activities in the VFMCRP Territory and the VFMCRP Field. For the initial development plan, the companies have agreed to certain cost sharing arrangements. VFMCRP will be responsible for all other development costs that VFMCRP considers necessary to develop the Product for the use of the Product for the VFMCRP Initial Indication in the VFMCRP Territory in the VFMCRP Field except as otherwise provided in the VFMCRP Agreement. The clinical studies provided for in the development activities are expected to commence in 2018.

In connection with the VFMCRP Agreement, the parties entered into a letter agreement pursuant to which EirGen granted to VFMCRP an exclusive option (the “Option”) to acquire an exclusive license under certain EirGen patents and technology to use, import, offer for sale, sell, distribute and commercialize the Product in the United States solely for the treatment of secondary hyperparathyroidism in dialysis patients with chronic kidney disease and vitamin D insufficiency (the “Dialysis Indication”). Upon exercise of the Option, VFMCRP will reimburse EirGen for all of the development costs incurred by EirGen with respect to the Product for the Dialysis Indication in the United States. VFMCRP would also pay EirGen up to an additional aggregate amount of $555 million of sales-based milestones upon the achievement of certain milestones and would be obligated to pay royalties at percentage rates that range from the mid-teens to the mid-twenties on sales of the Product in the United States for the Dialysis Indication. To date, VFMCRP has not exercised its option.

EirGen is also eligible to receive up to an additional $37 million in Regulatory Milestones and $195 million in Sales Milestones. Payments received for Regulatory Milestones and Sales Milestones are non-refundable. The Regulatory Milestones are payable if and when VFMCRP obtains approval from certain regulatory authorities and will be recognized as revenue in the period in which the associated milestone is achieved, assuming all other revenue recognition criteria are met. We account for the Sales Milestones as royalties and Sales Milestones payments will be recognized as revenue in the period in which the associated milestone is achieved or sales occur, assuming all other revenue recognition criteria are met. To date, no revenue has been recognized related to the milestones or royalties.

Table of Contents

Pfizer Inc.

In December 2014, we entered into an exclusive worldwide agreement with Pfizer Inc. (“Pfizer”) for the development and commercialization of our long-acting hGH-CTP for the treatment of growth hormone deficiency (“GHD”) in adults and children, as well as for the treatment of growth failure in children born small for gestational age (“SGA”) (the “Pfizer Transaction”).

The Pfizer Transaction closed in January 2015 following the termination of the waiting period under the Hart-Scott-Rodino Act. Under the terms of the Pfizer Transaction, we received non-refundable and non-creditable upfront payments of $295.0 million and are eligible to receive up to an additional $275.0 million upon the achievement of certain regulatory milestones. Pfizer received the exclusive license to commercialize hGH-CTP worldwide. In addition, we are eligible to receive initial tiered royalty payments associated with the commercialization of hGH-CTP for Adult GHD with percentage rates ranging from the high teens to mid-twenties. Upon the launch of hGH-CTP for Pediatric GHD in certain major markets, the royalties will transition to regional, tiered gross profit sharing for both hGH-CTP and Pfizer’s Genotropin®.

The agreement with Pfizer will remain in effect until the last sale of the licensed product, unless earlier terminated as permitted under the agreement. In addition to termination rights for material breach and bankruptcy, Pfizer is permitted to terminate the Agreement in its entirety, or with respect to one or more world regions, without cause after a specified notice period. If the Agreement is terminated by us for Pfizer’s uncured material breach, or by Pfizer without cause, provision has been made for transition of product and product responsibilities to us for the terminated regions, as well as continued supply of product by Pfizer or transfer of supply to us in order to support the terminated regions.

We are recognizing the non-refundable $295.0 million upfront payments as the research and development services are completed and had contract liabilities related to the Pfizer Transaction of $100.1 million at June 30, 2018, of which $58.8 million was classified in Accrued expenses and $41.3 million was classified in Other long-term liabilities.

The Pfizer Transaction includes milestone payments of $275.0 million upon the achievement of certain milestones. The milestones range from $20.0 million to $90.0 million each and are based on achievement of regulatory approval in the U.S. and regulatory approval and price approval in other major markets. The milestone payments will be recognized as revenue in the period in which the associated milestone is achieved, assuming all other revenue recognition criteria are met. To date, no revenue has been recognized related to the achievement of the milestones.

TESARO

In November 2009, we entered into an asset purchase agreement (the “NK-1 Agreement”) under which we acquired VARUBI™ (rolapitant) and other neurokinin-1 (“NK-1”) assets from Merck. In December 2010, we entered into an exclusive license agreement with TESARO, in which we out-licensed the development, manufacture, commercialization and distribution of our lead NK-1 candidate, VARUBI™ (the “TESARO License”). Under the terms of the license, we received a $6.0 million upfront payment from TESARO and we received $30 million of milestone payments from TESARO upon achievement of certain regulatory and commercial sale milestones and we are eligible to receive additional commercial milestone payments of up to $85 million if specified levels of annual net sales are achieved. The sales based milestone payments will be recognized as revenue in full in the period in which the associated sales occur. During the six months ended June 30, 2018 and 2017, no revenue was recognized related to the achievement of the milestones under the TESARO License.

TESARO is also obligated to pay us tiered royalties on annual net sales achieved in the United States and Europe at percentage rates that range from the low double digits to the low twenties, and outside of the United States and Europe at low double-digit percentage rates. Royalties will be recognized in the period the sales occur. TESARO assumed responsibility for clinical development and commercialization of licensed products at its expense. Under the NK-1 Agreement, we will continue to receive royalties on a country-by-country and product-by-product basis until the later of the date that all of the patent rights licensed from us and covering VARUBI™ expire, are invalidated or are not enforceable and 12 years from the first commercial sale of the product.

If TESARO elects to develop and commercialize VARUBI™ in Japan through a third-party licensee, TESARO will share equally with us all amounts it receives in connection with such activities, subject to certain exceptions and deductions.

The term of the license will remain in force until the expiration of the royalty term in each country, unless we terminate the license earlier for TESARO’s material breach of the license or bankruptcy. TESARO has a right to terminate the license at any time during the term for any reason on three months’ written notice.

TESARO announced during the first quarter of 2018 that it has elected to suspend further distribution of Varubi IV.

Table of Contents

Pharmsynthez

In April 2013, we entered into a series of concurrent transactions with Pharmsynthez, a Russian pharmaceutical company traded on the Moscow Stock Exchange, pursuant to which we acquired an equity method investment in Pharmsynthez (ownership 9%). We also granted rights to certain technologies in the Russian Federation, Ukraine, Belarus, Azerbaijan and Kazakhstan (the “Pharmsynthez Territories”) to Pharmsynthez and agreed to perform certain development activities. We will receive from Pharmsynthez royalties on net sales of products incorporating the technologies in the Pharmsynthez Territories, as well as a percentage of any sublicense income from third parties for the technologies in the Pharmsynthez Territories.

RXi Pharmaceuticals Corporation

In March 2013, we completed the sale to RXi of substantially all of our assets in the field of RNA interference (the “RNAi Assets”) (collectively, the “Asset Purchase Agreement”). Pursuant to the Asset Purchase Agreement, RXi will be required to pay us up to $50.0 million in milestone payments upon the successful development and commercialization of each drug developed by RXi, certain of its affiliates or any of its or their licensees or sublicensees utilizing patents included within the RNAi Assets (each, a “Qualified Drug”). In addition, RXi will also be required to pay us royalties equal to: (a) a mid single-digit percentage of “Net Sales” (as defined in the Asset Purchase Agreement) with respect to each Qualified Drug sold for an ophthalmologic use during the applicable “Royalty Period” (as defined in the Asset Purchase Agreement); and (b) a low single-digit percentage of net sales with respect to each Qualified Drug sold for a non-ophthalmologic use during the applicable Royalty Period.

Other

We have completed strategic deals with numerous institutions and commercial partners. In connection with these agreements, upon the achievement of certain milestones we are obligated to make certain payments and have royalty obligations upon sales of products developed under the license agreements. At this time, we are unable to estimate the timing and amounts of payments as the obligations are based on future development of the licensed products.

NOTE 14

SEGMENTS

We manage our operations in two reportable segments, pharmaceutical and diagnostics. The pharmaceutical segment consists of our pharmaceutical operations we acquired in Chile, Mexico, Ireland, Israel and Spain and our pharmaceutical research and development. The diagnostics segment primarily consists of our clinical laboratory operations we acquired through the acquisition of BioReference and our point-of-care operations. There are no significant inter-segment sales. We evaluate the performance of each segment based on operating profit or loss. There is no inter-segment allocation of interest expense and income taxes.

Table of Contents

Information regarding our operations and assets for our operating segments and the unallocated corporate operations as well as geographic information are as follows:



	For the three months ended June 30,						For the six months ended June 30,
(In thousands)	2018			2017			2018			2017
Revenue from services:
Pharmaceutical	$	—		$	—		$	—		$	—
Diagnostics	216,055			233,912			427,369			462,456
Corporate	—			—			—			—
	$	216,055		$	233,912		$	427,369		$	462,456
Revenue from products:
Pharmaceutical	$	28,523		$	28,966		$	56,374		$	51,197
Diagnostics	—			—			—			—
Corporate	—			—			—			—
	$	28,523		$	28,966		$	56,374		$	51,197
Revenue from transfer of intellectual property and other:
Pharmaceutical	$	19,107		$	29,723		$	34,855		$	45,328
Diagnostics	—			—			—			—
Corporate	—			—			—			—
	$	19,107		$	29,723		$	34,855		$	45,328
Operating loss:
Pharmaceutical	$	2,165		$	(8,009	)	$	(20,783	)	$	(34,154	)
Diagnostics	1,475			(4,944		)	(6,543		)	(8,044		)
Corporate	(8,748		)	(12,878		)	(20,393		)	(28,849		)
	$	(5,108	)	$	(25,831	)	$	(47,719	)	$	(71,047	)
Depreciation and amortization:
Pharmaceutical	$	6,752		$	6,694		$	13,492		$	13,469
Diagnostics	17,989			18,827			35,975			37,752
Corporate	21			30			51			60
	$	24,762		$	25,551		$	49,518		$	51,281
Loss from investment in investees:
Pharmaceutical	$	(6,942	)	$	(5,309	)	$	(9,114	)	$	(7,123	)
Diagnostics	(271		)	(319		)	(555		)	(635		)
Corporate	—			—			—			—
	$	(7,213	)	$	(5,628	)	$	(9,669	)	$	(7,758	)
Revenues:
United States	$	222,535		$	244,650		$	437,845		$	474,084
Ireland	20,778			22,525			38,060			39,734
Chile	11,937			11,899			23,670			22,020
Spain	4,592			5,118			10,125			9,623
Israel	2,526			7,654			6,141			11,872
Mexico	1,302			724			2,723			1,589
Other	15			31			34			59
	$	263,685		$	292,601		$	518,598		$	558,981

Table of Contents



(In thousands)	June 30, 2018		December 31, 2017
Assets:
Pharmaceutical	$	1,258,293	$	1,287,964
Diagnostics	1,217,456		1,241,388
Corporate	55,201		60,604
	$	2,530,950	$	2,589,956
Goodwill:
Pharmaceutical	$	261,447	$	264,313
Diagnostics	452,787		452,786
Corporate	—		—
	$	714,234	$	717,099

One customer represented more than 10% of our total consolidated revenue during the three months ended June 30, 2018 and two customers represented more than 10% of our total consolidated revenue during the six months ended June 30, 2018. One customer represented more than 10% of our total consolidated revenue during the three and six months ended June 30, 2017. As of June 30, 2018, one customer represented more than 10% of our accounts receivable balance. As of December 31, 2017, no customer represented more than 10% of our accounts receivable balance.

NOTE 15 SUBSEQUENT EVENTS

We have reviewed all subsequent events and transactions that occurred after the date of our June 30, 2018 Condensed Consolidated Balance Sheet date, through the time of filing this Quarterly Report on Form 10-Q.

Table of Contents

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

OVERVIEW

You should read this discussion together with the unaudited Condensed Consolidated Financial Statements, related Notes, and other financial information included elsewhere in this report and in our Annual Report on Form 10-K for the year ended December 31, 2017 (the “Form 10-K”). The following discussion contains assumptions, estimates and other forward-looking statements that involve a number of risks and uncertainties, including those discussed under “Risk Factors,” in Part II, Item 1A of our Form 10-K for the year ended December 31, 2017, and described from time to time in our other reports filed with the Securities and Exchange Commission. These risks could cause our actual results to differ materially from those anticipated in these forward-looking statements.

We are a diversified healthcare company that seeks to establish industry-leading positions in large and rapidly growing medical markets. Our diagnostics business includes BioReference Laboratories (“BioReference”), the nation’s third-largest clinical laboratory with a core genetic testing business and an almost 400-person sales and marketing team to drive growth and leverage new products, including the 4Kscore prostate cancer test and the Claros 1 in-office immunoassay platform (in development). Our pharmaceutical business features Rayaldee, an FDA-approved treatment for secondary hyperparathyroidism (“SHPT”) in adults with stage 3 or 4 chronic kidney disease (“CKD”) and vitamin D insufficiency (launched in November 2016), OPK88004, a selective androgen receptor modulator being developed for benign prostatic hyperplasia, OPK88003, a once or twice weekly oxyntomodulin for type 2 diabetes and obesity which is a clinically advanced drug candidate among the new class of GLP-1 glucagon receptor dual agonists (Phase 2b), and OPK88002, an NK-1 antagonist to treat pruritis (itching) in dialysis patients. Our pharmaceutical business also features hGH-CTP, a once-weekly human growth hormone injection (in Phase 3 and partnered with Pfizer).

We operate established pharmaceutical platforms in Spain, Ireland, Chile and Mexico, which are generating revenue and from which we expect to generate positive cash flow and facilitate future market entry for our products currently in development. We have a development and commercial supply pharmaceutical company, as well as a global supply chain operation and holding company in Ireland, which we expect will play an important role in the development, manufacturing, distribution and approval of a wide variety of drugs with an emphasis on high potency products. We also own a specialty active pharmaceutical ingredients (“APIs”) manufacturer in Israel, which we expect will facilitate the development of our pipeline of molecules and compounds for our proprietary molecular diagnostic and therapeutic products.

RECENT DEVELOPMENTS

In July 2018, we announced that our partner Vifor Fresenius Medical Care Renal Pharma (VFMCRP) has received approval from Health Canada to market Rayaldee in Canada for the treatment of SHPT in adults with CKD and vitamin D insufficiency.

In June 2018, we announced the completed enrollment of 110 subjects in a Phase 2b dose escalation trial of OPK88003 to treat type 2 diabetes and obesity. The primary efficacy endpoint is the reduction of HbA1c levels over a 30-week period; weight loss and improvement of blood lipid profiles are secondary endpoints.

In May 2018, we announced the appointment of Geoff Monk as General Manager with overall responsibility for BioReference Laboratories, Inc., the third-largest clinical laboratory in the United States.

Table of Contents

RESULTS OF OPERATIONS

FOR THE THREE MONTHS ENDED JUNE 30, 2018 AND 2017

Effective January 1, 2018, we adopted Accounting Standards Codification Topic 606, Revenue from Contracts with Customers, using the full retrospective transition method. Under this method, we have revised our Condensed Consolidated Financial Statements for the years ended December 31, 2017 and 2016, and applicable interim periods within those years, as if Topic 606 had been effective for those periods. For further discussion on the impact of adopting Topic 606, refer to Note 2 to the Condensed Consolidated Financial Statements.



Revenues	For the three months ended June 30,
(In thousands)	2018		2017		Change
Revenue from services	$	216,055	$	233,912	$	(17,857	)
Revenue from products	28,523		28,966		(443		)
Revenue from transfer of intellectual property and other	19,107		29,723		(10,616		)
Total revenues	$	263,685	$	292,601	$	(28,916	)

The decrease in Revenue from services is primarily attributable to decreased overall reimbursement rates for clinical testing, net of rate increases for our genomics testing. The net decrease in Revenue from services related to overall reimbursement, including the effect of the Protecting Access to Medicare Act of 2014 (“PAMA”), was $17.1 million for the three months ended June 30, 2018. Revenue from products was consistent with the comparative period in 2017. Revenue from transfer of intellectual property for the three months ended June 30, 2018 and 2017 principally reflects $16.3 million and $18.3 million, respectively, of revenue related to the Pfizer Transaction. Revenue from transfer of intellectual property for the three months ended June 30, 2017 also includes $10.0 million of revenue from a milestone payment from our licensee, TESARO. The composition of Revenue from services by payor for the three months ended June 30, 2018 and 2017 is as follow:



	Three months ended June 30,
(In thousands)	2018		2017
Healthcare insurers	$	92,033	$	104,366
Government payers	72,459		80,037
Client payers	45,828		42,961
Patients	5,735		6,548
Total	$	216,055	$	233,912

Cost of revenue. Cost of revenue for the three months ended June 30, 2018 decreased $7.3 million compared to 2017. Cost of service revenue decreased in the second quarter of 2018 compared to 2017 due to changes in the mix of clinical testing performed at BioReference. The increase in the cost of product revenue is attributable to changes in the product mix of items sold during the period. Cost of revenue for the three months ended June 30, 2018 and 2017 was as follows:



Cost of Revenue	For the three months ended June 30,
(In thousands)	2018		2017		Change
Cost of service revenue	$	134,408	$	143,901	$	(9,493	)
Cost of product revenue	15,652		13,505		2,147
Total cost of revenue	$	150,060	$	157,406	$	(7,346	)

Selling, general and administrative expenses. Selling, general and administrative expenses for the three months ended June 30, 2018 and 2017, were $87.7 million and $105.6 million, respectively. The decrease in selling, general and administrative expenses was primarily due to decreased expenses at BioReference due to planned cost reduction initiatives and to a decrease in corporate expenses. Selling, general and administrative expenses during the three months ended June 30, 2018 and 2017, include equity-based compensation expense of $3.6 million and $4.3 million, respectively.

Research and development expenses. Research and development expenses for the three months ended June 30, 2018 and 2017, were $29.2 million and $33.1 million, respectively. Research and development costs include external and internal expenses. External expenses include clinical and non-clinical activities performed by contract research organizations, lab

Table of Contents

services, purchases of drug and diagnostic product materials and manufacturing development costs. We track external research and development expenses by individual program for phase 3 clinical trials for drug approval and pre-market approvals (“PMAs”) for diagnostics tests, if any. Internal expenses include employee-related expenses including salaries, benefits and equity-based compensation expense. Other internal research and development expenses are incurred to support overall research and development activities and include expenses related to general overhead and facilities.

The following table summarizes the components of our research and development expenses:



Research and Development Expenses	For the three months ended June 30,
	2018		2017
External expenses:
Phase 3 clinical trials	$	4,828	$	3,464
Manufacturing expense for biological products	6,376		13,881
PMA studies	—		356
Earlier-stage programs	2,449		1,261
Research and development employee-related expenses	9,582		5,985
Other internal research and development expenses	5,976		8,181
Total research and development expenses	$	29,211	$	33,128

The decrease in research and development expenses is primarily due to a decrease in research and development expenses related to a Factor VIIa drug for hemophilia, and to a decrease in manufacturing related expenses for hGH-CTP. Research and development expenses for the three months ended June 30, 2018 and 2017 include equity-based compensation expense of $1.2 million and $1.4 million, respectively. We expect our research and development expenses to increase as we continue to expand our research and development of potential future products.

Contingent consideration. Contingent consideration for the three months ended June 30, 2018 and 2017, were $15.4 million of income and $4.4 million of expense, respectively. The change in contingent consideration income (expense) was primarily attributable to changes in assumptions regarding the timing of achievement of future milestones for OPKO Renal. The contingent consideration liabilities at June 30, 2018 relate to potential amounts payable to former stockholders of CURNA, OPKO Diagnostics and OPKO Renal pursuant to our acquisition agreements in January 2011, October 2011 and March 2013, respectively.

Amortization of intangible assets. Amortization of intangible assets was $17.2 million and $18.0 million, respectively, for the three months ended June 30, 2018 and 2017. Amortization expense reflects the amortization of acquired intangible assets with defined useful lives. Our indefinite lived IPR&D assets will not be amortized until the underlying development programs are completed. Upon obtaining regulatory approval by the U.S. FDA, the IPR&D assets will be accounted for as a finite-lived intangible asset and amortized on a straight-line basis over its estimated useful life.

Interest income. Interest income for the three months ended June 30, 2018 and 2017 was not significant as our cash investment strategy emphasizes the security of the principal invested and fulfillment of liquidity needs.

Interest expense. Interest expense for the three months ended June 30, 2018 and 2017 was $2.7 million and $1.5 million, respectively. Interest expense is principally related to interest incurred on the 2033 Senior Notes, interest incurred on BioReference’s outstanding debt under its credit facility and interest incurred on the 2023 Convertible Notes issued in February 2018. The increase in interest expense for the three months ended June 30, 2018 is primarily due to interest incurred on the the 2023 Convertible Notes and to higher outstanding debt under BioReference’s credit facility in 2018 compared to 2017.

Fair value changes of derivative instruments, net. Fair value changes of derivative instruments, net for the three months ended June 30, 2018 and 2017, was $2.2 million and $5.5 million of income, respectively. Derivative income for the three months ended June 30, 2018 principally related to the change in fair value of warrants to purchase additional shares of Neovasc and Xenetic. Derivative income for the three months ended June 30, 2017 principally related to the change in the fair value of the embedded derivatives in the 2033 Senior Notes.

Other income (expense), net. Other income (expense), net for the three months ended June 30, 2018 and 2017, were $8.6 million of income and $0.5 million of expense, respectively. Other income for the three months ended June 30, 2018 primarily consists of net unrealized gains recognized during the period on equity securities. Other expense for the three months ended June 30, 2017 primarily consisted of a $0.6 million other-than-temporary impairment charge to write our investment in Xenetic down to its fair value.

Table of Contents

Income tax benefit (provision). Our income tax benefit (provision) for the three months ended June 30, 2018 and 2017 was $(2.0) million and $11.0 million, respectively, and reflects quarterly results using our expected effective tax rate. For the three months ended June 30, 2018, the tax rate differed from the U.S. federal statutory rate of 21% primarily due to the valuation allowance against certain U.S. and non-U.S. deferred tax assets, the relative mix in earnings and losses in the U.S. versus foreign tax jurisdictions, and the impact of certain discrete tax events and operating results in tax jurisdictions which do not result in a tax benefit.

Loss from investments in investees. We have made investments in other early stage companies that we perceive to have valuable proprietary technology and significant potential to create value for us as a shareholder or member. We account for these investments under the equity method of accounting, resulting in the recording of our proportionate share of their losses until our share of their loss exceeds our investment. Until the investees’ technologies are commercialized, if ever, we anticipate they will report a net loss. Loss from investments in investees was $7.2 million and $5.6 million for the three months ended June 30, 2018 and 2017, respectively.

FOR THE SIX MONTHS ENDED JUNE 30, 2018 AND 2017



Revenues	For the six months ended June 30,
(In thousands)	2018		2017		Change
Revenue from services	$	427,369	$	462,456	$	(35,087	)
Revenue from products	56,374		51,197		5,177
Revenue from transfer of intellectual property and other	34,855		45,328		(10,473		)
Total revenues	$	518,598	$	558,981	$	(40,383	)

The decrease in Revenue from services is primarily attributable to decreased overall reimbursement rates and volume for clinical testing, which was partially offset by increased reimbursement and volume for our genomics testing. The net decrease in Revenue from services related to reimbursement, including the effect of PAMA, and volume was $32.9 million and $1.3 million, respectively, for the six months ended June 30, 2018. The increase in Revenue from products is primarily attributable to $8.5 million of revenue from sales of Rayaldee, which was partially offset by a decrease in revenue at FineTech. Revenue from transfer of intellectual property for the six months ended June 30, 2018 and 2017 principally reflects $31.0 million and $32.4 million, respectively, of revenue related to the Pfizer Transaction. Revenue from transfer of intellectual property for the six months ended June 30, 2017 also includes $10.0 million of revenue from a milestone payment from our licensee, TESARO. The composition of Revenue from services by payor for the six months ended June 30, 2018 and 2017 is as follow:



	Six months ended June 30,
(In thousands)	2018		2017
Healthcare insurers	$	192,986	$	217,062
Government payers	139,595		157,090
Client payers	83,357		76,900
Patients	11,431		11,404
Total	$	427,369	$	462,456

Cost of revenue. Cost of revenue for the six months ended June 30, 2018 decreased $8.1 million compared to 2017. Cost of service revenue decreased in the first half of 2018 compared to 2017 due to a decrease in volume at BioReference. The increase in the cost of product revenue is attributable to changes in the product mix of items sold during the period. Cost of revenue for the six months ended June 30, 2018 and 2017 were as follows:



Cost of Revenue	For the six months ended June 30,
(In thousands)	2018		2017		Change
Cost of service revenue	$	273,849	$	283,867	$	(10,018	)
Cost of product revenue	30,300		28,334		1,966
Total cost of revenue	$	304,149	$	312,201	$	(8,052	)

Table of Contents

Selling, general and administrative expenses. Selling, general and administrative expenses for the six months ended June 30, 2018 and 2017, were $179.2 million and $215.5 million, respectively. The decrease in selling, general and administrative expenses was primarily due to decreased expenses at BioReference due to planned cost reduction initiatives and to a decrease in corporate expenses. Selling, general and administrative expenses during the six months ended June 30, 2018 and 2017, include equity-based compensation expense of $7.8 million and $12.1 million, respectively.

Research and development expenses. Research and development expenses for the six months ended June 30, 2018 and 2017, were $62.1 million and $59.7 million, respectively. Research and development costs include external and internal expenses. External expenses include clinical and non-clinical activities performed by contract research organizations, lab services, purchases of drug and diagnostic product materials and manufacturing development costs. We track external research and development expenses by individual program for phase 3 clinical trials for drug approval and PMAs for diagnostics tests, if any. Internal expenses include employee-related expenses including salaries, benefits and equity-based compensation expense. Other internal research and development expenses are incurred to support overall research and development activities and include expenses related to general overhead and facilities.

The following table summarizes the components of our research and development expenses:



Research and Development Expenses	For the six months ended June 30,
	2018		2017
External expenses:
Phase 3 clinical trials	$	8,606	$	8,079
Manufacturing expense for biological products	17,670		20,275
PMA studies	59		445
Earlier-stage programs	5,615		3,255
Research and development employee-related expenses	18,233		12,738
Other internal research and development expenses	11,914		14,893
Total research and development expenses	$	62,097	$	59,685

The increase in research and development expenses is primarily due to an increase in research and development expenses related to a once or twice weekly oxyntomodulin for type 2 diabetes and to a selective androgen receptor modulator being developed for benign prostatic hyperplasia. Research and development expenses for the six months ended June 30, 2018 and 2017 include equity-based compensation expense of $2.3 million and $2.7 million, respectively. We expect our research and development expenses to increase as we continue to expand our research and development of potential future products.

Contingent consideration. Contingent consideration for the six months ended June 30, 2018 and 2017, were $13.6 million of income and $6.7 million of expense, respectively. The change in contingent consideration income (expense) was primarily attributable to changes in assumptions regarding the timing of achievement of future milestones for OPKO Renal.

Amortization of intangible assets. Amortization of intangible assets was $34.5 million and $35.9 million, respectively, for the six months ended June 30, 2018 and 2017. Amortization expense reflects the amortization of acquired intangible assets with defined useful lives. Our indefinite lived IPR&D assets will not be amortized until the underlying development programs are completed. Upon obtaining regulatory approval by the U.S. FDA, the IPR&D assets will be accounted for as a finite-lived intangible asset and amortized on a straight-line basis over its estimated useful life.

Interest income. Interest income for the six months ended June 30, 2018 and 2017 was not significant as our cash investment strategy emphasizes the security of the principal invested and fulfillment of liquidity needs.

Interest expense. Interest expense for the six months ended June 30, 2018 and 2017 was $5.0 million and $2.9 million, respectively. Interest expense is principally related to interest incurred on the 2033 Senior Notes, interest incurred on BioReference’s outstanding debt under its credit facility and interest incurred on the 2023 Convertible Notes issued in February 2018. The increase in interest expense for the six months ended June 30, 2018 is primarily due to interest incurred on the 2023 Convertible Notes and to higher outstanding debt under BioReference’s credit facility in 2018 compared to 2017.

Fair value changes of derivative instruments, net. Fair value changes of derivative instruments, net for the six months ended June 30, 2018 and 2017, was $3.6 million and $9.5 million of income, respectively. Derivative income for the six months ended June 30, 2018 principally related to the change in fair value of warrants to purchase additional shares of Neovasc. and Xenetic. Derivative income for the six months ended June 30, 2017 principally related to the change in the fair value of the embedded derivatives in the 2033 Senior Notes.

Table of Contents

Other income (expense), net. Other income (expense), net for the six months ended June 30, 2018 and 2017, were $10.5 million and $2.5 million of income, respectively. Other income for the six months ended June 30, 2018 primarily consists of net unrealized gains recognized during the period on equity securities. Other income for the six months ended June 30, 2017 primarily consists of a $3.0 million gain on the sale of non-strategic assets at a wholly-owned BioReference subsidiary.

Income tax benefit (provision). Our income tax benefit (provision) for the six months ended June 30, 2018 and 2017 was $(1.1) million and $17.9 million, respectively, and reflects quarterly results using our expected effective tax rate. For the six months ended June 30, 2018, the tax rate differed from the U.S. federal statutory rate of 21% primarily due to the valuation allowance against certain U.S. and non-U.S. deferred tax assets, the relative mix in earnings and losses in the U.S. versus foreign tax jurisdictions, and the impact of certain discrete tax events and operating results in tax jurisdictions which do not result in a tax benefit.

Loss from investments in investees. We have made investments in other early stage companies that we perceive to have valuable proprietary technology and significant potential to create value for us as a shareholder or member. We account for these investments under the equity method of accounting, resulting in the recording of our proportionate share of their losses until our share of their loss exceeds our investment. Until the investees’ technologies are commercialized, if ever, we anticipate they will report a net loss. Loss from investments in investees was $9.7 million and $7.8 million for the six months ended June 30, 2018 and 2017, respectively.

Table of Contents

LIQUIDITY AND CAPITAL RESOURCES

At June 30, 2018, we had cash and cash equivalents of approximately $80.4 million. Cash used in operations of $52.6 million during 2018 principally reflects expenses related to general and administrative activities of our corporate operations, research and development activities and commercialization activities related to Rayaldee. Cash used in investing activities primarily reflects capital expenditures of $12.8 million. Cash provided by financing activities primarily reflects the issuance of $55.0 million of 2023 Convertible Notes in February 2018. We have not generated sustained positive cash flow sufficient to offset our operating and other expenses and our primary source of cash has been from the public and private placement of stock, the issuance of the 2033 Senior Notes and 2023 Convertible Notes and credit facilities available to us.

In February 2018, we issued the 2023 Convertible Notes in the aggregate principal amount of $55.0 million. The 2023 Convertible Notes mature 5 years from the date of issuance. Each holder of a 2023 Convertible Note has the option, from time to time, to convert all or any portion of the outstanding principal balance of such 2023 Convertible Note, together with accrued and unpaid interest thereon, into shares of our Common Stock, par value $0.01 per share, at a conversion price of $5.00 per share of Common Stock (the “Shares”). We may redeem all or any part of the then issued and outstanding 2023 Convertible Notes, together with accrued and unpaid interest thereon, pro ratably among the holders, upon no fewer than 30 days, and no more than 60 days, notice to the holders. The 2023 Convertible Notes contain customary events of default and representations and warranties of OPKO. We are using the proceeds of the 2023 Convertible Notes for general corporate purposes.

The issuance of the 2023 Convertible Notes and the issuance of the Shares, if any, upon conversion thereof was not, and will not be, respectively, registered under the Securities Act, pursuant to the exemption provided by Section 4(a)(2) thereof, and we have not agreed to register the Shares if or when such Shares are issued. Purchasers of the 2023 Convertible Notes include an affiliate of Dr. Phillip Frost, M.D., our Chairman and Chief Executive Officer, and Dr. Jane H. Hsiao, Ph.D., MBA, our Vice-Chairman and Chief Technical Officer.

On October 12, 2017, EirGen, our wholly-owned subsidiary, and Japan Tobacco Inc. (“JT”) entered into a Development and License Agreement (the “JT Agreement”) granting JT the exclusive rights for the development and commercialization of Rayaldee in Japan (the “JT Territory”). The license grant to JT covers the therapeutic and preventative use of Rayaldee for (i) SHPT in non-dialysis and dialysis patients with CKD, (ii) rickets, and (iii) osteomalacia, as well as such additional indications as may be added to the scope of the license subject to the terms of the JT Agreement. In connection with the transaction, OPKO received an initial upfront payment of $6 million, and OPKO will receive another $6 million upon the initiation of OPKO’s planned phase 2 study for Rayaldee in dialysis patients in the U.S. OPKO is also eligible to receive up to an additional aggregate amount of $31 million upon the achievement of certain regulatory and development milestones by JT for Rayaldee in the JT Territory, and $75 million upon the achievement of certain sales based milestones by JT in the JT Territory. OPKO will also receive tiered, double digit royalty payments at rates ranging from low double digits to mid-teens on sales of Rayaldee within the JT Territory. JT will, at its sole cost and expense, be responsible for performing all development activities necessary to obtain all regulatory approvals for Rayaldee in Japan and for all commercial activities pertaining to Rayaldee in Japan, except for certain preclinical expenses for which OPKO has agreed to reimburse JT up to a capped amount.

Pursuant to the Commitment Letter, we committed to provide, or to arrange from a third-party lender, a line of credit for VACG in the amount of $50.0 million (the “Facility”). Funds drawn under the Facility would be contributed by VACG to VACO in order to satisfy the financial stability requirement of VACO in connection with its submission of the RFP. VACG would not be permitted to draw down on the Facility unless and until the VHA awards a contract to VACO. The Facility would have a maturity of 5 years. Interest on the Facility would be payable at a rate equal to 6.5% per annum, payable quarterly in arrears. The Facility is subject to the negotiation of definitive documentation conditions customary for transactions of such type and otherwise acceptable to VACG and the lender under the Facility.

Table of Contents

In November 2016, we launched commercial sales for Rayaldee in the U.S. market. The FDA approved Rayaldee extended release capsules in June 2016 for the treatment of SHPT in adults with stage 3 or 4 CKD and serum total 25-hydroxyvitamin D levels less than 30 ng/mL. We have a highly specialized sales and marketing team dedicated to the launch and commercialization of Rayaldee, and we increased the sales and marketing team in the second half of 2017 as market access improved and prescription trends increased.

In May 2016, EirGen, our wholly-owned subsidiary, partnered with VFMCRP through a Development and License Agreement for the development and commercialization of Rayaldee in Europe, Canada, Mexico, Australia, South Korea and certain other international markets. The license to VFMCRP potentially covers all therapeutic and prophylactic uses of the product in human patients, provided that initially the license is for the use of the product for the treatment or prevention of SHPT related to patients with stage 3 or 4 chronic kidney disease and vitamin D insufficiency/deficiency (“VFMCRP Initial Indication”). We received a non-refundable and non-creditable upfront payment of $50 million and are eligible to receive up to an additional $232 million upon the achievement of certain regulatory and sales-based milestones. In addition, we are eligible to receive tiered royalties on sales of the product at percentage rates that range from the mid-teens to the mid-twenties or a minimum royalty, whichever is greater, upon commencement of sales of the product.

As part of the arrangement, the companies will share responsibility for the conduct of trials specified within an agreed-upon development plan, with each company leading certain activities within the plan. For the initial development plan, the companies have agreed to certain cost sharing arrangements. VFMCRP will be responsible for all other development costs that VFMCRP considers necessary to develop the product for the VFMCRP Initial Indication in the VFMCRP Territory except as otherwise provided in the VFMCRP Agreement. EirGen also granted to VFMCRP an option to acquire an exclusive license to use, import, offer for sale, sell, distribute and commercialize the product in the United States for treatment of SHPT in dialysis patients with stage 5 CKD and vitamin D insufficiency (the “Dialysis Indication”). Upon exercise of the Option, VFMCRP will reimburse EirGen for all of the development costs incurred by EirGen with respect to the product for the Dialysis Indication in the United States. VFMCRP would also pay EirGen up to an additional aggregate amount of $555 million upon the achievement of certain milestones and would be obligated to pay royalties on sales of the product at percentage rates that range from the mid-teens to the mid-twenties or a minimum royalty, whichever is greater, upon commencement of sales of the product.

In January 2015, we partnered with Pfizer through a worldwide agreement for the development and commercialization of our long-acting hGH-CTP for the treatment of GHD in adults and children, as well as for the treatment of growth failure in children born SGA. Under the terms of the agreements with Pfizer, we received non-refundable and non-creditable upfront payments of $295 million in 2015 and are eligible to receive up to an additional $275 million upon the achievement of certain regulatory milestones. Pfizer received the exclusive license to commercialize hGH-CTP worldwide. In addition, we are eligible to receive initial tiered royalty payments associated with the commercialization of hGH-CTP for Adult GHD with percentage rates ranging from the high teens to mid-twenties. Upon the launch of hGH-CTP for Pediatric GHD in certain major markets, the royalties will transition to regional, tiered gross profit sharing for both hGH-CTP and Pfizer’s Genotropin®.

We will lead the clinical activities and will be responsible for funding the development programs for the key indications, which includes Adult and Pediatric GHD and Pediatric SGA. Pfizer will be responsible for all development costs for additional indications as well as all post-marketing studies. In addition, Pfizer will fund the commercialization activities for all indications and lead the manufacturing activities covered by the global development plan. In December 2016, we announced preliminary topline data from our Phase 3, double blind, placebo controlled study of hGH-CTP in adults with GHD. Although there was no statistically significant difference between hGH-CTP and placebo on the primary endpoint of change in trunk fat mass from baseline to 26 weeks, after unblinding the study, we identified an exceptional value of trunk fat mass reduction in the placebo group that may have affected the primary outcome.

We have completed post-hoc sensitivity analyses to evaluate the influence of outliers on the primary endpoint results using multiple statistical approaches. Analyses that excluded outliers showed a statistically significant difference between hGH-CTP and placebo on the change in trunk fat mass. Additional analyses that did not exclude outliers showed mixed results. Following completion of the analyses, OPKO and Pfizer agreed that OPKO may proceed to discuss a possible BLA submission with the FDA. We believe there is a path for submission in which the FDA would assess the totality of the data, including all relevant efficacy and safety data in adult and pediatric patients. We will continue to assess the regulatory strategy for the adult indication going forward, including the timing of a possible submission.

We are constructing a research, development and manufacturing center in Waterford, Ireland, for which we will incur between $40 million and $45 million for the construction and validation of the facility. Construction of the facility began in the fourth quarter of 2016 with expected completion in 2019. Currently, we plan to fund the project from cash on hand or from third party funding sources that may be available to us. Through June 30, 2018, the cumulative expenditures we incurred to date on the construction of the facility was approximately $37.0 million.

Table of Contents

In January 2013, we issued $175.0 million of the 2033 Senior Notes. The 2033 Senior Notes were sold in a private placement in reliance on exemptions from registration under the Securities Act. At June 30, 2018, $31.9 million principal amount of 2033 Senior Notes was outstanding. Holders of the 2033 Senior Notes may require us to repurchase the 2033 Senior Notes for 100% of their principal amount, plus accrued and unpaid interest, on February 1, 2019, February 1, 2023 and February 1, 2028, or following the occurrence of a fundamental change as defined in the indenture governing the 2033 Senior Notes.

In connection with our acquisitions of CURNA, OPKO Diagnostics and OPKO Renal, we agreed to pay future consideration to the sellers upon the achievement of certain events, including up to an additional $19.1 million in shares of our Common Stock to the former stockholders of OPKO Diagnostics upon and subject to the achievement of certain milestones; and up to an additional $125.0 million in either shares of our Common Stock or cash, at our option subject to the achievement of certain milestones, to the former shareholders of OPKO Renal.

As of June 30, 2018, the total availability under our Credit Agreement with CB and our lines of credit with financial institutions in Chile and Spain was $127.4 million, of which $109.5 million was used and outstanding as of June 30, 2018. The weighted average interest rate on these lines of credit is approximately 4.7%. These lines of credit are short-term and are used primarily as a source of working capital. The highest balance at any time during the six months ended June 30, 2018, was $114.9 million. We intend to continue to enter into these lines of credit as needed. There is no assurance that these lines of credit or other funding sources will be available to us on acceptable terms, or at all, in the future.

We believe that the cash and cash equivalents on hand at June 30, 2018, the amounts available to be borrowed under our lines of credit and the proceeds from the 2023 Convertible Promissory Notes which we issued in the first quarter of 2018 are sufficient to meet our anticipated cash requirements for operations and debt service beyond the next 12 months. We based this estimate on assumptions that may prove to be wrong or are subject to change, and we may be required to use our available cash resources sooner than we currently expect. If we acquire additional assets or companies, accelerate our product development programs or initiate additional clinical trials, we will need additional funds. Our future cash requirements will depend on a number of factors, including our relationship with Pfizer, the commercial success of Rayaldee, BioReference’s financial performance, possible acquisitions, the continued progress of research and development of our product candidates, the timing and outcome of clinical trials and regulatory approvals, the costs involved in preparing, filing, prosecuting, maintaining, defending, and enforcing patent claims and other intellectual property rights, the status of competitive products, the availability of financing, our success in developing markets for our product candidates and results of government investigations, payor claims, and legal proceedings that may arise. If we are not able to secure additional funding when needed, we may have to delay, reduce the scope of, or eliminate one or more of our clinical trials or research and development programs or possible acquisitions.

Table of Contents

The following table provides information as of June 30, 2018, with respect to the amounts and timing of our known contractual obligation payments due by period.



Contractual obligations (In thousands)	Remaining six months ending December 31, 2018		2019		2020		2021		2022		Thereafter		Total
Open purchase orders	$	82,466	$	1,933	$	51	$	—	$	—	$	—	$	84,450
Operating leases	9,684		16,262		10,361		6,928		3,304		3,637		50,176
Capital leases	1,526		2,908		2,478		1,771		675		445		9,803
2033 Senior Notes and 2023 Convertible Notes	—		31,850		—		—		—		55,000		86,850
Deferred payments	5,000		5,000		—		—		—		—		10,000
Mortgages and other debts payable	2,198		1,129		498		462		359		4,644		9,290
Lines of credit	3,855		—		105,539		—		—		—		109,394
Severance payments	3,568		—		—		—		—		—		3,568
Interest commitments	514		215		41		30		16		13,713		14,529
Total	$	108,811	$	59,297	$	118,968	$	9,191	$	4,354	$	77,439	$	378,060

The preceding table does not include information where the amounts of the obligations are not currently determinable, including the following:

- Contractual obligations in connection with clinical trials, which span over two years, and that depend on patient enrollment. The total amount of expenditures is dependent on the actual number of patients enrolled and as such, the contracts do not specify the maximum amount we may owe.

- Product license agreements effective during the lesser of 15 years or patent expiration whereby payments and amounts are determined by applying a royalty rate on uncapped future sales.

- Contingent consideration that includes payments upon achievement of certain milestones including meeting development milestones such as the completion of successful clinical trials, NDA approvals by the FDA and revenue milestones upon the achievement of certain revenue targets all of which are anticipated to be paid within the next seven years and are payable in either shares of our Common Stock or cash, at our option, and that may aggregate up to $159.1 million.

Table of Contents

CRITICAL ACCOUNTING POLICIES AND ESTIMATES

Accounting estimates. The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ significantly from these estimates.

Goodwill and intangible assets. Goodwill and other intangible assets, including IPR&D, acquired in business combinations, licensing and other transactions at both June 30, 2018 and December 31, 2017 was $2.0 billion, representing approximately 79% of total assets at June 30, 2018.

Assets acquired and liabilities assumed in business combinations, licensing and other transactions are generally recognized at the date of acquisition at their respective fair values. Any excess of the purchase price over the estimated fair values of the net assets acquired is recognized as goodwill. We determined the fair value of intangible assets, including IPR&D, using the “income method.” This method starts with a forecast of net cash flows, risk adjusted for estimated probabilities of technical and regulatory success (for IPR&D) and adjusted to present value using an appropriate discount rate that reflects the risk associated with the cash flow streams. All assets are valued from a market participant view which might be different than our specific views. The valuation process is very complex and requires significant input and judgment using internal and external sources. Although a valuation is required to be finalized within a one-year period, it must consider all and only those facts and evidence which existed at the acquisition date. The most complex and judgmental matters applicable to the valuation process are summarized below:

•

Unit of account – Most intangible assets are valued as single global assets rather than multiple assets for each jurisdiction or indication after considering the development stage, expected levels of incremental costs to obtain additional approvals, risks associated with further development, amount and timing of benefits expected to be derived in the future, expected patent lives in various jurisdictions and the intention to promote the asset as a global brand.

•

Estimated useful life – The asset life expected to contribute meaningful cash flows is determined after considering all pertinent matters associated with the asset, including expected regulatory approval dates (if unapproved), exclusivity periods and other legal, regulatory or contractual provisions as well as the effects of any obsolescence, demand, competition, and other economic factors, including barriers to entry.

•

Probability of Technical and Regulatory Success (“PTRS”) Rate – PTRS rates are determined based upon industry averages considering the respective program’s development stage and disease indication and adjusted for specific information or data known at the acquisition date. Subsequent clinical results or other internal or external data obtained could alter the PTRS rate and materially impact the estimated fair value of the intangible asset in subsequent periods leading to impairment charges.

•

Projections – Future revenues are estimated after considering many factors such as initial market opportunity, pricing, sales trajectories to peak sales levels, competitive environment and product evolution. Future costs and expenses are estimated after considering historical market trends, market participant synergies and the timing and level of additional development costs to obtain the initial or additional regulatory approvals, maintain or further enhance the product. We generally assume initial positive cash flows to commence shortly after the receipt of expected regulatory approvals which typically may not occur for a number of years. Actual cash flows attributed to the project are likely to be different than those assumed since projections are subjected to multiple factors including trial results and regulatory matters which could materially change the ultimate commercial success of the asset as well as significantly alter the costs to develop the respective asset into commercially viable products.


•	Tax rates – The expected future income is tax effected using a market participant tax rate. In determining the tax rate, we consider the jurisdiction in which the intellectual property is held and location of research and manufacturing infrastructure. We also consider that any repatriation of earnings would likely have U.S. tax consequences.


•	Discount rate – Discount rates are selected after considering the risks inherent in the future cash flows; the assessment of the asset’s life cycle and the competitive trends impacting the asset, including consideration of any technical, legal, regulatory, or economic barriers to entry, as well as expected changes in standards of practice for indications addressed by the asset.

Goodwill was $714.2 million and $717.1 million, respectively, at June 30, 2018 and December 31, 2017. Goodwill is tested at least annually for impairment or when events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable, by assessing qualitative factors or performing a quantitative analysis in determining whether it is more likely than not that its fair value exceeds the carrying value. Examples of qualitative factors include our share price, our

Table of Contents

financial performance compared to budgets, long-term financial plans, macroeconomic, industry and market conditions as well as the substantial excess of fair value over the carrying value of net assets from the annual impairment test previously performed.

The estimated fair value of a reporting unit is highly sensitive to changes in projections and assumptions; therefore, in some instances, changes in these assumptions could potentially lead to impairment. We perform sensitivity analyses around our assumptions in order to assess the reasonableness of the assumptions and the results of our testing. Ultimately, future potential changes in these assumptions may impact the estimated fair value of a reporting unit and cause the fair value of the reporting unit to be below its carrying value. We believe that our estimates are consistent with assumptions that marketplace participants would use in their estimates of fair value. However, if actual results are not consistent with our estimates and assumptions, we may be exposed to an impairment charge that could be material.

Intangible assets, net were $1.3 billion, including IPR&D of $645.7 million and $647.3 million, respectively, at June 30, 2018 and December 31, 2017. Intangible assets are tested for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable, although IPR&D is required to be tested at least annually until the project is completed or abandoned. Upon obtaining regulatory approval, the IPR&D asset is then accounted for as a finite-lived intangible asset and amortized on a straight-line basis over its estimated useful life. If the project is abandoned, the IPR&D asset is charged to expense.

IPR&D is tested for impairment by assessing qualitative factors or performing a quantitative analysis in determining whether it is more likely than not that its fair value exceeds the carrying amount. If the carrying amount of the IPR&D exceeds its fair value, an impairment loss shall be recognized in an amount equal to that excess. Intangible assets with defined lives are tested for impairment by a comparison of the carrying amount of the asset to its estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated undiscounted future cash flows, then an impairment charge is recognized for the amount by which the carrying amount of the asset exceeds the fair value of the asset.

Intangible assets are highly vulnerable to impairment charges, particularly newly acquired assets for recently launched products and IPR&D. These assets are initially measured at fair value and therefore any reduction in expectations used in the valuations could potentially lead to impairment. Some of the more common potential risks leading to impairment include competition, earlier than expected loss of exclusivity, pricing pressures, adverse regulatory changes or clinical trial results, delay or failure to obtain regulatory approval and additional development costs, inability to achieve expected synergies, higher operating costs, changes in tax laws and other macro-economic changes.

Considering the high risk nature of research and development and the industry’s success rate of bringing developmental compounds to market, IPR&D impairment charges are likely to occur in future periods. IPR&D is closely monitored and assessed each period for impairment indicators.

We amortize intangible assets with definite lives on a straight-line basis over their estimated useful lives, ranging from 3 to 20 years. We use the straight-line method of amortization as there is no reliably determinable pattern in which the economic benefits of our intangible assets are consumed or otherwise used up. Amortization expense was $34.5 million and $35.9 million for the six months ended June 30, 2018 and 2017, respectively.

Revenue recognition. Effective January 1, 2018, we adopted Accounting Standards Codification Topic 606, Revenue from Contracts with Customers. We generate revenues from services, products and intellectual property as follows:

Revenue from services. Revenue for laboratory services is recognized at the time test results are reported, which approximates when services are provided and the performance obligations are satisfied. Services are provided to patients covered by various third-party payor programs including various managed care organizations, as well as the Medicare and Medicaid programs. Billings for services are included in revenue net of allowances for contractual discounts, allowances for differences between the amounts billed and estimated program payment amounts, and implicit price concessions provided to uninsured patients which are all elements of variable consideration.

The following are descriptions of our payors for laboratory services:

Table of Contents

The complexities and ambiguities of billing, reimbursement regulations and claims processing, as well as issues unique to Medicare and Medicaid programs, require us to estimate the potential for retroactive adjustments as an element of variable consideration in the recognition of revenue in the period the related services are rendered. Actual amounts are adjusted in the period those adjustments become known.

The composition of Revenue from services by payor for the three and six months ended June 30, 2018 and 2017 is as follow:



	Three months ended June 30,				Six months ended June 30,
(In thousands)	2018		2017		2018		2017
Healthcare insurers	$	92,033	$	104,366	$	192,986	$	217,062
Government payers	72,459		80,037		139,595		157,090
Client payers	45,828		42,961		83,357		76,900
Patients	5,735		6,548		11,431		11,404
Total	$	216,055	$	233,912	$	427,369	$	462,456

Table of Contents

Revenue from products. We recognize revenue from product sales when a customer obtains control of promised goods or services. The amount of revenue that is recorded reflects the consideration that we expect to receive in exchange for those goods or services. Our estimates for sales returns and allowances are based upon the historical patterns of product returns and allowances taken, matched against the sales from which they originated, and our evaluation of specific factors that may increase or decrease the risk of product returns. Product revenues are recorded net of estimated rebates, chargebacks, discounts, co-pay assistance and other deductions (collectively, “Sales Deductions”) as well as estimated product returns which are all elements of variable consideration. Allowances are recorded as a reduction of revenue at the time product revenues are recognized. The actual amounts of consideration ultimately received may differ from our estimates. If actual results in the future vary from our estimates, we will adjust these estimates, which would affect Revenue from products in the period such variances become known.

The following table presents an analysis of product sales allowances and accruals as contract liabilities for the six months ended June 30, 2018:



(In thousands)	Chargebacks, discounts, rebates and fees			Governmental			Returns			Total
Balance at December 31, 2017	$	233		$	348		$	437		$	1,018
Provision related to current period sales	2,188			2,936			—			5,124
Credits or payments made	(1,697		)	(2,557		)	(311		)	(4,565		)
Balance at June 30, 2018	$	724		$	727		$	126		$	1,577

Total gross Rayaldee sales										$	13,582
Provision for Rayaldee sales allowances and accruals as a percentage of gross Rayaldee sales										38		%

Taxes collected from customers related to revenues from services and revenues from products are excluded from revenues.

Revenue from intellectual property. We recognize revenues from the transfer of intellectual property generated through license, development, collaboration and/or commercialization agreements. The terms of these agreements typically include payment to us for one or more of the following: non-refundable, up-front license fees; development and commercialization milestone payments; funding of research and/or development activities; and royalties on sales of licensed products. Revenue is recognized upon satisfaction of a performance obligation by transferring control of a good or service to the customer.

Table of Contents

license fees based on the relative value prescribed to the license compared to the total value of the arrangement. The revenue is recognized when the license is transferred to the customer and the customer is able to use and benefit from the license. For licenses that are not distinct from other obligations identified in the arrangement, we utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time. If the combined performance obligation is satisfied over time, we apply an appropriate method of measuring progress for purposes of recognizing revenue from nonrefundable, upfront license fees. We evaluate the measure of progress each reporting period and, if necessary, adjust the measure of performance and related revenue recognition.

Development and Regulatory Milestone Payments: Depending on facts and circumstances, we may conclude that it is appropriate to include the milestone in the estimated transaction price or that it is appropriate to fully constrain the milestone. A milestone payment is included in the transaction price in the reporting period that we conclude that it is probable that recording revenue in the period will not result in a significant reversal in amounts recognized in future periods. We may record revenues from certain milestones in a reporting period before the milestone is achieved if we conclude that achievement of the milestone is probable and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods. We record a corresponding contract asset when this conclusion is reached. Milestone payments that have been fully constrained are not included in the transaction price to date. These milestones remain fully constrained until we conclude that achievement of the milestone is probable and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods. We re-evaluate the probability of achievement of such development milestones and any related constraint each reporting period. We adjust our estimate of the overall transaction price, including the amount of revenue recorded, if necessary.

For the three and six months ended June 30, 2018, revenue from transfer of intellectual property principally reflects $16.3 million and $31.0 million of revenue, respectively related to the Pfizer Transaction. For the three and six months ended June 30, 2017, revenue from transfer of intellectual property principally reflects and $18.3 million and $32.4 million of revenue, respectively related to the Pfizer Transaction. Refer to Note 13. Total contract liabilities included in Accrued expenses and Other long-term liabilities was $109.6 million and $140.4 million at June 30, 2018 and December 31, 2017, respectively. The contract liability balance at June 30, 2018 relates primarily to the Pfizer Transaction.

Table of Contents

On December 22, 2017, the 2017 Tax Cuts and Jobs Act (the “Tax Act”) was enacted into law and the new legislation contains several key tax provisions, including a reduction of the corporate income tax rate from 35% to 21% effective January 1, 2018, and a one-time mandatory transition tax on accumulated foreign earnings, among others. We are required to recognize the effect of the tax law changes in the period of enactment, such as remeasuring our U.S. deferred tax assets and liabilities, as well as reassessing the net realizability of our deferred tax assets and liabilities. In December 2017, the SEC staff issued Staff Accounting Bulletin No. 118, Income Tax Accounting Implications of the Tax Act (“SAB 118”), which allows us to record provisional amounts during a measurement period not to extend beyond one year of the enactment date. Through June 30, 2018, we did not have any significant adjustments to our provisional amounts. As we continue to perform our analysis of the Tax Act, and interpret any additional accounting guidance issued by the FASB, the U.S. Department of the Treasury and the IRS, we may make adjustments to these provisional amounts.

Equity-based compensation. We measure the cost of employee services received in exchange for an award of equity instruments based on the grant-date fair value of the award. That cost is recognized in the Condensed Consolidated Statement of Operations over the period during which an employee is required to provide service in exchange for the award. We record excess tax benefits, realized from the exercise of stock options, as cash flows from operations. Equity-based compensation arrangements to non-employees are recorded at their fair value on the measurement date. The measurement of equity-based compensation to non-employees is subject to periodic adjustment as the underlying equity instruments vest. We estimate the grant-date fair value of our stock option grants using a valuation model known as the Black-Scholes-Merton formula or the “Black-Scholes Model.” The Black-Scholes Model requires the use of several variables to estimate the grant-date fair value of stock options including expected term, expected volatility, expected dividends and risk-free interest rate. We perform analyses to calculate and select the appropriate variable assumptions used in the Black-Scholes Model and to estimate forfeitures of equity-based awards. We are required to adjust our forfeiture estimates on at least an annual basis based on the number of share-based awards that ultimately vest. The selection of assumptions and estimated forfeiture rates is subject to significant judgment and future changes to our assumptions and estimates which may have a material impact on our Condensed Consolidated Financial Statements.

Table of Contents

RECENT ACCOUNTING PRONOUNCEMENTS

Recently adopted accounting pronouncements.


•	For all reporting periods presented before January 1, 2018, we have not restated revenue from contracts that begin and are completed within the same annual reporting period.


•	For all reporting periods presented before January 1, 2018, we have not disclosed the amount of the transaction price allocated to the remaining performance obligations or an explanation of when we expect to recognize that amount as revenue.


•	We have applied the practical expedient provided for by Topic 606 by not adjusting the transaction price for significant financing components for periods less than one year.

Condensed Consolidated Statement of Operations



	For the three months ended June 30, 2017 (in thousands)
	As adjusted under Topic 606		As originally reported		Effect of change
Revenue from services	$	233,912	$	256,671	$	(22,759	)
Revenue from transfer of intellectual property and other	29,723		28,576		1,147
Selling, general and administrative	105,579		128,338		(22,759		)
Research and development	33,128		32,593		535

Table of Contents



	For the six months ended June 30, 2017 (in thousands)
	As adjusted under Topic 606		As originally reported		Effect of change
Revenue from services	$	462,456	$	511,956	$	(49,500	)
Revenue from transfer of intellectual property and other	45,328		47,154		(1,826		)
Selling, general and administrative	215,523		265,023		(49,500		)
Research and development	59,685		58,615		1,070

Condensed Consolidated Balance Sheet



	December 31, 2017 (in thousands)
	As adjusted under Topic 606			As originally reported			Effect of change
Other current assets and prepaid expenses	$	42,513		$	37,113		$	5,400
Accrued expenses	230,301			215,102			15,199
Other long-term liabilities, principally contract liabilities, contingent consideration and line of credit	239,955			219,954			20,001
Accumulated deficit	(1,036,959		)	(1,007,159		)	(29,800		)

Condensed Consolidated Statement of Cash Flows



	For the six months ended June 30, 2017 (in thousands)
	As adjusted under Topic 606			As originally reported			Effect of change
Net loss	$	(51,419	)	$	(48,523	)	$	(2,896	)
Contract liabilities	(31,122		)	(34,018		)	2,896

Table of Contents

Pending accounting pronouncements.

Table of Contents

Item 3. Quantitative and Qualitative Disclosures About Market Risk

In the normal course of doing business, we are exposed to the risks associated with foreign currency exchange rates and changes in interest rates.

Foreign Currency Exchange Rate Risk – We operate globally and, as such, we are subject to foreign exchange risk in our commercial operations as portions of our revenues are exposed to changes in foreign currency exchange rates, primarily the Chilean Peso, the Mexican Peso, the Euro and the New Israeli Shekel.

Although we do not speculate in the foreign exchange market, we may from time to time manage exposures that arise in the normal course of business related to fluctuations in foreign currency exchange rates by entering into offsetting positions through the use of foreign exchange forward contracts. Certain firmly committed transactions may be hedged with foreign exchange forward contracts. As exchange rates change, gains and losses on the exposed transactions are partially offset by gains and losses related to the hedging contracts. Both the exposed transactions and the hedging contracts are translated and fair valued, respectively, at current spot rates, with gains and losses included in earnings.

Our derivative activities, which consist of foreign exchange forward contracts, are initiated to economically hedge forecasted cash flows that are exposed to foreign currency risk. The foreign exchange forward contracts generally require us to exchange local currencies for foreign currencies based on pre-established exchange rates at the contracts’ maturity dates. As exchange rates change, gains and losses on these contracts are generated based on the change in the exchange rates that are recognized in the Condensed Consolidated Statements of Operations and offset the impact of the change in exchange rates on the foreign currency cash flows that are hedged. If the counterparties to the exchange contracts do not fulfill their obligations to deliver the contracted currencies, we could be at risk for currency related fluctuations. Our foreign exchange forward contracts primarily hedge exchange rates on the Chilean Peso to the U.S. dollar. If Chilean Pesos were to strengthen or weaken in relation to the U.S. dollar, our loss or gain on hedged foreign currency cash-flows would be offset by the derivative contracts, with a net effect of zero.

We do not engage in trading market risk sensitive instruments or purchasing hedging instruments or “other than trading” instruments that are likely to expose us to significant market risk, whether interest rate, foreign currency exchange, commodity price, or equity price risk.

Interest Rate Risk – Our exposure to interest rate risk relates to our cash and investments and to our borrowings. We generally maintain an investment portfolio of money market funds and marketable securities. The securities in our investment portfolio are not leveraged, and are, due to their very short-term nature, subject to minimal interest rate risk. We currently do not hedge interest rate exposure. Because of the short-term maturities of our investments, we do not believe that a change in market interest rates would have a significant negative impact on the value of our investment portfolio except for reduced income in a low interest rate environment.

At June 30, 2018, we had cash and cash equivalents of $80.4 million. The weighted average interest rate related to our cash and cash equivalents for the six months ended June 30, 2018 was less than 1%. As of June 30, 2018, the principal outstanding balance under our Credit Agreement with JPMorgan Chase Bank, N.A. and our Chilean and Spanish lines of credit was $109.5 million in the aggregate at a weighted average interest rate of approximately 4.7%.

Our $31.9 million aggregate principal amount of our 2033 Senior Notes has a fixed interest rate of 3% and our $55.0 million aggregate principal amount of our 2023 Convertible Notes has a fixed interest rate of 5%, and therefore are not subject to fluctuations in market interest rates.

The primary objective of our investment activities is to preserve principal while at the same time maximizing yields without significantly increasing risk. To achieve this objective, we may invest our excess cash in debt instruments of the U.S. Government and its agencies, bank obligations, repurchase agreements and high-quality corporate issuers, and money market funds that invest in such debt instruments, and, by policy, restrict our exposure to any single corporate issuer by imposing concentration limits. To minimize the exposure due to adverse shifts in interest rates, we maintain investments at an average maturity of generally less than three months.

Table of Contents

Item 4. Controls and Procedures

Disclosure Controls and Procedures

Our management, with the participation of our Chief Executive Officer and our Chief Financial Officer, have evaluated the effectiveness of the Company’s disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) as of the end of the period covered by this Quarterly Report on Form 10-Q. Our disclosure controls and procedures are designed to provide reasonable assurance that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the rules and forms of the Securities and Exchange Commission. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company’s management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure. Based on this evaluation, management concluded that our disclosure controls and procedures were effective as of June 30, 2018.

Changes to the Company’s Internal Control Over Financial Reporting

We have implemented new controls as part of our effort to adopt Accounting Standards Update (“ASU”) No. 2014-09, “Revenue from Contracts with Customers.” The adoption of the ASU requires the implementation of new accounting processes which necessitates changes to our internal controls over financial reporting.

These changes to the Company’s internal control over financial reporting that occurred since the beginning of 2018 have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.

Table of Contents

PART II. OTHER INFORMATION

Item 1. Legal Proceedings

We are, from time to time, party to various legal proceedings arising out of our business. During the reporting period, there have been no material changes to the description of legal proceedings set forth in our Annual Report on Form 10-K for the year ended December 31, 2017.

Table of Contents

Item 1A. Risk Factors

Our operations and financial results are subject to various risks and uncertainties, including those described in Part I, Item 1A, “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2017, which could adversely affect our business, financial condition, results of operations, cash flows, and the trading price of our common and capital stock. There have been no material changes to our risk factors since our Annual Report on Form 10-K for the year ended December 31, 2017.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

None.

Item 3. Defaults Upon Senior Securities

None.

Item 4. Mine Safety Disclosures

Not Applicable.

Item 5. Other Information

None.

Table of Contents

Item 6. Exhibits



Exhibit 3.1(1)	Amended and Restated Certificate of Incorporation.
Exhibit 3.2(2)	Amended and Restated By-Laws.
Exhibit 3.3(3)	Certificate of Designation of Series D Preferred Stock.
Exhibit 4.3(4)	Indenture, dated as of January 30, 2013, between OPKO Health, Inc. and Wells Fargo Bank, National Association.
Exhibit 10.1*	Amendment No. 7 to Credit Agreement by and between BioReference Laboratories, Inc. and certain of its subsidiaries, and JPMorgan Chase, N.A. dated February 28, 2018.
Exhibit 31.1	Certification by Phillip Frost, Chief Executive Officer, pursuant to Rule 13a-14(a) and 15d-14(a) of the Securities and Exchange Act of 1934 as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 for the quarterly period ended June 30, 2018.
Exhibit 31.2	Certification by Adam Logal, Chief Financial Officer, pursuant to Rule 13a-14(a) and 15d-14(a) of the Securities and Exchange Act of 1934 as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 for the quarterly period ended June 30, 2018.
Exhibit 32.1	Certification by Phillip Frost, Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 for the quarterly period ended June 30, 2018.
Exhibit 32.2	Certification by Adam Logal, Chief Financial Officer, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 for the quarterly period ended June 30, 2018.
Exhibit 101.INS	XBRL Instance Document
Exhibit 101.SCH	XBRL Taxonomy Extension Schema Document
Exhibit 101.CAL	XBRL Taxonomy Extension Calculation Linkbase Document
Exhibit 101.DEF	XBRL Taxonomy Extension Definition Linkbase Document
Exhibit 101.LAB	XBRL Taxonomy Extension Label Linkbase Document
Exhibit 101.PRE	XBRL Taxonomy Extension Presentation Linkbase Document


*	Filed herewith.


⁽¹⁾	Filed with the Company’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 12, 2013 for the Company’s three month period ended September 30, 2013, and incorporated herein by reference.


⁽²⁾	Filed with the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 31, 2008, and incorporated herein by reference.


⁽³⁾	Filed with the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on September 24, 2009, and incorporated herein by reference.


⁽⁴⁾	Filed with the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on February 5, 2013, and incorporated herein by reference.

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.



Date: August 7, 2018		OPKO Health, Inc.

		/s/ Adam Logal
		Adam Logal
		Senior Vice President, Chief Financial Officer,
		Chief Accounting Officer and Treasurer

EX-10.1 2 amendmentno7tobrlijpmcredi.htm EXHIBIT 10.1 Exhibit

EXECUTION VERSION

WAIVER UNDER AND
AMENDMENT NO. 7 TO CREDIT AGREEMENT

AMENDMENT NO. 7 TO CREDIT AGREEMENT (this “Amendment”), dated as of February 28, 2018, is entered into among BIO-REFERENCE LABORATORIES, INC., a New Jersey corporation (“Company”), the Subsidiary Borrowers party hereto (“Subsidiary Borrowers,” and together with Company, each a “Borrower” and, collectively, the “Borrowers”), the other Loan Parties party hereto, the Lenders party hereto, and JPMORGAN CHASE BANK, N.A., as the administrative agent for the Lenders (the “Administrative Agent”).

W I T N E S S E T H :

WHEREAS, the Borrowers, the other Loan Parties party thereto, the Lenders party thereto, and the Administrative Agent have executed and delivered that certain Credit Agreement dated as of November 5, 2015, as amended by Amendment No. 1 to Credit Agreement dated as of February 29, 2016, as amended by Amendment No. 2 to Credit Agreement dated as of September 26, 2016, as amended by Amendment No. 3 to Credit Agreement dated as of March 17, 2017, as amended by Amendment No. 4 to Credit Agreement dated as of August 7, 2017, as amended by Amendment No. 5 to Credit Agreement dated as of November 8, 2017, and as amended by Amendment No. 6 to Credit Agreement dated as of December 22, 2017 (as further amended, restated, supplemented, or otherwise modified from time to time prior to the date hereof, the “Credit Agreement”);

WHEREAS, the Borrowers failed to comply with Section 6.12 of the Credit Agreement by violating the Fixed Charge Coverage Ratio covenant for the fiscal quarter ending on or about December 31, 2017, and such non-compliance constituted an Event of Default under paragraph (d) of Article VII of the Credit Agreement (the “FCCR Default”; the FCCR Default, together with any Default or Event of Default which exists or may exist under the Loan Documents to the extent any such Default or Event of Default occurred solely because of the existence of the FCCR Default, collectively, the “Specified Events of Default”); and

WHEREAS, the Borrowers have requested that the Lenders and the Administrative Agent make certain amendments to the Credit Agreement and waive the Specified Events of Default, and the Lenders party hereto, constituting all Lenders under the Credit Agreement, have agreed to such amendments and such waiver, subject to the terms and conditions hereof.

NOW, THEREFORE, for and in consideration of the above premises and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged by the parties hereto, each of the Borrowers, the other Loan Parties, the Lenders and the Administrative Agent hereby covenant and agree as follows:

SECTION 1. Definitions. Unless otherwise specifically defined herein, each term used herein (and in the recitals above) which is defined in the Credit Agreement shall have the meaning assigned to such term in the Credit Agreement. As of the date hereof, each reference in the Credit Agreement to “this Agreement,” “hereunder,” “hereof,” “herein,” or words of like import, and each reference in the other Loan Documents to the Credit Agreement (including, without limitation, by

NAI-1503470788v8

means of words like “thereunder,” “thereof” and words of like import), shall mean and be a reference to the Credit Agreement, as amended hereby.

SECTION 2. Waiver. The Lenders have agreed to and hereby do, subject to the terms hereof and subject to the satisfaction of the conditions precedent established herein, waive each of the Specified Events of Default.

SECTION 3. Amendments to Credit Agreement. Effective as of the Amendment No. 7 Effective Date (as defined below), the Credit Agreement is hereby amended as follows:

(a) Amendments to Section 1.01 of the Credit Agreement.

(i) Section 1.01 of the Credit Agreement is hereby amended by adding the following definitions in appropriate alphabetical order:

“Amendment No. 7 Effective Date” means February 28, 2018.

“FCCR Availability” means, at any time, an amount equal to the sum of (a) the lesser of (i) the Aggregate Revolving Commitment and (ii) the Borrowing Base plus (b) Qualified Cash in an amount approved by the Administrative Agent in its sole discretion not to exceed $11,250,000 minus (c) the Aggregate Revolving Exposure (calculated, with respect to any Defaulting Lender, as if such Defaulting Lender had funded its Applicable Percentage of all outstanding Borrowings), all as determined by the Administrative Agent in its Permitted Discretion in accordance with this Agreement.

(ii) Each of the following definitions in Section 1.01 of the Credit Agreement is amended so that it reads, in its entirety, as follows:

“Dominion Period” means (a) any period during which any Event of Default has occurred and is continuing or (b) any period (i) commencing at any time when FCCR Availability shall be less than the greater of (A) $22,500,000 and (B) 12.5% of the Aggregate Revolving Commitment, in each case under this clause (b), for a period of at least five (5) consecutive Business Days, and (ii) ending when FCCR Availability shall have been greater than the greater of (A) $22,500,000 and (B) 12.5% of the Aggregate Revolving Commitment for a period of thirty (30) consecutive days.

“Increased Reporting Period” means any period (a) commencing either (i) on the date on which the Administrative Agent sends notice to the Borrower (which notice may be provided via e-mail in accordance with Section 9.01) that Modified Availability has been less than the greater of (A) $26,250,000 and (B) 15% of the Aggregate Revolving Commitment, in each case for a period of five (5) consecutive Business Days, or (ii) upon the occurrence and continuance of an Event of Default, and (b) ending on the date on which Modified Availability has been equal to or greater than the greater of (i) $26,250,000 and (ii) 15% of the Aggregate Revolving Commitment for a period of ten (10) consecutive days, so long as no Event of Default is in existence.

“LTM EBITDA” means (a) for the four fiscal quarter period ending December 31, 2017, and any prior period, EBITDA for such period as set forth in the certificate of the Borrower Representative delivered pursuant to Section 5.01(d) for such period, (b) for the

NAI-1503470788v8 2

fiscal quarter ending March 31, 2018, EBITDA for such fiscal quarter multiplied by four, (c) for the fiscal quarter ending June 30, 2018, EBITDA for the most recently completed two consecutive fiscal quarters multiplied by two, (d) for the fiscal quarter ending September 30, 2018, EBITDA for the most recently completed three consecutive fiscal quarters multiplied by four-thirds, and (e) for the fiscal quarter ending December 31, 2018, and for each fiscal quarter thereafter, EBITDA for the most recently completed four consecutive fiscal quarters.

“LTM Fixed Charges” means (a) for the four fiscal quarter period ending December 31, 2017, and any prior period, Fixed Charges for such period as set forth in the certificate of the Borrower Representative delivered pursuant to Section 5.01(d) for such period, (b) for the fiscal quarter ending March 31, 2018, Fixed Charges for such fiscal quarter multiplied by four, (c) for the fiscal quarter ending June 30, 2018, Fixed Charges for the most recently completed two consecutive fiscal quarters multiplied by two, (d) for the fiscal quarter ending September 30, 2018, Fixed Charges for the most recently completed three consecutive fiscal quarters multiplied by four-thirds, and (e) for the Fiscal Quarter ending December 31, 2018, and for each fiscal quarter thereafter, Fixed Charges for the most recently completed four consecutive fiscal quarters; provided that, for the purposes of (b) through (d) above, dividends and distributions included in the definition of Fixed Charges shall not be annualized but shall be included in the amount actually paid in cash during the period from the Effective Date to the last day of the relevant fiscal quarter.

“LTM Unfinanced Capital Expenditures” means (a) for the four fiscal quarter period ending December 31, 2017, and any prior period, Unfinanced Capital Expenditures for such period as set forth in the certificate of the Borrower Representative delivered pursuant to Section 5.01(d) for such period, (b) for the fiscal quarter ending March 31, 2018, Unfinanced Capital Expenditures for such fiscal quarter multiplied by four, (c) for the fiscal quarter ending June 30, 2018, Unfinanced Capital Expenditures for the most recently completed two consecutive fiscal quarters multiplied by two, (d) for the fiscal quarter ending September 30, 2018, Unfinanced Capital Expenditures for the most recently completed three consecutive fiscal quarters multiplied by four-thirds, and (e) for the Fiscal Quarter ending December 31, 2018, and for each fiscal quarter thereafter, Unfinanced Capital Expenditures for the most recently completed four consecutive fiscal quarters.

“Modified Availability” means, at any time, an amount equal to the sum of (a) the lesser of (i) the Aggregate Revolving Commitment and (ii) the Borrowing Base plus (b) Qualified Cash in an amount not to exceed $13,125,000 minus (c) the Aggregate Revolving Exposure (calculated, with respect to any Defaulting Lender, as if such Defaulting Lender had funded its Applicable Percentage of all outstanding Borrowings), all as determined by the Administrative Agent in its Permitted Discretion in accordance with this Agreement.

“Qualified Cash” means cash of any Loan Party on deposit in a Deposit Account (as defined in the Security Agreement) subject to a Deposit Account Control Agreement (as defined in the Security Agreement).

(b) Amendment to Section 6.12 of the Credit Agreement. Section 6.12 of the Credit Agreement is amended so that it reads, in its entirety, as follows:

NAI-1503470788v8 3

Section 6.12 Fixed Charge Coverage Ratio. The Borrowers will not permit the Fixed Charge Coverage Ratio as of the last day of any fiscal quarter, commencing with the fiscal quarter ending immediately preceding the date on which the Borrowers’ FCCR Availability is less than the greater of (a) $22,500,000 and (b) 12.5% of the Aggregate Revolving Commitment, to be less than 1.0 to 1.0. Once such covenant is in effect, compliance with the covenant will be discontinued, so long as no Event of Default shall have occurred and be continuing: (i) on the day immediately succeeding the last day of the fiscal quarter which includes the 30th consecutive day on which the Borrowers’ FCCR Availability remains in excess of the greater of (a) $22,500,000 and (b) 12.5% of the Aggregate Revolving Commitment, and (ii) no more than three (3) times in any period of twelve (12) consecutive months.

SECTION 4. Conditions Precedent. This Amendment shall become effective on the date (such date, the “Amendment No. 7 Effective Date”) the following conditions precedent shall have been satisfied:

(a) receipt by the Administrative Agent of signatures to this Amendment from the parties listed on the signature pages hereto; and

(b) the Administrative Agent shall have received from the Borrowers (or the Administrative Agent shall be satisfied with arrangements made for the payment thereof) all other costs, fees, and expenses owed by the Borrowers to the Administrative Agent in connection with this Amendment, including, without limitation, reasonable attorneys’ fees and expenses, in accordance with Section 9.03 of the Credit Agreement.

SECTION 5. Miscellaneous.

(a) Representations and Warranties. To induce the Administrative Agent and Lenders to enter into this Amendment, the Borrowers hereby represent and warrant to the Administrative Agent and the Lenders that all representations and warranties of the Borrowers contained in Article III of the Credit Agreement or any other Loan Document are true and correct in all material respects with the same effect as though made on and as of the Amendment No. 7 Effective Date (except with respect to representations and warranties made as of an expressed date, which representations and warranties are true and correct in all material respects as of such date).

(b) No Offset. To induce the Administrative Agent and Lenders to enter into this Amendment, the Borrowers hereby acknowledge and agree that, as of the date hereof, and after giving effect to the terms hereof, there exists no right of offset, defense, counterclaim, claim, or objection in favor of the Borrowers or arising out of or with respect to any of the loans or other obligations of the Borrowers owed by the Borrowers under the Credit Agreement or any other Loan Document.

(d) Effect of Amendment. Except as set forth expressly herein, all terms of the Credit Agreement and the other Loan Documents shall be and remain in full force and effect, and shall

NAI-1503470788v8 4

constitute the legal, valid, binding, and enforceable obligations of the Borrowers, enforceable in accordance with their terms, subject to applicable bankruptcy, insolvency, reorganization, moratorium or other laws affecting creditors’ rights generally and subject to general principles of equity, regardless of whether considered in a proceeding in equity or at law.

(e) No Novation or Mutual Departure. The Borrowers expressly acknowledge and agree that (i) this Amendment does not constitute or establish, a novation with respect to the Credit Agreement or any of the other Loan Documents, or a mutual departure from the strict terms, provisions, and conditions thereof, other than with respect to the amendments set forth in Section 3 above and the limited waiver set forth in Section 2 above, and (ii) nothing in this Amendment shall affect or limit the Administrative Agent’s or any Lender’s right to (x) demand payment of the Obligations under, or demand strict performance of the terms, provisions and conditions of, the Credit Agreement and the other Loan Documents (in each case, as amended hereby and subject to the limited waiver set forth in Section 2 above), as applicable, (y) exercise any and all rights, powers, and remedies under the Credit Agreement or the other Loan Documents (in each case, as amended hereby and subject to the limited waiver set forth in Section 2 above) or at law or in equity, or (z) do any and all of the foregoing, immediately at any time during the occurrence of an Event of Default and in each case, in accordance with the terms and provisions of the Credit Agreement and the other Loan Documents (in each case, as amended hereby and subject to the limited waiver set forth in Section 2 above).

(f) Counterparts. This Amendment may be executed in any number of counterparts and by different parties hereto in separate counterparts, each of which when so executed and delivered shall be deemed to be an original and all of which counterparts, taken together, shall constitute but one and the same instrument. This Amendment may be executed by each party on separate copies, which copies, when combined so as to include the signatures of all parties, shall constitute a single counterpart of this Amendment.

(g) Fax or Other Transmission. Delivery by one or more parties hereto of an executed counterpart of this Amendment via facsimile, telecopy, or other electronic method of transmission pursuant to which the signature of such party can be seen (including, without limitation, Adobe Corporation’s Portable Document Format) shall have the same force and effect as the delivery of an original executed counterpart of this Amendment. Any party delivering an executed counterpart of this Amendment by facsimile or other electronic method of transmission shall also deliver an original executed counterpart, but the failure to do so shall not affect the validity, enforceability, or binding effect of this Amendment.

(h) Recitals Incorporated Herein. The preamble and the recitals to this Amendment are hereby incorporated herein by this reference.

(i) Section References. Section titles and references used in this Amendment shall be without substantive meaning or content of any kind whatsoever and are not a part of the agreements among the parties hereto evidenced hereby.

NAI-1503470788v8 5

(j) Governing Law. This Amendment shall be governed by and construed in accordance with the internal laws (and not the law of conflicts) of the State of New York, but giving effect to federal laws applicable to national banks.

(k) Severability. Any provision of this Amendment which is prohibited or unenforceable shall be ineffective to the extent of such prohibition or unenforceability without invalidating the remaining provisions hereof in that jurisdiction or affecting the validity or enforceability of such provision in any other jurisdiction.

(l) Reaffirmation of Loan Parties. Each Loan Party (i) consents to the execution and delivery of this Amendment, (ii) reaffirms all of its obligations and covenants under the Loan Documents (including, without limitation, the Collateral Documents and the Loan Guaranty) to which it is a party, and (iii) agrees that, except to the extent amended hereby, none of its respective obligations and covenants under the Loan Documents shall be reduced or limited by the execution and delivery of this Amendment.

[SIGNATURES ON FOLLOWING PAGES.]

NAI-1503470788v8 6

IN WITNESS WHEREOF, the Borrowers, the other Loan Parties, the Administrative Agent and the Lenders have caused this Amendment to be duly executed by their respective duly authorized officers as of the day and year first above written.

BORROWERS:

BIO-REFERENCE LABORATORIES, INC.

GENEDX, INC.

FLORIDA CLINICAL LABORATORY, INC.

MERIDIAN CLINICAL LABORATORY CORP.

By: /s/ Adam Logal

Name:

Title:

OTHER LOAN PARTIES:

CAREEVOLVE.COM, INC.

BRLI-GENPATH DIAGNOSTICS, INC.

GENEDX MENA LLC

By: /s/ Adam Logal

Name:

Title:

Approved for Signature

OPKO Legal Dept.

By: /s/ Yesica Saint Malo

Date: February 28, 2018

[BRLI – Amendment No. 7 to Credit Agreement]

JPMORGAN CHASE BANK, N.A.,

Individually as a Lender and as Administrative Agent, Issuing Bank and Swingline Lender

By: /s/Eric A. Anderson

Name: Eric A. Anderson

Title: Authorized Officer

[BRLI – Amendment No. 7 to Credit Agreement]

EX-31.1 3 opk-6302018xex311.htm EXHIBIT 31.1 Exhibit

Exhibit 31.1

CERTIFICATIONS

I, Phillip Frost, certify that:


(1)	I have reviewed this Quarterly Report on Form 10-Q of OPKO Health, Inc.;


(2)	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;


(3)	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;


(4)	The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:


(a)	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;


(b)	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;


(c)	Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and


(d)	Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and


(5)	The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):


(a)	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and


(b)	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.



Date: August 7, 2018	/s/ Phillip Frost, M.D.
	Phillip Frost, M.D.
	Chief Executive Officer

EX-31.2 4 opk-6302018xex312.htm EXHIBIT 31.2 Exhibit

Exhibit 31.2

CERTIFICATIONS

I, Adam Logal, certify that:


(1)	I have reviewed this Quarterly Report on Form 10-Q of OPKO Health, Inc.;


(2)	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;


(3)	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;


(4)	The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:


(a)	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;


(b)	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;


(c)	Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and


(d)	Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and


(5)	The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):


(a)	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and


(b)	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.



Date: August 7, 2018	/s/ Adam Logal
	Adam Logal
	Senior Vice President, Chief Financial Officer, Chief Accounting Officer and Treasurer

EX-32.1 5 opk-6302018xex321.htm EXHIBIT 32.1 Exhibit

Exhibit 32.1

Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

(Subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code)

Pursuant to 18 U.S.C. Section 1350, as adopted pursuant Section 906 of the Sarbanes-Oxley Act of 2002, I, Phillip Frost, Chief Executive Officer of OPKO Health, Inc. (the “Company”), hereby certify that:

The Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2018 (the “Form 10-Q”) of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and the information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company.



Date: August 7, 2018	/s/ Phillip Frost, M.D.
	Phillip Frost, M.D.
	Chief Executive Officer

EX-32.2 6 opk-6302018xex322.htm EXHIBIT 32.2 Exhibit

Exhibit 32.2

Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

(Subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code)

Pursuant to 18 U.S.C. Section 1350, as adopted pursuant Section 906 of the Sarbanes-Oxley Act of 2002, I, Adam Logal, Chief Financial Officer of OPKO Health, Inc. (the “Company”), hereby certify that:



Date: August 7, 2018	/s/ Adam Logal
	Adam Logal
	Senior Vice President, Chief Financial Officer Chief Accounting Officer and Treasurer

EX-101.INS 7 opk-20180630.xml XBRL INSTANCE DOCUMENT 0000944809 2018-01-01 2018-06-30 0000944809 2018-08-01 0000944809 2017-12-31 0000944809 2018-06-30 0000944809 2018-04-01 2018-06-30 0000944809 us-gaap:ServiceMember 2018-01-01 2018-06-30 0000944809 us-gaap:ProductMember 2017-04-01 2017-06-30 0000944809 2017-04-01 2017-06-30 0000944809 2017-01-01 2017-06-30 0000944809 opk:TransferOfIntellectualPropertyAndOtherMember 2018-01-01 2018-06-30 0000944809 opk:TransferOfIntellectualPropertyAndOtherMember 2017-04-01 2017-06-30 0000944809 us-gaap:ServiceMember 2017-01-01 2017-06-30 0000944809 us-gaap:ServiceMember 2017-04-01 2017-06-30 0000944809 us-gaap:ProductMember 2018-04-01 2018-06-30 0000944809 us-gaap:ProductMember 2017-01-01 2017-06-30 0000944809 opk:TransferOfIntellectualPropertyAndOtherMember 2018-04-01 2018-06-30 0000944809 opk:TransferOfIntellectualPropertyAndOtherMember 2017-01-01 2017-06-30 0000944809 us-gaap:ProductMember 2018-01-01 2018-06-30 0000944809 us-gaap:ServiceMember 2018-04-01 2018-06-30 0000944809 opk:OPKOHealthEuropeMember 2017-01-01 2017-06-30 0000944809 2016-12-31 0000944809 2017-06-30 0000944809 opk:OPKOHealthEuropeMember 2018-01-01 2018-06-30 0000944809 srt:RestatementAdjustmentMember us-gaap:AccountingStandardsUpdate201409Member 2017-04-01 2017-06-30 0000944809 opk:TransferOfIntellectualPropertyAndOtherMember srt:RestatementAdjustmentMember us-gaap:AccountingStandardsUpdate201409Member 2017-04-01 2017-06-30 0000944809 opk:TransferOfIntellectualPropertyAndOtherMember srt:ScenarioPreviouslyReportedMember 2017-04-01 2017-06-30 0000944809 srt:ScenarioPreviouslyReportedMember 2017-04-01 2017-06-30 0000944809 us-gaap:ServiceMember srt:ScenarioPreviouslyReportedMember 2017-04-01 2017-06-30 0000944809 us-gaap:ServiceMember srt:RestatementAdjustmentMember us-gaap:AccountingStandardsUpdate201409Member 2017-04-01 2017-06-30 0000944809 srt:MinimumMember opk:AutomobilesandAircraftMember 2018-01-01 2018-06-30 0000944809 us-gaap:AccountsReceivableMember us-gaap:GovernmentContractsConcentrationRiskMember 2018-06-30 2018-06-30 0000944809 srt:MaximumMember us-gaap:BuildingAndBuildingImprovementsMember 2018-01-01 2018-06-30 0000944809 srt:RestatementAdjustmentMember us-gaap:AccountingStandardsUpdate201409Member 2017-01-01 2017-12-31 0000944809 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2018-06-30 2018-06-30 0000944809 srt:MinimumMember us-gaap:FurnitureAndFixturesMember 2018-01-01 2018-06-30 0000944809 srt:MaximumMember 2018-01-01 2018-06-30 0000944809 srt:MaximumMember opk:AutomobilesandAircraftMember 2018-01-01 2018-06-30 0000944809 us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2018-01-01 2018-06-30 0000944809 srt:MaximumMember us-gaap:FurnitureAndFixturesMember 2018-01-01 2018-06-30 0000944809 srt:MaximumMember us-gaap:MachineryAndEquipmentMember 2018-01-01 2018-06-30 0000944809 srt:MinimumMember us-gaap:BuildingAndBuildingImprovementsMember 2018-01-01 2018-06-30 0000944809 us-gaap:AccountsReceivableMember us-gaap:GovernmentContractsConcentrationRiskMember 2017-12-31 2017-12-31 0000944809 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2017-12-31 2017-12-31 0000944809 srt:MinimumMember us-gaap:MachineryAndEquipmentMember 2018-01-01 2018-06-30 0000944809 srt:MinimumMember 2018-01-01 2018-06-30 0000944809 opk:TransferOfIntellectualPropertyAndOtherMember srt:RestatementAdjustmentMember us-gaap:AccountingStandardsUpdate201409Member us-gaap:TransferredOverTimeMember 2017-01-01 2017-06-30 0000944809 us-gaap:AccountingStandardsUpdate201601Member us-gaap:RetainedEarningsMember 2018-01-01 0000944809 opk:TransferOfIntellectualPropertyAndOtherMember srt:ScenarioPreviouslyReportedMember 2017-01-01 2017-06-30 0000944809 srt:ScenarioPreviouslyReportedMember 2017-01-01 2017-06-30 0000944809 srt:RestatementAdjustmentMember us-gaap:AccountingStandardsUpdate201409Member 2017-01-01 2017-06-30 0000944809 opk:TransferOfIntellectualPropertyAndOtherMember srt:RestatementAdjustmentMember us-gaap:AccountingStandardsUpdate201409Member 2017-01-01 2017-06-30 0000944809 us-gaap:ServiceMember srt:ScenarioPreviouslyReportedMember 2017-01-01 2017-06-30 0000944809 us-gaap:ServiceMember srt:RestatementAdjustmentMember us-gaap:AccountingStandardsUpdate201409Member 2017-01-01 2017-06-30 0000944809 srt:RestatementAdjustmentMember us-gaap:AccountingStandardsUpdate201409Member 2017-12-31 0000944809 srt:ScenarioPreviouslyReportedMember 2017-12-31 0000944809 us-gaap:CommonStockMember 2018-04-01 2018-06-30 0000944809 us-gaap:CommonStockMember 2018-01-01 2018-06-30 0000944809 opk:A2033SeniorNotesMember 2017-04-01 2017-06-30 0000944809 opk:A2033SeniorNotesMember 2018-04-01 2018-06-30 0000944809 us-gaap:EmployeeStockOptionMember 2017-04-01 2017-06-30 0000944809 opk:A2033SeniorNotesMember 2017-01-01 2017-06-30 0000944809 us-gaap:WarrantMember 2017-04-01 2017-06-30 0000944809 us-gaap:EmployeeStockOptionMember 2018-04-01 2018-06-30 0000944809 opk:A2033SeniorNotesMember 2018-01-01 2018-06-30 0000944809 us-gaap:WarrantMember 2017-01-01 2017-06-30 0000944809 us-gaap:WarrantMember 2018-04-01 2018-06-30 0000944809 us-gaap:WarrantMember 2018-01-01 2018-06-30 0000944809 us-gaap:EmployeeStockOptionMember 2017-01-01 2017-06-30 0000944809 us-gaap:EmployeeStockOptionMember 2018-01-01 2018-06-30 0000944809 us-gaap:TechnologyBasedIntangibleAssetsMember 2017-12-31 0000944809 us-gaap:TradeNamesMember 2017-12-31 0000944809 us-gaap:OtherIntangibleAssetsMember 2017-12-31 0000944809 us-gaap:CustomerRelationshipsMember 2018-06-30 0000944809 us-gaap:TradeNamesMember 2018-06-30 0000944809 us-gaap:LicensingAgreementsMember 2018-06-30 0000944809 us-gaap:CustomerRelationshipsMember 2017-12-31 0000944809 opk:ProductRegistrationsMember 2017-12-31 0000944809 opk:ProductRegistrationsMember 2018-06-30 0000944809 us-gaap:OtherIntangibleAssetsMember 2018-06-30 0000944809 us-gaap:NoncompeteAgreementsMember 2018-06-30 0000944809 us-gaap:NoncompeteAgreementsMember 2017-12-31 0000944809 us-gaap:TechnologyBasedIntangibleAssetsMember 2018-06-30 0000944809 us-gaap:LicensingAgreementsMember 2017-12-31 0000944809 opk:OpkoDiagnosticsMember opk:DiagnosticsMember 2017-12-31 0000944809 opk:BioReferenceMember opk:DiagnosticsMember 2018-06-30 0000944809 opk:CURNAMember opk:PharmaceuticalMember 2017-12-31 0000944809 opk:OPKORentalMember opk:PharmaceuticalMember 2018-01-01 2018-06-30 0000944809 opk:EirGenPharmaLimitedMember opk:PharmaceuticalMember 2017-12-31 0000944809 opk:TransitionTherapeuticsInc.Member opk:PharmaceuticalMember 2018-01-01 2018-06-30 0000944809 opk:OPKORentalMember opk:PharmaceuticalMember 2017-12-31 0000944809 opk:FineTechMember opk:PharmaceuticalMember 2018-06-30 0000944809 opk:EirGenPharmaLimitedMember opk:PharmaceuticalMember 2018-01-01 2018-06-30 0000944809 opk:OpkoDiagnosticsMember opk:DiagnosticsMember 2018-01-01 2018-06-30 0000944809 opk:ClarosMember opk:DiagnosticsMember 2017-12-31 0000944809 opk:OPKOHealthEuropeMember opk:PharmaceuticalMember 2018-06-30 0000944809 opk:EirGenPharmaLimitedMember opk:PharmaceuticalMember 2018-06-30 0000944809 opk:OPKOBiologicsMember opk:PharmaceuticalMember 2018-06-30 0000944809 opk:TransitionTherapeuticsInc.Member opk:PharmaceuticalMember 2017-12-31 0000944809 opk:FineTechMember opk:PharmaceuticalMember 2017-12-31 0000944809 opk:FineTechMember opk:PharmaceuticalMember 2018-01-01 2018-06-30 0000944809 opk:CURNAMember opk:PharmaceuticalMember 2018-01-01 2018-06-30 0000944809 opk:OPKOBiologicsMember opk:PharmaceuticalMember 2017-12-31 0000944809 opk:OPKORentalMember opk:PharmaceuticalMember 2018-06-30 0000944809 opk:ClarosMember opk:DiagnosticsMember 2018-01-01 2018-06-30 0000944809 opk:BioReferenceMember opk:DiagnosticsMember 2018-01-01 2018-06-30 0000944809 opk:OpkoDiagnosticsMember opk:DiagnosticsMember 2018-06-30 0000944809 opk:BioReferenceMember opk:DiagnosticsMember 2017-12-31 0000944809 opk:TransitionTherapeuticsInc.Member opk:PharmaceuticalMember 2018-06-30 0000944809 opk:ClarosMember opk:DiagnosticsMember 2018-06-30 0000944809 opk:OPKOHealthEuropeMember opk:PharmaceuticalMember 2017-12-31 0000944809 opk:OPKOHealthEuropeMember opk:PharmaceuticalMember 2018-01-01 2018-06-30 0000944809 opk:OPKOBiologicsMember opk:PharmaceuticalMember 2018-01-01 2018-06-30 0000944809 opk:OpkoChileMember opk:PharmaceuticalMember 2018-01-01 2018-06-30 0000944809 opk:CURNAMember opk:PharmaceuticalMember 2018-06-30 0000944809 opk:OpkoChileMember opk:PharmaceuticalMember 2017-12-31 0000944809 opk:OpkoChileMember opk:PharmaceuticalMember 2018-06-30 0000944809 opk:NeovascMember 2018-06-30 0000944809 opk:ZebraMember us-gaap:SeriesAPreferredStockMember 2018-06-30 0000944809 opk:NonInvasiveMonitoringSystemsInc.Member 2018-06-30 0000944809 opk:ZebraMember 2018-06-30 0000944809 opk:XeneticBiosciencesInc.Member 2018-06-30 0000944809 opk:BioCardiaInc.Member 2018-06-30 0000944809 opk:RxiPharmaceuticalsCorporationMember 2018-06-30 0000944809 opk:PharmsynthezMember 2018-06-30 0000944809 opk:CocrystalMember 2018-06-30 0000944809 opk:InCellDxIncMember 2018-06-30 0000944809 opk:EloxxPharmaceuticalsMember 2018-06-30 0000944809 opk:RxiMember 2018-06-30 0000944809 opk:VBIVaccinesIncMember 2018-06-30 0000944809 opk:ChromaDexMember 2018-06-30 0000944809 opk:ZebraMember us-gaap:RestrictedStockMember 2018-01-01 2018-06-30 0000944809 opk:MabVaxTherapeuticsHoldingsInc.Member 2018-06-30 0000944809 opk:EirGenPharmaLimitedOPKOEuropeandBioReferenceMember 2017-12-31 0000944809 opk:EirGenPharmaLimitedOPKOEuropeandBioReferenceMember 2018-06-30 0000944809 opk:BbvaBankMember 2018-06-30 0000944809 opk:SantanderBank2MemberMember 2018-06-30 0000944809 opk:BankOfChileMember 2018-06-30 0000944809 opk:EstadoBankMember 2018-06-30 0000944809 opk:SantanderBankMember 2018-06-30 0000944809 opk:BbvaBankMember 2017-12-31 0000944809 opk:SecurityMember 2018-06-30 0000944809 opk:BilbaoVizcayaBankMember 2018-06-30 0000944809 opk:SantanderBank2MemberMember 2017-12-31 0000944809 opk:BiceBankMember 2018-06-30 0000944809 opk:JPMorganChaseMember 2018-06-30 0000944809 opk:ItauBankMember 2017-12-31 0000944809 opk:ItauBankMember 2018-06-30 0000944809 opk:ScotiabankMember 2018-06-30 0000944809 opk:SecurityMember 2017-12-31 0000944809 opk:BiceBankMember 2017-12-31 0000944809 opk:JPMorganChaseMember 2017-12-31 0000944809 opk:BilbaoVizcayaBankMember 2017-12-31 0000944809 opk:EstadoBankMember 2017-12-31 0000944809 opk:BankOfChileMember 2017-12-31 0000944809 opk:ScotiabankMember 2017-12-31 0000944809 opk:SantanderBankMember 2017-12-31 0000944809 opk:NotesDueFebruary12033Member us-gaap:ConvertibleNotesPayableMember 2015-04-01 2015-04-30 0000944809 opk:NotesDueFebruary12033Member us-gaap:ConvertibleNotesPayableMember 2013-01-30 2013-01-30 0000944809 us-gaap:LineOfCreditMember 2018-06-30 0000944809 opk:NotesDueFebruary12033Member us-gaap:SeniorNotesMember 2013-01-30 0000944809 opk:A5ConvertibleNotesMember us-gaap:ConvertibleDebtMember 2018-02-01 2018-02-28 0000944809 opk:NotesDueFebruary12033Member us-gaap:ConvertibleNotesPayableMember 2015-04-30 0000944809 opk:OPKOHealthEuropeMember 2017-12-31 0000944809 us-gaap:LineOfCreditMember 2017-12-31 0000944809 opk:NotesDueFebruary12033Member us-gaap:DebtInstrumentRedemptionPeriodOneMember us-gaap:ConvertibleNotesPayableMember 2013-01-30 2013-01-30 0000944809 opk:BioReferenceMember 2018-06-30 0000944809 srt:MaximumMember opk:NotesDueFebruary12033Member us-gaap:ConvertibleNotesPayableMember 2013-01-30 2013-01-30 0000944809 us-gaap:RevolvingCreditFacilityMember opk:NewCreditAgreementMember us-gaap:LineOfCreditMember opk:LondonInterbankOfferedRateLIBORFirstTwelveMonthsAdjustedforEurocurrencyLiabilitiesMember 2015-11-01 2015-11-30 0000944809 opk:NotesDueFebruary12033Member us-gaap:ConvertibleDebtMember 2013-01-01 2016-12-31 0000944809 us-gaap:RevolvingCreditFacilityMember opk:NewCreditAgreementMember us-gaap:LineOfCreditMember opk:LondonInterbankOfferedRateLIBORThereafterAdjustedforEurocurrencyLiabilitiesMember 2015-11-01 2015-11-30 0000944809 srt:MinimumMember opk:OPKOHealthEuropeMember 2018-06-30 0000944809 opk:OPKOHealthEuropeMember 2018-06-30 0000944809 us-gaap:RevolvingCreditFacilityMember opk:NewCreditAgreementMember us-gaap:LineOfCreditMember 2015-11-01 2015-11-30 0000944809 srt:MaximumMember opk:OPKOHealthEuropeMember 2018-06-30 0000944809 opk:NotesDueFebruary12033Member us-gaap:ConvertibleDebtMember us-gaap:CommonStockMember 2013-01-01 2016-12-31 0000944809 us-gaap:RevolvingCreditFacilityMember opk:NewCreditAgreementMember us-gaap:LineOfCreditMember opk:LondonInterbankOfferedRateLIBORFirstTwelveMonthsMember 2015-11-01 2015-11-30 0000944809 us-gaap:RevolvingCreditFacilityMember opk:NewCreditAgreementMember us-gaap:LineOfCreditMember 2015-11-30 0000944809 us-gaap:RevolvingCreditFacilityMember opk:NewCreditAgreementMember us-gaap:LineOfCreditMember opk:LondonInterbankOfferedRateLIBORThereafterMember 2015-11-01 2015-11-30 0000944809 opk:NotesDueFebruary12033Member us-gaap:ConvertibleNotesPayableMember 2013-01-30 0000944809 us-gaap:BridgeLoanMember opk:NewCreditAgreementMember us-gaap:LineOfCreditMember 2015-11-30 0000944809 srt:MinimumMember opk:NotesDueFebruary12033Member us-gaap:ConvertibleNotesPayableMember 2013-01-30 2013-01-30 0000944809 opk:A5ConvertibleNotesMember us-gaap:ConvertibleDebtMember 2018-02-28 0000944809 opk:NotesDueFebruary12033Member us-gaap:SeniorNotesMember 2013-01-30 2013-01-30 0000944809 us-gaap:RevolvingCreditFacilityMember opk:NewCreditAgreementMember us-gaap:LineOfCreditMember 2018-06-30 0000944809 opk:NotesDueFebruary12033Member us-gaap:DebtInstrumentRedemptionPeriodTwoMember us-gaap:ConvertibleNotesPayableMember 2013-01-30 2013-01-30 0000944809 us-gaap:LetterOfCreditMember opk:NewCreditAgreementMember us-gaap:LineOfCreditMember 2015-11-30 0000944809 us-gaap:RevolvingCreditFacilityMember opk:NewCreditAgreementMember us-gaap:LineOfCreditMember us-gaap:LondonInterbankOfferedRateLIBORMember 2015-11-01 2015-11-30 0000944809 us-gaap:SeniorNotesMember 2017-12-31 0000944809 us-gaap:SeniorNotesMember 2018-06-30 0000944809 us-gaap:SeniorNotesMember 2018-01-01 2018-06-30 0000944809 us-gaap:AccumulatedTranslationAdjustmentMember 2018-01-01 2018-06-30 0000944809 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-12-31 0000944809 us-gaap:AccumulatedTranslationAdjustmentMember 2018-06-30 0000944809 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2018-01-01 2018-06-30 0000944809 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-01-01 2018-06-30 0000944809 us-gaap:AccumulatedTranslationAdjustmentMember 2017-12-31 0000944809 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2017-12-31 0000944809 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-06-30 0000944809 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2018-06-30 0000944809 opk:ContingentConsiderationMember 2018-01-01 2018-06-30 0000944809 opk:ContingentConsiderationMember 2017-12-31 0000944809 opk:ContingentConsiderationMember 2018-06-30 0000944809 us-gaap:AccruedLiabilitiesMember 2017-12-31 0000944809 us-gaap:OtherNoncurrentLiabilitiesMember 2017-12-31 0000944809 us-gaap:OtherNoncurrentLiabilitiesMember 2018-06-30 0000944809 us-gaap:AccruedLiabilitiesMember 2018-06-30 0000944809 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2018-06-30 0000944809 us-gaap:FairValueInputsLevel3Member opk:ContingentConsiderationMember us-gaap:FairValueMeasurementsRecurringMember 2018-06-30 0000944809 us-gaap:FairValueInputsLevel1Member opk:ContingentConsiderationMember us-gaap:FairValueMeasurementsRecurringMember 2018-06-30 0000944809 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2018-06-30 0000944809 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2018-06-30 0000944809 us-gaap:ForwardContractsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2018-06-30 0000944809 us-gaap:ForwardContractsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2018-06-30 0000944809 us-gaap:FairValueMeasurementsRecurringMember 2018-06-30 0000944809 us-gaap:FairValueInputsLevel2Member opk:ContingentConsiderationMember us-gaap:FairValueMeasurementsRecurringMember 2018-06-30 0000944809 opk:ContingentConsiderationMember us-gaap:FairValueMeasurementsRecurringMember 2018-06-30 0000944809 us-gaap:ForwardContractsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2018-06-30 0000944809 us-gaap:ForwardContractsMember us-gaap:FairValueMeasurementsRecurringMember 2018-06-30 0000944809 opk:ContingentConsiderationMember us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000944809 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000944809 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000944809 us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000944809 us-gaap:FairValueInputsLevel3Member opk:ContingentConsiderationMember us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000944809 us-gaap:FairValueInputsLevel2Member us-gaap:ForwardContractsMember us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000944809 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000944809 us-gaap:FairValueInputsLevel2Member opk:ContingentConsiderationMember us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000944809 us-gaap:FairValueInputsLevel1Member us-gaap:ForwardContractsMember us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000944809 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000944809 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000944809 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000944809 us-gaap:ForwardContractsMember us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000944809 us-gaap:FairValueInputsLevel3Member us-gaap:ForwardContractsMember us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000944809 us-gaap:FairValueInputsLevel1Member opk:ContingentConsiderationMember us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000944809 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000944809 us-gaap:NondesignatedMember 2017-04-01 2017-06-30 0000944809 us-gaap:ConvertibleNotesPayableMember us-gaap:NondesignatedMember 2018-04-01 2018-06-30 0000944809 us-gaap:ConvertibleNotesPayableMember us-gaap:NondesignatedMember 2017-04-01 2017-06-30 0000944809 us-gaap:ForwardContractsMember us-gaap:NondesignatedMember 2018-04-01 2018-06-30 0000944809 us-gaap:StockOptionMember us-gaap:NondesignatedMember 2018-01-01 2018-06-30 0000944809 us-gaap:ForwardContractsMember us-gaap:NondesignatedMember 2017-01-01 2017-06-30 0000944809 us-gaap:NondesignatedMember 2018-04-01 2018-06-30 0000944809 us-gaap:ConvertibleNotesPayableMember us-gaap:NondesignatedMember 2017-01-01 2017-06-30 0000944809 us-gaap:NondesignatedMember 2018-01-01 2018-06-30 0000944809 us-gaap:ForwardContractsMember us-gaap:NondesignatedMember 2017-04-01 2017-06-30 0000944809 us-gaap:StockOptionMember us-gaap:NondesignatedMember 2017-04-01 2017-06-30 0000944809 us-gaap:ForwardContractsMember us-gaap:NondesignatedMember 2018-01-01 2018-06-30 0000944809 us-gaap:ConvertibleNotesPayableMember us-gaap:NondesignatedMember 2018-01-01 2018-06-30 0000944809 us-gaap:StockOptionMember us-gaap:NondesignatedMember 2017-01-01 2017-06-30 0000944809 us-gaap:NondesignatedMember 2017-01-01 2017-06-30 0000944809 us-gaap:StockOptionMember us-gaap:NondesignatedMember 2018-04-01 2018-06-30 0000944809 us-gaap:InvestmentsMember us-gaap:StockOptionMember us-gaap:NondesignatedMember 2018-06-30 0000944809 us-gaap:InvestmentsMember us-gaap:StockOptionMember us-gaap:NondesignatedMember 2017-12-31 0000944809 opk:PrepaidExpensesandOtherCurrentAssetsAccruedExpensesMember us-gaap:ForwardContractsMember us-gaap:NondesignatedMember 2017-12-31 0000944809 opk:PrepaidExpensesandOtherCurrentAssetsAccruedExpensesMember us-gaap:ForwardContractsMember us-gaap:NondesignatedMember 2018-06-30 0000944809 opk:FrostRealEstateHoldingsLLCMember 2017-01-01 0000944809 opk:ReimbursementOfTravelExpenseMember opk:DrFrostMember 2017-01-01 2017-06-30 0000944809 opk:MuseumofScienceIncMember opk:DrFrostandMrPfennigerMember 2016-11-30 0000944809 opk:ReimbursementOfTravelExpenseMember opk:DrFrostMember 2018-04-01 2018-06-30 0000944809 opk:MabVaxTherapeuticsHoldingsInc.Member 2017-07-01 2017-07-31 0000944809 opk:NeovascMember opk:SeriesBWarrantMember 2018-04-01 2018-04-30 0000944809 opk:CocrystalMember 2016-08-01 2016-08-31 0000944809 opk:MabVaxTherapeuticsHoldingsInc.Member 2017-05-01 2017-05-31 0000944809 opk:MabVaxTherapeuticsHoldingsInc.Member opk:SeriesLPreferredStockMember 2017-05-01 2017-05-31 0000944809 opk:CocrystalMember us-gaap:CommonStockMember 2017-04-01 2017-04-30 0000944809 opk:MuseumofScienceIncMember opk:DrFrostandMrPfennigerMember 2016-11-01 2016-11-30 0000944809 opk:MabVaxTherapeuticsHoldingsInc.Member opk:SeriesIPreferredStockMember 2017-05-01 2017-05-31 0000944809 opk:CocrystalMember us-gaap:ConvertibleDebtMember us-gaap:CommonStockMember 2018-05-01 2018-05-31 0000944809 opk:ZebraMember 2018-01-01 2018-06-30 0000944809 opk:ReimbursementOfTravelExpenseMember opk:DrFrostMember 2017-04-01 2017-06-30 0000944809 opk:NeovascMember opk:SeriesAWarrantMember 2017-11-30 0000944809 opk:NeovascMember us-gaap:CommonStockMember 2017-11-01 2017-11-30 0000944809 opk:NIMSMember 2018-06-30 0000944809 opk:ReimbursementOfTravelExpenseMember opk:DrFrostMember 2018-01-01 2018-06-30 0000944809 opk:NeovascMember 2017-11-01 2017-11-30 0000944809 opk:NeovascMember opk:SeriesBWarrantMember 2017-11-30 0000944809 opk:NeovascMember opk:SeriesCWarrantMember 2017-11-30 0000944809 opk:ChromadexCorporationMember 2018-06-30 0000944809 opk:MabVaxTherapeuticsHoldingsInc.Member us-gaap:SeriesGPreferredStockMember 2017-07-01 2017-07-31 0000944809 opk:CocrystalMember us-gaap:CommonStockMember 2016-08-01 2016-08-31 0000944809 opk:CocrystalMember us-gaap:ConvertibleDebtMember 2018-02-01 2018-02-28 0000944809 opk:CocrystalMember 2017-04-01 2017-04-30 0000944809 opk:VeteransAccountableCareGroupLLCMember us-gaap:LineOfCreditMember 2017-08-01 2017-08-31 0000944809 opk:VeteransAccountableCareGroupLLCMember us-gaap:LineOfCreditMember 2017-08-31 0000944809 opk:PfizerMember opk:TransferOfIntellectualPropertyAndOtherMember us-gaap:CollaborativeArrangementProductAgreementMember 2017-04-01 2017-06-30 0000944809 opk:PfizerMember opk:TransferOfIntellectualPropertyAndOtherMember us-gaap:CollaborativeArrangementProductAgreementMember 2018-04-01 2018-06-30 0000944809 opk:PfizerMember opk:TransferOfIntellectualPropertyAndOtherMember us-gaap:CollaborativeArrangementProductAgreementMember 2018-01-01 2018-06-30 0000944809 opk:RayaldeeMember 2018-04-01 2018-06-30 0000944809 opk:PfizerMember opk:TransferOfIntellectualPropertyAndOtherMember us-gaap:CollaborativeArrangementProductAgreementMember 2017-01-01 2017-06-30 0000944809 opk:RayaldeeMember 2018-01-01 2018-06-30 0000944809 opk:RayaldeeMember opk:SalesReturnsMember 2018-06-30 0000944809 opk:RayaldeeMember opk:GovernmentalMember 2017-12-31 0000944809 opk:RayaldeeMember opk:SalesReturnsMember 2018-01-01 2018-06-30 0000944809 opk:RayaldeeMember opk:ChargebacksDiscountsRebatesAndFeesMember 2018-01-01 2018-06-30 0000944809 opk:RayaldeeMember opk:SalesReturnsMember 2017-12-31 0000944809 opk:RayaldeeMember opk:ChargebacksDiscountsRebatesAndFeesMember 2017-12-31 0000944809 opk:RayaldeeMember 2018-06-30 0000944809 opk:RayaldeeMember opk:ChargebacksDiscountsRebatesAndFeesMember 2018-06-30 0000944809 opk:RayaldeeMember opk:GovernmentalMember 2018-01-01 2018-06-30 0000944809 opk:RayaldeeMember 2017-12-31 0000944809 opk:RayaldeeMember opk:GovernmentalMember 2018-06-30 0000944809 opk:GovernmentPayersMember 2017-01-01 2017-06-30 0000944809 opk:PatientsMember 2018-04-01 2018-06-30 0000944809 opk:PatientsMember 2017-04-01 2017-06-30 0000944809 opk:HealthInsurersMember 2018-04-01 2018-06-30 0000944809 opk:HealthInsurersMember 2018-01-01 2018-06-30 0000944809 opk:GovernmentPayersMember 2018-01-01 2018-06-30 0000944809 opk:HealthInsurersMember 2017-04-01 2017-06-30 0000944809 opk:ClientPayersMember 2017-04-01 2017-06-30 0000944809 opk:HealthInsurersMember 2017-01-01 2017-06-30 0000944809 opk:GovernmentPayersMember 2018-04-01 2018-06-30 0000944809 opk:ClientPayersMember 2017-01-01 2017-06-30 0000944809 opk:PatientsMember 2017-01-01 2017-06-30 0000944809 opk:PatientsMember 2018-01-01 2018-06-30 0000944809 opk:ClientPayersMember 2018-04-01 2018-06-30 0000944809 opk:GovernmentPayersMember 2017-04-01 2017-06-30 0000944809 opk:ClientPayersMember 2018-01-01 2018-06-30 0000944809 opk:SalesRevenueMember 2017-10-12 2017-10-12 0000944809 opk:ViforFreseniusMedicalCarePharmaLtdMember opk:LaunchandSalesbasedMilestonesMember 2016-05-01 2016-05-31 0000944809 opk:RxiPharmaceuticalsCorporationMember 2013-03-31 0000944809 opk:RegulatoryAndDevelopmentMember 2017-10-12 2017-10-12 0000944809 opk:ViforFreseniusMedicalCarePharmaLtdMember opk:DevelopmentandLicenseAgreementMember 2016-05-01 2016-05-31 0000944809 opk:PfizerMember us-gaap:CollaborativeArrangementProductAgreementMember 2015-01-01 2015-01-31 0000944809 opk:ViforFreseniusMedicalCarePharmaLtdMember opk:RegulatoryMilestonesMember 2016-05-01 2016-05-31 0000944809 opk:ViforFreseniusMedicalCarePharmaLtdMember 2016-05-01 2018-06-30 0000944809 opk:PhaseTwoInitiationMember 2017-10-12 2017-10-12 0000944809 2017-10-12 2018-06-30 0000944809 opk:TesaroMember 2010-12-01 2010-12-31 0000944809 opk:PfizerMember srt:MinimumMember us-gaap:CollaborativeArrangementProductAgreementMember 2015-01-01 2015-01-31 0000944809 opk:PfizerMember us-gaap:CollaborativeArrangementProductAgreementMember 2018-06-30 0000944809 2017-10-12 2017-10-12 0000944809 opk:TesaroMember 2018-01-01 2018-06-30 0000944809 opk:PfizerMember us-gaap:CollaborativeArrangementProductAgreementMember 2015-01-01 2018-06-30 0000944809 opk:ViforFreseniusMedicalCarePharmaLtdMember opk:ExclusiveOptionMember 2016-05-01 2016-05-31 0000944809 opk:PfizerMember us-gaap:AccruedLiabilitiesMember us-gaap:CollaborativeArrangementProductAgreementMember 2018-06-30 0000944809 opk:TesaroMember 2010-12-01 2018-06-30 0000944809 opk:PfizerMember srt:MaximumMember us-gaap:CollaborativeArrangementProductAgreementMember 2015-01-01 2015-01-31 0000944809 opk:PfizerMember us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:CollaborativeArrangementProductAgreementMember 2018-06-30 0000944809 opk:TesaroMember 2017-01-01 2017-06-30 0000944809 us-gaap:OperatingSegmentsMember opk:PharmaceuticalMember 2017-12-31 0000944809 us-gaap:OperatingSegmentsMember opk:DiagnosticsMember 2018-06-30 0000944809 us-gaap:OperatingSegmentsMember opk:DiagnosticsMember 2017-12-31 0000944809 us-gaap:CorporateNonSegmentMember 2017-12-31 0000944809 us-gaap:CorporateNonSegmentMember 2018-06-30 0000944809 us-gaap:OperatingSegmentsMember opk:PharmaceuticalMember 2018-06-30 0000944809 opk:Customer1Member us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2018-04-01 2018-06-30 0000944809 us-gaap:IntersegmentEliminationMember 2018-01-01 2018-06-30 0000944809 opk:Customer1Member us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2018-01-01 2018-06-30 0000944809 opk:Customer2Member us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2018-01-01 2018-06-30 0000944809 us-gaap:OperatingSegmentsMember opk:DiagnosticsMember 2017-04-01 2017-06-30 0000944809 us-gaap:OperatingSegmentsMember us-gaap:ServiceMember opk:DiagnosticsMember 2017-01-01 2017-06-30 0000944809 us-gaap:OperatingSegmentsMember us-gaap:ServiceMember opk:PharmaceuticalMember 2018-01-01 2018-06-30 0000944809 us-gaap:OperatingSegmentsMember opk:PharmaceuticalMember 2018-01-01 2018-06-30 0000944809 country:US 2018-04-01 2018-06-30 0000944809 country:IE 2017-04-01 2017-06-30 0000944809 country:IL 2018-04-01 2018-06-30 0000944809 us-gaap:CorporateNonSegmentMember opk:TransferOfIntellectualPropertyAndOtherMember 2018-04-01 2018-06-30 0000944809 us-gaap:OperatingSegmentsMember opk:DiagnosticsMember 2018-04-01 2018-06-30 0000944809 us-gaap:OperatingSegmentsMember opk:PharmaceuticalMember 2017-01-01 2017-06-30 0000944809 opk:OtherCountriesMember 2018-01-01 2018-06-30 0000944809 us-gaap:OperatingSegmentsMember us-gaap:ServiceMember opk:DiagnosticsMember 2017-04-01 2017-06-30 0000944809 country:ES 2017-01-01 2017-06-30 0000944809 us-gaap:CorporateNonSegmentMember opk:TransferOfIntellectualPropertyAndOtherMember 2017-04-01 2017-06-30 0000944809 us-gaap:OperatingSegmentsMember opk:DiagnosticsMember 2018-01-01 2018-06-30 0000944809 country:MX 2017-04-01 2017-06-30 0000944809 us-gaap:OperatingSegmentsMember us-gaap:ServiceMember opk:PharmaceuticalMember 2017-01-01 2017-06-30 0000944809 us-gaap:OperatingSegmentsMember opk:TransferOfIntellectualPropertyAndOtherMember opk:PharmaceuticalMember 2018-04-01 2018-06-30 0000944809 us-gaap:OperatingSegmentsMember us-gaap:ProductMember opk:PharmaceuticalMember 2017-04-01 2017-06-30 0000944809 us-gaap:OperatingSegmentsMember opk:TransferOfIntellectualPropertyAndOtherMember opk:DiagnosticsMember 2018-01-01 2018-06-30 0000944809 us-gaap:OperatingSegmentsMember us-gaap:ProductMember opk:PharmaceuticalMember 2018-01-01 2018-06-30 0000944809 country:IE 2018-04-01 2018-06-30 0000944809 us-gaap:OperatingSegmentsMember opk:PharmaceuticalMember 2018-04-01 2018-06-30 0000944809 us-gaap:OperatingSegmentsMember us-gaap:ProductMember opk:PharmaceuticalMember 2018-04-01 2018-06-30 0000944809 country:CL 2018-01-01 2018-06-30 0000944809 country:US 2017-01-01 2017-06-30 0000944809 us-gaap:CorporateNonSegmentMember opk:TransferOfIntellectualPropertyAndOtherMember 2017-01-01 2017-06-30 0000944809 opk:OtherCountriesMember 2018-04-01 2018-06-30 0000944809 country:MX 2018-01-01 2018-06-30 0000944809 us-gaap:CorporateNonSegmentMember 2017-01-01 2017-06-30 0000944809 us-gaap:OperatingSegmentsMember us-gaap:ServiceMember opk:PharmaceuticalMember 2017-04-01 2017-06-30 0000944809 us-gaap:OperatingSegmentsMember opk:TransferOfIntellectualPropertyAndOtherMember opk:DiagnosticsMember 2017-04-01 2017-06-30 0000944809 us-gaap:CorporateNonSegmentMember 2018-01-01 2018-06-30 0000944809 us-gaap:OperatingSegmentsMember us-gaap:ServiceMember opk:PharmaceuticalMember 2018-04-01 2018-06-30 0000944809 opk:OtherCountriesMember 2017-01-01 2017-06-30 0000944809 country:ES 2017-04-01 2017-06-30 0000944809 us-gaap:OperatingSegmentsMember opk:PharmaceuticalMember 2017-04-01 2017-06-30 0000944809 country:IL 2017-04-01 2017-06-30 0000944809 opk:OtherCountriesMember 2017-04-01 2017-06-30 0000944809 us-gaap:CorporateNonSegmentMember us-gaap:ServiceMember 2017-04-01 2017-06-30 0000944809 us-gaap:CorporateNonSegmentMember 2017-04-01 2017-06-30 0000944809 us-gaap:CorporateNonSegmentMember us-gaap:ServiceMember 2018-01-01 2018-06-30 0000944809 country:MX 2017-01-01 2017-06-30 0000944809 us-gaap:CorporateNonSegmentMember us-gaap:ServiceMember 2018-04-01 2018-06-30 0000944809 us-gaap:OperatingSegmentsMember opk:DiagnosticsMember 2017-01-01 2017-06-30 0000944809 country:MX 2018-04-01 2018-06-30 0000944809 country:CL 2018-04-01 2018-06-30 0000944809 us-gaap:OperatingSegmentsMember opk:TransferOfIntellectualPropertyAndOtherMember opk:DiagnosticsMember 2018-04-01 2018-06-30 0000944809 us-gaap:CorporateNonSegmentMember 2018-04-01 2018-06-30 0000944809 us-gaap:OperatingSegmentsMember us-gaap:ServiceMember opk:DiagnosticsMember 2018-04-01 2018-06-30 0000944809 us-gaap:CorporateNonSegmentMember us-gaap:ServiceMember 2017-01-01 2017-06-30 0000944809 us-gaap:OperatingSegmentsMember opk:TransferOfIntellectualPropertyAndOtherMember opk:PharmaceuticalMember 2017-04-01 2017-06-30 0000944809 us-gaap:OperatingSegmentsMember us-gaap:ProductMember opk:PharmaceuticalMember 2017-01-01 2017-06-30 0000944809 country:US 2018-01-01 2018-06-30 0000944809 country:IE 2017-01-01 2017-06-30 0000944809 country:IL 2017-01-01 2017-06-30 0000944809 us-gaap:OperatingSegmentsMember opk:TransferOfIntellectualPropertyAndOtherMember opk:PharmaceuticalMember 2017-01-01 2017-06-30 0000944809 country:US 2017-04-01 2017-06-30 0000944809 country:IL 2018-01-01 2018-06-30 0000944809 us-gaap:OperatingSegmentsMember us-gaap:ServiceMember opk:DiagnosticsMember 2018-01-01 2018-06-30 0000944809 us-gaap:CorporateNonSegmentMember opk:TransferOfIntellectualPropertyAndOtherMember 2018-01-01 2018-06-30 0000944809 country:IE 2018-01-01 2018-06-30 0000944809 country:ES 2018-04-01 2018-06-30 0000944809 country:CL 2017-04-01 2017-06-30 0000944809 us-gaap:OperatingSegmentsMember opk:TransferOfIntellectualPropertyAndOtherMember opk:DiagnosticsMember 2017-01-01 2017-06-30 0000944809 us-gaap:OperatingSegmentsMember opk:TransferOfIntellectualPropertyAndOtherMember opk:PharmaceuticalMember 2018-01-01 2018-06-30 0000944809 country:ES 2018-01-01 2018-06-30 0000944809 country:CL 2017-01-01 2017-06-30 0000944809 opk:Customer1Member us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2017-01-01 2017-06-30 opk:Segment iso4217:USD iso4217:USD xbrli:shares xbrli:pure xbrli:shares utreg:D opk:employee opk:institution opk:conversion_right utreg:sqft false --12-31 Q2 2018 2018-06-30 10-Q 0000944809 559770995 Large Accelerated Filer Opko Health, Inc. 12191000 11598000 0.38 -4565000 -1697000 -2557000 -311000 107607 1667 50714 1700000 4868000 4967000 2000000000 2000000000 106909044 100000 85000000 P12Y 275000000.0 555000000 195000000 37000000 P3M 90000000.0 20000000.0 30000000 295000000 1546000 806000 0.15 P60D P30D 1 0.01 538544 11 11 50000000.0 19703000 162602 138889 2054794 706000 0.05 0.00 0.00 0.04 0.02 0.01 0.01 -11288000 -43661000 1012000 -39646000 9519000 14819000 230000 -77000 1502000 2931000 2722000 4989000 136000 385000 27000 67000 6000000.0 275000000.0 400 81000 86000 0 0 0 4876000 4876000 4876000 0 -0.1 6000000 31000000 75000000 6000000 P4Y 1000000 900000 187875 272857 186323 186323 539500 1646372 332000 332000 351625 1373515 145677 145677 1799000 18138000 21319000

8798000

2031000

74307000

69061000

166962000

154269000

165516000

152777000

50377000

46621000

4609000

3604000

230301000

15199000

215102000

200992000

2355000

1727000

-528000

-13004000

2889256000

2901086000

15800000

11500000

1018000

233000

348000

437000

1577000

724000

727000

126000

1400000

1446000

1492000

1500000

1109000

112000

99000

74000

1183000

17953000

35881000

35900000

17227000

34500000

34498000

16520314

16545495

29500

2589956000

60604000

1241388000

1287964000

2530950000

55201000

1217456000

1258293000

348861000

321562000

12568000

3333000

15901000

22350000

1822000

24172000

4366000

6738000

-15358000

-13599000

41400000

11800000

29600000

27700000

2000000

25700000

11750000

2042000

29603000

25712000

3399000

3166000

7786000

6638000

168733000

130530000

91499000

80381000

107000

-38203000

-11118000

400000

33000

700000

2900000

22000

500000

2054794

822192

0.01

750000000

560023745

560169422

5600000

5602000

-6033000

-38480000

-18666000

-61791000

0.032

0.158

0.026

0.174

0.1

0.10

0.1

140400000

109600000

100100000

61388000

61846000

58800000

78990000

47720000

41300000

4800000

8500000

29160000

55894000

13505000

143901000

28334000

283867000

15652000

134408000

30300000

273849000

-4900000

143200000.0

21539873

0.0135

0.0035

0.015

0.005

0.025

31850000

7.07

5.00

0.14148

0.1414827

9.19

1.3

175000000.0

55000000.0

0.03

0.065

0.05

P5Y

2565000

1456000

0.030

0.042

0.030

0.047

125000

51000

-23039000

-2026000

148729000

148255000

15400000

15000000

25551000

30000

18827000

6694000

51281000

60000

37752000

13469000

24762000

21000

17989000

6752000

49518000

51000

35975000

13492000

23000

3333000

1799000

317000

-23000

5069000

-31000

444000

5482000

10014000

17000

-512000

9519000

332000

1916000

2248000

57000

3587000

3644000

-0.03

-0.09

-0.01

-0.09

-0.04

-0.11

-0.01

-0.09

877000

-64000

-5069000

-10014000

0.05

0.09

0.29

0.06

0.01

0.09

0.10

0.05

0.29

40100000

363300000

174600000

-143500000

15547000

12461000

22350000

11289000

11402000

939000

-13599000

41353000

27754000

P20Y

P3Y

198935000

231996000

10475000

448345000

10305000

16372000

5799000

340921000

50553000

9694000

447225000

10246000

16367000

5696000

340815000

50494000

683835000

648541000

5482000

9519000

2248000

3644000

-5628000

-319000

-5309000

-7758000

-635000

-7123000

-7213000

-271000

-6942000

-9669000

-555000

-9114000

-113000

2473000

495000

717099000

452786000

264313000

401821000

4827000

17977000

89226000

11698000

139784000

7898000

2069000

5203000

32988000

3608000

714234000

452787000

261447000

401800000

401821000

4827000

17977000

87025000

11698000

139784000

7701000

2069000

4896000

32988000

3448000

-2865000

-2201000

-197000

-307000

-160000

-22248000

-61565000

3029000

-38520000

-5628000

-7758000

-7213000

-9669000

-10960000

-17904000

2017000

1126000

4321000

5251000

9439000

-8092000

30865000

-12440000

-3837000

-15820000

-31122000

2896000

-34018000

29800000

-30812000

443000

-894000

254000

146000

-3692000

3730000

4816000

4725000

647347000

645714000

425400000

652000

1291000

748000

785000

21012000

16783000

49333000

46753000

7467000

5800000

6565000

4726000

5873000

3910000

4800000

1200000

1260000

734378000

720454000

2589956000

2530950000

316534000

306861000

317000

41353000

317000

41670000

27754000

417844000

413593000

114664000

1598000

1665000

1819000

2111000

446000

104152000

1988000

384000

501000

109496000

502000

250000

798000

757000

1179000

105539000

102000

262000

9000

98000

0.0050

P5Y

0.066

0.055

0.029

0.055

0.0401

0.0267

0.055

0.05

0.055

196900000

3800000

3250000

2500000

292000

3500000

1810000

175000000

350000

4500000

1800000

98000

20000000.0

175000000.0

50000000.0

11926000

6465000

3643000

29160000

9290000

30343000

1632000

2821000

1567000

2011000

1704000

6469000

0.063

0.018

40642000

45497000

104152000

105539000

33915000

53211000

-16412000

-11666000

-56583000

-52599000

-16916000

-51419000

-6201000

-49315000

-21333000

-60142000

-6201000

-49315000

3583000

9482000

8137000

9199000

318432000

630028000

268793000

566317000

-25831000

-12878000

-4944000

-8009000

-71047000

-28849000

-8044000

-34154000

-5108000

-8748000

1475000

2165000

-47719000

-20393000

-6543000

-20783000

79364000

65421000

3838000

4764000

5615000

5246000

-7600000

10495000

13088000

-12465000

-7600000

-4876000

-12476000

-7600000

-594000

-206000

-743000

21546000

24986000

17857000

22131000

239955000

20001000

219954000

209444000

-533000

2509000

8584000

10477000

1294000

2198000

2000000

1000000

3000000

1000000

500000

100000

3000000

1000000

5000

16805000

12792000

42513000

5400000

37113000

41651000

3532000

3259000

55000000

1916000

318000

50000000

45524000

18817000

1286000

3398000

840000

-16916000

-51419000

-2896000

-48523000

-6201000

-49315000

146557000

150156000

P5Y

P40Y

P12Y

P8Y

P3Y

P10Y

P5Y

P3Y

500000

200000

5124000

2188000

2936000

84400000

121000

141000

61000

140000

13525000

20924000

33128000

535000

32593000

59685000

1070000

58615000

29211000

62097000

-1036959000

-29800000

-1007159000

-1081397000

292601000

29723000

28966000

233912000

18300000

42961000

80037000

104366000

6548000

29723000

1147000

28576000

28966000

233912000

-22759000

256671000

11899000

5118000

22525000

7654000

724000

244650000

31000

558981000

45328000

51197000

462456000

32400000

76900000

157090000

217062000

11404000

45328000

-1826000

-2900000

47154000

51197000

462456000

-49500000

511956000

22020000

9623000

39734000

11872000

1589000

474084000

59000

-29800000

263685000

19107000

28523000

216055000

16300000

45828000

72459000

92033000

5735000

19107000

28523000

216055000

11937000

4592000

20778000

2526000

1302000

222535000

15000

518598000

34855000

56374000

427369000

31000000

83357000

139595000

192986000

11431000

13582000

34855000

56374000

427369000

23670000

10125000

38060000

6141000

2723000

437845000

34000

105579000

-22759000

128338000

215523000

-49500000

265023000

87653000

179172000

30343000

15844000

11514000

303000

1000000000

1855578000

4876000

-528000

-5404000

1810496000

-13004000

8207000

10278000

549907

1791000

0.29

564164000

564163808

563617000

563617274

559541000

559541253

559508000

559507732

559347540

559348000

558892375

558892000

559541253

559541000

559508000

559507732

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table reflects the accounting method, carrying value and underlying equity in net assets of our unconsolidated investments as of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June 30, 2018</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:52%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:21%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:21%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;text-decoration:underline;">(in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Investment type</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Investment Carrying Value</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Underlying Equity in Net Assets</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Equity method investments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,703</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,547</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Variable interest entity, equity method</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">706</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Equity securities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,350</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Equity securities with no readily determinable fair value</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">939</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Warrants and options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,799</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total carrying value of investments</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">45,497</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr></table></div></div><div style="line-height:174%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;"></font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ACQUISITIONS, INVESTMENTS AND LICENSES</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Investments</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table reflects the accounting method, carrying value and underlying equity in net assets of our unconsolidated investments as of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June 30, 2018</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:52%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:21%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:21%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;text-decoration:underline;">(in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Investment type</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Investment Carrying Value</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Underlying Equity in Net Assets</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Equity method investments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,703</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,547</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Variable interest entity, equity method</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">706</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Equity securities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,350</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Equity securities with no readily determinable fair value</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">939</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Warrants and options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,799</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total carrying value of investments</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">45,497</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr></table></div></div><div style="line-height:174%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Equity method investments</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our equity method investments consist of investments in Pharmsynthez (ownership </font><font style="font-family:inherit;font-size:10pt;">9%</font><font style="font-family:inherit;font-size:10pt;">), Cocrystal Pharma, Inc. (“COCP”) (</font><font style="font-family:inherit;font-size:10pt;">9%</font><font style="font-family:inherit;font-size:10pt;">), Non-Invasive Monitoring Systems, Inc. (“NIMS”) (</font><font style="font-family:inherit;font-size:10pt;">1%</font><font style="font-family:inherit;font-size:10pt;">), Neovasc, Inc. (“Neovasc”) (</font><font style="font-family:inherit;font-size:10pt;">6%</font><font style="font-family:inherit;font-size:10pt;">), VBI Vaccines Inc. (“VBI”) (</font><font style="font-family:inherit;font-size:10pt;">10%</font><font style="font-family:inherit;font-size:10pt;">), InCellDx, Inc. (</font><font style="font-family:inherit;font-size:10pt;">29%</font><font style="font-family:inherit;font-size:10pt;">), BioCardia, Inc. (“BioCardia”) (</font><font style="font-family:inherit;font-size:10pt;">5%</font><font style="font-family:inherit;font-size:10pt;">), and Xenetic Biosciences, Inc. (“Xenetic”) (</font><font style="font-family:inherit;font-size:10pt;">5%</font><font style="font-family:inherit;font-size:10pt;">). The total assets, liabilities, and net losses of our equity method investees as of and for the </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">six months ended June 30, 2018</font><font style="font-family:inherit;font-size:10pt;"> were </font><font style="font-family:inherit;font-size:10pt;">$363.3 million</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$174.6 million</font><font style="font-family:inherit;font-size:10pt;">, and </font><font style="font-family:inherit;font-size:10pt;">$143.5 million</font><font style="font-family:inherit;font-size:10pt;">, respectively. We have determined that we and/or our related parties can significantly influence the success of our equity method investments through our board representation and/or voting power. Accordingly, we account for our investment in these entities under the equity method and record our proportionate share of their losses in Loss from investments in investees in our Condensed Consolidated Statements of Operations. The aggregate value of our equity method investments based on the quoted market price of their common stock and the number of shares held by us as of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June 30, 2018</font><font style="font-family:inherit;font-size:10pt;"> is </font><font style="font-family:inherit;font-size:10pt;">$40.1 million</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Equity Securities</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our equity securities consist of investments in RXi Pharmaceuticals Corporation (“RXi”) (ownership </font><font style="font-family:inherit;font-size:10pt;">1%</font><font style="font-family:inherit;font-size:10pt;">), ChromaDex Corporation (</font><font style="font-family:inherit;font-size:10pt;">0%</font><font style="font-family:inherit;font-size:10pt;">), MabVax Therapeutics Holdings, Inc. (“MabVax”) (</font><font style="font-family:inherit;font-size:10pt;">2%</font><font style="font-family:inherit;font-size:10pt;">), and Eloxx Pharmaceuticals, Inc. (“Eloxx”) (</font><font style="font-family:inherit;font-size:10pt;">4%</font><font style="font-family:inherit;font-size:10pt;">). We have determined that our ownership, along with that of our related parties, does not provide us with significant influence over the operations of these investments. Accordingly, we account for our investment in these entities as equity securities, and we record changes in the fair value of these investments in Other income (expense) each reporting period when they have readily determinable fair value. Equity securities without a readily determinable fair value are adjusted to fair value when an observable price change can be identified. Net gains and losses on our equity securities for the </font><font style="font-family:inherit;font-size:10pt;">six months ended June 30, 2018</font><font style="font-family:inherit;font-size:10pt;"> are as follows:</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td style="width:78%;" rowspan="1" colspan="1"></td><td style="width:2%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;text-decoration:underline;">(in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Equity Securities</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">For the six months ended June 30, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net gains recognized during the period on equity securities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,289</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less: Net losses realized during the period on equity securities sold during the period</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(113</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unrealized net gains and losses recognized during the period on equity securities still held at the reporting date</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,402</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Sales of investments</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Gains (losses) included in earnings from sales of our investments are recorded in Other income (expense), net in our Condensed Consolidated Statements of Operations. We did not have significant sales activity during the </font><font style="font-family:inherit;font-size:10pt;">six months ended June 30, 2018</font><font style="font-family:inherit;font-size:10pt;"> and 2017. The cost of securities sold is based on the specific identification method. </font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Warrants and options</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition to our equity method investments and equity securities, we hold options to purchase </font><font style="font-family:inherit;font-size:10pt;">0.4 million</font><font style="font-family:inherit;font-size:10pt;"> additional shares of BioCardia, </font><font style="font-family:inherit;font-size:10pt;">0.1 million</font><font style="font-family:inherit;font-size:10pt;"> of which are vested as of </font><font style="font-family:inherit;font-size:10pt;">June 30, 2018</font><font style="font-family:inherit;font-size:10pt;">, and </font><font style="font-family:inherit;font-size:10pt;">33 thousand</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">0.7 million</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">0.5 million</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">22 thousand</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2.9 million</font><font style="font-family:inherit;font-size:10pt;"> of warrants to purchase additional shares of COCP, InCellDx, Inc., Xenetic, RXi and NeoVasc, respectively. We recorded the changes in the fair value of the options and warrants in Fair value changes of derivative instruments, net in our Condensed Consolidated Statements of Operations. We also recorded the fair value of the options and warrants in Investments, net in our Condensed Consolidated Balance Sheets. See further discussion of the Company’s options and warrants in Note 8 and Note 9.</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Investments in variable interest entities</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have determined that we hold variable interests in Zebra Biologics, Inc. (“Zebra”). We made this determination as a result of our assessment that Zebra does not have sufficient resources to carry out its principal activities without additional financial support. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We own </font><font style="font-family:inherit;font-size:10pt;">1,260,000</font><font style="font-family:inherit;font-size:10pt;"> shares of Zebra Series A-2 Preferred Stock and </font><font style="font-family:inherit;font-size:10pt;">900,000</font><font style="font-family:inherit;font-size:10pt;"> shares of Zebra restricted common stock (ownership </font><font style="font-family:inherit;font-size:10pt;">29%</font><font style="font-family:inherit;font-size:10pt;"> at </font><font style="font-family:inherit;font-size:10pt;">June 30, 2018</font><font style="font-family:inherit;font-size:10pt;">). Zebra is a privately held biotechnology company focused on the discovery and development of biosuperior antibody therapeutics and complex drugs. Dr. Richard Lerner, M.D., a member of our Board of Directors, is a founder of Zebra and, along with Dr. Frost, serves as a member of Zebra’s Board of Directors. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In order to determine the primary beneficiary of Zebra, we evaluated our investment and our related parties’ investment, as well as our investment combined with the related party group’s investment to identify if we had the power to direct the activities that most significantly impact the economic performance of Zebra. Based on the capital structure, governing documents and overall business operations of Zebra, we determined that, while a VIE, we do not have the power to direct the activities that most significantly impact Zebra’s economic performance and have no obligation to fund expected losses. We did determine, however, that we can significantly influence the success of Zebra through our board representation and voting power. Therefore, we have the ability to exercise significant influence over Zebra’s operations and account for our investment in Zebra under the equity method.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Concentration of credit risk and allowance for doubtful accounts</font><font style="font-family:inherit;font-size:10pt;">. Financial instruments that potentially subject us to concentrations of credit risk consist primarily of accounts receivable. Substantially all of our accounts receivable are with either companies in the healthcare industry or patients. However, credit risk is limited due to the number of our clients as well as their dispersion across many different geographic regions.</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">While we have receivables due from federal and state governmental agencies, we do not believe that such receivables represent a credit risk since the related healthcare programs are funded by federal and state governments, and payment is primarily dependent upon submitting appropriate documentation. At </font><font style="font-family:inherit;font-size:10pt;">June 30, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December 31, 2017</font><font style="font-family:inherit;font-size:10pt;">, receivable balances (net of contractual adjustments) from Medicare and Medicaid were </font><font style="font-family:inherit;font-size:10pt;">17.4%</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">15.8%</font><font style="font-family:inherit;font-size:10pt;">, respectively, of our consolidated Accounts receivable, net.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The portion of our accounts receivable due from individual patients comprises the largest portion of credit risk. At </font><font style="font-family:inherit;font-size:10pt;">June 30, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December 31, 2017</font><font style="font-family:inherit;font-size:10pt;">, receivables due from patients represent approximately </font><font style="font-family:inherit;font-size:10pt;">2.6%</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">3.2%</font><font style="font-family:inherit;font-size:10pt;">, respectively, of our consolidated Accounts receivable, net. </font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We assess the collectability of accounts receivable balances by considering factors such as historical collection experience, customer credit worthiness, the age of accounts receivable balances, regulatory changes and current economic conditions and trends that may affect a customer’s ability to pay. Actual results could differ from those estimates. Our reported net income (loss) is directly affected by our estimate of the collectability of accounts receivable.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;"></font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:67%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;text-decoration:underline;">(In thousands)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">June 30, <br clear="none"/>2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">December 31, <br clear="none"/>2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts receivable, net:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts receivable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">154,269</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">166,962</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less: allowance for doubtful accounts</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,492</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,446</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">152,777</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">165,516</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Inventories, net:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Consumable supplies</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24,986</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,546</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Finished products</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,783</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,012</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Work in-process</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,910</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,873</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Raw materials</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,800</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,467</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less: inventory reserve</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,726</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,565</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">46,753</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">49,333</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other current assets and prepaid expenses:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Taxes recoverable</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,319</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,138</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other receivables</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,031</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,798</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prepaid supplies</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,278</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,207</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prepaid insurance</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,259</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,532</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,764</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,838</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41,651</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">42,513</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intangible assets, net:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Customer relationships</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">447,225</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">448,345</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Technologies</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">340,815</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">340,921</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Trade names</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50,494</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50,553</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Licenses</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,246</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,305</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Covenants not to compete</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,367</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,372</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Product registrations</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,694</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,475</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,696</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,799</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less: accumulated amortization</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(231,996</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(198,935</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">648,541</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">683,835</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued expenses:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contract liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">61,846</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">61,388</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Employee benefits</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">46,621</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50,377</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Clinical trials</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,598</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,191</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Taxes payable</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,604</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,609</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contingent consideration</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,042</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,750</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Capital leases short-term</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,166</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,399</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Milestone payment</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,967</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,868</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Professional fees</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,727</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,355</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">65,421</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">79,364</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">200,992</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">230,301</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr></table></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:67%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;text-decoration:underline;">(In thousands)</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">June 30, <br clear="none"/>2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">December 31, <br clear="none"/>2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other long-term liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contract liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">47,720</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">78,990</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Line of credit</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">105,539</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">104,152</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contingent consideration</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,712</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29,603</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Mortgages and other debts payable</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,704</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,567</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Capital leases long-term</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,638</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,786</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,131</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,857</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">209,444</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">239,955</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table reconciles the beginning and ending balances of our Level 3 assets and liabilities as of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June 30, 2018</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:80%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">June 30, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;text-decoration:underline;">(In thousands)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Contingent</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">consideration</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at December 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41,353</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Change in fair value:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Included in results of operations</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(13,599</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at June 30, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27,754</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:6px;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table presents an analysis of product sales allowances and accruals as contract liabilities for the </font><font style="font-family:inherit;font-size:10pt;">six months ended June 30, 2018</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17" rowspan="1"></td></tr><tr><td style="width:47%;" rowspan="1" colspan="1"></td><td style="width:2%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:2%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:2%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:2%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;text-decoration:underline;">(In thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Chargebacks, discounts, rebates and fees</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Governmental </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Returns</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at December 31, 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">233</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">348</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">437</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,018</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">  Provision related to current period sales</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,188</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,936</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,124</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">  Credits or payments made</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,697</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,557</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(311</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,565</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at June 30, 2018</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">724</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">727</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">126</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,577</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total gross </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Rayaldee</font><font style="font-family:inherit;font-size:10pt;"> sales</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,582</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Provision for </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Rayaldee</font><font style="font-family:inherit;font-size:10pt;"> sales allowances and accruals as a percentage of gross </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Rayaldee</font><font style="font-family:inherit;font-size:10pt;"> sales</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">STRATEGIC ALLIANCES</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Japan Tobacco Inc.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On October 12, 2017, EirGen, our wholly-owned subsidiary, and Japan Tobacco Inc. (“JT”) entered into a Development and License Agreement (the “JT Agreement”) granting JT the exclusive rights for the development and commercialization of </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Rayaldee</font><font style="font-family:inherit;font-size:10pt;"> in Japan (the “JT Territory”). The license grant to JT covers the therapeutic and preventative use of the product for (i) SHPT in non-dialysis and dialysis patients with CKD, (ii) rickets, and (iii) osteomalacia (the “JT Initial Indications”), as well as such additional indications as may be added to the scope of the license subject to the terms of the JT Agreement (the “JT Additional Indications” and together with the JT Initial Indications, the “JT Field”). </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with the license, OPKO received an initial upfront payment of </font><font style="font-family:inherit;font-size:10pt;">$6 million</font><font style="font-family:inherit;font-size:10pt;">. OPKO will receive another </font><font style="font-family:inherit;font-size:10pt;">$6 million</font><font style="font-family:inherit;font-size:10pt;"> upon the initiation of OPKO’s planned phase 2 study for </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Rayaldee</font><font style="font-family:inherit;font-size:10pt;"> in dialysis patients in the U.S. OPKO is also eligible to receive up to an additional aggregate amount of </font><font style="font-family:inherit;font-size:10pt;">$31 million</font><font style="font-family:inherit;font-size:10pt;"> upon the achievement of certain regulatory and development milestones by JT for </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Rayaldee</font><font style="font-family:inherit;font-size:10pt;"> in the JT Territory, and </font><font style="font-family:inherit;font-size:10pt;">$75 million</font><font style="font-family:inherit;font-size:10pt;"> upon the achievement of certain sales based milestones by JT in the JT Territory. OPKO will also receive tiered, double digit royalty payments at rates ranging from low double digits to mid-teens on net sales of </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Rayaldee </font><font style="font-family:inherit;font-size:10pt;">within the JT Territory. JT will, at its sole cost and expense, be responsible for performing all development activities necessary to obtain all regulatory approvals for </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Rayaldee</font><font style="font-family:inherit;font-size:10pt;"> in Japan and for all commercial activities pertaining to </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Rayaldee</font><font style="font-family:inherit;font-size:10pt;"> in Japan, except for certain preclinical expenses which OPKO has agreed to reimburse JT up to a capped amount.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The JT Agreement provides for the following: (1) an exclusive license in the JT Territory in the JT Field for the development and commercialization of </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Rayaldee</font><font style="font-family:inherit;font-size:10pt;">; and (2) at JT’s option, EirGen will supply products to support the development, sale and commercialization of the products to JT in the JT Territory. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The initial consideration primarily includes the non-refundable </font><font style="font-family:inherit;font-size:10pt;">$6 million</font><font style="font-family:inherit;font-size:10pt;"> upfront payment and </font><font style="font-family:inherit;font-size:10pt;">$6 million</font><font style="font-family:inherit;font-size:10pt;"> of probable variable consideration we will receive upon the initiation of our planned phase 2 study for </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Rayaldee</font><font style="font-family:inherit;font-size:10pt;"> in dialysis patients in the U.S. The initial consideration will be recognized over the performance period through 2021, when we anticipate completing the transfer of license materials specified in the JT Agreement and our performance obligation is complete.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are also eligible to receive up to </font><font style="font-family:inherit;font-size:10pt;">$31 million</font><font style="font-family:inherit;font-size:10pt;"> in regulatory and development milestones and </font><font style="font-family:inherit;font-size:10pt;">$75 million</font><font style="font-family:inherit;font-size:10pt;"> in sales milestones. Payments received for regulatory, development and sales milestones are non-refundable. The milestones are payable if and when the associated milestone is achieved and will be recognized as revenue in the period in which the associated milestone is achieved, assuming all other revenue recognition criteria are met. To date, </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> revenue has been recognized related to these milestones.</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Vifor Fresenius Medical Care Renal Pharma Ltd</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2016, EirGen, our wholly-owned subsidiary, and Vifor Fresenius Medical Care Renal Pharma Ltd (“VFMCRP”), entered into a Development and License Agreement (the “VFMCRP Agreement”) for the development and commercialization of </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Rayaldee</font><font style="font-family:inherit;font-size:10pt;"> (the “Product”) worldwide, except for (i) the United States, (ii) any country in Central America or South America (excluding Mexico), (iii) Russia, (iv) China, (v) Japan, (vi) Ukraine, (vii) Belorussia, (viii) Azerbaijan, (ix) Kazakhstan, and (x) Taiwan (the “VFMCRP Territory”). The license to VFMCRP potentially covers all therapeutic and prophylactic uses of the Product in human patients (the “VFMCRP Field”), provided that initially the license is for the use of the Product for the treatment or prevention of SHPT related to patients with stage 3 or 4 chronic kidney disease and vitamin D insufficiency/deficiency (the “VFMCRP Initial Indication”).</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the terms of the VFMCRP Agreement, EirGen granted to VFMCRP an exclusive license in the VFMCRP Territory in the VFMCRP Field to use certain EirGen patents and technology to make, have made, use, sell, offer for sale, and import Products and to develop, commercialize, have commercialized, and otherwise exploit the Product. EirGen received a non-refundable and non-creditable initial payment of </font><font style="font-family:inherit;font-size:10pt;">$50 million</font><font style="font-family:inherit;font-size:10pt;">, which was recognized in Revenue from the transfer of intellectual property and other in our Condensed Consolidated Statement of Operations in 2016. EirGen is also eligible to receive up to an additional </font><font style="font-family:inherit;font-size:10pt;">$37 million</font><font style="font-family:inherit;font-size:10pt;"> in regulatory milestones (“Regulatory Milestones”) and </font><font style="font-family:inherit;font-size:10pt;">$195 million</font><font style="font-family:inherit;font-size:10pt;"> in launch and sales-based milestones (“Sales Milestones”), and will receive tiered royalties on sales of the product at percentage rates that range from the mid-teens to the mid-twenties or a minimum royalty, whichever is greater, upon the commencement of sales of the Product within the VFMCRP Territory and in the VFMCRP Field.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We plan to share responsibility with VFMCRP for the conduct of trials specified within an agreed-upon development plan, with each company leading certain activities within the plan. EirGen will lead the manufacturing activities within and outside the VFMCRP Territory and the commercialization activities outside the VFMCRP Territory and outside the VFMCRP Field in the VFMCRP Territory and VFMCRP will lead the commercialization activities in the VFMCRP Territory and the VFMCRP Field. For the initial development plan, the companies have agreed to certain cost sharing arrangements. VFMCRP will be responsible for all other development costs that VFMCRP considers necessary to develop the Product for the use of the Product for the VFMCRP Initial Indication in the VFMCRP Territory in the VFMCRP Field except as otherwise provided in the VFMCRP Agreement. The clinical studies provided for in the development activities are expected to commence in 2018. </font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with the VFMCRP Agreement, the parties entered into a letter agreement pursuant to which EirGen granted to VFMCRP an exclusive option (the “Option”) to acquire an exclusive license under certain EirGen patents and technology to use, import, offer for sale, sell, distribute and commercialize the Product in the United States solely for the treatment of secondary hyperparathyroidism in dialysis patients with chronic kidney disease and vitamin D insufficiency (the “Dialysis Indication”). Upon exercise of the Option, VFMCRP will reimburse EirGen for all of the development costs incurred by EirGen with respect to the Product for the Dialysis Indication in the United States. VFMCRP would also pay EirGen up to an additional aggregate amount of </font><font style="font-family:inherit;font-size:10pt;">$555 million</font><font style="font-family:inherit;font-size:10pt;"> of sales-based milestones upon the achievement of certain milestones and would be obligated to pay royalties at percentage rates that range from the mid-teens to the mid-twenties on sales of the Product in the United States for the Dialysis Indication. To date, VFMCRP has not exercised its option.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">EirGen is also eligible to receive up to an additional </font><font style="font-family:inherit;font-size:10pt;">$37 million</font><font style="font-family:inherit;font-size:10pt;"> in Regulatory Milestones and </font><font style="font-family:inherit;font-size:10pt;">$195 million</font><font style="font-family:inherit;font-size:10pt;"> in Sales Milestones. Payments received for Regulatory Milestones and Sales Milestones are non-refundable. The Regulatory Milestones are payable if and when VFMCRP obtains approval from certain regulatory authorities and will be recognized as revenue in the period in which the associated milestone is achieved, assuming all other revenue recognition criteria are met. We account for the Sales Milestones as royalties and Sales Milestones payments will be recognized as revenue in the period in which the associated milestone is achieved or sales occur, assuming all other revenue recognition criteria are met. To date, </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> revenue has been recognized related to the milestones or royalties.</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Pfizer Inc.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In December 2014, we entered into an exclusive worldwide agreement with Pfizer Inc. (“Pfizer”) for the development and commercialization of our long-acting hGH-CTP for the treatment of growth hormone deficiency (“GHD”) in adults and children, as well as for the treatment of growth failure in children born small for gestational age (“SGA”) (the “Pfizer Transaction”). </font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Pfizer Transaction closed in January 2015 following the termination of the waiting period under the Hart-Scott-Rodino Act. Under the terms of the Pfizer Transaction, we received non-refundable and non-creditable upfront payments of </font><font style="font-family:inherit;font-size:10pt;">$295.0 million</font><font style="font-family:inherit;font-size:10pt;"> and are eligible to receive up to an additional </font><font style="font-family:inherit;font-size:10pt;">$275.0 million</font><font style="font-family:inherit;font-size:10pt;"> upon the achievement of certain regulatory milestones. Pfizer received the exclusive license to commercialize hGH-CTP worldwide. In addition, we are eligible to receive initial tiered royalty payments associated with the commercialization of hGH-CTP for Adult GHD with percentage rates ranging from the high teens to mid-twenties. Upon the launch of hGH-CTP for Pediatric GHD in certain major markets, the royalties will transition to regional, tiered gross profit sharing for both hGH-CTP and Pfizer’s Genotropin®.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The agreement with Pfizer will remain in effect until the last sale of the licensed product, unless earlier terminated as permitted under the agreement. In addition to termination rights for material breach and bankruptcy, Pfizer is permitted to terminate the Agreement in its entirety, or with respect to one or more world regions, without cause after a specified notice period. If the Agreement is terminated by us for Pfizer’s uncured material breach, or by Pfizer without cause, provision has been made for transition of product and product responsibilities to us for the terminated regions, as well as continued supply of product by Pfizer or transfer of supply to us in order to support the terminated regions. </font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are recognizing the non-refundable </font><font style="font-family:inherit;font-size:10pt;">$295.0 million</font><font style="font-family:inherit;font-size:10pt;"> upfront payments as the research and development services are completed and had contract liabilities related to the Pfizer Transaction of </font><font style="font-family:inherit;font-size:10pt;">$100.1 million</font><font style="font-family:inherit;font-size:10pt;"> at </font><font style="font-family:inherit;font-size:10pt;">June 30, 2018</font><font style="font-family:inherit;font-size:10pt;">, of which </font><font style="font-family:inherit;font-size:10pt;">$58.8 million</font><font style="font-family:inherit;font-size:10pt;"> was classified in Accrued expenses and </font><font style="font-family:inherit;font-size:10pt;">$41.3 million</font><font style="font-family:inherit;font-size:10pt;"> was classified in Other long-term liabilities.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Pfizer Transaction includes milestone payments of </font><font style="font-family:inherit;font-size:10pt;">$275.0 million</font><font style="font-family:inherit;font-size:10pt;"> upon the achievement of certain milestones. The milestones range from </font><font style="font-family:inherit;font-size:10pt;">$20.0 million</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">$90.0 million</font><font style="font-family:inherit;font-size:10pt;"> each and are based on achievement of regulatory approval in the U.S. and regulatory approval and price approval in other major markets. The milestone payments will be recognized as revenue in the period in which the associated milestone is achieved, assuming all other revenue recognition criteria are met. To date, </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> revenue has been recognized related to the achievement of the milestones.</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">TESARO</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In November 2009, we entered into an asset purchase agreement (the “NK-1 Agreement”) under which we acquired VARUBI™ (rolapitant) and other neurokinin-1 (“NK-1”) assets from Merck. In December 2010, we entered into an exclusive license agreement with TESARO, in which we out-licensed the development, manufacture, commercialization and distribution of our lead NK-1 candidate, VARUBI™ (the “TESARO License”). Under the terms of the license, we received a </font><font style="font-family:inherit;font-size:10pt;">$6.0 million</font><font style="font-family:inherit;font-size:10pt;"> upfront payment from TESARO and we received </font><font style="font-family:inherit;font-size:10pt;">$30 million</font><font style="font-family:inherit;font-size:10pt;"> of milestone payments from TESARO upon achievement of certain regulatory and commercial sale milestones and we are eligible to receive additional commercial milestone payments of up to </font><font style="font-family:inherit;font-size:10pt;">$85 million</font><font style="font-family:inherit;font-size:10pt;"> if specified levels of annual net sales are achieved. The sales based milestone payments will be recognized as revenue in full in the period in which the associated sales occur. During the </font><font style="font-family:inherit;font-size:10pt;">six months ended June 30, 2018</font><font style="font-family:inherit;font-size:10pt;"> and 2017, </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> revenue was recognized related to the achievement of the milestones under the TESARO License. </font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">TESARO is also obligated to pay us tiered royalties on annual net sales achieved in the United States and Europe at percentage rates that range from the low double digits to the low twenties, and outside of the United States and Europe at low double-digit percentage rates. Royalties will be recognized in the period the sales occur. TESARO assumed responsibility for clinical development and commercialization of licensed products at its expense. Under the NK-1 Agreement, we will continue to receive royalties on a country-by-country and product-by-product basis until the later of the date that all of the patent rights licensed from us and covering VARUBI™ expire, are invalidated or are not enforceable and </font><font style="font-family:inherit;font-size:10pt;">12</font><font style="font-family:inherit;font-size:10pt;"> years from the first commercial sale of the product. </font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If TESARO elects to develop and commercialize VARUBI™ in Japan through a third-party licensee, TESARO will share equally with us all amounts it receives in connection with such activities, subject to certain exceptions and deductions.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The term of the license will remain in force until the expiration of the royalty term in each country, unless we terminate the license earlier for TESARO’s material breach of the license or bankruptcy. TESARO has a right to terminate the license at any time during the term for any reason on </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> months’ written notice.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">TESARO announced during the first quarter of 2018 that it has elected to suspend further distribution of Varubi IV. </font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Pharmsynthez </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In April 2013, we entered into a series of concurrent transactions with Pharmsynthez, a Russian pharmaceutical company traded on the Moscow Stock Exchange, pursuant to which we acquired an equity method investment in Pharmsynthez (ownership </font><font style="font-family:inherit;font-size:10pt;">9%</font><font style="font-family:inherit;font-size:10pt;">). We also granted rights to certain technologies in the Russian Federation, Ukraine, Belarus, Azerbaijan and Kazakhstan (the “Pharmsynthez Territories”) to Pharmsynthez and agreed to perform certain development activities. We will receive from Pharmsynthez royalties on net sales of products incorporating the technologies in the Pharmsynthez Territories, as well as a percentage of any sublicense income from third parties for the technologies in the Pharmsynthez Territories. </font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">RXi Pharmaceuticals Corporation</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March 2013, we completed the sale to RXi of substantially all of our assets in the field of RNA interference (the “RNAi Assets”) (collectively, the “Asset Purchase Agreement”). Pursuant to the Asset Purchase Agreement, RXi will be required to pay us up to </font><font style="font-family:inherit;font-size:10pt;">$50.0 million</font><font style="font-family:inherit;font-size:10pt;"> in milestone payments upon the successful development and commercialization of each drug developed by RXi, certain of its affiliates or any of its or their licensees or sublicensees utilizing patents included within the RNAi Assets (each, a “Qualified Drug”). In addition, RXi will also be required to pay us royalties equal to: (a) a mid single-digit percentage of “Net Sales” (as defined in the Asset Purchase Agreement) with respect to each Qualified Drug sold for an ophthalmologic use during the applicable “Royalty Period” (as defined in the Asset Purchase Agreement); and (b) a low single-digit percentage of net sales with respect to each Qualified Drug sold for a non-ophthalmologic use during the applicable Royalty Period.</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Other</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have completed strategic deals with numerous institutions and commercial partners. In connection with these agreements, upon the achievement of certain milestones we are obligated to make certain payments and have royalty obligations upon sales of products developed under the license agreements. At this time, we are unable to estimate the timing and amounts of payments as the obligations are based on future development of the licensed products.</font></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS)</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For the </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">six months ended June 30, 2018</font><font style="font-family:inherit;font-size:10pt;">, changes in Accumulated other comprehensive income (loss), net of tax, were as follows:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:59%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;text-decoration:underline;">(In thousands)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Foreign</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">currency</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">gain (loss) in</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Accumulated</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">OCI</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at December 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5,404</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,876</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(528</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;text-indent:26px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other comprehensive loss before reclassifications</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7,600</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7,600</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Reclassification adjustment due to adoption of ASU 2016-01</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,876</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,876</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net other comprehensive loss</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7,600</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,876</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(12,476</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at June 30, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(13,004</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(13,004</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">DEBT</font><font style="font-family:inherit;font-size:10pt;">    </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2018, we issued a series of </font><font style="font-family:inherit;font-size:10pt;">5%</font><font style="font-family:inherit;font-size:10pt;"> Convertible Promissory Notes (the “2023 Convertible Notes”) in the aggregate principal amount of </font><font style="font-family:inherit;font-size:10pt;">$55.0 million</font><font style="font-family:inherit;font-size:10pt;">. The 2023 Convertible Notes mature </font><font style="font-family:inherit;font-size:10pt;">5</font><font style="font-family:inherit;font-size:10pt;"> years from the date of issuance. Each holder of a 2023 Convertible Note has the option, from time to time, to convert all or any portion of the outstanding principal balance of such 2023 Convertible Note, together with accrued and unpaid interest thereon, into shares of our Common Stock, par value </font><font style="font-family:inherit;font-size:10pt;">$0.01</font><font style="font-family:inherit;font-size:10pt;"> per share, at a conversion price of </font><font style="font-family:inherit;font-size:10pt;">$5.00</font><font style="font-family:inherit;font-size:10pt;"> per share of Common Stock (the “Shares”). We may redeem all or any part of the then issued and outstanding 2023 Convertible Notes, together with accrued and unpaid interest thereon, pro ratably among the holders, upon no fewer than </font><font style="font-family:inherit;font-size:10pt;">30</font><font style="font-family:inherit;font-size:10pt;"> days, and no more than </font><font style="font-family:inherit;font-size:10pt;">60</font><font style="font-family:inherit;font-size:10pt;"> days, notice to the holders. The 2023 Convertible Notes contain customary events of default and representations and warranties of OPKO. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The issuance of the 2023 Convertible Notes and the issuance of the Shares, if any, upon conversion thereof was not, and will not be, respectively, registered under the Securities Act of 1933, pursuant to the exemption provided by Section 4(a)(2) thereof, and we have not agreed to register the Shares if or when such Shares are issued. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Purchasers of the 2023 Convertible Notes include an affiliate of Dr. Phillip Frost, M.D., our Chairman and Chief Executive Officer, and Dr. Jane H. Hsiao, Ph.D., MBA, our Vice-Chairman and Chief Technical Officer. </font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2013, we entered into note purchase agreements (the “2033 Senior Notes”) with qualified institutional buyers and accredited investors (collectively, the “Purchasers”) in a private placement in reliance on exemptions from registration under the Securities Act. The 2033 Senior Notes were issued on </font><font style="font-family:inherit;font-size:10pt;">January 30, 2013</font><font style="font-family:inherit;font-size:10pt;">. The 2033 Senior Notes, which totaled </font><font style="font-family:inherit;font-size:10pt;">$175.0 million</font><font style="font-family:inherit;font-size:10pt;"> in original principal amount, bear interest at the rate of </font><font style="font-family:inherit;font-size:10pt;">3.00%</font><font style="font-family:inherit;font-size:10pt;"> per year, payable semiannually on February 1 and August 1 of each year. The 2033 Senior Notes will mature on </font><font style="font-family:inherit;font-size:10pt;">February 1, 2033</font><font style="font-family:inherit;font-size:10pt;">, unless earlier repurchased, redeemed or converted. Upon a fundamental change as defined in the Indenture, dated as of January 30, 2013, by and between the Company and Wells Fargo Bank N.A., as trustee, governing the 2033 Senior Notes (the “Indenture”), subject to certain exceptions, the holders may require us to repurchase all or any portion of their 2033 Senior Notes for cash at a repurchase price equal to </font><font style="font-family:inherit;font-size:10pt;">100%</font><font style="font-family:inherit;font-size:10pt;"> of the principal amount of the 2033 Senior Notes being repurchased, plus any accrued and unpaid interest to but not including the related fundamental change repurchase date.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table sets forth information related to the 2033 Senior Notes which is included in our Condensed Consolidated Balance Sheets as of </font><font style="font-family:inherit;font-size:10pt;">December 31, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June 30, 2018</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:53%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;text-decoration:underline;">(In thousands)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2033 Senior Notes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Discount</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Debt Issuance Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at December 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31,850</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,565</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(125</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29,160</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amortization of debt discount and debt issuance costs</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,109</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">74</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,183</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at June 30, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31,850</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,456</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(51</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30,343</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The 2033 Senior Notes will be convertible at any time on or after November 1, 2032, through the second scheduled trading day immediately preceding the maturity date, at the option of the holders. Additionally, holders may convert their 2033 Senior Notes prior to the close of business on the scheduled trading day immediately preceding November 1, 2032, under the following circumstances: (1) conversion based upon satisfaction of the trading price condition relating to the 2033 Senior Notes; (2) conversion based on the Common Stock price; (3) conversion based upon the occurrence of specified corporate events; or (4) if we call the 2033 Senior Notes for redemption. The 2033 Senior Notes will be convertible into cash, shares of our Common Stock, or a combination of cash and shares of Common Stock, at our election unless we have made an irrevocable election of net share settlement. The initial conversion rate for the 2033 Senior Notes will be </font><font style="font-family:inherit;font-size:10pt;">141.48</font><font style="font-family:inherit;font-size:10pt;"> shares of Common Stock per </font><font style="font-family:inherit;font-size:10pt;">$1,000</font><font style="font-family:inherit;font-size:10pt;"> principal amount of 2033 Senior Notes (equivalent to an initial conversion price of approximately </font><font style="font-family:inherit;font-size:10pt;">$7.07</font><font style="font-family:inherit;font-size:10pt;"> per share of Common Stock), and will be subject to adjustment upon the occurrence of certain events. In addition, we will, in certain circumstances, increase the conversion rate for holders who convert their 2033 Senior Notes in connection with a make-whole fundamental change (as defined in the Indenture). Holders of the 2033 Senior Notes may require us to repurchase the 2033 Senior Notes for </font><font style="font-family:inherit;font-size:10pt;">100%</font><font style="font-family:inherit;font-size:10pt;"> of their principal amount, plus accrued and unpaid interest, on February 1, 2019, February 1, 2023 and February 1, 2028, or following the occurrence of a fundamental change as defined in the indenture governing the 2033 Senior Notes. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Before February 1, 2019, we may redeem for cash any or all of the 2033 Senior Notes but only if the last reported sale price of our Common Stock exceeds </font><font style="font-family:inherit;font-size:10pt;">130%</font><font style="font-family:inherit;font-size:10pt;"> of the applicable conversion price for at least </font><font style="font-family:inherit;font-size:10pt;">20</font><font style="font-family:inherit;font-size:10pt;"> trading days during the </font><font style="font-family:inherit;font-size:10pt;">30</font><font style="font-family:inherit;font-size:10pt;"> consecutive trading day period ending on the trading day immediately prior to the date on which we deliver the redemption notice. The redemption price will equal </font><font style="font-family:inherit;font-size:10pt;">100%</font><font style="font-family:inherit;font-size:10pt;"> of the principal amount of the 2033 Senior Notes to be redeemed, plus any accrued and unpaid interest to but not including the redemption date. On or after February 1, 2019, we may redeem for cash any or all of the 2033 Senior Notes at a redemption price of </font><font style="font-family:inherit;font-size:10pt;">100%</font><font style="font-family:inherit;font-size:10pt;"> of the principal amount of the 2033 Senior Notes to be redeemed, plus any accrued and unpaid interest up to but not including the redemption date.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The terms of the 2033 Senior Notes, include, among others: (i) rights to convert into shares of our Common Stock, including upon a fundamental change; and (ii) a coupon make-whole payment in the event of a conversion by the holders of the 2033 Senior Notes on or after February 1, 2017 but prior to February 1, 2019. We determined that these specific terms were considered to be embedded derivatives. Embedded derivatives are required to be separated from the host contract, the 2033 Senior Notes, and carried at fair value when: (a) the embedded derivative possesses economic characteristics that are not clearly and closely related to the economic characteristics of the host contract; and (b) a separate, stand-alone instrument with the same terms would qualify as a derivative instrument. We concluded that the embedded derivatives within the 2033 Senior Notes meet these criteria and, as such, were valued separate and apart from the 2033 Senior Notes and recorded at fair value each reporting period.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For accounting and financial reporting purposes, we combined these embedded derivatives and valued them together as one unit of accounting. In 2017, certain terms of the embedded derivatives expired pursuant to the original agreement and the embedded derivatives no longer met the criteria to be separated from the host contract and, as a result, the embedded derivatives are no longer required to be valued separate and apart from the 2033 Senior Notes and were reclassified to additional paid in capital. Accordingly, there was </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> derivative income (loss) for the </font><font style="font-family:inherit;font-size:10pt;">six months ended June 30, 2018</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">From 2013 to 2016, holders of the 2033 Senior Notes converted </font><font style="font-family:inherit;font-size:10pt;">$143.2 million</font><font style="font-family:inherit;font-size:10pt;"> in aggregate principal amount into an aggregate of </font><font style="font-family:inherit;font-size:10pt;">21,539,873</font><font style="font-family:inherit;font-size:10pt;"> shares of the Company’s Common Stock.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In April 2015, we initially announced that our 2033 Senior Notes were convertible through June 2015 by holders of such notes. This conversion right was triggered because the closing price per share of our Common Stock exceeded </font><font style="font-family:inherit;font-size:10pt;">$9.19</font><font style="font-family:inherit;font-size:10pt;">, or </font><font style="font-family:inherit;font-size:10pt;">130%</font><font style="font-family:inherit;font-size:10pt;"> of the initial conversion price of </font><font style="font-family:inherit;font-size:10pt;">$7.07</font><font style="font-family:inherit;font-size:10pt;">, for at least </font><font style="font-family:inherit;font-size:10pt;">20</font><font style="font-family:inherit;font-size:10pt;"> of </font><font style="font-family:inherit;font-size:10pt;">30</font><font style="font-family:inherit;font-size:10pt;"> consecutive trading days during the applicable measurement period. We have elected to satisfy our conversion obligation under the 2033 Senior Notes in shares of our Common Stock. Our 2033 Senior Notes continued to be convertible by holders of such notes for the remainder of 2015, 2016 and the first quarter of 2017. They may become convertible again if </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;"> or more of the conversion conditions specified in the Indenture is satisfied during future measurement periods. Pursuant to the Indenture, a holder who elects to convert the 2033 Senior Notes will receive </font><font style="font-family:inherit;font-size:10pt;">141.4827</font><font style="font-family:inherit;font-size:10pt;"> shares of our Common Stock plus such number of additional shares as is applicable on the conversion date per </font><font style="font-family:inherit;font-size:10pt;">$1,000</font><font style="font-family:inherit;font-size:10pt;"> principal amount of 2033 Senior Notes based on the early conversion provisions in the Indenture. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In November 2015, BioReference and certain of its subsidiaries entered into a credit agreement with JPMorgan Chase Bank, N.A. (“CB”), as lender and administrative agent, as amended (the “Credit Agreement”). The Credit Agreement provides for a </font><font style="font-family:inherit;font-size:10pt;">$175.0 million</font><font style="font-family:inherit;font-size:10pt;"> secured revolving credit facility and includes a </font><font style="font-family:inherit;font-size:10pt;">$20.0 million</font><font style="font-family:inherit;font-size:10pt;"> sub-facility for swingline loans and a </font><font style="font-family:inherit;font-size:10pt;">$20.0 million</font><font style="font-family:inherit;font-size:10pt;"> sub-facility for the issuance of letters of credit. BioReference may increase the credit facility to up to </font><font style="font-family:inherit;font-size:10pt;">$275.0 million</font><font style="font-family:inherit;font-size:10pt;"> on a secured basis, subject to the satisfaction of specified conditions. The Credit Agreement matures on November 5, 2020 and is guaranteed by all of BioReference’s domestic subsidiaries. The Credit Agreement is also secured by substantially all assets of BioReference and its domestic subsidiaries, as well as a non-recourse pledge by us of our equity interest in BioReference. Availability under the Credit Agreement is based on a borrowing base comprised of eligible accounts receivables of BioReference and certain of its subsidiaries, as specified therein. As of </font><font style="font-family:inherit;font-size:10pt;">June 30, 2018</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> additional funds were available to be borrowed under the Credit Agreement. Principal under the Credit Agreement is due upon maturity on November 5, 2020.</font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At BioReference’s option, borrowings under the Credit Agreement (other than swingline loans) will bear interest at (i) the CB floating rate (defined as the higher of (a) the prime rate and (b) the LIBOR rate (adjusted for statutory reserve requirements for Eurocurrency liabilities) for an interest period of one month plus </font><font style="font-family:inherit;font-size:10pt;">2.50%</font><font style="font-family:inherit;font-size:10pt;">) plus an applicable margin of </font><font style="font-family:inherit;font-size:10pt;">0.35%</font><font style="font-family:inherit;font-size:10pt;"> for the first 12 months and </font><font style="font-family:inherit;font-size:10pt;">0.50%</font><font style="font-family:inherit;font-size:10pt;"> thereafter or (ii) the LIBOR rate (adjusted for statutory reserve requirements for Eurocurrency liabilities) plus an applicable margin of </font><font style="font-family:inherit;font-size:10pt;">1.35%</font><font style="font-family:inherit;font-size:10pt;"> for the first 12 months and </font><font style="font-family:inherit;font-size:10pt;">1.50%</font><font style="font-family:inherit;font-size:10pt;"> thereafter. Swingline loans will bear interest at the CB floating rate plus the applicable margin. The Credit Agreement also calls for other customary fees and charges, including an unused commitment fee of </font><font style="font-family:inherit;font-size:10pt;">0.50%</font><font style="font-family:inherit;font-size:10pt;"> of the lending commitments. </font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2018, BioReference and certain of its subsidiaries entered into Amendment No. 7 to the Credit Agreement, which amended the Credit Agreement to permit BioReference and its subsidiaries to use cash on hand, up to a maximum amount set forth in the amendment, to meet the availability requirements that otherwise would trigger (i) covenants that would require BioReference to maintain a minimum fixed charge coverage ratio and provide certain increased reporting under the Credit Agreement and (ii) CB’s right, as agent for the lenders under the Credit Agreement, to exercise sole dominion over funds held in certain accounts of BioReference. The other terms of the Credit Agreement remain unchanged.</font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Credit Agreement contains customary covenants and restrictions, including, without limitation, covenants that require BioReference and its subsidiaries to maintain a minimum fixed charge coverage ratio if availability under the new credit facility falls below a specified amount and to comply with laws and restrictions on the ability of BioReference and its subsidiaries to incur additional indebtedness or to pay dividends and make certain other distributions to the Company, subject to certain exceptions as specified therein. Failure to comply with these covenants would constitute an event of default under the Credit Agreement, notwithstanding the ability of BioReference to meet its debt service obligations. The Credit Agreement also includes various customary remedies for the lenders following an event of default, including the acceleration of repayment of outstanding amounts under the Credit Agreement and execution upon the collateral securing obligations under the Credit Agreement. Substantially all the assets of BioReference and its subsidiaries are restricted from sale, transfer, lease, disposal or distributions to the Company, subject to certain exceptions. BioReference and its subsidiaries net assets as of </font><font style="font-family:inherit;font-size:10pt;">June 30, 2018</font><font style="font-family:inherit;font-size:10pt;"> were approximately </font><font style="font-family:inherit;font-size:10pt;">$1.0 billion</font><font style="font-family:inherit;font-size:10pt;">, which includes goodwill of </font><font style="font-family:inherit;font-size:10pt;">$401.8 million</font><font style="font-family:inherit;font-size:10pt;"> and intangible assets of </font><font style="font-family:inherit;font-size:10pt;">$425.4 million</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition to the Credit Agreement with CB, we have line of credit agreements with </font><font style="font-family:inherit;font-size:10pt;">eleven</font><font style="font-family:inherit;font-size:10pt;"> other financial institutions as of </font><font style="font-family:inherit;font-size:10pt;">June 30, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December 31, 2017</font><font style="font-family:inherit;font-size:10pt;"> in the United States, Chile and Spain. These lines of credit are used primarily as a source of working capital for inventory purchases.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes the amounts outstanding under the BioReference, Chilean and Spanish lines of credit:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="15" rowspan="1"></td></tr><tr><td style="width:40%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;text-decoration:underline;">(Dollars in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> Balance Outstanding</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Lender</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Interest rate on</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">borrowings at June 30, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Credit line</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">capacity</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">June 30, <br clear="none"/>2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">December 31,</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2017</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">JPMorgan Chase</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.01%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">175,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">105,539</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">104,152</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Itau Bank</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.50%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,810</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,179</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">446</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Bank of Chile</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.60%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,800</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">502</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,598</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">BICE Bank</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.50%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,500</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">798</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,819</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">BBVA Bank</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.50%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,250</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">250</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,665</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Security Bank</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.50%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">98</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">98</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">501</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Estado Bank</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.50%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,500</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">757</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,111</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Santander Bank</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.50%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,500</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">262</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,988</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Scotiabank</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.00%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,800</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">384</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Banco Bilbao Vizcaya</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.90%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">292</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Santander Bank</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.67%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">350</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">102</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">196,900</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">109,496</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">114,664</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At </font><font style="font-family:inherit;font-size:10pt;">June 30, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December 31, 2017</font><font style="font-family:inherit;font-size:10pt;">, the weighted average interest rate on our lines of credit was approximately </font><font style="font-family:inherit;font-size:10pt;">4.7%</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">4.2%</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At </font><font style="font-family:inherit;font-size:10pt;">June 30, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December 31, 2017</font><font style="font-family:inherit;font-size:10pt;">, we had notes payable and other debt (excluding the 2033 Senior Notes, the 2023 Convertible Notes, the Credit Agreement and amounts outstanding under lines of credit) as follows:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:59%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;text-decoration:underline;">(In thousands)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">June 30, <br clear="none"/>2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">December 31,</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current portion of notes payable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,821</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,632</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other long-term liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,469</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,011</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,290</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,643</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The notes and other debt mature at various dates ranging from </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2018</font><font style="font-family:inherit;font-size:10pt;"> through </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2024</font><font style="font-family:inherit;font-size:10pt;"> bearing variable interest rates from </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">1.8%</font><font style="font-family:inherit;font-size:10pt;"> up to </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">6.3%</font><font style="font-family:inherit;font-size:10pt;">. The weighted average interest rate on the notes and other debt at </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June 30, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December 31, 2017</font><font style="font-family:inherit;font-size:10pt;">, was </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">3.0%</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">3.0%</font><font style="font-family:inherit;font-size:10pt;">, respectively. The notes are secured by our office space in Barcelona.</font></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:6px;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The composition of Revenue from services by payor for the three and </font><font style="font-family:inherit;font-size:10pt;">six months ended June 30, 2018</font><font style="font-family:inherit;font-size:10pt;"> and 2017 is as follow:</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Three months ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Six months ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;text-decoration:underline;">(In thousands)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Healthcare insurers</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">92,033</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">104,366</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">192,986</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">217,062</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Government payers</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">72,459</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">80,037</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">139,595</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">157,090</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Client payers</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">45,828</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">42,961</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">83,357</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">76,900</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Patients</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,735</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,548</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,431</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,404</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">216,055</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">233,912</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">427,369</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">462,456</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">FAIR VALUE MEASUREMENTS</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We record fair values at an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement determined based on assumptions that market participants would use in pricing an asset or liability. We utilize a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. These tiers include: Level 1, defined as observable inputs such as quoted prices in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">June 30, 2018</font><font style="font-family:inherit;font-size:10pt;">, we have equity securities (refer to Note 5), forward foreign currency exchange contracts for inventory purchases (refer to Note 9) and contingent consideration related to the acquisitions of CURNA, OPKO Diagnostics and OPKO Renal that are required to be measured at fair value on a recurring basis. In addition, in connection with our investment and our consulting agreement with BioCardia, we record the related BioCardia options at fair value as well as the warrants from COCP, InCellDx, Inc., Xenetic, RXi and Neovasc.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our financial assets and liabilities measured at fair value on a recurring basis are as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Fair value measurements as of June 30, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;text-decoration:underline;">(In thousands)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Quoted</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">prices in</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">active</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">markets for</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">identical</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">assets</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(Level 1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Significant</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">other</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">observable</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(Level 2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Significant</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">unobservable</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(Level 3)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Total</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Assets:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Equity securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,350</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,350</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common stock options/warrants</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,799</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,799</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forward contracts</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total assets</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,350</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,822</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24,172</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contingent consideration</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27,754</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27,754</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total liabilities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27,754</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27,754</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Fair value measurements as of December 31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;text-decoration:underline;">(In thousands)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Quoted</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">prices in</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">active</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">markets for</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">identical</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">assets</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(Level 1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Significant</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">other</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">observable</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(Level 2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Significant</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">unobservable</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(Level 3)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Total</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Assets:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Money market funds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">107</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">107</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Equity securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,461</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,461</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common stock options/warrants</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,333</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,333</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total assets</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,568</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,333</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,901</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forward contracts</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">317</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">317</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contingent consideration</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41,353</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41,353</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total liabilities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">317</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41,353</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41,670</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">There have been no transfers between Level 1 and Level 2 and no transfers to or from Level 3 of the fair value hierarchy.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">June 30, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December 31, 2017</font><font style="font-family:inherit;font-size:10pt;">, the carrying value of our other financial instrument assets approximates their fair value due to their short-term nature or variable rate of interest.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table reconciles the beginning and ending balances of our Level 3 assets and liabilities as of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June 30, 2018</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:80%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">June 30, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;text-decoration:underline;">(In thousands)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Contingent</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">consideration</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at December 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41,353</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Change in fair value:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Included in results of operations</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(13,599</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at June 30, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27,754</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The estimated fair values of our financial instruments have been determined by using available market information and what we believe to be appropriate valuation methodologies. We use the following methods and assumptions in estimating fair value:</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Contingent consideration</font><font style="font-family:inherit;font-size:10pt;"> – We estimate the fair value of the contingent consideration utilizing a discounted cash flow model for the expected payments based on estimated timing and expected revenues. We use several discount rates depending on each type of contingent consideration related to OPKO Diagnostics, CURNA and OPKO Renal transactions. If estimated future sales were to decrease by </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">10%</font><font style="font-family:inherit;font-size:10pt;">, the contingent consideration related to OPKO Renal, which represents the majority of our contingent consideration liability, would decrease by </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$1.7 million</font><font style="font-family:inherit;font-size:10pt;">. As of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June 30, 2018</font><font style="font-family:inherit;font-size:10pt;">, of the </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$27.7 million</font><font style="font-family:inherit;font-size:10pt;"> of contingent consideration, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$2.0 million</font><font style="font-family:inherit;font-size:10pt;"> is recorded in Accrued expenses and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$25.7 million</font><font style="font-family:inherit;font-size:10pt;"> is recorded in Other long-term liabilities. As of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December 31, 2017</font><font style="font-family:inherit;font-size:10pt;">, of the </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$41.4 million</font><font style="font-family:inherit;font-size:10pt;"> of contingent consideration, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$11.8 million</font><font style="font-family:inherit;font-size:10pt;"> is recorded in Accrued expenses and </font><font style="font-family:inherit;font-size:10pt;">$29.6 million</font><font style="font-family:inherit;font-size:10pt;"> is recorded in Other long-term liabilities.</font></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Recently adopted accounting pronouncements</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2014, the Financial Accounting Standards Board (the “FASB”) issued Accounting Standards Update (“ASU”) No. 2014-09, “Revenue from Contracts with Customers.” ASU 2014-09, as amended and codified into Topic 606, clarifies the principles for recognizing revenue and develops a common revenue standard for GAAP that removes inconsistencies and weaknesses in revenue requirements, provides a more robust framework for addressing revenue issues, improves comparability of revenue recognition practices across entities, industries, jurisdictions, and capital markets, provides more useful information to users of financial statements through improved disclosure requirements and simplifies the preparation of financial statements by reducing the number of requirements to which an entity must refer. As required, we adopted ASU 2014-09 on January 1, 2018 using the full retrospective approach, and have elected to use the following practical expedients that are permitted under the rules of the adoption, which have been applied consistently to all contracts within all reporting periods presented:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">•</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For all reporting periods presented before January 1, 2018, we have not restated revenue from contracts that begin and are completed within the same annual reporting period.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">•</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For all reporting periods presented before January 1, 2018, we have not disclosed the amount of the transaction price allocated to the remaining performance obligations or an explanation of when we expect to recognize that amount as revenue.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">•</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have applied the practical expedient provided for by Topic 606 by not adjusting the transaction price for significant financing components for periods less than one year. </font></div></td></tr></table><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As a result of adopting ASU 2014-09 on January 1, 2018 using the full retrospective approach, we revised our comparative financial statements for the prior years as if Topic 606 had been effective for those periods. As a result, the following financial statement line items for 2017 were affected:</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Condensed Consolidated Statement of Operations</font></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:50%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">For the three months ended June 30, 2017</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">As adjusted under Topic 606</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">As originally reported</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Effect of change</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue from services</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">233,912</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">256,671</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(22,759</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue from transfer of intellectual property and other</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29,723</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28,576</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,147</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Selling, general and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">105,579</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">128,338</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(22,759</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33,128</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32,593</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">535</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:50%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">For the six months ended June 30, 2017</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">As adjusted under Topic 606</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">As originally reported</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Effect of change</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue from services</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">462,456</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">511,956</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(49,500</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue from transfer of intellectual property and other</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">45,328</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">47,154</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,826</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Selling, general and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">215,523</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">265,023</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(49,500</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">59,685</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">58,615</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,070</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Condensed Consolidated Balance Sheet</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:50%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">December 31, 2017</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">As adjusted under Topic 606</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">As originally reported</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Effect of change</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other current assets and prepaid expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">42,513</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">37,113</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,400</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued expenses</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">230,301</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">215,102</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,199</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other long-term liabilities, principally contract liabilities, contingent consideration and line of credit</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">239,955</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">219,954</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,001</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accumulated deficit</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,036,959</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,007,159</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(29,800</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Condensed Consolidated Statement of Cash Flows</font></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:50%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">For the six months ended June 30, 2017<br clear="none"/>(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">As adjusted under Topic 606</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">As originally reported</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Effect of change</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(51,419</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(48,523</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,896</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contract liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(31,122</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(34,018</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,896</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The most significant change above relates to amounts in our clinical laboratory operations that were historically classified as provision for bad debts, primarily related to patient responsibility, which are considered an element of variable consideration as an implicit price concession in determining revenues under Topic 606. Accordingly, we report uncollectible balances associated with individual patients as a reduction of the transaction price and therefore as a reduction in Revenue from services when historically these amounts were classified as provision for bad debts within Selling, general and administrative expenses. </font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition, under Topic 606, the upfront consideration received for a license and contract services combined performance obligation is recognized as revenue to the extent of costs incurred based on the length of the expected performance period and the subjectivity in estimating progress towards satisfaction of the performance obligation. Under previous accounting, we recognized revenue over the expected performance period. The adoption of Topic 606 resulted in a cumulative revenue reduction of </font><font style="font-family:inherit;font-size:10pt;">$29.8 million</font><font style="font-family:inherit;font-size:10pt;"> and an increase of our accumulated deficit balance as of December 31, 2017; with a corresponding increase in our contract liabilities. For the six months ended June 30, 2017, Revenue from the transfer of intellectual property and other was reduced by </font><font style="font-family:inherit;font-size:10pt;">$2.9 million</font><font style="font-family:inherit;font-size:10pt;"> for the change in accounting. For a further discussion of the adoption of Topic 606, see Note 12, “Revenue Recognition.”</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2016, the FASB issued ASU No. 2016-01, “Financial Instruments - Overall (Subtopic 825-10),” which addresses certain aspects of recognition, measurement, presentation, and disclosure of financial instruments. The ASU requires equity investments (except those accounted for under the equity method of accounting or those that result in consolidation of the investee) to be measured at fair value with changes in fair value recognized in net income. As a result of the required adoption of ASU 2016-01 on January 1, 2018, we recorded a cumulative-effect adjustment to reclassify our net unrealized gains on our equity securities of </font><font style="font-family:inherit;font-size:10pt;">$4.9 million</font><font style="font-family:inherit;font-size:10pt;"> as of January 1, 2018 from Accumulated other comprehensive loss to Accumulated deficit in our Condensed Consolidated Balance Sheet. Changes in the fair value of our equity securities subsequent to the adoption of ASU 2016-01 on January 1, 2018 will be recognized in net income.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August 2016, the FASB issued ASU No. 2016-15, “Statement of Cash Flows (Topic 230),” which addresses the classification of eight specific cash flow issues with the objective of reducing the existing diversity in practice. The required adoption of ASU 2016-15 in the first quarter of 2018 did not have a significant impact on our Condensed Consolidated Financial Statements. </font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2017, the FASB issued ASU No. 2017-01, “Business Combinations (Topic 805),” which clarifies the definition of a business to assist entities in evaluating whether transactions should be accounted for acquisitions (or disposals) of assets or businesses. The required adoption of ASU 2017-01 in the first quarter of 2018 did not have a significant impact on our Condensed Consolidated Financial Statements. </font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Pending accounting pronouncements</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2016, the FASB issued ASU No. 2016-02, “Leases (Topic 842),” which will require organizations that lease assets with lease terms of more than 12 months to recognize assets and liabilities for the rights and obligations created by those leases on their balance sheets. The ASU will also require new qualitative and quantitative disclosures to help investors and other financial statement users better understand the amount, timing, and uncertainty of cash flows arising from leases. ASU 2016-02 will be effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years, with early adoption permitted. We have begun a process to identify a complete population of our leases. Such process includes reviewing various contracts to identify whether such arrangements convey the right to control the use of an identified asset. The determination of the impact of this new guidance is ongoing and, as such, we are not able to reasonably estimate the effect the adoption of this new standard will have on our financial statements. Based on our preliminary assessment of this ASU, we believe the new standard will have a significant impact on our Condensed Consolidated Balance Sheet, which has not yet been quantified.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2017, the FASB issued ASU No. 2017-04, “Intangibles - Goodwill and Other (Topic 350),” which simplifies how an entity is required to test for goodwill impairment. ASU 2017-04 will be effective for annual or interim goodwill impairment tests in fiscal years beginning after December 15, 2019, with early adoption permitted after January 1, 2017. We are currently evaluating the impact of this new guidance on our Condensed Consolidated Financial Statements.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In June 2018, the FASB issued ASU No. 2018-07, “Compensation - Stock Compensation (Topic 718),” which expands the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from nonemployees. ASU 2018-07 will be effective for public business entities for fiscal years beginning after December 15, 2018, including interim periods within that fiscal year, with early adoption permitted. We are currently evaluating the impact of this new guidance on our Condensed Consolidated Financial Statements.</font></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">REVENUE RECOGNITION</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Effective January 1, 2018, we adopted Accounting Standards Codification Topic 606, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers</font><font style="font-family:inherit;font-size:10pt;">. We generate revenues from services, products and intellectual property as follows:</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue from services</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue for laboratory services is recognized at the time test results are reported, which approximates when services are provided and the performance obligations are satisfied. Services are provided to patients covered by various third-party payor programs including various managed care organizations, as well as the Medicare and Medicaid programs. Billings for services are included in revenue net of allowances for contractual discounts, allowances for differences between the amounts billed and estimated program payment amounts, and implicit price concessions provided to uninsured patients which are all elements of variable consideration.    </font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following are descriptions of our payors for laboratory services:</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Healthcare Insurers</font><font style="font-family:inherit;font-size:10pt;">. Reimbursements from healthcare insurers are based on negotiated fee-for-service schedules. Revenues consist of amounts billed, net of contractual allowances for differences between amounts billed and the estimated consideration we expect to receive from such payers, which considers historical denial and collection experience and the terms of our contractual arrangements. Adjustments to the allowances, based on actual receipts from the third-party payers, are recorded upon settlement. </font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Government Payers</font><font style="font-family:inherit;font-size:10pt;">. Reimbursements from government payers are based on fee-for-service schedules set by governmental authorities, including traditional Medicare and Medicaid. Revenues consist of amounts billed, net of contractual allowances for differences between amounts billed and the estimated consideration we expect to receive from such payers, which considers historical denial and collection experience and the terms of our contractual arrangements. Adjustments to the allowances, based on actual receipts from the government payers, are recorded upon settlement.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Client Payers</font><font style="font-family:inherit;font-size:10pt;">. Client payers include physicians, hospitals, employers, and other institutions for which services are performed on a wholesale basis, and are billed and recognized as revenue based on negotiated fee schedules. </font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Patients</font><font style="font-family:inherit;font-size:10pt;">. Uninsured patients are billed based on established patient fee schedules or fees negotiated with physicians on behalf of their patients. Insured patients (including amounts for coinsurance and deductible responsibilities) are billed based on fees negotiated with healthcare insurers. Collection of billings from patients is subject to credit risk and ability of the patients to pay. Revenues consist of amounts billed net of discounts provided to uninsured patients in accordance with our policies and implicit price concessions. Implicit price concessions represent differences between amounts billed and the estimated consideration that we expect to receive from patients, which considers historical collection experience and other factors including current market conditions. Adjustments to the estimated allowances, based on actual receipts from the patients, are recorded upon settlement. </font></div><div style="line-height:120%;padding-bottom:6px;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The complexities and ambiguities of billing, reimbursement regulations and claims processing, as well as issues unique to Medicare and Medicaid programs, require us to estimate the potential for retroactive adjustments as an element of variable consideration in the recognition of revenue in the period the related services are rendered.  Actual amounts are adjusted in the period those adjustments become known. </font></div><div style="line-height:120%;padding-bottom:6px;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Third-party payers, including government programs, may decide to deny payment or recoup payments for testing they contend were improperly billed or not medically necessary, against their coverage determinations, or for which they believe they have otherwise overpaid (including as a result of their own error), and we may be required to refund payments already received. Our revenues may be subject to retroactive adjustment as a result of these factors among others, including without limitation, differing interpretations of billing and coding guidance and changes by government agencies and payors in interpretations, requirements, and “conditions of participation” in various programs. We have processed requests for recoupment from third-party payers in the ordinary course of our business, and it is likely that we will continue to do so in the future. If a third-party payer denies payment for testing or recoups money from us in a later period, reimbursement revenue for our testing could decline. </font></div><div style="line-height:120%;padding-bottom:6px;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As an integral part of our billing compliance program, we periodically assess our billing and coding practices, respond to payor audits on a routine basis, and investigate reported failures or suspected failures to comply with federal and state healthcare reimbursement requirements, as well as overpayment claims which may arise from time to time without fault on the part of the Company. We may have an obligation to reimburse Medicare, Medicaid, and third-party payers for overpayments regardless of fault. We have periodically identified and reported overpayments, reimbursed payors for overpayments and taken appropriate corrective action. </font></div><div style="line-height:120%;padding-bottom:6px;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Settlements with third-party payors for retroactive adjustments due to audits, reviews or investigations are also considered variable consideration and are included in the determination of the estimated transaction price for providing services. These settlements are estimated based on the terms of the payment agreement with the payor, correspondence from the payor and our historical settlement activity, including an assessment of the probability a significant reversal of cumulative revenue recognized will occur when the uncertainty is subsequently resolved. Estimated settlements are adjusted in future periods as adjustments become known (that is, new information becomes available), or as years are settled or are no longer subject to such audits, reviews, and investigations.</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The composition of Revenue from services by payor for the three and </font><font style="font-family:inherit;font-size:10pt;">six months ended June 30, 2018</font><font style="font-family:inherit;font-size:10pt;"> and 2017 is as follow:</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Three months ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Six months ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;text-decoration:underline;">(In thousands)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Healthcare insurers</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">92,033</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">104,366</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">192,986</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">217,062</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Government payers</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">72,459</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">80,037</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">139,595</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">157,090</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Client payers</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">45,828</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">42,961</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">83,357</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">76,900</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Patients</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,735</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,548</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,431</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,404</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">216,055</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">233,912</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">427,369</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">462,456</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:6px;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue from products</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We recognize revenue from product sales when a customer obtains control of promised goods or services. The amount of revenue that is recorded reflects the consideration that we expect to receive in exchange for those goods or services. Our estimates for sales returns and allowances are based upon the historical patterns of product returns and allowances taken, matched against the sales from which they originated, and our evaluation of specific factors that may increase or decrease the risk of product returns. Product revenues are recorded net of estimated rebates, chargebacks, discounts, co-pay assistance and other deductions (collectively, “Sales Deductions”) as well as estimated product returns which are all elements of variable consideration. Allowances are recorded as a reduction of revenue at the time product revenues are recognized. The actual amounts of consideration ultimately received may differ from our estimates. If actual results in the future vary from our estimates, we will adjust these estimates, which would affect Revenue from products in the period such variances become known.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We launched </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Rayaldee</font><font style="font-family:inherit;font-size:10pt;"> in the U.S. through our dedicated renal sales force in November 2016. </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Rayaldee</font><font style="font-family:inherit;font-size:10pt;"> is distributed in the U.S. principally through the retail pharmacy channel, which initiates with the largest wholesalers in the U.S. (collectively, “</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Rayaldee</font><font style="font-family:inherit;font-size:10pt;"> Customers”). In addition to distribution agreements with </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Rayaldee </font><font style="font-family:inherit;font-size:10pt;">Customers, we have entered into arrangements with many healthcare providers and payers that provide for government-mandated and/or privately-negotiated rebates, chargebacks and discounts with respect to the purchase of </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Rayaldee</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We recognize revenue for shipments of </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Rayaldee</font><font style="font-family:inherit;font-size:10pt;"> at the time of delivery to customers after estimating Sales Deductions and product returns as elements of variable consideration utilizing historical information and market research projections. For the three and </font><font style="font-family:inherit;font-size:10pt;">six months ended June 30, 2018</font><font style="font-family:inherit;font-size:10pt;">, we recognized </font><font style="font-family:inherit;font-size:10pt;">$4.8 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$8.5 million</font><font style="font-family:inherit;font-size:10pt;"> in net product revenue from sales of </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Rayaldee</font><font style="font-family:inherit;font-size:10pt;">. Amounts shipped prior to June 30, 2017 were insignificant and no revenue was recognized from sales of </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Rayaldee</font><font style="font-family:inherit;font-size:10pt;"> for the three and six months ended June 30, 2017.</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table presents an analysis of product sales allowances and accruals as contract liabilities for the </font><font style="font-family:inherit;font-size:10pt;">six months ended June 30, 2018</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17" rowspan="1"></td></tr><tr><td style="width:47%;" rowspan="1" colspan="1"></td><td style="width:2%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:2%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:2%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:2%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;text-decoration:underline;">(In thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Chargebacks, discounts, rebates and fees</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Governmental </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Returns</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at December 31, 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">233</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">348</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">437</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,018</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">  Provision related to current period sales</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,188</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,936</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,124</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">  Credits or payments made</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,697</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,557</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(311</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,565</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at June 30, 2018</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">724</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">727</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">126</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,577</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total gross </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Rayaldee</font><font style="font-family:inherit;font-size:10pt;"> sales</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,582</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Provision for </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Rayaldee</font><font style="font-family:inherit;font-size:10pt;"> sales allowances and accruals as a percentage of gross </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Rayaldee</font><font style="font-family:inherit;font-size:10pt;"> sales</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;padding-bottom:6px;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Taxes collected from customers related to revenues from services and revenues from products are excluded from revenues.</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue from intellectual property</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We recognize revenues from the transfer of intellectual property generated through license, development, collaboration and/or commercialization agreements. The terms of these agreements typically include payment to us for one or more of the following: non-refundable, up-front license fees; development and commercialization milestone payments; funding of research and/or development activities; and royalties on sales of licensed products. Revenue is recognized upon satisfaction of a performance obligation by transferring control of a good or service to the customer. </font></div><div style="line-height:120%;padding-bottom:6px;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For research, development and/or commercialization agreements that result in revenues, we identify all material performance obligations, which may include a license to intellectual property and know-how, and research and development activities. In order to determine the transaction price, in addition to any upfront payment, we estimate the amount of variable consideration at the outset of the contract either utilizing the expected value or most likely amount method, depending on the facts and circumstances relative to the contract. We constrain (reduce) our estimates of variable consideration such that it is probable that a significant reversal of previously recognized revenue will not occur throughout the life of the contract. When determining if variable consideration should be constrained, we consider whether there are factors outside of our control that could result in a significant reversal of revenue. In making these assessments, we consider the likelihood and magnitude of a potential reversal of revenue. These estimates are re-assessed each reporting period as required. </font></div><div style="line-height:120%;padding-bottom:6px;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Upfront License Fees: If a license to our intellectual property is determined to be functional intellectual property distinct from the other performance obligations identified in the arrangement, we recognize revenue from nonrefundable, upfront license fees based on the relative value prescribed to the license compared to the total value of the arrangement. The revenue is recognized when the license is transferred to the customer and the customer is able to use and benefit from the license. For licenses that are not distinct from other obligations identified in the arrangement, we utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time. If the combined performance obligation is satisfied over time, we apply an appropriate method of measuring progress for purposes of recognizing revenue from nonrefundable, upfront license fees. We evaluate the measure of progress each reporting period and, if necessary, adjust the measure of performance and related revenue recognition.</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Development and Regulatory Milestone Payments: Depending on facts and circumstances, we may conclude that it is appropriate to include the milestone in the estimated transaction price or that it is appropriate to fully constrain the milestone. A milestone payment is included in the transaction price in the reporting period that we conclude that it is probable that recording revenue in the period will not result in a significant reversal in amounts recognized in future periods. We may record revenues from certain milestones in a reporting period before the milestone is achieved if we conclude that achievement of the milestone is probable and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods. We record a corresponding contract asset when this conclusion is reached. Milestone payments that have been fully constrained are not included in the transaction price to date. These milestones remain fully constrained until we conclude that achievement of the milestone is probable and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods. We re-evaluate the probability of achievement of such development milestones and any related constraint each reporting period. We adjust our estimate of the overall transaction price, including the amount of revenue recorded, if necessary.</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and Development Activities: If we are entitled to reimbursement from our customers for specified research and development expenses, we account for them as separate performance obligations if distinct. We also determine whether the research and development funding would result in revenues or an offset to research and development expenses in accordance with provisions of gross or net revenue presentation. The corresponding revenues or offset to research and development expenses are recognized as the related performance obligations are satisfied.</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Sales-based Milestone and Royalty Payments: Our customers may be required to pay us sales-based milestone payments or royalties on future sales of commercial products. We recognize revenues related to sales-based milestone and royalty payments upon the later to occur of (i) achievement of the customer’s underlying sales or (ii) satisfaction of any performance obligation(s) related to these sales, in each case assuming the license to our intellectual property is deemed to be the predominant item to which the sales-based milestones and/or royalties relate.</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other Potential Products and Services: Arrangements may include an option for license rights, future supply of drug substance or drug product for either clinical development or commercial supply at the licensee’s election. We assess if these options provide a material right to the licensee and if so, they are accounted for as separate performance obligations at the inception of the contract and revenue is recognized only if the option is exercised and products or services are subsequently delivered or when the rights expire. If the promise is based on market terms and not considered a material right, the option is accounted for if and when exercised. If we are entitled to additional payments when the licensee exercises these options, any additional payments are generally recorded in license or other revenues when the licensee obtains control of the goods, which is upon delivery.</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For the three and </font><font style="font-family:inherit;font-size:10pt;">six months ended June 30, 2018</font><font style="font-family:inherit;font-size:10pt;">, revenue from transfer of intellectual property principally reflects </font><font style="font-family:inherit;font-size:10pt;">$16.3 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$31.0 million</font><font style="font-family:inherit;font-size:10pt;"> of revenue, respectively related to the Pfizer Transaction (as defined below). For the three and six months ended June 30, 2017, revenue from transfer of intellectual property principally reflects and </font><font style="font-family:inherit;font-size:10pt;">$18.3 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$32.4 million</font><font style="font-family:inherit;font-size:10pt;"> of revenue, respectively related to the Pfizer Transaction. Refer to Note 13. Total contract liabilities included in Accrued expenses and Other long-term liabilities was </font><font style="font-family:inherit;font-size:10pt;">$109.6 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$140.4 million</font><font style="font-family:inherit;font-size:10pt;"> at </font><font style="font-family:inherit;font-size:10pt;">June 30, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December 31, 2017</font><font style="font-family:inherit;font-size:10pt;">, respectively. The contract liability balance at </font><font style="font-family:inherit;font-size:10pt;">June 30, 2018</font><font style="font-family:inherit;font-size:10pt;"> relates primarily to the Pfizer Transaction.</font></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For the </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">six months ended June 30, 2018</font><font style="font-family:inherit;font-size:10pt;">, changes in Accumulated other comprehensive income (loss), net of tax, were as follows:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:59%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;text-decoration:underline;">(In thousands)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Foreign</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">currency</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">gain (loss) in</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Accumulated</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">OCI</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at December 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5,404</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,876</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(528</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;text-indent:26px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other comprehensive loss before reclassifications</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7,600</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7,600</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Reclassification adjustment due to adoption of ASU 2016-01</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,876</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,876</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net other comprehensive loss</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7,600</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,876</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(12,476</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at June 30, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(13,004</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(13,004</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table sets forth information related to the 2033 Senior Notes which is included in our Condensed Consolidated Balance Sheets as of </font><font style="font-family:inherit;font-size:10pt;">December 31, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June 30, 2018</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:53%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;text-decoration:underline;">(In thousands)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2033 Senior Notes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Discount</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Debt Issuance Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at December 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31,850</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,565</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(125</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29,160</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amortization of debt discount and debt issuance costs</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,109</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">74</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,183</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at June 30, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31,850</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,456</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(51</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30,343</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At </font><font style="font-family:inherit;font-size:10pt;">June 30, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December 31, 2017</font><font style="font-family:inherit;font-size:10pt;">, we had notes payable and other debt (excluding the 2033 Senior Notes, the 2023 Convertible Notes, the Credit Agreement and amounts outstanding under lines of credit) as follows:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:59%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;text-decoration:underline;">(In thousands)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">June 30, <br clear="none"/>2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">December 31,</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current portion of notes payable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,821</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,632</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other long-term liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,469</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,011</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,290</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,643</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes the losses and gains recorded for the three and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">six months ended June 30, 2018</font><font style="font-family:inherit;font-size:10pt;"> and 2017:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:53%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Three months ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Six months ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;text-decoration:underline;">(In thousands)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Derivative gain (loss):</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common Stock options/warrants </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,916</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">444</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,587</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(512</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2033 Senior Notes</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,069</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,014</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forward contracts</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">332</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(31</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">57</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,248</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,482</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,644</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,519</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes the fair values and the presentation of our derivative assets (liabilities) in the Condensed Consolidated Balance Sheets:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="10" rowspan="1"></td></tr><tr><td style="width:37%;" rowspan="1" colspan="1"></td><td style="width:39%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;text-decoration:underline;">(In thousands)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Balance Sheet Component</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">June 30, <br clear="none"/>2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">December 31, <br clear="none"/>2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Derivative financial instruments:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:middle;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common Stock options/warrants</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Investments, net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,799</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,333</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forward contracts</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unrealized gains on forward contracts are recorded in Other current assets and prepaid expenses. Unrealized (losses) on forward contracts are recorded in Accrued expenses.</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(317</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;padding-left:0px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table sets forth the computation of basic and diluted loss per share: </font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">For the three months ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">For the six months ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;text-decoration:underline;">(In thousands, except per share data)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2018</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2018</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Numerator</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss, basic</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,201</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(16,916</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(49,315</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(51,419</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">  Add: Interest on 2033 Senior Notes</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">652</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,291</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">  Change in FV of embedded derivative income</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5,069</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(10,014</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss, diluted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,201</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(21,333</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(49,315</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(60,142</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Denominator</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;text-decoration:underline;">(Shares in thousands)</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted average common shares outstanding, basic</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">559,541</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">559,348</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">559,508</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">558,892</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Effect of dilutive securities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">  Stock options</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">  Warrants</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">  2033 Senior Notes</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,816</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,725</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">     Dilutive potential shares</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,816</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,725</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted average common shares outstanding, diluted</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">559,541</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">564,164</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">559,508</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">563,617</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss per share, basic</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.01</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.03</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.09</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.09</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss per share, diluted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.01</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.04</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.09</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.11</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our financial assets and liabilities measured at fair value on a recurring basis are as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Fair value measurements as of June 30, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;text-decoration:underline;">(In thousands)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Quoted</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">prices in</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">active</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">markets for</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">identical</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">assets</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(Level 1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Significant</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">other</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">observable</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(Level 2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Significant</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">unobservable</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(Level 3)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Total</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Assets:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Equity securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,350</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,350</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common stock options/warrants</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,799</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,799</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forward contracts</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total assets</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,350</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,822</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24,172</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contingent consideration</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27,754</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27,754</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total liabilities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27,754</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27,754</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Fair value measurements as of December 31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;text-decoration:underline;">(In thousands)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Quoted</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">prices in</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">active</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">markets for</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">identical</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">assets</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(Level 1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Significant</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">other</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">observable</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(Level 2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Significant</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">unobservable</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(Level 3)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Total</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Assets:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Money market funds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">107</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">107</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Equity securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,461</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,461</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common stock options/warrants</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,333</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,333</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total assets</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,568</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,333</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,901</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forward contracts</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">317</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">317</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contingent consideration</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41,353</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41,353</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total liabilities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">317</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41,353</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41,670</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes the changes in Goodwill during the </font><font style="font-family:inherit;font-size:10pt;">six months ended June 30, 2018</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:50%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;text-decoration:underline;">(In thousands)</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Balance at January 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Foreign exchange and other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Balance at June 30</font><font style="font-family:inherit;font-size:8pt;">th</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pharmaceuticals</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">CURNA</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,827</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,827</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">EirGen</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">89,226</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,201</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">87,025</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">FineTech</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,698</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,698</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">OPKO Chile</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,203</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(307</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,896</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">OPKO Biologics</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">139,784</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">139,784</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">OPKO Health Europe</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,898</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(197</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,701</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">OPKO Renal</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,069</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,069</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Transition Therapeutics</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,608</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(160</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,448</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Diagnostics</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">BioReference</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">401,821</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">401,821</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">OPKO Diagnostics</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,977</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,977</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">OPKO Lab</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32,988</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32,988</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">717,099</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,865</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">714,234</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes the amounts outstanding under the BioReference, Chilean and Spanish lines of credit:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="15" rowspan="1"></td></tr><tr><td style="width:40%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;text-decoration:underline;">(Dollars in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> Balance Outstanding</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Lender</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Interest rate on</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">borrowings at June 30, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Credit line</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">capacity</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">June 30, <br clear="none"/>2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">December 31,</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2017</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">JPMorgan Chase</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.01%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">175,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">105,539</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">104,152</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Itau Bank</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.50%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,810</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,179</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">446</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Bank of Chile</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.60%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,800</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">502</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,598</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">BICE Bank</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.50%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,500</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">798</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,819</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">BBVA Bank</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.50%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,250</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">250</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,665</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Security Bank</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.50%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">98</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">98</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">501</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Estado Bank</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.50%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,500</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">757</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,111</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Santander Bank</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.50%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,500</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">262</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,988</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Scotiabank</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.00%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,800</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">384</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Banco Bilbao Vizcaya</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.90%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">292</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Santander Bank</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.67%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">350</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">102</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">196,900</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">109,496</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">114,664</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As a result, the following financial statement line items for 2017 were affected:</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Condensed Consolidated Statement of Operations</font></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:50%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">For the three months ended June 30, 2017</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">As adjusted under Topic 606</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">As originally reported</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Effect of change</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue from services</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">233,912</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">256,671</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(22,759</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue from transfer of intellectual property and other</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29,723</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28,576</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,147</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Selling, general and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">105,579</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">128,338</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(22,759</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33,128</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32,593</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">535</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:50%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">For the six months ended June 30, 2017</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">As adjusted under Topic 606</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">As originally reported</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Effect of change</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue from services</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">462,456</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">511,956</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(49,500</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue from transfer of intellectual property and other</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">45,328</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">47,154</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,826</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Selling, general and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">215,523</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">265,023</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(49,500</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">59,685</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">58,615</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,070</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Condensed Consolidated Balance Sheet</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:50%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">December 31, 2017</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">As adjusted under Topic 606</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">As originally reported</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Effect of change</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other current assets and prepaid expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">42,513</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">37,113</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,400</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued expenses</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">230,301</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">215,102</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,199</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other long-term liabilities, principally contract liabilities, contingent consideration and line of credit</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">239,955</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">219,954</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,001</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accumulated deficit</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,036,959</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,007,159</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(29,800</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Condensed Consolidated Statement of Cash Flows</font></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:50%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">For the six months ended June 30, 2017<br clear="none"/>(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">As adjusted under Topic 606</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">As originally reported</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Effect of change</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(51,419</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(48,523</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,896</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contract liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(31,122</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(34,018</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,896</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Information regarding our operations and assets for our operating segments and the unallocated corporate operations as well as geographic information are as follows:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">For the three months ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">For the six months ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;text-decoration:underline;">(In thousands)</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2017</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue from services:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pharmaceutical</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Diagnostics</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">216,055</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">233,912</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">427,369</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">462,456</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">216,055</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">233,912</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">427,369</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">462,456</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue from products:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pharmaceutical</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28,523</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28,966</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">56,374</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">51,197</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Diagnostics</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28,523</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28,966</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">56,374</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">51,197</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue from transfer of intellectual property and other: </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pharmaceutical</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,107</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29,723</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34,855</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">45,328</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Diagnostics</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,107</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29,723</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34,855</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">45,328</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Operating loss:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pharmaceutical</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,165</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(8,009</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(20,783</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(34,154</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Diagnostics</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,475</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,944</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,543</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(8,044</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(8,748</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(12,878</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(20,393</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(28,849</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5,108</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(25,831</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(47,719</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(71,047</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Depreciation and amortization:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pharmaceutical</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,752</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,694</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,492</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,469</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Diagnostics</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,989</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,827</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35,975</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">37,752</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">51</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">60</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24,762</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,551</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">49,518</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">51,281</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss from investment in investees:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pharmaceutical</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,942</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5,309</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(9,114</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7,123</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Diagnostics</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(271</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(319</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(555</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(635</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7,213</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5,628</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(9,669</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7,758</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenues:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">United States</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">222,535</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">244,650</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">437,845</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">474,084</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ireland</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,778</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,525</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38,060</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">39,734</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chile</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,937</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,899</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23,670</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,020</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Spain</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,592</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,118</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,125</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,623</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Israel</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,526</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,654</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,141</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,872</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Mexico</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,302</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">724</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,723</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,589</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">59</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">263,685</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">292,601</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">518,598</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">558,981</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:71%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;text-decoration:underline;">(In thousands)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">June 30, <br clear="none"/>2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">December 31, <br clear="none"/>2017</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Assets:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pharmaceutical</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,258,293</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,287,964</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Diagnostics</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,217,456</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,241,388</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">55,201</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">60,604</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,530,950</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,589,956</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Goodwill:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pharmaceutical</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">261,447</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">264,313</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Diagnostics</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">452,787</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">452,786</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">714,234</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">717,099</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SEGMENTS</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We manage our operations in </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">two</font><font style="font-family:inherit;font-size:10pt;"> reportable segments, pharmaceutical and diagnostics. The pharmaceutical segment consists of our pharmaceutical operations we acquired in Chile, Mexico, Ireland, Israel and Spain and our pharmaceutical research and development. The diagnostics segment primarily consists of our clinical laboratory operations we acquired through the acquisition of BioReference and our point-of-care operations. There are </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">no</font><font style="font-family:inherit;font-size:10pt;"> significant inter-segment sales. We evaluate the performance of each segment based on operating profit or loss. There is </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">no</font><font style="font-family:inherit;font-size:10pt;"> inter-segment allocation of interest expense and income taxes.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Information regarding our operations and assets for our operating segments and the unallocated corporate operations as well as geographic information are as follows:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">For the three months ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">For the six months ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;text-decoration:underline;">(In thousands)</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2017</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue from services:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pharmaceutical</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Diagnostics</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">216,055</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">233,912</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">427,369</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">462,456</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">216,055</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">233,912</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">427,369</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">462,456</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue from products:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pharmaceutical</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28,523</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28,966</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">56,374</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">51,197</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Diagnostics</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28,523</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28,966</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">56,374</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">51,197</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue from transfer of intellectual property and other: </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pharmaceutical</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,107</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29,723</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34,855</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">45,328</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Diagnostics</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,107</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29,723</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34,855</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">45,328</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Operating loss:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pharmaceutical</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,165</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(8,009</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(20,783</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(34,154</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Diagnostics</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,475</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,944</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,543</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(8,044</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(8,748</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(12,878</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(20,393</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(28,849</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5,108</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(25,831</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(47,719</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(71,047</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Depreciation and amortization:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pharmaceutical</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,752</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,694</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,492</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,469</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Diagnostics</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,989</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,827</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35,975</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">37,752</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">51</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">60</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24,762</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,551</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">49,518</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">51,281</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss from investment in investees:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pharmaceutical</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,942</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5,309</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(9,114</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7,123</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Diagnostics</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(271</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(319</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(555</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(635</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7,213</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5,628</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(9,669</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7,758</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenues:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">United States</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">222,535</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">244,650</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">437,845</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">474,084</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ireland</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,778</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,525</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38,060</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">39,734</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chile</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,937</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,899</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23,670</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,020</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Spain</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,592</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,118</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,125</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,623</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Israel</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,526</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,654</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,141</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,872</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Mexico</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,302</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">724</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,723</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,589</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">59</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">263,685</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">292,601</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">518,598</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">558,981</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:71%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;text-decoration:underline;">(In thousands)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">June 30, <br clear="none"/>2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">December 31, <br clear="none"/>2017</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Assets:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pharmaceutical</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,258,293</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,287,964</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Diagnostics</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,217,456</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,241,388</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">55,201</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">60,604</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,530,950</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,589,956</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Goodwill:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pharmaceutical</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">261,447</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">264,313</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Diagnostics</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">452,787</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">452,786</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">714,234</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">717,099</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;padding-left:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">One</font><font style="font-family:inherit;font-size:10pt;"> customer represented more than </font><font style="font-family:inherit;font-size:10pt;">10%</font><font style="font-family:inherit;font-size:10pt;"> of our total consolidated revenue during the </font><font style="font-family:inherit;font-size:10pt;">three months ended June 30, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;"> customers represented more than </font><font style="font-family:inherit;font-size:10pt;">10%</font><font style="font-family:inherit;font-size:10pt;"> of our total consolidated revenue during the </font><font style="font-family:inherit;font-size:10pt;">six months ended June 30, 2018</font><font style="font-family:inherit;font-size:10pt;">. </font><font style="font-family:inherit;font-size:10pt;">One</font><font style="font-family:inherit;font-size:10pt;"> customer represented more than </font><font style="font-family:inherit;font-size:10pt;">10%</font><font style="font-family:inherit;font-size:10pt;"> of our total consolidated revenue during the three and </font><font style="font-family:inherit;font-size:10pt;">six months ended June 30, 2017</font><font style="font-family:inherit;font-size:10pt;">. As of </font><font style="font-family:inherit;font-size:10pt;">June 30, 2018</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;"> customer represented more than </font><font style="font-family:inherit;font-size:10pt;">10%</font><font style="font-family:inherit;font-size:10pt;"> of our accounts receivable balance. As of </font><font style="font-family:inherit;font-size:10pt;">December 31, 2017</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> customer represented more than </font><font style="font-family:inherit;font-size:10pt;">10%</font><font style="font-family:inherit;font-size:10pt;"> of our accounts receivable balance.</font></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Basis of presentation</font><font style="font-family:inherit;font-size:10pt;">. The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all information and notes required by GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of only normal recurring adjustments or otherwise disclosed herein) considered necessary to present fairly the Company’s results of operations, financial position and cash flows have been made. The results of operations and cash flows for the three and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">six months ended June 30, 2018</font><font style="font-family:inherit;font-size:10pt;">, are not necessarily indicative of the results of operations and cash flows that may be reported for the remainder of 2018 or any future periods. The unaudited Condensed Consolidated Financial Statements should be read in conjunction with the Consolidated Financial Statements and the Notes to Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended </font><font style="font-family:inherit;font-size:10pt;">December 31, 2017</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Principles of consolidation</font><font style="font-family:inherit;font-size:10pt;">. The accompanying unaudited Condensed Consolidated Financial Statements include the accounts of OPKO Health, Inc. and of our wholly-owned subsidiaries. All intercompany accounts and transactions are eliminated in consolidation. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Use of estimates</font><font style="font-family:inherit;font-size:10pt;">. The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ significantly from these estimates.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Cash and cash equivalents</font><font style="font-family:inherit;font-size:10pt;">. Cash and cash equivalents include short-term, interest-bearing instruments with original maturities of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">90 days</font><font style="font-family:inherit;font-size:10pt;"> or less at the date of purchase. We also consider all highly liquid investments with original maturities at the date of purchase of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">90 days</font><font style="font-family:inherit;font-size:10pt;"> or less as cash equivalents. These investments include money markets, bank deposits, certificates of deposit and U.S. treasury securities. </font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Inventories</font><font style="font-family:inherit;font-size:10pt;">. Inventories are valued at the lower of cost and net realizable value. Cost is determined by the first-in, first-out method. We consider such factors as the amount of inventory on hand, estimated time required to sell such inventories, remaining shelf-life, and current market conditions to determine whether inventories are stated at the lower of cost and net realizable value. Inventories at our diagnostics segment consist primarily of purchased laboratory supplies, which is used in our testing laboratories. Inventory obsolescence expense for the six months ended </font><font style="font-family:inherit;font-size:10pt;">June 30, 2018</font><font style="font-family:inherit;font-size:10pt;"> and 2017 was </font><font style="font-family:inherit;font-size:10pt;">$1.2 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$4.8 million</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Pre-launch inventories</font><font style="font-family:inherit;font-size:10pt;">. We may accumulate commercial quantities of certain product candidates prior to the date we anticipate that such products will receive final U.S. FDA approval.  The accumulation of such pre-launch inventories involves the risk that such products may not be approved for marketing by the FDA on a timely basis, or ever.  This risk notwithstanding, we may accumulate pre-launch inventories of certain products when such action is appropriate in relation to the commercial value of the product launch opportunity.  In accordance with our policy, this pre-launch inventory is expensed.  </font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Goodwill and intangible assets</font><font style="font-family:inherit;font-size:10pt;">. Goodwill represents the difference between the purchase price and the estimated fair value of the net assets acquired accounted for by the acquisition method of accounting and arose from our acquisitions. Refer to Note 4. Goodwill, in-process research and development (“IPR&D”) and other intangible assets acquired in business combinations, licensing and other transactions at both </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June 30, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December 31, 2017</font><font style="font-family:inherit;font-size:10pt;"> was </font><font style="font-family:inherit;font-size:10pt;">$2.0 billion</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Assets acquired and liabilities assumed in business combinations, licensing and other transactions are generally recognized at the date of acquisition at their respective fair values. We determined the fair value of intangible assets, including IPR&D, using the “income method.”</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Goodwill is tested at least annually for impairment, or when events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable, by assessing qualitative factors or performing a quantitative analysis in determining whether it is more likely than not that its fair value exceeds the carrying value.</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intangible assets are tested for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable, although IPR&D is required to be tested at least annually until the project is completed or abandoned. Upon obtaining regulatory approval, the IPR&D asset is then accounted for as a finite-lived intangible asset and amortized on a straight-line basis over its estimated useful life. If the project is abandoned, the IPR&D asset is charged to expense. </font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We amortize intangible assets with definite lives on a straight-line basis over their estimated useful lives, ranging from </font><font style="font-family:inherit;font-size:10pt;">3</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">20</font><font style="font-family:inherit;font-size:10pt;"> years. We use the straight-line method of amortization as there is no reliably determinable pattern in which the economic benefits of our intangible assets are consumed or otherwise used up. Amortization expense was </font><font style="font-family:inherit;font-size:10pt;">$34.5 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$35.9 million</font><font style="font-family:inherit;font-size:10pt;"> for the </font><font style="font-family:inherit;font-size:10pt;">six months ended June 30, 2018</font><font style="font-family:inherit;font-size:10pt;"> and 2017, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Fair value measurements</font><font style="font-family:inherit;font-size:10pt;">. The carrying amounts of our cash and cash equivalents, accounts receivable, accounts payable and short-term debt approximate their fair value due to the short-term maturities of these instruments. Investments that are considered equity securities as of </font><font style="font-family:inherit;font-size:10pt;">June 30, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December 31, 2017</font><font style="font-family:inherit;font-size:10pt;"> are carried at fair value. Our debt under the credit agreement with JPMorgan Chase Bank, N.A. approximates fair value due to the variable rate of interest.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In evaluating the fair value information, considerable judgment is required to interpret the market data used to develop the estimates. The use of different market assumptions and/or different valuation techniques may have a material effect on the estimated fair value amounts. Accordingly, the estimates of fair value presented herein may not be indicative of the amounts that could be realized in a current market exchange. Refer to Note 8.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Contingent consideration</font><font style="font-family:inherit;font-size:10pt;">. Each period we revalue the contingent consideration obligations associated with certain prior acquisitions to their fair value and record increases in the fair value as contingent consideration expense and decreases in the fair value as a reduction in contingent consideration expense. Changes in contingent consideration result from changes in the assumptions regarding probabilities of successful achievement of related milestones, the estimated timing in which the milestones are achieved and the discount rate used to estimate the fair value of the liability. Contingent consideration may change significantly as our development programs progress, revenue estimates evolve and additional data is obtained, impacting our assumptions. The assumptions used in estimating fair value require significant judgment. The use of different assumptions and judgments could result in a materially different estimate of fair value which may have a material impact on our results from operations and financial position.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Derivative financial instruments</font><font style="font-family:inherit;font-size:10pt;">. We record derivative financial instruments on our Condensed Consolidated Balance Sheet at their fair value and recognize the changes in the fair value in our Condensed Consolidated Statement of Operations when they occur, the only exception being derivatives that qualify as hedges. For the derivative instrument to qualify as a hedge, we are required to meet strict hedge effectiveness and contemporaneous documentation requirements at the initiation of the hedge and assess the hedge effectiveness on an ongoing basis over the life of the hedge. At </font><font style="font-family:inherit;font-size:10pt;">June 30, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December 31, 2017</font><font style="font-family:inherit;font-size:10pt;">, our foreign currency forward contracts held to economically hedge inventory purchases did not meet the documentation requirements to be designated as hedges. Accordingly, we recognize all changes in the fair values of our derivatives instruments, net, in our Condensed Consolidated Statements of Operations. Refer to Note 9.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Property, plant and equipment</font><font style="font-family:inherit;font-size:10pt;">. Property, plant and equipment are recorded at cost. Depreciation is provided using the straight-line method over the estimated useful lives of the assets and includes amortization expense for assets capitalized under capital leases. The estimated useful lives by asset class are as follows: software - </font><font style="font-family:inherit;font-size:10pt;">3</font><font style="font-family:inherit;font-size:10pt;"> years, machinery, medical and other equipment - </font><font style="font-family:inherit;font-size:10pt;">5</font><font style="font-family:inherit;font-size:10pt;">-</font><font style="font-family:inherit;font-size:10pt;">8</font><font style="font-family:inherit;font-size:10pt;"> years, furniture and fixtures - </font><font style="font-family:inherit;font-size:10pt;">5</font><font style="font-family:inherit;font-size:10pt;">-</font><font style="font-family:inherit;font-size:10pt;">12</font><font style="font-family:inherit;font-size:10pt;"> years, leasehold improvements - the lesser of their useful life or the lease term, buildings and improvements - </font><font style="font-family:inherit;font-size:10pt;">10</font><font style="font-family:inherit;font-size:10pt;">-</font><font style="font-family:inherit;font-size:10pt;">40</font><font style="font-family:inherit;font-size:10pt;"> years, automobiles - </font><font style="font-family:inherit;font-size:10pt;">3</font><font style="font-family:inherit;font-size:10pt;">-</font><font style="font-family:inherit;font-size:10pt;">5</font><font style="font-family:inherit;font-size:10pt;"> years. Expenditures for repairs and maintenance are charged to expense as incurred. Depreciation expense was </font><font style="font-family:inherit;font-size:10pt;">$15.0 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$15.4 million</font><font style="font-family:inherit;font-size:10pt;"> for the </font><font style="font-family:inherit;font-size:10pt;">six months ended June 30, 2018</font><font style="font-family:inherit;font-size:10pt;"> and 2017, respectively. Assets held under capital leases are included within Property, plant and equipment, net in our Condensed Consolidated Balance Sheet and are amortized over the shorter of their useful lives or the expected term of their related leases.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Impairment of long-lived assets. </font><font style="font-family:inherit;font-size:10pt;">Long-lived assets, such as property and equipment, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated future cash flows, then an impairment charge is recognized for the amount by which the carrying amount of the asset exceeds the fair value of the asset.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Income taxes. </font><font style="font-family:inherit;font-size:10pt;">Income taxes are accounted for under the asset-and-liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and the respective tax bases and for operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period that includes the enactment date. We periodically evaluate the realizability of our net deferred tax assets. Our tax accruals are analyzed periodically and adjustments are made as events occur to warrant such adjustment. Valuation allowances on certain U.S. deferred tax assets and non-U.S. deferred tax assets are established, because realization of these tax benefits through future taxable income does not meet the more-likely-than-not threshold.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On December 22, 2017, the 2017 Tax Cuts and Jobs Act (the “Tax Act”) was enacted into law and the new legislation contains several key tax provisions, including a reduction of the corporate income tax rate from 35% to 21% effective January 1, 2018, and a one-time mandatory transition tax on accumulated foreign earnings, among others. We are required to recognize the effect of the tax law changes in the period of enactment, such as remeasuring our U.S. deferred tax assets and liabilities, as well as reassessing the net realizability of our deferred tax assets and liabilities. In December 2017, the SEC staff issued Staff Accounting Bulletin No. 118, Income Tax Accounting Implications of the Tax Act (“SAB 118”), which allows us to record provisional amounts during a measurement period not to extend beyond one year of the enactment date. Through </font><font style="font-family:inherit;font-size:10pt;">June 30, 2018</font><font style="font-family:inherit;font-size:10pt;">, we did not have any significant adjustments to our provisional amounts. As we continue to perform our analysis of the Tax Act, and interpret any additional accounting guidance issued by the FASB, the U.S. Department of the Treasury and the IRS, we may make adjustments to these provisional amounts.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Effective January 1, 2018, the Tax Act provides for a new global intangible low-taxed income (GILTI) provision. Under the GILTI provision, certain foreign subsidiary earnings in excess of an allowable return on the foreign subsidiary’s tangible assets are included in U.S. taxable income. We are now subject to GILTI but have not triggered an income inclusion as of </font><font style="font-family:inherit;font-size:10pt;">June 30, 2018</font><font style="font-family:inherit;font-size:10pt;">. Any future inclusion is expected to be offset by net operating loss carry forwards in the U.S. We are still evaluating, pending further interpretive guidance, whether to make a policy election to treat the GILTI tax as a period expense or to provide U.S. deferred taxes on foreign temporary differences that are expected to generate GILTI income when they reverse in future years.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We anticipate future impacts at a U.S. state and local tax level related to the Tax Act; however, the limited amount of statutory and interpretive guidance available from applicable state and local tax authorities is not sufficient to reasonably estimate the impact. Consequently, for those jurisdictions, we have not recorded provisional amounts and have continued to apply ASC 740 based on the provisions of the tax laws that were in effect immediately prior to Tax Act enactment.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We operate in various countries and tax jurisdictions globally.  For interim reporting purposes, we record income taxes based on the expected effective income tax rate taking into consideration year to date and global forecasted tax results.  For the three and </font><font style="font-family:inherit;font-size:10pt;">six months ended June 30, 2018</font><font style="font-family:inherit;font-size:10pt;">, the tax rate differed from the U.S. federal statutory rate of </font><font style="font-family:inherit;font-size:10pt;">21%</font><font style="font-family:inherit;font-size:10pt;"> primarily due to the valuation allowance against certain U.S. and non-U.S. deferred tax assets, the relative mix in earnings and losses in the U.S. versus foreign tax jurisdictions, and the impact of certain discrete tax events and operating results in tax jurisdictions which do not result in a tax benefit.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue recognition</font><font style="font-family:inherit;font-size:10pt;">. Effective January 1, 2018, we adopted Accounting Standards Codification Topic 606, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers</font><font style="font-family:inherit;font-size:10pt;"> (“Topic 606”). We recognize revenue when a customer obtains control of promised goods or services. The amount of revenue that is recorded reflects the consideration that we expect to receive in exchange for those goods or services. We apply the following five-step model in order to determine this amount: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) we satisfy a performance obligation. </font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We only apply the five-step model to contracts when it is probable that we will collect the consideration we are entitled to in exchange for the goods or services we transfer to the customer. At contract inception, once the contract is determined to be within the scope of Topic 606, we review the contract to determine which performance obligations we must deliver and which of these performance obligations are distinct. We recognize as revenue the amount of the transaction price that is allocated to the respective performance obligation when the performance obligation is satisfied or as it is satisfied. For a complete discussion of accounting for Revenues from services, Revenues from products and Revenue from transfer of intellectual property and other, see Note 12, “Revenue Recognition.”</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Concentration of credit risk and allowance for doubtful accounts</font><font style="font-family:inherit;font-size:10pt;">. Financial instruments that potentially subject us to concentrations of credit risk consist primarily of accounts receivable. Substantially all of our accounts receivable are with either companies in the healthcare industry or patients. However, credit risk is limited due to the number of our clients as well as their dispersion across many different geographic regions.</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">While we have receivables due from federal and state governmental agencies, we do not believe that such receivables represent a credit risk since the related healthcare programs are funded by federal and state governments, and payment is primarily dependent upon submitting appropriate documentation. At </font><font style="font-family:inherit;font-size:10pt;">June 30, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December 31, 2017</font><font style="font-family:inherit;font-size:10pt;">, receivable balances (net of contractual adjustments) from Medicare and Medicaid were </font><font style="font-family:inherit;font-size:10pt;">17.4%</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">15.8%</font><font style="font-family:inherit;font-size:10pt;">, respectively, of our consolidated Accounts receivable, net.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The portion of our accounts receivable due from individual patients comprises the largest portion of credit risk. At </font><font style="font-family:inherit;font-size:10pt;">June 30, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December 31, 2017</font><font style="font-family:inherit;font-size:10pt;">, receivables due from patients represent approximately </font><font style="font-family:inherit;font-size:10pt;">2.6%</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">3.2%</font><font style="font-family:inherit;font-size:10pt;">, respectively, of our consolidated Accounts receivable, net. </font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We assess the collectability of accounts receivable balances by considering factors such as historical collection experience, customer credit worthiness, the age of accounts receivable balances, regulatory changes and current economic conditions and trends that may affect a customer’s ability to pay. Actual results could differ from those estimates. Our reported net income (loss) is directly affected by our estimate of the collectability of accounts receivable. The allowance for doubtful accounts was </font><font style="font-family:inherit;font-size:10pt;">$1.5 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$1.4 million</font><font style="font-family:inherit;font-size:10pt;"> at </font><font style="font-family:inherit;font-size:10pt;">June 30, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December 31, 2017</font><font style="font-family:inherit;font-size:10pt;">, respectively. The provision for bad debts for the </font><font style="font-family:inherit;font-size:10pt;">six months ended June 30, 2018</font><font style="font-family:inherit;font-size:10pt;"> and 2017 was </font><font style="font-family:inherit;font-size:10pt;">$0.2 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$0.5 million</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Equity-based compensation</font><font style="font-family:inherit;font-size:10pt;">. We measure the cost of employee services received in exchange for an award of equity instruments based on the grant-date fair value of the award. That cost is recognized in the Condensed Consolidated Statement of Operations over the period during which an employee is required to provide service in exchange for the award. We record excess tax benefits, realized from the exercise of stock options, as cash flows from operations. Equity-based compensation arrangements to non-employees are recorded at their fair value on the measurement date. The measurement of equity-based compensation to non-employees is subject to periodic adjustment as the underlying equity instruments vest. During the </font><font style="font-family:inherit;font-size:10pt;">six months ended June 30, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, we recorded </font><font style="font-family:inherit;font-size:10pt;">$11.5 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$15.8 million</font><font style="font-family:inherit;font-size:10pt;">, respectively, of equity-based compensation expense. </font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Research and development expenses. </font><font style="font-family:inherit;font-size:10pt;">Research and development expenses include external and internal expenses. External expenses include clinical and non-clinical activities performed by contract research organizations, lab services, purchases of drug and diagnostic product materials and manufacturing development costs. Research and development employee-related expenses include salaries, benefits and equity-based compensation expense. Other internal research and development expenses are incurred to support overall research and development activities and include expenses related to general overhead and facilities. We expense these costs in the period in which they are incurred. We estimate our liabilities for research and development expenses in order to match the recognition of expenses to the period in which the actual services are received. As such, accrued liabilities related to third party research and development activities are recognized based upon our estimate of services received and degree of completion of the services in accordance with the specific third party contract.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development expense includes costs for in-process research and development projects acquired in asset acquisitions which have not reached technological feasibility and which have no alternative future use. For in-process research and development projects acquired in business combinations, the in-process research and development project is capitalized and evaluated for impairment until the development process has been completed. Once the development process has been completed the asset will be amortized over its remaining useful life.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Segment reporting</font><font style="font-family:inherit;font-size:10pt;">. Our chief operating decision-maker (“CODM”) is Phillip Frost, M.D., our Chairman and Chief Executive Officer. Our CODM reviews our operating results and operating plans and makes resource allocation decisions on a Company-wide or aggregate basis. We manage our operations in </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;"> reportable segments, pharmaceutical and diagnostics. The pharmaceutical segment consists of our pharmaceutical operations we acquired in Chile, Mexico, Ireland, Israel and Spain and our pharmaceutical research and development. The diagnostics segment primarily consists of clinical laboratory operations we acquired through the acquisition of BioReference and point-of-care operations. There are no significant inter-segment sales. We evaluate the performance of each segment based on operating profit or loss. There is no inter-segment allocation of interest expense and income taxes. Refer to Note 14.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Shipping and handling costs. </font><font style="font-family:inherit;font-size:10pt;">We do not charge customers for shipping and handling costs. Shipping and handling costs are classified as Cost of revenues in the Condensed Consolidated Statement of Operations.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Foreign currency translation</font><font style="font-family:inherit;font-size:10pt;">. The financial statements of certain of our foreign operations are measured using the local currency as the functional currency. The local currency assets and liabilities are generally translated at the rate of exchange to the United States (“U.S.”) dollar on the balance sheet date and the local currency revenues and expenses are translated at average rates of exchange to the U.S. dollar during the reporting periods. Foreign currency transaction gains (losses) have been reflected as a component of Other income (expense), net within the Condensed Consolidated Statement of Operations and foreign currency translation gains (losses) have been included as a component of the Condensed Consolidated Statement of Comprehensive Loss. </font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Variable interest entities</font><font style="font-family:inherit;font-size:10pt;">. The consolidation of a variable interest entity (“VIE”) is required when an enterprise has a controlling financial interest. A controlling financial interest in a VIE will have both of the following characteristics: (a) the power to direct the activities of a VIE that most significantly impact the VIE’s economic performance and (b) the obligation to absorb losses of the VIE that could potentially be significant to the VIE. Refer to Note 5.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Investments</font><font style="font-family:inherit;font-size:10pt;">. We have made strategic investments in development stage and emerging companies. We record these investments as equity method investments or as equity securities based on our percentage of ownership and whether we have significant influence over the operations of the investees. For investments classified under the equity method of accounting, we record our proportionate share of their losses in Losses from investments in investees in our Condensed Consolidated Statements of Operations. Refer to Note 5. For investments classified as equity securities, we record changes in their fair value as Other income (expense) in our Condensed Consolidated Statements of Operations based on their closing price per share at the end of each reporting period unless the equity security does not have a readily determinable fair value. Refer to Note 5.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Recently adopted accounting pronouncements</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2014, the Financial Accounting Standards Board (the “FASB”) issued Accounting Standards Update (“ASU”) No. 2014-09, “Revenue from Contracts with Customers.” ASU 2014-09, as amended and codified into Topic 606, clarifies the principles for recognizing revenue and develops a common revenue standard for GAAP that removes inconsistencies and weaknesses in revenue requirements, provides a more robust framework for addressing revenue issues, improves comparability of revenue recognition practices across entities, industries, jurisdictions, and capital markets, provides more useful information to users of financial statements through improved disclosure requirements and simplifies the preparation of financial statements by reducing the number of requirements to which an entity must refer. As required, we adopted ASU 2014-09 on January 1, 2018 using the full retrospective approach, and have elected to use the following practical expedients that are permitted under the rules of the adoption, which have been applied consistently to all contracts within all reporting periods presented:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">•</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For all reporting periods presented before January 1, 2018, we have not restated revenue from contracts that begin and are completed within the same annual reporting period.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">•</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For all reporting periods presented before January 1, 2018, we have not disclosed the amount of the transaction price allocated to the remaining performance obligations or an explanation of when we expect to recognize that amount as revenue.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">•</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have applied the practical expedient provided for by Topic 606 by not adjusting the transaction price for significant financing components for periods less than one year. </font></div></td></tr></table><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As a result of adopting ASU 2014-09 on January 1, 2018 using the full retrospective approach, we revised our comparative financial statements for the prior years as if Topic 606 had been effective for those periods. As a result, the following financial statement line items for 2017 were affected:</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Condensed Consolidated Statement of Operations</font></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:50%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">For the three months ended June 30, 2017</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">As adjusted under Topic 606</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">As originally reported</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Effect of change</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue from services</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">233,912</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">256,671</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(22,759</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue from transfer of intellectual property and other</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29,723</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28,576</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,147</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Selling, general and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">105,579</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">128,338</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(22,759</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33,128</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32,593</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">535</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:50%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">For the six months ended June 30, 2017</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">As adjusted under Topic 606</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">As originally reported</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Effect of change</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue from services</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">462,456</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">511,956</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(49,500</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue from transfer of intellectual property and other</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">45,328</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">47,154</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,826</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Selling, general and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">215,523</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">265,023</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(49,500</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">59,685</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">58,615</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,070</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Condensed Consolidated Balance Sheet</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:50%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">December 31, 2017</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">As adjusted under Topic 606</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">As originally reported</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Effect of change</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other current assets and prepaid expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">42,513</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">37,113</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,400</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued expenses</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">230,301</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">215,102</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,199</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other long-term liabilities, principally contract liabilities, contingent consideration and line of credit</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">239,955</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">219,954</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,001</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accumulated deficit</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,036,959</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,007,159</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(29,800</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Condensed Consolidated Statement of Cash Flows</font></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:50%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">For the six months ended June 30, 2017<br clear="none"/>(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">As adjusted under Topic 606</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">As originally reported</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Effect of change</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(51,419</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(48,523</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,896</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contract liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(31,122</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(34,018</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,896</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The most significant change above relates to amounts in our clinical laboratory operations that were historically classified as provision for bad debts, primarily related to patient responsibility, which are considered an element of variable consideration as an implicit price concession in determining revenues under Topic 606. Accordingly, we report uncollectible balances associated with individual patients as a reduction of the transaction price and therefore as a reduction in Revenue from services when historically these amounts were classified as provision for bad debts within Selling, general and administrative expenses. </font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition, under Topic 606, the upfront consideration received for a license and contract services combined performance obligation is recognized as revenue to the extent of costs incurred based on the length of the expected performance period and the subjectivity in estimating progress towards satisfaction of the performance obligation. Under previous accounting, we recognized revenue over the expected performance period. The adoption of Topic 606 resulted in a cumulative revenue reduction of </font><font style="font-family:inherit;font-size:10pt;">$29.8 million</font><font style="font-family:inherit;font-size:10pt;"> and an increase of our accumulated deficit balance as of December 31, 2017; with a corresponding increase in our contract liabilities. For the six months ended June 30, 2017, Revenue from the transfer of intellectual property and other was reduced by </font><font style="font-family:inherit;font-size:10pt;">$2.9 million</font><font style="font-family:inherit;font-size:10pt;"> for the change in accounting. For a further discussion of the adoption of Topic 606, see Note 12, “Revenue Recognition.”</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2016, the FASB issued ASU No. 2016-01, “Financial Instruments - Overall (Subtopic 825-10),” which addresses certain aspects of recognition, measurement, presentation, and disclosure of financial instruments. The ASU requires equity investments (except those accounted for under the equity method of accounting or those that result in consolidation of the investee) to be measured at fair value with changes in fair value recognized in net income. As a result of the required adoption of ASU 2016-01 on January 1, 2018, we recorded a cumulative-effect adjustment to reclassify our net unrealized gains on our equity securities of </font><font style="font-family:inherit;font-size:10pt;">$4.9 million</font><font style="font-family:inherit;font-size:10pt;"> as of January 1, 2018 from Accumulated other comprehensive loss to Accumulated deficit in our Condensed Consolidated Balance Sheet. Changes in the fair value of our equity securities subsequent to the adoption of ASU 2016-01 on January 1, 2018 will be recognized in net income.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August 2016, the FASB issued ASU No. 2016-15, “Statement of Cash Flows (Topic 230),” which addresses the classification of eight specific cash flow issues with the objective of reducing the existing diversity in practice. The required adoption of ASU 2016-15 in the first quarter of 2018 did not have a significant impact on our Condensed Consolidated Financial Statements. </font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2017, the FASB issued ASU No. 2017-01, “Business Combinations (Topic 805),” which clarifies the definition of a business to assist entities in evaluating whether transactions should be accounted for acquisitions (or disposals) of assets or businesses. The required adoption of ASU 2017-01 in the first quarter of 2018 did not have a significant impact on our Condensed Consolidated Financial Statements. </font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Pending accounting pronouncements</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2016, the FASB issued ASU No. 2016-02, “Leases (Topic 842),” which will require organizations that lease assets with lease terms of more than 12 months to recognize assets and liabilities for the rights and obligations created by those leases on their balance sheets. The ASU will also require new qualitative and quantitative disclosures to help investors and other financial statement users better understand the amount, timing, and uncertainty of cash flows arising from leases. ASU 2016-02 will be effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years, with early adoption permitted. We have begun a process to identify a complete population of our leases. Such process includes reviewing various contracts to identify whether such arrangements convey the right to control the use of an identified asset. The determination of the impact of this new guidance is ongoing and, as such, we are not able to reasonably estimate the effect the adoption of this new standard will have on our financial statements. Based on our preliminary assessment of this ASU, we believe the new standard will have a significant impact on our Condensed Consolidated Balance Sheet, which has not yet been quantified.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2017, the FASB issued ASU No. 2017-04, “Intangibles - Goodwill and Other (Topic 350),” which simplifies how an entity is required to test for goodwill impairment. ASU 2017-04 will be effective for annual or interim goodwill impairment tests in fiscal years beginning after December 15, 2019, with early adoption permitted after January 1, 2017. We are currently evaluating the impact of this new guidance on our Condensed Consolidated Financial Statements.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In June 2018, the FASB issued ASU No. 2018-07, “Compensation - Stock Compensation (Topic 718),” which expands the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from nonemployees. ASU 2018-07 will be effective for public business entities for fiscal years beginning after December 15, 2018, including interim periods within that fiscal year, with early adoption permitted. We are currently evaluating the impact of this new guidance on our Condensed Consolidated Financial Statements.</font></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">COMPOSITION OF CERTAIN FINANCIAL STATEMENT CAPTIONS</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:67%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;text-decoration:underline;">(In thousands)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">June 30, <br clear="none"/>2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">December 31, <br clear="none"/>2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts receivable, net:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts receivable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">154,269</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">166,962</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less: allowance for doubtful accounts</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,492</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,446</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">152,777</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">165,516</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Inventories, net:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Consumable supplies</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24,986</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,546</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Finished products</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,783</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,012</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Work in-process</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,910</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,873</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Raw materials</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,800</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,467</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less: inventory reserve</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,726</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,565</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">46,753</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">49,333</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other current assets and prepaid expenses:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Taxes recoverable</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,319</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,138</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other receivables</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,031</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,798</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prepaid supplies</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,278</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,207</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prepaid insurance</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,259</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,532</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,764</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,838</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41,651</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">42,513</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intangible assets, net:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Customer relationships</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">447,225</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">448,345</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Technologies</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">340,815</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">340,921</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Trade names</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50,494</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50,553</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Licenses</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,246</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,305</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Covenants not to compete</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,367</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,372</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Product registrations</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,694</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,475</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,696</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,799</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less: accumulated amortization</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(231,996</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(198,935</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">648,541</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">683,835</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued expenses:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contract liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">61,846</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">61,388</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Employee benefits</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">46,621</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50,377</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Clinical trials</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,598</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,191</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Taxes payable</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,604</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,609</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contingent consideration</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,042</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,750</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Capital leases short-term</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,166</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,399</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Milestone payment</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,967</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,868</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Professional fees</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,727</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,355</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">65,421</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">79,364</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">200,992</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">230,301</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr></table></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:67%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;text-decoration:underline;">(In thousands)</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">June 30, <br clear="none"/>2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">December 31, <br clear="none"/>2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other long-term liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contract liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">47,720</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">78,990</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Line of credit</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">105,539</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">104,152</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contingent consideration</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,712</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29,603</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Mortgages and other debts payable</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,704</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,567</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Capital leases long-term</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,638</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,786</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,131</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,857</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">209,444</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">239,955</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All of the intangible assets and goodwill acquired relate to our acquisitions of principally OPKO Renal, OPKO Biologics, EirGen Pharma Limited (“EirGen”) and BioReference. We do not anticipate capitalizing the cost of product registration renewals, rather we expect to expense these costs, as incurred. Our goodwill is not tax deductible for income tax purposes in any jurisdiction we operate in.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The changes in value of the intangible assets and goodwill during the </font><font style="font-family:inherit;font-size:10pt;">six months ended June 30, 2018</font><font style="font-family:inherit;font-size:10pt;"> are primarily due to foreign currency fluctuations between the Chilean Peso, the Euro and the Shekel against the U.S. dollar. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes the changes in Goodwill during the </font><font style="font-family:inherit;font-size:10pt;">six months ended June 30, 2018</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:50%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;text-decoration:underline;">(In thousands)</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Balance at January 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Foreign exchange and other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Balance at June 30</font><font style="font-family:inherit;font-size:8pt;">th</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pharmaceuticals</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">CURNA</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,827</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,827</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">EirGen</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">89,226</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,201</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">87,025</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">FineTech</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,698</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,698</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">OPKO Chile</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,203</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(307</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,896</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">OPKO Biologics</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">139,784</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">139,784</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">OPKO Health Europe</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,898</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(197</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,701</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">OPKO Renal</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,069</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,069</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Transition Therapeutics</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,608</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(160</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,448</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Diagnostics</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">BioReference</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">401,821</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">401,821</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">OPKO Diagnostics</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,977</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,977</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">OPKO Lab</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32,988</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32,988</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">717,099</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,865</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">714,234</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net gains and losses on our equity securities for the </font><font style="font-family:inherit;font-size:10pt;">six months ended June 30, 2018</font><font style="font-family:inherit;font-size:10pt;"> are as follows:</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td style="width:78%;" rowspan="1" colspan="1"></td><td style="width:2%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;text-decoration:underline;">(in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Equity Securities</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">For the six months ended June 30, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net gains recognized during the period on equity securities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,289</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less: Net losses realized during the period on equity securities sold during the period</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(113</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unrealized net gains and losses recognized during the period on equity securities still held at the reporting date</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,402</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Use of estimates</font><font style="font-family:inherit;font-size:10pt;">. The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ significantly from these estimates.</font></div></div>

EX-101.SCH 8 opk-20180630.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 2107100 - Disclosure - Accumulated Other Comprehensive Income (Loss) link:presentationLink link:calculationLink link:definitionLink 2407402 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Details) link:presentationLink link:calculationLink link:definitionLink 2307301 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Tables) link:presentationLink link:calculationLink link:definitionLink 2105100 - Disclosure - Acquisitions, Investments and Licenses link:presentationLink link:calculationLink link:definitionLink 2405404 - Disclosure - Acquisitions, Investments and Licenses - Available for Sale Investments, Sale of Investments and Warrants and Options Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2405403 - Disclosure - Acquisitions, Investments and Licenses - Equity and Cost Method Investments Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2405405 - Disclosure - Acquisitions, Investments and Licenses - Schedule of Net Gains and Losses on Equity Securities (Details) link:presentationLink link:calculationLink link:definitionLink 2405402 - Disclosure - Acquisitions, Investments and Licenses - Summary of Investments (Details) link:presentationLink link:calculationLink link:definitionLink 2305301 - Disclosure - Acquisitions, Investments and Licenses (Tables) link:presentationLink link:calculationLink link:definitionLink 2405406 - Disclosure - Acquisitions, Investments and Licenses - Variable Interest Entities Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2101100 - Disclosure - Business and Organization link:presentationLink link:calculationLink link:definitionLink 2401401 - Disclosure - Business and Organization (Details) link:presentationLink link:calculationLink link:definitionLink 2111100 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 2411401 - Disclosure - Commitments and Contingencies (Details) link:presentationLink link:calculationLink link:definitionLink 2104100 - Disclosure - Composition of Certain Financial Statement Captions link:presentationLink link:calculationLink link:definitionLink 2404403 - Disclosure - Composition of Certain Financial Statement Captions - Changes in Goodwill (Details) link:presentationLink link:calculationLink link:definitionLink 2404402 - Disclosure - Composition of Certain Financial Statement Captions (Details) link:presentationLink link:calculationLink link:definitionLink 2304301 - Disclosure - Composition of Certain Financial Statement Captions (Tables) link:presentationLink link:calculationLink link:definitionLink 1001000 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 1001501 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1005000 - Statement - Condensed Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 1003000 - Statement - Condensed Consolidated Statements of Comprehensive Loss link:presentationLink link:calculationLink link:definitionLink 1002000 - Statement - Condensed Consolidated Statements of Operations link:presentationLink link:calculationLink link:definitionLink 2106100 - Disclosure - Debt link:presentationLink link:calculationLink link:definitionLink 2406404 - Disclosure - Debt - Lines Of Credit (Details) link:presentationLink link:calculationLink link:definitionLink 2406405 - Disclosure - Debt - Mortgage Notes And Other Debt (Details) link:presentationLink link:calculationLink link:definitionLink 2406402 - Disclosure - Debt - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2406403 - Disclosure - Debt - Notes (Details) link:presentationLink link:calculationLink link:definitionLink 2306301 - Disclosure - Debt (Tables) link:presentationLink link:calculationLink link:definitionLink 2109100 - Disclosure - Derivative Contracts link:presentationLink link:calculationLink link:definitionLink 2409402 - Disclosure - Derivative Contracts - Balance Sheet Component (Details) link:presentationLink link:calculationLink link:definitionLink 2409403 - Disclosure - Derivative Contracts - Derivative Gains (Losses) (Details) link:presentationLink link:calculationLink link:definitionLink 2309301 - Disclosure - Derivative Contracts (Tables) link:presentationLink link:calculationLink link:definitionLink 0001000 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 2103100 - Disclosure - Earnings (Loss) Per Share link:presentationLink link:calculationLink link:definitionLink 2403403 - Disclosure - Earnings (Loss) Per Share - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2403402 - Disclosure - Earnings (Loss) Per Share - Schedule of Earnings (Loss) Per Share, Basic and Diluted (Details) link:presentationLink link:calculationLink link:definitionLink 2303301 - Disclosure - Earnings (Loss) Per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 2108100 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 2408402 - Disclosure - Fair Value Measurements - Assets And Liabilities Measured At Fair Value (Details) link:presentationLink link:calculationLink link:definitionLink 2408403 - Disclosure - Fair Value Measurements - Level 3 Reconciliation (Details) link:presentationLink link:calculationLink link:definitionLink 2408404 - Disclosure - Fair Value Measurements - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2308301 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 2110100 - Disclosure - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 2410401 - Disclosure - Related Party Transactions (Details) link:presentationLink link:calculationLink link:definitionLink 2112100 - Disclosure - Revenue Recognition link:presentationLink link:calculationLink link:definitionLink 2412403 - Disclosure - Revenue Recognition - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2412402 - Disclosure - Revenue Recognition - Schedule of Disaggregation of Revenue (Details) link:presentationLink link:calculationLink link:definitionLink 2412404 - Disclosure - Revenue Recognition - Schedule of Product Sales Allowances and Accruals (Details) link:presentationLink link:calculationLink link:definitionLink 2312301 - Disclosure - Revenue Recognition (Tables) link:presentationLink link:calculationLink link:definitionLink 2115100 - Disclosure - Segments link:presentationLink link:calculationLink link:definitionLink 2415402 - Disclosure - Segments - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2415403 - Disclosure - Segments - Operations and Assets Information (Details) link:presentationLink link:calculationLink link:definitionLink 2315301 - Disclosure - Segments (Tables) link:presentationLink link:calculationLink link:definitionLink 2114100 - Disclosure - Strategic Alliances link:presentationLink link:calculationLink link:definitionLink 2414401 - Disclosure - Strategic Alliances (Details) link:presentationLink link:calculationLink link:definitionLink 2116100 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 2102100 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 2402403 - Disclosure - Summary of Significant Accounting Policies (Details) link:presentationLink link:calculationLink link:definitionLink 2202201 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 2402404 - Disclosure - Summary of Significant Accounting Policies - Schedule of Topic 606 Impact (Details) link:presentationLink link:calculationLink link:definitionLink 2302302 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 9 opk-20180630_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 10 opk-20180630_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 11 opk-20180630_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Accounting Policies [Abstract] New Accounting Pronouncements or Change in Accounting Principle [Table] New Accounting Pronouncements or Change in Accounting Principle [Table] Product and Service [Axis] Product and Service [Axis] Product and Service [Domain] Product and Service [Domain] Services Service [Member] Transfer of intellectual property and other Transfer Of Intellectual Property And Other [Member] Transfer Of Intellectual Property And Other [Member] Adjustments for New Accounting Pronouncements [Axis] Adjustments for New Accounting Pronouncements [Axis] Type of Adoption [Domain] Type of Adoption [Domain] Accounting Standards Update 2014-09 Accounting Standards Update 2014-09 [Member] Restatement [Axis] Restatement [Axis] Restatement [Domain] Restatement [Domain] Effect of change Restatement Adjustment [Member] As originally reported Previously Reported [Member] New Accounting Pronouncements or Change in Accounting Principle [Line Items] New Accounting Pronouncements or Change in Accounting Principle [Line Items] Condensed Consolidated Statement of Operations Income Statement [Abstract] Total revenues Revenue from Contract with Customer, Excluding Assessed Tax Selling, general and administrative Selling, General and Administrative Expense Research and development Research and Development Expense Condensed Consolidated Balance Sheet Statement of Financial Position [Abstract] Other current assets and prepaid expenses Prepaid Expense and Other Assets, Current Accrued expenses Accrued Liabilities, Current Other long-term liabilities, principally contract liabilities, contingent consideration and line of credit Other Liabilities, Noncurrent Accumulated deficit Retained Earnings (Accumulated Deficit) Condensed Consolidated Statement of Cash Flows Statement of Cash Flows [Abstract] Net loss Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Contract liabilities Increase (Decrease) in Contract with Customer, Liability Earnings Per Share [Abstract] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Securities [Axis] Antidilutive Securities [Axis] Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Stock options Employee Stock Option [Member] Warrants Warrant [Member] 2033 Senior Notes 2033 Senior Notes [Member] 2033 Senior Notes [Member] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Net loss, basic Net Income (Loss) Available to Common Stockholders, Basic Add: Interest on 2033 Senior Notes Interest on Convertible Debt, Net of Tax Change in FV of embedded derivative income Embedded Derivative, Gain (Loss) on Embedded Derivative, Net Net loss, diluted Net Income (Loss) Available to Common Stockholders, Diluted Weighted average common shares outstanding, basic Weighted Average Number of Shares Outstanding, Basic Dilutive potential shares Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements Weighted average common shares outstanding, diluted Weighted Average Number of Shares Outstanding, Diluted Loss per share, basic (in dollars per share) Earnings Per Share, Basic Loss per share, diluted (in dollars per share) Earnings Per Share, Diluted Summary of Significant Accounting Policies [Table] Summary of Significant Accounting Policies [Table] Summary of Significant Accounting Policies [Table] Timing of Transfer of Good or Service [Axis] Timing of Transfer of Good or Service [Axis] Timing of Transfer of Good or Service [Domain] Timing of Transfer of Good or Service [Domain] Transferred over Time Transferred over Time [Member] Equity Components [Axis] Equity Components [Axis] Equity Component [Domain] Equity Component [Domain] Accumulated Deficit Retained Earnings [Member] Accounting Standards Update 2016-01 Accounting Standards Update 2016-01 [Member] Property, Plant and Equipment, Type [Axis] Property, Plant and Equipment, Type [Axis] Property, Plant and Equipment, Type [Domain] Property, Plant and Equipment, Type [Domain] Software Software and Software Development Costs [Member] Machinery, Medical and Other Equipment Machinery and Equipment [Member] Furniture and Fixtures Furniture and Fixtures [Member] Buildings and Improvements Building and Building Improvements [Member] Automobiles and Aircraft Automobiles and Aircraft [Member] Automobiles and Aircraft [Member] Concentration Risk Type [Axis] Concentration Risk Type [Axis] Concentration Risk Type [Domain] Concentration Risk Type [Domain] Government Contracts Concentration Risk Government Contracts Concentration Risk [Member] Customer Concentration Risk Customer Concentration Risk [Member] Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Accounts Receivable Accounts Receivable [Member] Range [Axis] Range [Axis] Range [Domain] Range [Domain] Minimum Minimum [Member] Maximum Maximum [Member] Summary of Significant Accounting Policies [Line Items] Summary of Significant Accounting Policies [Line Items] Summary of Significant Accounting Policies [Line Items] Provision for inventory obsolescence Inventory Write-down Goodwill, in-process research and development and other intangible assets acquired Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Goodwill and Intangible Assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Goodwill and Intangible Assets Intangible assets, estimated useful lives Finite-Lived Intangible Asset, Useful Life Amortization expense Amortization of Intangible Assets Property, plant and equipment, estimated useful lives Property, Plant and Equipment, Useful Life Depreciation expense Depreciation Concentration percentage Concentration Risk, Percentage Allowance for doubtful accounts receivable Allowance for Doubtful Accounts Receivable, Current Provision related to current period sales Provision for Doubtful Accounts Equity-based compensation expense Allocated Share-based Compensation Expense Number of reportable segments Number of Reportable Segments Reduction in revenue from transfer of intellectual property and other Accumulated deficit Increase in contract liabilities Cumulative effect of new accounting update Cumulative Effect of New Accounting Principle in Period of Adoption Debt Disclosure [Abstract] Schedule of Long-term Debt Instruments [Table] Schedule of Long-term Debt Instruments [Table] Long-term Debt, Type [Axis] Long-term Debt, Type [Axis] Long-term Debt, Type [Domain] Long-term Debt, Type [Domain] Senior Notes Senior Notes [Member] Debt Instrument [Line Items] Debt Instrument [Line Items] Debt Instrument [Roll Forward] Debt Instrument [Roll Forward] Debt Instrument [Roll Forward] 2033 Senior Notes, beginning balance Long-term Debt, Gross Discount, beginning balance Debt Instrument, Unamortized Discount Debt issuance cost, beginning balance Debt Issuance Costs, Net Total, beginning balance Long-term Debt Amortization of debt discount Amortization of Debt Discount (Premium) Amortization of debt issuance costs Amortization of Debt Issuance Costs Amortization of debt discount and debt issuance costs Amortization of Debt Issuance Costs and Discounts 2033 Senior Notes, ending balance Discount, ending balance Debt issuance cost, ending balance Total, ending balance Fair Value Disclosures [Abstract] Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Reconciliation of the Beginning and Ending Balances of Level 3 Assets and Liabilities Fair Value, Assets And Liabilities Measured On Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Reconciles beginning and ending balances of level three assets and liabilities. Derivative Instruments and Hedging Activities Disclosure [Abstract] Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table] Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table] Hedging Designation [Axis] Hedging Designation [Axis] Hedging Designation [Domain] Hedging Designation [Domain] Not Designated as Hedging Instrument Not Designated as Hedging Instrument [Member] Derivative Instrument Risk [Axis] Derivative Instrument [Axis] Derivative Contract Type [Domain] Derivative Contract [Domain] Common Stock options/warrants Equity Option [Member] Forward contracts Forward Contracts [Member] Balance Sheet Location [Axis] Balance Sheet Location [Axis] Balance Sheet Location [Domain] Balance Sheet Location [Domain] Investments, net Investments [Member] Unrealized gains on forward contracts are recorded in Other current assets and prepaid expenses. Unrealized (losses) on forward contracts are recorded in Accrued expenses. Prepaid Expenses and Other Current Assets (Accrued Expenses) [Member] Prepaid Expenses and Other Current Assets (Accrued Expenses) [Member] Derivatives, Fair Value [Line Items] Derivatives, Fair Value [Line Items] Common stock options/warrants Derivative Asset, Fair Value, Gross Asset Derivative liability, fair value Derivative Liability, Fair Value, Gross Liability Fair Value Measurements, Recurring and Nonrecurring [Table] Fair Value Measurements, Recurring and Nonrecurring [Table] Accrued Expenses Accrued Liabilities [Member] Other Noncurrent Liabilities Other Noncurrent Liabilities [Member] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Percentage of decrease in future sales Percentage Of Increase Decrease In Future Sales Percentage of increase decrease in future sales. Decrease of estimated future sales in amount Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration If Estimated Future Sales Decrease Ten Percent Business combination contingent consideration arrangements change in amount of contingent consideration if estimated future sales decrease ten percent. Contingent consideration Business Combination, Contingent Consideration, Liability Organization, Consolidation and Presentation of Financial Statements [Abstract] Condensed Financial Statements [Table] Condensed Financial Statements [Table] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Customer relationships Customer Relationships [Member] Technologies Technology-Based Intangible Assets [Member] Trade names Trade Names [Member] Licenses Licensing Agreements [Member] Covenants not to compete Noncompete Agreements [Member] Product registrations Product Registrations [Member] Product Registrations [Member] Other Other Intangible Assets [Member] Condensed Financial Statements, Captions [Line Items] Condensed Financial Statements, Captions [Line Items] Accounts receivable, net: Accounts Receivable, Net [Abstract] Accounts receivable Accounts Receivable, Gross, Current Less: allowance for doubtful accounts Accounts receivable, net Accounts Receivable, Net, Current Inventories, net: Inventory, Net [Abstract] Consumable supplies Other Inventory, Supplies, Gross Finished products Inventory, Finished Goods, Gross Work in-process Inventory, Work in Process, Gross Raw materials Inventory, Raw Materials, Gross Less: inventory reserve Inventory Valuation Reserves Inventory, net Inventory, Net Other current assets and prepaid expenses: Prepaid Expense and Other Assets, Current [Abstract] Taxes recoverable Taxes Recoverable, Current Taxes Recoverable, Current Other receivables Accounts and Other Receivables, Net, Current Prepaid supplies Prepaid Supplies Prepaid insurance Prepaid Insurance Other Other Assets, Current Other current assets and prepaid expenses Intangible assets, net: Finite-Lived Intangible Assets, Net [Abstract] Intangible assets Finite-Lived Intangible Assets, Gross Less: accumulated amortization Finite-Lived Intangible Assets, Accumulated Amortization Intangible assets, net Finite-Lived Intangible Assets, Net Accrued expenses: Accrued Liabilities, Current [Abstract] Contract liabilities Contract with Customer, Liability, Current Employee benefits Accrued Employee Benefits, Current Clinical trials Accrued Clinical Trials, Current Accrued clinical trials. Taxes payable Accrued Income Taxes, Current Contingent consideration Business Combination, Contingent Consideration, Liability, Current Capital leases short-term Capital Lease Obligations, Current Milestone payment Business Combination, Deferred Acquisition Payments, Net of Discount, Current Deferred acquisition payments net of discount. Professional fees Accrued Professional Fees, Current Other Other Accrued Liabilities, Current Accrued expenses Other long-term liabilities: Other Liabilities, Noncurrent [Abstract] Contract liabilities Contract with Customer, Liability, Noncurrent Line of credit Long-term Line of Credit, Noncurrent Contingent consideration Business Combination, Contingent Consideration, Liability, Noncurrent Mortgages and other debts payable Long-term Debt, Excluding Current Maturities Capital leases long-term Capital Lease Obligations, Noncurrent Other Other Liabilities and Deferred Revenue, Noncurrent Other long-term liabilities BUSINESS AND ORGANIZATION Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Fair Value, Assets And Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Fair Value, Assets And Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Fair Value, Assets And Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Liability Class [Axis] Liability Class [Axis] Fair Value by Liability Class [Domain] Fair Value by Liability Class [Domain] Contingent consideration Contingent Consideration [Member] Contingent consideration. Fair Value, Assets And Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Fair Value, Assets And Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] [Line Items] for Fair Value, Assets And Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Beginning Balance Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value Included in results of operations Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings Ending Balance EX-101.PRE 12 opk-20180630_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 13 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	6 Months Ended
Document and Entity Information - shares	Jun. 30, 2018	Aug. 01, 2018
Document and Entity Information [Abstract]
Entity Registrant Name	Opko Health, Inc.
Entity Central Index Key	0000944809
Document Type	10-Q
Document Period End Date	Jun. 30, 2018
Amendment Flag	false
Document Fiscal Year Focus	2018
Document Fiscal Period Focus	Q2
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		559,770,995

XML 14 R2.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2018	Dec. 31, 2017
Current assets:
Cash and cash equivalents	$ 80,381	$ 91,499
Accounts receivable, net	152,777	165,516
Inventory, net	46,753	49,333
Other current assets and prepaid expenses	41,651	42,513
Total current assets	321,562	348,861
Property, plant and equipment, net	150,156	146,557
Intangible assets, net	648,541	683,835
In-process research and development	645,714	647,347
Goodwill	714,234	717,099
Investments	45,497	40,642
Other assets	5,246	5,615
Total assets	2,530,950	2,589,956
Current liabilities:
Accounts payable	69,061	74,307
Accrued expenses	200,992	230,301
Current portion of 2033 Senior Notes	30,343	0
Current portion of lines of credit and notes payable	6,465	11,926
Total current liabilities	306,861	316,534
2023 Convertible Notes and 2033 Senior Notes	55,894	29,160
Deferred tax liabilities, net	148,255	148,729
Other long-term liabilities, principally contract liabilities, contingent consideration and line of credit	209,444	239,955
Total long-term liabilities	413,593	417,844
Total liabilities	720,454	734,378
Equity:
Common Stock - $0.01 par value, 750,000,000 shares authorized; 560,169,422 and 560,023,745 shares issued at June 30, 2018 and December 31, 2017, respectively	5,602	5,600
Treasury Stock - 549,907 and 549,907 shares at June 30, 2018 and December 31, 2017, respectively	(1,791)	(1,791)
Additional paid-in capital	2,901,086	2,889,256
Accumulated other comprehensive loss	(13,004)	(528)
Accumulated deficit	(1,081,397)	(1,036,959)
Total shareholders’ equity	1,810,496	1,855,578
Total liabilities and equity	$ 2,530,950	$ 2,589,956

XML 15 R3.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Jun. 30, 2018	Dec. 31, 2017
Statement of Financial Position [Abstract]
Common Stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common Stock, shares authorized (in shares)	750,000,000	750,000,000
Common Stock, shares issued (in shares)	560,169,422	560,023,745
Treasury stock, shares (in shares)	549,907	549,907

XML 16 R4.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Revenues:
Total revenues	$ 263,685	$ 292,601	$ 518,598	$ 558,981
Costs and expenses:
Selling, general and administrative	87,653	105,579	179,172	215,523
Research and development	29,211	33,128	62,097	59,685
Contingent consideration	(15,358)	4,366	(13,599)	6,738
Amortization of intangible assets	17,227	17,953	34,498	35,881
Total costs and expenses	268,793	318,432	566,317	630,028
Operating loss	(5,108)	(25,831)	(47,719)	(71,047)
Other income and (expense), net:
Interest income	27	136	67	385
Interest expense	(2,722)	(1,502)	(4,989)	(2,931)
Fair value changes of derivative instruments, net	2,248	5,482	3,644	9,519
Other income (expense), net	8,584	(533)	10,477	2,509
Other income and (expense), net	8,137	3,583	9,199	9,482
Income (loss) before income taxes and investment losses	3,029	(22,248)	(38,520)	(61,565)
Income tax benefit (provision)	(2,017)	10,960	(1,126)	17,904
Net income (loss) before investment losses	1,012	(11,288)	(39,646)	(43,661)
Loss from investments in investees	(7,213)	(5,628)	(9,669)	(7,758)
Net loss	$ (6,201)	$ (16,916)	$ (49,315)	$ (51,419)
Loss per share:
Loss per share, basic (in dollars per share)	$ (0.01)	$ (0.03)	$ (0.09)	$ (0.09)
Loss per share, diluted (in dollars per share)	$ (0.01)	$ (0.04)	$ (0.09)	$ (0.11)
Weighted average common shares outstanding, basic	559,541,253	559,347,540	559,507,732	558,892,375
Weighted average common shares outstanding, diluted (in shares)	559,541,253	564,163,808	559,507,732	563,617,274
Services
Revenues:
Total revenues	$ 216,055	$ 233,912	$ 427,369	$ 462,456
Costs and expenses:
Cost of service revenue	134,408	143,901	273,849	283,867
Products
Revenues:
Total revenues	28,523	28,966	56,374	51,197
Costs and expenses:
Cost of service revenue	15,652	13,505	30,300	28,334
Transfer of intellectual property and other
Revenues:
Total revenues	$ 19,107	$ 29,723	$ 34,855	$ 45,328

XML 17 R5.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Statement of Comprehensive Income [Abstract]
Net loss	$ (6,201)	$ (16,916)	$ (49,315)	$ (51,419)
Other comprehensive income (loss), net of tax:
Change in foreign currency translation and other comprehensive income (loss)	(12,465)	10,495	(7,600)	13,088
Investments:
Change in unrealized loss, net of tax	0	(206)	0	(743)
Reclassification adjustment due to adoption of ASU 2016-01	0	0	(4,876)	0
Reclassification adjustments for losses included in net loss, net of tax	0	594	0	594
Comprehensive loss	$ (18,666)	$ (6,033)	$ (61,791)	$ (38,480)

- Definition

The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=114867106&loc=SL7669619-108580

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=114867106&loc=SL7669625-108580

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (c)(1)
-URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 6: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4J
-URI http://asc.fasb.org/extlink&oid=84234705&loc=SL4591551-111686

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3000-108585

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 19
-URI http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599

Reference 10: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4K
-URI http://asc.fasb.org/extlink&oid=84234705&loc=SL4591552-111686

+ Details

XML 18 R6.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017
Cash flows from operating activities:
Net loss	$ (49,315)	$ (51,419)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Depreciation and amortization	49,518	51,281
Non-cash interest	2,198	1,294
Amortization of deferred financing costs	99	112
Losses from investments in investees	9,669	7,758
Equity-based compensation – employees and non-employees	11,514	15,844
Gain on disposal of fixed assets	(495)	(2,473)
Change in fair value of equity securities and derivative instruments	(14,819)	(9,519)
Change in fair value of contingent consideration	(13,599)	6,738
Deferred income tax benefit	(2,026)	(23,039)
Changes in assets and liabilities, net of the effects of acquisitions:
Accounts receivable, net	12,440	(30,865)
Inventory, net	894	(443)
Other current assets and prepaid expenses	(3,730)	3,692
Other assets	(146)	(254)
Accounts payable	(8,092)	9,439
Foreign currency measurement	(77)	230
Contract liabilities	(30,812)	(31,122)
Accrued expenses and other liabilities	(15,820)	(3,837)
Net cash used in operating activities	(52,599)	(56,583)
Cash flows from investing activities:
Investments in investees	(1,000)	(3,000)
Proceeds from sale of equity securities	1,286	0
Purchase of marketable securities	0	(5)
Proceeds from the sale of property, plant and equipment	840	3,398
Capital expenditures	(12,792)	(16,805)
Net cash used in investing activities	(11,666)	(16,412)
Cash flows from financing activities:
Issuance of 2033 Senior Notes, including to related parties	55,000	0
Proceeds from the exercise of Common Stock options and warrants	318	1,916
Borrowings on lines of credit	18,817	45,524
Repayments of lines of credit	(20,924)	(13,525)
Net cash provided by financing activities	53,211	33,915
Effect of exchange rate changes on cash and cash equivalents	(64)	877
Net decrease in cash and cash equivalents	(11,118)	(38,203)
Cash and cash equivalents at beginning of period	91,499	168,733
Cash and cash equivalents at end of period	80,381	130,530
SUPPLEMENTAL INFORMATION:
Interest paid	785	748
Income taxes paid, net of refunds	5,251	4,321
Shares issued upon the conversion of:
Common Stock options and warrants, surrendered in net exercise	806	1,546
OPKO Health Europe
Issuance of capital stock for contingent consideration settlement:
OPKO Health Europe	$ 0	$ 303

XML 19 R7.htm IDEA: XBRL DOCUMENT

Business and Organization	6 Months Ended
Business and Organization	Jun. 30, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
BUSINESS AND ORGANIZATION	BUSINESS AND ORGANIZATION We are a diversified healthcare company that seeks to establish industry-leading positions in large and rapidly growing medical markets. Our diagnostics business includes BioReference Laboratories, Inc. (“BioReference”), the nation’s third-largest clinical laboratory with a core genetic testing business and an almost 400-person sales and marketing team to drive growth and leverage new products, including the 4Kscore prostate cancer test and the Claros 1 in-office immunoassay platform (in development). Our pharmaceutical business features Rayaldee, an FDA-approved treatment for secondary hyperparathyroidism (“SHPT”) in adults with stage 3 or 4 chronic kidney disease (“CKD”) and vitamin D insufficiency (launched in November 2016), OPK88004, a selective androgen receptor modulator being developed for benign prostatic hyperplasia, OPK88003, a once or twice weekly oxyntomodulin for type 2 diabetes and obesity which is a clinically advanced drug candidate among the new class of GLP-1 glucagon receptor dual agonists (Phase 2b), and 88002, an NK-1 antagonist to treat pruritis (itching) in dialysis patients. Our pharmaceutical business also features hGH-CTP, a once-weekly human growth hormone injection (in Phase 3 and partnered with Pfizer). We are incorporated in Delaware and our principal executive offices are located in leased offices in Miami, Florida. Through BioReference, we provide laboratory testing services, primarily to customers in the larger metropolitan areas across New York, New Jersey, Maryland, Pennsylvania, Delaware, Washington, DC, Florida, California, Texas, Illinois and Massachusetts as well as to customers in a number of other states. We offer a comprehensive test menu of clinical diagnostics for blood, urine, and tissue analysis. This includes hematology, clinical chemistry, immunoassay, infectious diseases, serology, hormones, and toxicology assays, as well as Pap smear, anatomic pathology (biopsies) and other types of tissue analysis. We market our laboratory testing services directly to physicians, geneticists, hospitals, clinics, correctional and other health facilities. We operate established pharmaceutical platforms in Ireland, Chile, Spain, and Mexico, which are generating revenue and which we expect to facilitate future market entry for our products currently in development. In addition, we have a development and commercial supply pharmaceutical company and a global supply chain operation and holding company in Ireland. We own a specialty active pharmaceutical ingredients (“APIs”) manufacturer in Israel, which we expect will facilitate the development of our pipeline of molecules and compounds for our molecular diagnostic and therapeutic products. Our research and development activities are primarily performed at facilities in Miramar, FL, Woburn, MA, Waterford, Ireland, Kiryat Gat, Israel, and Barcelona, Spain.

XML 20 R8.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies

6 Months Ended

Jun. 30, 2018

Accounting Policies [Abstract]

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Investments. We have made strategic investments in development stage and emerging companies. We record these investments as equity method investments or as equity securities based on our percentage of ownership and whether we have significant influence over the operations of the investees. For investments classified under the equity method of accounting, we record our proportionate share of their losses in Losses from investments in investees in our Condensed Consolidated Statements of Operations. Refer to Note 5. For investments classified as equity securities, we record changes in their fair value as Other income (expense) in our Condensed Consolidated Statements of Operations based on their closing price per share at the end of each reporting period unless the equity security does not have a readily determinable fair value. Refer to Note 5.

Recently adopted accounting pronouncements.


•	For all reporting periods presented before January 1, 2018, we have not restated revenue from contracts that begin and are completed within the same annual reporting period.


•	For all reporting periods presented before January 1, 2018, we have not disclosed the amount of the transaction price allocated to the remaining performance obligations or an explanation of when we expect to recognize that amount as revenue.


•	We have applied the practical expedient provided for by Topic 606 by not adjusting the transaction price for significant financing components for periods less than one year.

Condensed Consolidated Statement of Operations



	For the three months ended June 30, 2017 (in thousands)
	As adjusted under Topic 606		As originally reported		Effect of change
Revenue from services	$	233,912	$	256,671	$	(22,759	)
Revenue from transfer of intellectual property and other	29,723		28,576		1,147
Selling, general and administrative	105,579		128,338		(22,759		)
Research and development	33,128		32,593		535



	For the six months ended June 30, 2017 (in thousands)
	As adjusted under Topic 606		As originally reported		Effect of change
Revenue from services	$	462,456	$	511,956	$	(49,500	)
Revenue from transfer of intellectual property and other	45,328		47,154		(1,826		)
Selling, general and administrative	215,523		265,023		(49,500		)
Research and development	59,685		58,615		1,070

Condensed Consolidated Balance Sheet



	December 31, 2017 (in thousands)
	As adjusted under Topic 606			As originally reported			Effect of change
Other current assets and prepaid expenses	$	42,513		$	37,113		$	5,400
Accrued expenses	230,301			215,102			15,199
Other long-term liabilities, principally contract liabilities, contingent consideration and line of credit	239,955			219,954			20,001
Accumulated deficit	(1,036,959		)	(1,007,159		)	(29,800		)

Condensed Consolidated Statement of Cash Flows



	For the six months ended June 30, 2017 (in thousands)
	As adjusted under Topic 606			As originally reported			Effect of change
Net loss	$	(51,419	)	$	(48,523	)	$	(2,896	)
Contract liabilities	(31,122		)	(34,018		)	2,896

Pending accounting pronouncements.

XML 21 R9.htm IDEA: XBRL DOCUMENT

Earnings (Loss) Per Share

6 Months Ended

Jun. 30, 2018

Earnings Per Share [Abstract]

Earnings (Loss) Per Share

EARNINGS (LOSS) PER SHARE



	For the three months ended June 30,						For the six months ended June 30,
(In thousands, except per share data)	2018			2017			2018			2017
Numerator
Net loss, basic	$	(6,201	)	$	(16,916	)	$	(49,315	)	$	(51,419	)
Add: Interest on 2033 Senior Notes	—			652			—			1,291
Change in FV of embedded derivative income	—			(5,069		)	—			(10,014		)
Net loss, diluted	$	(6,201	)	$	(21,333	)	$	(49,315	)	$	(60,142	)

Denominator
(Shares in thousands)
Weighted average common shares outstanding, basic	559,541			559,348			559,508			558,892
Effect of dilutive securities:
Stock options	—			—			—			—
Warrants	—			—			—			—
2033 Senior Notes	—			4,816			—			4,725
Dilutive potential shares	—			4,816			—			4,725
Weighted average common shares outstanding, diluted	559,541			564,164			559,508			563,617

Loss per share, basic	$	(0.01	)	$	(0.03	)	$	(0.09	)	$	(0.09	)
Loss per share, diluted	$	(0.01	)	$	(0.04	)	$	(0.09	)	$	(0.11	)

XML 22 R10.htm IDEA: XBRL DOCUMENT

Composition of Certain Financial Statement Captions

6 Months Ended

Jun. 30, 2018

Organization, Consolidation and Presentation of Financial Statements [Abstract]

COMPOSITION OF CERTAIN FINANCIAL STATEMENT CAPTIONS



(In thousands)	June 30, 2018			December 31, 2017
Accounts receivable, net:
Accounts receivable	$	154,269		$	166,962
Less: allowance for doubtful accounts	(1,492		)	(1,446		)
	$	152,777		$	165,516
Inventories, net:
Consumable supplies	$	24,986		$	21,546
Finished products	16,783			21,012
Work in-process	3,910			5,873
Raw materials	5,800			7,467
Less: inventory reserve	(4,726		)	(6,565		)
	$	46,753		$	49,333
Other current assets and prepaid expenses:
Taxes recoverable	21,319			18,138
Other receivables	2,031			8,798
Prepaid supplies	10,278			8,207
Prepaid insurance	3,259			3,532
Other	4,764			3,838
	$	41,651		$	42,513
Intangible assets, net:
Customer relationships	$	447,225		$	448,345
Technologies	340,815			340,921
Trade names	50,494			50,553
Licenses	10,246			10,305
Covenants not to compete	16,367			16,372
Product registrations	9,694			10,475
Other	5,696			5,799
Less: accumulated amortization	(231,996		)	(198,935		)
	$	648,541		$	683,835
Accrued expenses:
Contract liabilities	$	61,846		$	61,388
Employee benefits	46,621			50,377
Clinical trials	11,598			12,191
Taxes payable	3,604			4,609
Contingent consideration	2,042			11,750
Capital leases short-term	3,166			3,399
Milestone payment	4,967			4,868
Professional fees	1,727			2,355
Other	65,421			79,364
	$	200,992		$	230,301



(In thousands)	June 30, 2018		December 31, 2017
Other long-term liabilities:
Contract liabilities	$	47,720	$	78,990
Line of credit	105,539		104,152
Contingent consideration	25,712		29,603
Mortgages and other debts payable	1,704		1,567
Capital leases long-term	6,638		7,786
Other	22,131		17,857
	$	209,444	$	239,955

The following table summarizes the changes in Goodwill during the six months ended June 30, 2018.



	2018
(In thousands)	Balance at January 1		Foreign exchange and other			Balance at June 30th
Pharmaceuticals
CURNA	$	4,827	$	—		$	4,827
EirGen	89,226		(2,201		)	87,025
FineTech	11,698		—			11,698
OPKO Chile	5,203		(307		)	4,896
OPKO Biologics	139,784		—			139,784
OPKO Health Europe	7,898		(197		)	7,701
OPKO Renal	2,069		—			2,069
Transition Therapeutics	3,608		(160		)	3,448

Diagnostics
BioReference	401,821		—			401,821
OPKO Diagnostics	17,977		—			17,977
OPKO Lab	32,988		—			32,988
	$	717,099	$	(2,865	)	$	714,234

XML 23 R11.htm IDEA: XBRL DOCUMENT

Acquisitions, Investments and Licenses

6 Months Ended

Jun. 30, 2018

Business Combinations [Abstract]

ACQUISITIONS, INVESTMENTS AND LICENSES

Investments

The following table reflects the accounting method, carrying value and underlying equity in net assets of our unconsolidated investments as of June 30, 2018:



(in thousands)
Investment type	Investment Carrying Value		Underlying Equity in Net Assets
Equity method investments	$	19,703	$	15,547
Variable interest entity, equity method	706		—
Equity securities	22,350
Equity securities with no readily determinable fair value	939
Warrants and options	1,799
Total carrying value of investments	$	45,497

Equity method investments

Equity Securities



(in thousands)
Equity Securities	For the six months ended June 30, 2018
Net gains recognized during the period on equity securities	$	11,289
Less: Net losses realized during the period on equity securities sold during the period	(113		)
Unrealized net gains and losses recognized during the period on equity securities still held at the reporting date	$	11,402

Sales of investments

Warrants and options

In addition to our equity method investments and equity securities, we hold options to purchase 0.4 million additional shares of BioCardia, 0.1 million of which are vested as of June 30, 2018, and 33 thousand, 0.7 million, 0.5 million, 22 thousand and 2.9 million of warrants to purchase additional shares of COCP, InCellDx, Inc., Xenetic, RXi and NeoVasc, respectively. We recorded the changes in the fair value of the options and warrants in Fair value changes of derivative instruments, net in our Condensed Consolidated Statements of Operations. We also recorded the fair value of the options and warrants in Investments, net in our Condensed Consolidated Balance Sheets. See further discussion of the Company’s options and warrants in Note 8 and Note 9.

Investments in variable interest entities

XML 24 R12.htm IDEA: XBRL DOCUMENT

Debt

6 Months Ended

Jun. 30, 2018

Debt Disclosure [Abstract]

DEBT

The following table sets forth information related to the 2033 Senior Notes which is included in our Condensed Consolidated Balance Sheets as of December 31, 2017 and June 30, 2018:



(In thousands)	2033 Senior Notes		Discount			Debt Issuance Cost			Total
Balance at December 31, 2017	$	31,850	$	(2,565	)	$	(125	)	$	29,160
Amortization of debt discount and debt issuance costs	—		1,109			74			1,183
Balance at June 30, 2018	$	31,850	$	(1,456	)	$	(51	)	$	30,343

Before February 1, 2019, we may redeem for cash any or all of the 2033 Senior Notes but only if the last reported sale price of our Common Stock exceeds 130% of the applicable conversion price for at least 20 trading days during the 30 consecutive trading day period ending on the trading day immediately prior to the date on which we deliver the redemption notice. The redemption price will equal 100% of the principal amount of the 2033 Senior Notes to be redeemed, plus any accrued and unpaid interest to but not including the redemption date. On or after February 1, 2019, we may redeem for cash any or all of the 2033 Senior Notes at a redemption price of 100% of the principal amount of the 2033 Senior Notes to be redeemed, plus any accrued and unpaid interest up to but not including the redemption date.

From 2013 to 2016, holders of the 2033 Senior Notes converted $143.2 million in aggregate principal amount into an aggregate of 21,539,873 shares of the Company’s Common Stock.

The following table summarizes the amounts outstanding under the BioReference, Chilean and Spanish lines of credit:



(Dollars in thousands)				Balance Outstanding
Lender	Interest rate on borrowings at June 30, 2018	Credit line capacity		June 30, 2018		December 31, 2017
JPMorgan Chase	4.01%	$	175,000	$	105,539	$	104,152
Itau Bank	5.50%	1,810		1,179		446
Bank of Chile	6.60%	3,800		502		1,598
BICE Bank	5.50%	2,500		798		1,819
BBVA Bank	5.50%	3,250		250		1,665
Security Bank	5.50%	98		98		501
Estado Bank	5.50%	3,500		757		2,111
Santander Bank	5.50%	4,500		262		1,988
Scotiabank	5.00%	1,800		9		384
Banco Bilbao Vizcaya	2.90%	292		—		—
Santander Bank	2.67%	350		102		—
Total		$	196,900	$	109,496	$	114,664

At June 30, 2018 and December 31, 2017, the weighted average interest rate on our lines of credit was approximately 4.7% and 4.2%, respectively.



(In thousands)	June 30, 2018		December 31, 2017
Current portion of notes payable	$	2,821	$	1,632
Other long-term liabilities	6,469		2,011
Total	$	9,290	$	3,643

XML 25 R13.htm IDEA: XBRL DOCUMENT

Accumulated Other Comprehensive Income (Loss)

6 Months Ended

Jun. 30, 2018

Equity [Abstract]

ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS)

For the six months ended June 30, 2018, changes in Accumulated other comprehensive income (loss), net of tax, were as follows:



(In thousands)	Foreign currency			Unrealized gain (loss) in Accumulated OCI			Total
Balance at December 31, 2017	$	(5,404	)	$	4,876		$	(528	)
Other comprehensive loss before reclassifications	(7,600		)	—			(7,600		)
Reclassification adjustment due to adoption of ASU 2016-01	—			(4,876		)	(4,876		)
Net other comprehensive loss	(7,600		)	(4,876		)	(12,476		)
Balance at June 30, 2018	$	(13,004	)	$	—		$	(13,004	)

XML 26 R14.htm IDEA: XBRL DOCUMENT

Fair Value Measurements

6 Months Ended

Jun. 30, 2018

Fair Value Disclosures [Abstract]

FAIR VALUE MEASUREMENTS

Our financial assets and liabilities measured at fair value on a recurring basis are as follows:



	Fair value measurements as of June 30, 2018
(In thousands)	Quoted prices in active markets for identical assets (Level 1)		Significant other observable inputs (Level 2)		Significant unobservable inputs (Level 3)		Total
Assets:
Equity securities	22,350		—		—		22,350
Common stock options/warrants	—		1,799		—		1,799
Forward contracts	—		23		—		23
Total assets	$	22,350	$	1,822	$	—	$	24,172
Liabilities:
Contingent consideration	—		—		27,754		27,754
Total liabilities	$	—	$	—	$	27,754	$	27,754



	Fair value measurements as of December 31, 2017
(In thousands)	Quoted prices in active markets for identical assets (Level 1)		Significant other observable inputs (Level 2)		Significant unobservable inputs (Level 3)		Total
Assets:
Money market funds	$	107	$	—	$	—	$	107
Equity securities	12,461		—		—		12,461
Common stock options/warrants	—		3,333		—		3,333
Total assets	$	12,568	$	3,333	$	—	$	15,901
Liabilities:
Forward contracts	—		317		—		317
Contingent consideration	—		—		41,353		41,353
Total liabilities	$	—	$	317	$	41,353	$	41,670

There have been no transfers between Level 1 and Level 2 and no transfers to or from Level 3 of the fair value hierarchy.

As of June 30, 2018 and December 31, 2017, the carrying value of our other financial instrument assets approximates their fair value due to their short-term nature or variable rate of interest.

The following table reconciles the beginning and ending balances of our Level 3 assets and liabilities as of June 30, 2018:



	June 30, 2018
(In thousands)	Contingent consideration
Balance at December 31, 2017	$	41,353
Change in fair value:
Included in results of operations	(13,599		)
Balance at June 30, 2018	$	27,754

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

XML 27 R15.htm IDEA: XBRL DOCUMENT

Derivative Contracts

6 Months Ended

Jun. 30, 2018

Derivative Instruments and Hedging Activities Disclosure [Abstract]

DERIVATIVE CONTRACTS

The following table summarizes the fair values and the presentation of our derivative assets (liabilities) in the Condensed Consolidated Balance Sheets:



(In thousands)	Balance Sheet Component	June 30, 2018		December 31, 2017
Derivative financial instruments:
Common Stock options/warrants	Investments, net	$	1,799	$	3,333
Forward contracts	Unrealized gains on forward contracts are recorded in Other current assets and prepaid expenses. Unrealized (losses) on forward contracts are recorded in Accrued expenses.	$	23	$	(317	)



	Three months ended June 30,					Six months ended June 30,
(In thousands)	2018		2017			2018		2017
Derivative gain (loss):
Common Stock options/warrants	$	1,916	$	444		$	3,587	$	(512	)
2033 Senior Notes	—		5,069			—		10,014
Forward contracts	332		(31		)	57		17
Total	$	2,248	$	5,482		$	3,644	$	9,519

XML 28 R16.htm IDEA: XBRL DOCUMENT

Related Party Transactions	6 Months Ended
Related Party Transactions	Jun. 30, 2018
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	RELATED PARTY TRANSACTIONS In February 2018, we issued the 2023 Convertible Notes in the aggregate principal amount of $55.0 million. Refer to Note 6. Purchasers of the 2023 Convertible Notes include an affiliate of Dr. Phillip Frost, M.D., our Chairman and Chief Executive Officer, and Dr. Jane H. Hsiao, Ph.D., MBA, our Vice-Chairman and Chief Technical Officer. We hold investments in Zebra (ownership 29%), Neovasc (6%), ChromaDex Corporation (0%), MabVax (2%), COCP (9%), NIMS (1%) and BioCardia (5%). These investments were considered related party transactions as a result of our executive management’s ownership interests and/or board representation in these entities. See further discussion of our investments in Note 5. In February 2018, we invested an additional $1.0 million in COCP for a convertible note, which was converted into 538,544 shares of its common stock in May 2018. In April 2017, we invested an additional $1.0 million in COCP for 138,889 shares of its common stock, and in August 2016, we had invested an additional $2.0 million in COCP for 162,602 shares of its common stock. In November 2017, we invested an additional $3.0 million in Neovasc for 2,054,794 shares of its common stock, 2,054,794 Series A warrants, 2,054,794 Series B warrants and 822,192 Series C warrants. In April 2018, we exercised our Series B warrants in a cashless exercise and received 106,909,044 shares on Neovasc common stock. In July 2017, we invested an additional $0.1 million in MabVax for 50,714 shares of common stock and in May 2017, we invested an additional $0.5 million in MabVax for 1,667 shares of Series L Preferred Stock and 107,607 shares of Series I Preferred Stock. In November 2016, we entered into a Pledge Agreement with the Museum of Science, Inc. and the Museum of Science Endowment Fund, Inc. pursuant to which we will contribute an aggregate of $1.0 million over a four-year period for constructing, equipping and the general operation of the Frost Science Museum. Dr. Frost and Mr. Pfenniger serve on the Board of Trustees of the Frost Science Museum and Mr. Pfenniger is the Vice Chairman of the Board of Trustees. We lease office space from Frost Real Estate Holdings, LLC (“Frost Holdings”) in Miami, Florida, where our principal executive offices are located. Effective January 1, 2017, we entered into an amendment to our lease agreement with Frost Holdings. The lease, as amended, is for approximately 29,500 square feet of space. The lease provides for payments of approximately $81 thousand per month in the first year increasing annually to $86 thousand per month in the third year, plus applicable sales tax. The rent is inclusive of operating expenses, property taxes and parking. Our wholly-owned subsidiary, BioReference, purchases and uses certain products acquired from InCellDx, Inc., a company in which we hold a 29% minority interest. We reimburse Dr. Frost for Company-related use by Dr. Frost and our other executives of an airplane owned by a company that is beneficially owned by Dr. Frost. We reimburse Dr. Frost for out-of-pocket operating costs for the use of the airplane by Dr. Frost or Company executives for Company-related business. We do not reimburse Dr. Frost for personal use of the airplane by Dr. Frost or any other executive. For the three and six months ended June 30, 2018, we recognized approximately $61 thousand and $140 thousand, respectively, for Company-related travel by Dr. Frost and other OPKO executives. For the three and six months ended June 30, 2017, we recognized $121 thousand and $141 thousand, respectively, for Company-related travel by Dr. Frost and other OPKO executives.

XML 29 R17.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies	6 Months Ended
Commitments and Contingencies	Jun. 30, 2018
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	COMMITMENTS AND CONTINGENCIES In connection with our acquisitions of CURNA, OPKO Diagnostics and OPKO Renal, we agreed to pay future consideration to the sellers upon the achievement of certain events. As a result, as of June 30, 2018, we have recorded $27.7 million as contingent consideration, with $2.0 million recorded within Accrued expenses and $25.7 million recorded within Other long-term liabilities in the accompanying Condensed Consolidated Balance Sheets. Refer to Note 4. In August 2017, we entered into a Commitment Letter (the “Commitment Letter”) with Veterans Accountable Care Group, LLC (“VACG”) in connection with submission of a bid by its affiliate, the Veterans Accountable Care Organization, LLC (“VACO”) in response to a request for proposal (“RFP”) from the Veterans Health Administration (“VA”) regarding its Community Care Network. If VACO is successful in its bid, we will acquire a fifteen percent (15%) membership interest in VACO. In addition, BioReference, our wholly-owned subsidiary, will provide laboratory services for the Community Care Network, a region which currently includes approximately 2,133,000 veterans in the states of Massachusetts, Maine, New Hampshire, Vermont, New York, Pennsylvania, New Jersey, Rhode Island, Connecticut, Maryland, Virginia, West Virginia, and North Carolina. Pursuant to the Commitment Letter, we committed to provide, or to arrange from a third party lender, a line of credit for VACG in the amount of $50.0 million (the “Facility”). Funds drawn under the Facility would be contributed by VACG to VACO in order to satisfy the financial stability requirement of VACO in connection with its submission of the RFP. VACG would not be permitted to draw down on the Facility unless and until the VHA awards a contract to VACO. The Facility would have a maturity of five years. Interest on the Facility would be payable at a rate equal to 6.5% per annum, payable quarterly in arrears. The Facility is subject to the negotiation of definitive documentation conditions customary for transactions of such type and otherwise acceptable to VACG and the lender under the Facility. We currently anticipate that a decision by the VHA with respect to the RFP will occur during 2018, although there can be no assurance that a decision will be made by such time or that, if favorable, such decision will not be challenged by participants in the RFP process or otherwise. We accrue a liability for legal contingencies when we believe that it is both probable that a liability has been incurred and that we can reasonably estimate the amount of the loss. We review established accruals and adjust them to reflect ongoing negotiations, settlements, rulings, advice of legal counsel and other relevant information. To the extent new information is obtained and our views on the probable outcomes of claims, suits, assessments, investigations or legal proceedings change, changes in our accrued liabilities would be recorded in the period in which such determination is made. For the matters referenced in the paragraph below, the amount of liability is not probable or the amount cannot be reasonably estimated; and, therefore, accruals have not been made. In addition, in accordance with the relevant authoritative guidance, for matters which the likelihood of material loss is at least reasonably possible, we provide disclosure of the possible loss or range of loss; however, if a reasonable estimate cannot be made, we will provide disclosure to that effect. From time to time, we may receive inquiries, document requests, or subpoenas from the Department of Justice, the Office of Inspector General and Office for Civil Rights (“OCR”) of the Department of Health and Human Services, the Centers for Medicare and Medicaid Services, various payors and fiscal intermediaries, and other state and federal regulators regarding investigations, audits and reviews. In addition to the matters discussed in this note, we are currently responding to subpoenas or document requests for various matters relating to our laboratory operations. Some pending or threatened proceedings against us may involve potentially substantial amounts as well as the possibility of civil, criminal, or administrative fines, penalties, or other sanctions, which could be material. Settlements of suits involving the types of issues that we routinely confront may require monetary payments as well as corporate integrity agreements. Additionally, qui tam or “whistleblower” actions initiated under the civil False Claims Act may be pending but placed under seal by the court to comply with the False Claims Act’s requirements for filing such suits. Also, from time to time, we may detect issues of non-compliance with federal healthcare laws pertaining to claims submission and reimbursement practices and/or financial relationships with physicians, among other things. We may avail ourselves of various mechanisms to address these issues, including participation in voluntary disclosure protocols. Participating in voluntary disclosure protocols can have the potential for significant settlement obligations or even enforcement action. The Company generally has cooperated, and intends to continue to cooperate, with appropriate regulatory authorities as and when investigations, audits and inquiries arise. We are a party to other litigation in the ordinary course of business. We do not believe that any such litigation will have a material adverse effect on our business, financial condition, results of operations or cash flows. In April 2017, the Civil Division of the United States Attorney’s Office for the Southern District of New York (the “SDNY”) informed BioReference that it believes that, from 2006 to the present, BioReference had, in violation of the False Claims Act, improperly billed Medicare and TRICARE (both are federal government healthcare programs) for clinical laboratory services provided to hospital inpatient beneficiaries at certain hospitals. BioReference is reviewing and assessing the allegations made by the SDNY, and, at this point, BioReference has not determined whether there is any merit to the SDNY’s claims nor can it determine the extent of any potential liability. While management cannot predict the outcome of these matters at this time, the ultimate outcome could be material to our business, financial condition, results of operations, and cash flows. We expect to continue to incur substantial research and development expenses, including expenses related to the hiring of personnel and additional clinical trials. We expect that selling, general and administrative expenses will also increase as we expand our sales, marketing and administrative staff and add infrastructure, particularly as it relates to the launch of Rayaldee. We do not anticipate that we will generate substantial revenue from the sale of proprietary pharmaceutical products or certain of our diagnostic products for some time and we have generated only limited revenue from our pharmaceutical operations in Chile, Mexico, Israel, Spain, and Ireland, and from sale of the 4Kscore test. If we acquire additional assets or companies, accelerate our product development programs or initiate additional clinical trials, we will need additional funds. If we are not able to secure additional funding when needed, we may have to delay, reduce the scope of, or eliminate one or more of our clinical trials or research and development programs or possible acquisitions. At June 30, 2018, we were committed to make future purchases for inventory and other items in 2018 that occur in the ordinary course of business under various purchase arrangements with fixed purchase provisions aggregating $84.4 million.

XML 30 R18.htm IDEA: XBRL DOCUMENT

Revenue Recognition

6 Months Ended

Jun. 30, 2018

Revenue from Contract with Customer [Abstract]

Revenue Recognition

REVENUE RECOGNITION

Revenue from services

The following are descriptions of our payors for laboratory services:

The composition of Revenue from services by payor for the three and six months ended June 30, 2018 and 2017 is as follow:



	Three months ended June 30,				Six months ended June 30,
(In thousands)	2018		2017		2018		2017
Healthcare insurers	$	92,033	$	104,366	$	192,986	$	217,062
Government payers	72,459		80,037		139,595		157,090
Client payers	45,828		42,961		83,357		76,900
Patients	5,735		6,548		11,431		11,404
Total	$	216,055	$	233,912	$	427,369	$	462,456

Revenue from products

The following table presents an analysis of product sales allowances and accruals as contract liabilities for the six months ended June 30, 2018:



(In thousands)	Chargebacks, discounts, rebates and fees			Governmental			Returns			Total
Balance at December 31, 2017	$	233		$	348		$	437		$	1,018
Provision related to current period sales	2,188			2,936			—			5,124
Credits or payments made	(1,697		)	(2,557		)	(311		)	(4,565		)
Balance at June 30, 2018	$	724		$	727		$	126		$	1,577

Total gross Rayaldee sales										$	13,582
Provision for Rayaldee sales allowances and accruals as a percentage of gross Rayaldee sales										38		%

Taxes collected from customers related to revenues from services and revenues from products are excluded from revenues.

Revenue from intellectual property

XML 31 R19.htm IDEA: XBRL DOCUMENT

Strategic Alliances	6 Months Ended
Strategic Alliances	Jun. 30, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
STRATEGIC ALLIANCES	STRATEGIC ALLIANCES Japan Tobacco Inc. On October 12, 2017, EirGen, our wholly-owned subsidiary, and Japan Tobacco Inc. (“JT”) entered into a Development and License Agreement (the “JT Agreement”) granting JT the exclusive rights for the development and commercialization of Rayaldee in Japan (the “JT Territory”). The license grant to JT covers the therapeutic and preventative use of the product for (i) SHPT in non-dialysis and dialysis patients with CKD, (ii) rickets, and (iii) osteomalacia (the “JT Initial Indications”), as well as such additional indications as may be added to the scope of the license subject to the terms of the JT Agreement (the “JT Additional Indications” and together with the JT Initial Indications, the “JT Field”). In connection with the license, OPKO received an initial upfront payment of $6 million. OPKO will receive another $6 million upon the initiation of OPKO’s planned phase 2 study for Rayaldee in dialysis patients in the U.S. OPKO is also eligible to receive up to an additional aggregate amount of $31 million upon the achievement of certain regulatory and development milestones by JT for Rayaldee in the JT Territory, and $75 million upon the achievement of certain sales based milestones by JT in the JT Territory. OPKO will also receive tiered, double digit royalty payments at rates ranging from low double digits to mid-teens on net sales of Rayaldee within the JT Territory. JT will, at its sole cost and expense, be responsible for performing all development activities necessary to obtain all regulatory approvals for Rayaldee in Japan and for all commercial activities pertaining to Rayaldee in Japan, except for certain preclinical expenses which OPKO has agreed to reimburse JT up to a capped amount. The JT Agreement provides for the following: (1) an exclusive license in the JT Territory in the JT Field for the development and commercialization of Rayaldee; and (2) at JT’s option, EirGen will supply products to support the development, sale and commercialization of the products to JT in the JT Territory. The initial consideration primarily includes the non-refundable $6 million upfront payment and $6 million of probable variable consideration we will receive upon the initiation of our planned phase 2 study for Rayaldee in dialysis patients in the U.S. The initial consideration will be recognized over the performance period through 2021, when we anticipate completing the transfer of license materials specified in the JT Agreement and our performance obligation is complete. We are also eligible to receive up to $31 million in regulatory and development milestones and $75 million in sales milestones. Payments received for regulatory, development and sales milestones are non-refundable. The milestones are payable if and when the associated milestone is achieved and will be recognized as revenue in the period in which the associated milestone is achieved, assuming all other revenue recognition criteria are met. To date, no revenue has been recognized related to these milestones. Vifor Fresenius Medical Care Renal Pharma Ltd In May 2016, EirGen, our wholly-owned subsidiary, and Vifor Fresenius Medical Care Renal Pharma Ltd (“VFMCRP”), entered into a Development and License Agreement (the “VFMCRP Agreement”) for the development and commercialization of Rayaldee (the “Product”) worldwide, except for (i) the United States, (ii) any country in Central America or South America (excluding Mexico), (iii) Russia, (iv) China, (v) Japan, (vi) Ukraine, (vii) Belorussia, (viii) Azerbaijan, (ix) Kazakhstan, and (x) Taiwan (the “VFMCRP Territory”). The license to VFMCRP potentially covers all therapeutic and prophylactic uses of the Product in human patients (the “VFMCRP Field”), provided that initially the license is for the use of the Product for the treatment or prevention of SHPT related to patients with stage 3 or 4 chronic kidney disease and vitamin D insufficiency/deficiency (the “VFMCRP Initial Indication”). Under the terms of the VFMCRP Agreement, EirGen granted to VFMCRP an exclusive license in the VFMCRP Territory in the VFMCRP Field to use certain EirGen patents and technology to make, have made, use, sell, offer for sale, and import Products and to develop, commercialize, have commercialized, and otherwise exploit the Product. EirGen received a non-refundable and non-creditable initial payment of $50 million, which was recognized in Revenue from the transfer of intellectual property and other in our Condensed Consolidated Statement of Operations in 2016. EirGen is also eligible to receive up to an additional $37 million in regulatory milestones (“Regulatory Milestones”) and $195 million in launch and sales-based milestones (“Sales Milestones”), and will receive tiered royalties on sales of the product at percentage rates that range from the mid-teens to the mid-twenties or a minimum royalty, whichever is greater, upon the commencement of sales of the Product within the VFMCRP Territory and in the VFMCRP Field. We plan to share responsibility with VFMCRP for the conduct of trials specified within an agreed-upon development plan, with each company leading certain activities within the plan. EirGen will lead the manufacturing activities within and outside the VFMCRP Territory and the commercialization activities outside the VFMCRP Territory and outside the VFMCRP Field in the VFMCRP Territory and VFMCRP will lead the commercialization activities in the VFMCRP Territory and the VFMCRP Field. For the initial development plan, the companies have agreed to certain cost sharing arrangements. VFMCRP will be responsible for all other development costs that VFMCRP considers necessary to develop the Product for the use of the Product for the VFMCRP Initial Indication in the VFMCRP Territory in the VFMCRP Field except as otherwise provided in the VFMCRP Agreement. The clinical studies provided for in the development activities are expected to commence in 2018. In connection with the VFMCRP Agreement, the parties entered into a letter agreement pursuant to which EirGen granted to VFMCRP an exclusive option (the “Option”) to acquire an exclusive license under certain EirGen patents and technology to use, import, offer for sale, sell, distribute and commercialize the Product in the United States solely for the treatment of secondary hyperparathyroidism in dialysis patients with chronic kidney disease and vitamin D insufficiency (the “Dialysis Indication”). Upon exercise of the Option, VFMCRP will reimburse EirGen for all of the development costs incurred by EirGen with respect to the Product for the Dialysis Indication in the United States. VFMCRP would also pay EirGen up to an additional aggregate amount of $555 million of sales-based milestones upon the achievement of certain milestones and would be obligated to pay royalties at percentage rates that range from the mid-teens to the mid-twenties on sales of the Product in the United States for the Dialysis Indication. To date, VFMCRP has not exercised its option. EirGen is also eligible to receive up to an additional $37 million in Regulatory Milestones and $195 million in Sales Milestones. Payments received for Regulatory Milestones and Sales Milestones are non-refundable. The Regulatory Milestones are payable if and when VFMCRP obtains approval from certain regulatory authorities and will be recognized as revenue in the period in which the associated milestone is achieved, assuming all other revenue recognition criteria are met. We account for the Sales Milestones as royalties and Sales Milestones payments will be recognized as revenue in the period in which the associated milestone is achieved or sales occur, assuming all other revenue recognition criteria are met. To date, no revenue has been recognized related to the milestones or royalties. Pfizer Inc. In December 2014, we entered into an exclusive worldwide agreement with Pfizer Inc. (“Pfizer”) for the development and commercialization of our long-acting hGH-CTP for the treatment of growth hormone deficiency (“GHD”) in adults and children, as well as for the treatment of growth failure in children born small for gestational age (“SGA”) (the “Pfizer Transaction”). The Pfizer Transaction closed in January 2015 following the termination of the waiting period under the Hart-Scott-Rodino Act. Under the terms of the Pfizer Transaction, we received non-refundable and non-creditable upfront payments of $295.0 million and are eligible to receive up to an additional $275.0 million upon the achievement of certain regulatory milestones. Pfizer received the exclusive license to commercialize hGH-CTP worldwide. In addition, we are eligible to receive initial tiered royalty payments associated with the commercialization of hGH-CTP for Adult GHD with percentage rates ranging from the high teens to mid-twenties. Upon the launch of hGH-CTP for Pediatric GHD in certain major markets, the royalties will transition to regional, tiered gross profit sharing for both hGH-CTP and Pfizer’s Genotropin®. The agreement with Pfizer will remain in effect until the last sale of the licensed product, unless earlier terminated as permitted under the agreement. In addition to termination rights for material breach and bankruptcy, Pfizer is permitted to terminate the Agreement in its entirety, or with respect to one or more world regions, without cause after a specified notice period. If the Agreement is terminated by us for Pfizer’s uncured material breach, or by Pfizer without cause, provision has been made for transition of product and product responsibilities to us for the terminated regions, as well as continued supply of product by Pfizer or transfer of supply to us in order to support the terminated regions. We are recognizing the non-refundable $295.0 million upfront payments as the research and development services are completed and had contract liabilities related to the Pfizer Transaction of $100.1 million at June 30, 2018, of which $58.8 million was classified in Accrued expenses and $41.3 million was classified in Other long-term liabilities. The Pfizer Transaction includes milestone payments of $275.0 million upon the achievement of certain milestones. The milestones range from $20.0 million to $90.0 million each and are based on achievement of regulatory approval in the U.S. and regulatory approval and price approval in other major markets. The milestone payments will be recognized as revenue in the period in which the associated milestone is achieved, assuming all other revenue recognition criteria are met. To date, no revenue has been recognized related to the achievement of the milestones. TESARO In November 2009, we entered into an asset purchase agreement (the “NK-1 Agreement”) under which we acquired VARUBI™ (rolapitant) and other neurokinin-1 (“NK-1”) assets from Merck. In December 2010, we entered into an exclusive license agreement with TESARO, in which we out-licensed the development, manufacture, commercialization and distribution of our lead NK-1 candidate, VARUBI™ (the “TESARO License”). Under the terms of the license, we received a $6.0 million upfront payment from TESARO and we received $30 million of milestone payments from TESARO upon achievement of certain regulatory and commercial sale milestones and we are eligible to receive additional commercial milestone payments of up to $85 million if specified levels of annual net sales are achieved. The sales based milestone payments will be recognized as revenue in full in the period in which the associated sales occur. During the six months ended June 30, 2018 and 2017, no revenue was recognized related to the achievement of the milestones under the TESARO License. TESARO is also obligated to pay us tiered royalties on annual net sales achieved in the United States and Europe at percentage rates that range from the low double digits to the low twenties, and outside of the United States and Europe at low double-digit percentage rates. Royalties will be recognized in the period the sales occur. TESARO assumed responsibility for clinical development and commercialization of licensed products at its expense. Under the NK-1 Agreement, we will continue to receive royalties on a country-by-country and product-by-product basis until the later of the date that all of the patent rights licensed from us and covering VARUBI™ expire, are invalidated or are not enforceable and 12 years from the first commercial sale of the product. If TESARO elects to develop and commercialize VARUBI™ in Japan through a third-party licensee, TESARO will share equally with us all amounts it receives in connection with such activities, subject to certain exceptions and deductions. The term of the license will remain in force until the expiration of the royalty term in each country, unless we terminate the license earlier for TESARO’s material breach of the license or bankruptcy. TESARO has a right to terminate the license at any time during the term for any reason on three months’ written notice. TESARO announced during the first quarter of 2018 that it has elected to suspend further distribution of Varubi IV. Pharmsynthez In April 2013, we entered into a series of concurrent transactions with Pharmsynthez, a Russian pharmaceutical company traded on the Moscow Stock Exchange, pursuant to which we acquired an equity method investment in Pharmsynthez (ownership 9%). We also granted rights to certain technologies in the Russian Federation, Ukraine, Belarus, Azerbaijan and Kazakhstan (the “Pharmsynthez Territories”) to Pharmsynthez and agreed to perform certain development activities. We will receive from Pharmsynthez royalties on net sales of products incorporating the technologies in the Pharmsynthez Territories, as well as a percentage of any sublicense income from third parties for the technologies in the Pharmsynthez Territories. RXi Pharmaceuticals Corporation In March 2013, we completed the sale to RXi of substantially all of our assets in the field of RNA interference (the “RNAi Assets”) (collectively, the “Asset Purchase Agreement”). Pursuant to the Asset Purchase Agreement, RXi will be required to pay us up to $50.0 million in milestone payments upon the successful development and commercialization of each drug developed by RXi, certain of its affiliates or any of its or their licensees or sublicensees utilizing patents included within the RNAi Assets (each, a “Qualified Drug”). In addition, RXi will also be required to pay us royalties equal to: (a) a mid single-digit percentage of “Net Sales” (as defined in the Asset Purchase Agreement) with respect to each Qualified Drug sold for an ophthalmologic use during the applicable “Royalty Period” (as defined in the Asset Purchase Agreement); and (b) a low single-digit percentage of net sales with respect to each Qualified Drug sold for a non-ophthalmologic use during the applicable Royalty Period. Other We have completed strategic deals with numerous institutions and commercial partners. In connection with these agreements, upon the achievement of certain milestones we are obligated to make certain payments and have royalty obligations upon sales of products developed under the license agreements. At this time, we are unable to estimate the timing and amounts of payments as the obligations are based on future development of the licensed products.

XML 32 R20.htm IDEA: XBRL DOCUMENT

Segments

6 Months Ended

Jun. 30, 2018

Segment Reporting [Abstract]

SEGMENTS

Information regarding our operations and assets for our operating segments and the unallocated corporate operations as well as geographic information are as follows:



	For the three months ended June 30,						For the six months ended June 30,
(In thousands)	2018			2017			2018			2017
Revenue from services:
Pharmaceutical	$	—		$	—		$	—		$	—
Diagnostics	216,055			233,912			427,369			462,456
Corporate	—			—			—			—
	$	216,055		$	233,912		$	427,369		$	462,456
Revenue from products:
Pharmaceutical	$	28,523		$	28,966		$	56,374		$	51,197
Diagnostics	—			—			—			—
Corporate	—			—			—			—
	$	28,523		$	28,966		$	56,374		$	51,197
Revenue from transfer of intellectual property and other:
Pharmaceutical	$	19,107		$	29,723		$	34,855		$	45,328
Diagnostics	—			—			—			—
Corporate	—			—			—			—
	$	19,107		$	29,723		$	34,855		$	45,328
Operating loss:
Pharmaceutical	$	2,165		$	(8,009	)	$	(20,783	)	$	(34,154	)
Diagnostics	1,475			(4,944		)	(6,543		)	(8,044		)
Corporate	(8,748		)	(12,878		)	(20,393		)	(28,849		)
	$	(5,108	)	$	(25,831	)	$	(47,719	)	$	(71,047	)
Depreciation and amortization:
Pharmaceutical	$	6,752		$	6,694		$	13,492		$	13,469
Diagnostics	17,989			18,827			35,975			37,752
Corporate	21			30			51			60
	$	24,762		$	25,551		$	49,518		$	51,281
Loss from investment in investees:
Pharmaceutical	$	(6,942	)	$	(5,309	)	$	(9,114	)	$	(7,123	)
Diagnostics	(271		)	(319		)	(555		)	(635		)
Corporate	—			—			—			—
	$	(7,213	)	$	(5,628	)	$	(9,669	)	$	(7,758	)
Revenues:
United States	$	222,535		$	244,650		$	437,845		$	474,084
Ireland	20,778			22,525			38,060			39,734
Chile	11,937			11,899			23,670			22,020
Spain	4,592			5,118			10,125			9,623
Israel	2,526			7,654			6,141			11,872
Mexico	1,302			724			2,723			1,589
Other	15			31			34			59
	$	263,685		$	292,601		$	518,598		$	558,981



(In thousands)	June 30, 2018		December 31, 2017
Assets:
Pharmaceutical	$	1,258,293	$	1,287,964
Diagnostics	1,217,456		1,241,388
Corporate	55,201		60,604
	$	2,530,950	$	2,589,956
Goodwill:
Pharmaceutical	$	261,447	$	264,313
Diagnostics	452,787		452,786
Corporate	—		—
	$	714,234	$	717,099

XML 33 R21.htm IDEA: XBRL DOCUMENT

Subsequent Events	6 Months Ended
Subsequent Events	Jun. 30, 2018
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	SUBSEQUENT EVENTS We have reviewed all subsequent events and transactions that occurred after the date of our June 30, 2018 Condensed Consolidated Balance Sheet date, through the time of filing this Quarterly Report on Form 10-Q.

XML 34 R22.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Policies)

6 Months Ended

Jun. 30, 2018

Accounting Policies [Abstract]

Basis of presentation

Principles of consolidation

Use of estimates

Cash and cash equivalents

Inventories

Goodwill and intangible assets

Fair value measurements

Contingent consideration

Derivative financial instruments

Property, plant and equipment

Impairment of long-lived assets

Income taxes

Revenue recognition and shipping and handling costs

Concentration of credit risk and allowance for doubtful accounts

Equity-based compensation

Research and development expenses

Segment reporting

Foreign currency translation

Variable interest entities

Investments

Recently adopted accounting pronouncements

Recently adopted accounting pronouncements.


•	For all reporting periods presented before January 1, 2018, we have not restated revenue from contracts that begin and are completed within the same annual reporting period.


•	For all reporting periods presented before January 1, 2018, we have not disclosed the amount of the transaction price allocated to the remaining performance obligations or an explanation of when we expect to recognize that amount as revenue.


•	We have applied the practical expedient provided for by Topic 606 by not adjusting the transaction price for significant financing components for periods less than one year.

Condensed Consolidated Statement of Operations



	For the three months ended June 30, 2017 (in thousands)
	As adjusted under Topic 606		As originally reported		Effect of change
Revenue from services	$	233,912	$	256,671	$	(22,759	)
Revenue from transfer of intellectual property and other	29,723		28,576		1,147
Selling, general and administrative	105,579		128,338		(22,759		)
Research and development	33,128		32,593		535



	For the six months ended June 30, 2017 (in thousands)
	As adjusted under Topic 606		As originally reported		Effect of change
Revenue from services	$	462,456	$	511,956	$	(49,500	)
Revenue from transfer of intellectual property and other	45,328		47,154		(1,826		)
Selling, general and administrative	215,523		265,023		(49,500		)
Research and development	59,685		58,615		1,070

Condensed Consolidated Balance Sheet



	December 31, 2017 (in thousands)
	As adjusted under Topic 606			As originally reported			Effect of change
Other current assets and prepaid expenses	$	42,513		$	37,113		$	5,400
Accrued expenses	230,301			215,102			15,199
Other long-term liabilities, principally contract liabilities, contingent consideration and line of credit	239,955			219,954			20,001
Accumulated deficit	(1,036,959		)	(1,007,159		)	(29,800		)

Condensed Consolidated Statement of Cash Flows



	For the six months ended June 30, 2017 (in thousands)
	As adjusted under Topic 606			As originally reported			Effect of change
Net loss	$	(51,419	)	$	(48,523	)	$	(2,896	)
Contract liabilities	(31,122		)	(34,018		)	2,896

Pending accounting pronouncements.

XML 35 R23.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Tables)

6 Months Ended

Jun. 30, 2018

Accounting Policies [Abstract]

Schedule of Topic 606 Impact

As a result, the following financial statement line items for 2017 were affected:

Condensed Consolidated Statement of Operations



	For the three months ended June 30, 2017 (in thousands)
	As adjusted under Topic 606		As originally reported		Effect of change
Revenue from services	$	233,912	$	256,671	$	(22,759	)
Revenue from transfer of intellectual property and other	29,723		28,576		1,147
Selling, general and administrative	105,579		128,338		(22,759		)
Research and development	33,128		32,593		535



	For the six months ended June 30, 2017 (in thousands)
	As adjusted under Topic 606		As originally reported		Effect of change
Revenue from services	$	462,456	$	511,956	$	(49,500	)
Revenue from transfer of intellectual property and other	45,328		47,154		(1,826		)
Selling, general and administrative	215,523		265,023		(49,500		)
Research and development	59,685		58,615		1,070

Condensed Consolidated Balance Sheet



	December 31, 2017 (in thousands)
	As adjusted under Topic 606			As originally reported			Effect of change
Other current assets and prepaid expenses	$	42,513		$	37,113		$	5,400
Accrued expenses	230,301			215,102			15,199
Other long-term liabilities, principally contract liabilities, contingent consideration and line of credit	239,955			219,954			20,001
Accumulated deficit	(1,036,959		)	(1,007,159		)	(29,800		)

Condensed Consolidated Statement of Cash Flows



	For the six months ended June 30, 2017 (in thousands)
	As adjusted under Topic 606			As originally reported			Effect of change
Net loss	$	(51,419	)	$	(48,523	)	$	(2,896	)
Contract liabilities	(31,122		)	(34,018		)	2,896

XML 36 R24.htm IDEA: XBRL DOCUMENT

Earnings (Loss) Per Share (Tables)

6 Months Ended

Jun. 30, 2018

Earnings Per Share [Abstract]

Schedule of Earnings (Loss) Per Share, Basic and Diluted

The following table sets forth the computation of basic and diluted loss per share:



	For the three months ended June 30,						For the six months ended June 30,
(In thousands, except per share data)	2018			2017			2018			2017
Numerator
Net loss, basic	$	(6,201	)	$	(16,916	)	$	(49,315	)	$	(51,419	)
Add: Interest on 2033 Senior Notes	—			652			—			1,291
Change in FV of embedded derivative income	—			(5,069		)	—			(10,014		)
Net loss, diluted	$	(6,201	)	$	(21,333	)	$	(49,315	)	$	(60,142	)

Denominator
(Shares in thousands)
Weighted average common shares outstanding, basic	559,541			559,348			559,508			558,892
Effect of dilutive securities:
Stock options	—			—			—			—
Warrants	—			—			—			—
2033 Senior Notes	—			4,816			—			4,725
Dilutive potential shares	—			4,816			—			4,725
Weighted average common shares outstanding, diluted	559,541			564,164			559,508			563,617

Loss per share, basic	$	(0.01	)	$	(0.03	)	$	(0.09	)	$	(0.09	)
Loss per share, diluted	$	(0.01	)	$	(0.04	)	$	(0.09	)	$	(0.11	)

XML 37 R25.htm IDEA: XBRL DOCUMENT

Composition of Certain Financial Statement Captions (Tables)

6 Months Ended

Jun. 30, 2018

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Composition of Certain Financial Statement Captions



(In thousands)	June 30, 2018			December 31, 2017
Accounts receivable, net:
Accounts receivable	$	154,269		$	166,962
Less: allowance for doubtful accounts	(1,492		)	(1,446		)
	$	152,777		$	165,516
Inventories, net:
Consumable supplies	$	24,986		$	21,546
Finished products	16,783			21,012
Work in-process	3,910			5,873
Raw materials	5,800			7,467
Less: inventory reserve	(4,726		)	(6,565		)
	$	46,753		$	49,333
Other current assets and prepaid expenses:
Taxes recoverable	21,319			18,138
Other receivables	2,031			8,798
Prepaid supplies	10,278			8,207
Prepaid insurance	3,259			3,532
Other	4,764			3,838
	$	41,651		$	42,513
Intangible assets, net:
Customer relationships	$	447,225		$	448,345
Technologies	340,815			340,921
Trade names	50,494			50,553
Licenses	10,246			10,305
Covenants not to compete	16,367			16,372
Product registrations	9,694			10,475
Other	5,696			5,799
Less: accumulated amortization	(231,996		)	(198,935		)
	$	648,541		$	683,835
Accrued expenses:
Contract liabilities	$	61,846		$	61,388
Employee benefits	46,621			50,377
Clinical trials	11,598			12,191
Taxes payable	3,604			4,609
Contingent consideration	2,042			11,750
Capital leases short-term	3,166			3,399
Milestone payment	4,967			4,868
Professional fees	1,727			2,355
Other	65,421			79,364
	$	200,992		$	230,301



(In thousands)	June 30, 2018		December 31, 2017
Other long-term liabilities:
Contract liabilities	$	47,720	$	78,990
Line of credit	105,539		104,152
Contingent consideration	25,712		29,603
Mortgages and other debts payable	1,704		1,567
Capital leases long-term	6,638		7,786
Other	22,131		17,857
	$	209,444	$	239,955

Changes in Goodwill

The following table summarizes the changes in Goodwill during the six months ended June 30, 2018.



	2018
(In thousands)	Balance at January 1		Foreign exchange and other			Balance at June 30th
Pharmaceuticals
CURNA	$	4,827	$	—		$	4,827
EirGen	89,226		(2,201		)	87,025
FineTech	11,698		—			11,698
OPKO Chile	5,203		(307		)	4,896
OPKO Biologics	139,784		—			139,784
OPKO Health Europe	7,898		(197		)	7,701
OPKO Renal	2,069		—			2,069
Transition Therapeutics	3,608		(160		)	3,448

Diagnostics
BioReference	401,821		—			401,821
OPKO Diagnostics	17,977		—			17,977
OPKO Lab	32,988		—			32,988
	$	717,099	$	(2,865	)	$	714,234

XML 38 R26.htm IDEA: XBRL DOCUMENT

Acquisitions, Investments and Licenses (Tables)

6 Months Ended

Jun. 30, 2018

Business Combinations [Abstract]

Accounting Method, Carrying Value and Underlying Equity in Net Assets of Unconsolidated Investments

The following table reflects the accounting method, carrying value and underlying equity in net assets of our unconsolidated investments as of June 30, 2018:



(in thousands)
Investment type	Investment Carrying Value		Underlying Equity in Net Assets
Equity method investments	$	19,703	$	15,547
Variable interest entity, equity method	706		—
Equity securities	22,350
Equity securities with no readily determinable fair value	939
Warrants and options	1,799
Total carrying value of investments	$	45,497

Schedule of Net Gains and Losses on Equity Securities

Net gains and losses on our equity securities for the six months ended June 30, 2018 are as follows:



(in thousands)
Equity Securities	For the six months ended June 30, 2018
Net gains recognized during the period on equity securities	$	11,289
Less: Net losses realized during the period on equity securities sold during the period	(113		)
Unrealized net gains and losses recognized during the period on equity securities still held at the reporting date	$	11,402

XML 39 R27.htm IDEA: XBRL DOCUMENT

Debt (Tables)

6 Months Ended

Jun. 30, 2018

Debt Disclosure [Abstract]

Summary of Lines of Credit

The following table summarizes the amounts outstanding under the BioReference, Chilean and Spanish lines of credit:



(Dollars in thousands)				Balance Outstanding
Lender	Interest rate on borrowings at June 30, 2018	Credit line capacity		June 30, 2018		December 31, 2017
JPMorgan Chase	4.01%	$	175,000	$	105,539	$	104,152
Itau Bank	5.50%	1,810		1,179		446
Bank of Chile	6.60%	3,800		502		1,598
BICE Bank	5.50%	2,500		798		1,819
BBVA Bank	5.50%	3,250		250		1,665
Security Bank	5.50%	98		98		501
Estado Bank	5.50%	3,500		757		2,111
Santander Bank	5.50%	4,500		262		1,988
Scotiabank	5.00%	1,800		9		384
Banco Bilbao Vizcaya	2.90%	292		—		—
Santander Bank	2.67%	350		102		—
Total		$	196,900	$	109,496	$	114,664

Schedule of Debt

The following table sets forth information related to the 2033 Senior Notes which is included in our Condensed Consolidated Balance Sheets as of December 31, 2017 and June 30, 2018:



(In thousands)	2033 Senior Notes		Discount			Debt Issuance Cost			Total
Balance at December 31, 2017	$	31,850	$	(2,565	)	$	(125	)	$	29,160
Amortization of debt discount and debt issuance costs	—		1,109			74			1,183
Balance at June 30, 2018	$	31,850	$	(1,456	)	$	(51	)	$	30,343



(In thousands)	June 30, 2018		December 31, 2017
Current portion of notes payable	$	2,821	$	1,632
Other long-term liabilities	6,469		2,011
Total	$	9,290	$	3,643

- Definition

Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=114775744&loc=d3e28541-108399

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(e),(f))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=114775744&loc=d3e28551-108399

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 470
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 55
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644

+ Details

XML 40 R28.htm IDEA: XBRL DOCUMENT

Accumulated Other Comprehensive Income (Loss) (Tables)

6 Months Ended

Jun. 30, 2018

Equity [Abstract]

Changes in Accumulated Other Comprehensive Income (Loss), Net of Tax

For the six months ended June 30, 2018, changes in Accumulated other comprehensive income (loss), net of tax, were as follows:



(In thousands)	Foreign currency			Unrealized gain (loss) in Accumulated OCI			Total
Balance at December 31, 2017	$	(5,404	)	$	4,876		$	(528	)
Other comprehensive loss before reclassifications	(7,600		)	—			(7,600		)
Reclassification adjustment due to adoption of ASU 2016-01	—			(4,876		)	(4,876		)
Net other comprehensive loss	(7,600		)	(4,876		)	(12,476		)
Balance at June 30, 2018	$	(13,004	)	$	—		$	(13,004	)

XML 41 R29.htm IDEA: XBRL DOCUMENT

Fair Value Measurements (Tables)

6 Months Ended

Jun. 30, 2018

Fair Value Disclosures [Abstract]

Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis

Our financial assets and liabilities measured at fair value on a recurring basis are as follows:



	Fair value measurements as of June 30, 2018
(In thousands)	Quoted prices in active markets for identical assets (Level 1)		Significant other observable inputs (Level 2)		Significant unobservable inputs (Level 3)		Total
Assets:
Equity securities	22,350		—		—		22,350
Common stock options/warrants	—		1,799		—		1,799
Forward contracts	—		23		—		23
Total assets	$	22,350	$	1,822	$	—	$	24,172
Liabilities:
Contingent consideration	—		—		27,754		27,754
Total liabilities	$	—	$	—	$	27,754	$	27,754



	Fair value measurements as of December 31, 2017
(In thousands)	Quoted prices in active markets for identical assets (Level 1)		Significant other observable inputs (Level 2)		Significant unobservable inputs (Level 3)		Total
Assets:
Money market funds	$	107	$	—	$	—	$	107
Equity securities	12,461		—		—		12,461
Common stock options/warrants	—		3,333		—		3,333
Total assets	$	12,568	$	3,333	$	—	$	15,901
Liabilities:
Forward contracts	—		317		—		317
Contingent consideration	—		—		41,353		41,353
Total liabilities	$	—	$	317	$	41,353	$	41,670

Reconciliation of the Beginning and Ending Balances of Level 3 Assets and Liabilities

The following table reconciles the beginning and ending balances of our Level 3 assets and liabilities as of June 30, 2018:



	June 30, 2018
(In thousands)	Contingent consideration
Balance at December 31, 2017	$	41,353
Change in fair value:
Included in results of operations	(13,599		)
Balance at June 30, 2018	$	27,754

XML 42 R30.htm IDEA: XBRL DOCUMENT

Derivative Contracts (Tables)

6 Months Ended

Jun. 30, 2018

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Fair Values and Presentation of Derivative Financial Instruments

The following table summarizes the fair values and the presentation of our derivative assets (liabilities) in the Condensed Consolidated Balance Sheets:



(In thousands)	Balance Sheet Component	June 30, 2018		December 31, 2017
Derivative financial instruments:
Common Stock options/warrants	Investments, net	$	1,799	$	3,333
Forward contracts	Unrealized gains on forward contracts are recorded in Other current assets and prepaid expenses. Unrealized (losses) on forward contracts are recorded in Accrued expenses.	$	23	$	(317	)

Summary of Derivative Instrument Losses and Gains Recorded

The following table summarizes the losses and gains recorded for the three and six months ended June 30, 2018 and 2017:



	Three months ended June 30,					Six months ended June 30,
(In thousands)	2018		2017			2018		2017
Derivative gain (loss):
Common Stock options/warrants	$	1,916	$	444		$	3,587	$	(512	)
2033 Senior Notes	—		5,069			—		10,014
Forward contracts	332		(31		)	57		17
Total	$	2,248	$	5,482		$	3,644	$	9,519

XML 43 R31.htm IDEA: XBRL DOCUMENT

Revenue Recognition (Tables)

6 Months Ended

Jun. 30, 2018

Revenue from Contract with Customer [Abstract]

Schedule of Disaggregation of Revenue

The composition of Revenue from services by payor for the three and six months ended June 30, 2018 and 2017 is as follow:



	Three months ended June 30,				Six months ended June 30,
(In thousands)	2018		2017		2018		2017
Healthcare insurers	$	92,033	$	104,366	$	192,986	$	217,062
Government payers	72,459		80,037		139,595		157,090
Client payers	45,828		42,961		83,357		76,900
Patients	5,735		6,548		11,431		11,404
Total	$	216,055	$	233,912	$	427,369	$	462,456

Schedule Of Product Sales Allowances And Accruals

The following table presents an analysis of product sales allowances and accruals as contract liabilities for the six months ended June 30, 2018:



(In thousands)	Chargebacks, discounts, rebates and fees			Governmental			Returns			Total
Balance at December 31, 2017	$	233		$	348		$	437		$	1,018
Provision related to current period sales	2,188			2,936			—			5,124
Credits or payments made	(1,697		)	(2,557		)	(311		)	(4,565		)
Balance at June 30, 2018	$	724		$	727		$	126		$	1,577

Total gross Rayaldee sales										$	13,582
Provision for Rayaldee sales allowances and accruals as a percentage of gross Rayaldee sales										38		%

XML 44 R32.htm IDEA: XBRL DOCUMENT

Segments (Tables)

6 Months Ended

Jun. 30, 2018

Segment Reporting [Abstract]

Operations and Assets for Operating Segments and Geographic Information

Information regarding our operations and assets for our operating segments and the unallocated corporate operations as well as geographic information are as follows:



	For the three months ended June 30,						For the six months ended June 30,
(In thousands)	2018			2017			2018			2017
Revenue from services:
Pharmaceutical	$	—		$	—		$	—		$	—
Diagnostics	216,055			233,912			427,369			462,456
Corporate	—			—			—			—
	$	216,055		$	233,912		$	427,369		$	462,456
Revenue from products:
Pharmaceutical	$	28,523		$	28,966		$	56,374		$	51,197
Diagnostics	—			—			—			—
Corporate	—			—			—			—
	$	28,523		$	28,966		$	56,374		$	51,197
Revenue from transfer of intellectual property and other:
Pharmaceutical	$	19,107		$	29,723		$	34,855		$	45,328
Diagnostics	—			—			—			—
Corporate	—			—			—			—
	$	19,107		$	29,723		$	34,855		$	45,328
Operating loss:
Pharmaceutical	$	2,165		$	(8,009	)	$	(20,783	)	$	(34,154	)
Diagnostics	1,475			(4,944		)	(6,543		)	(8,044		)
Corporate	(8,748		)	(12,878		)	(20,393		)	(28,849		)
	$	(5,108	)	$	(25,831	)	$	(47,719	)	$	(71,047	)
Depreciation and amortization:
Pharmaceutical	$	6,752		$	6,694		$	13,492		$	13,469
Diagnostics	17,989			18,827			35,975			37,752
Corporate	21			30			51			60
	$	24,762		$	25,551		$	49,518		$	51,281
Loss from investment in investees:
Pharmaceutical	$	(6,942	)	$	(5,309	)	$	(9,114	)	$	(7,123	)
Diagnostics	(271		)	(319		)	(555		)	(635		)
Corporate	—			—			—			—
	$	(7,213	)	$	(5,628	)	$	(9,669	)	$	(7,758	)
Revenues:
United States	$	222,535		$	244,650		$	437,845		$	474,084
Ireland	20,778			22,525			38,060			39,734
Chile	11,937			11,899			23,670			22,020
Spain	4,592			5,118			10,125			9,623
Israel	2,526			7,654			6,141			11,872
Mexico	1,302			724			2,723			1,589
Other	15			31			34			59
	$	263,685		$	292,601		$	518,598		$	558,981



(In thousands)	June 30, 2018		December 31, 2017
Assets:
Pharmaceutical	$	1,258,293	$	1,287,964
Diagnostics	1,217,456		1,241,388
Corporate	55,201		60,604
	$	2,530,950	$	2,589,956
Goodwill:
Pharmaceutical	$	261,447	$	264,313
Diagnostics	452,787		452,786
Corporate	—		—
	$	714,234	$	717,099

XML 45 R33.htm IDEA: XBRL DOCUMENT

Business and Organization (Details)	6 Months Ended
Business and Organization (Details)	Jun. 30, 2018 employee
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Number of sales employees	400

XML 46 R34.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Details) $ in Thousands			3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2018 USD ($)	Dec. 31, 2017 USD ($)	Jun. 30, 2018 USD ($)	Jun. 30, 2017 USD ($)	Jun. 30, 2018 USD ($) Segment	Jun. 30, 2017 USD ($)	Dec. 31, 2017 USD ($)	Jan. 01, 2018 USD ($)
Summary of Significant Accounting Policies [Line Items]
Provision for inventory obsolescence					$ 1,200	$ 4,800
Goodwill, in-process research and development and other intangible assets acquired	$ 2,000,000	$ 2,000,000	$ 2,000,000		2,000,000		$ 2,000,000
Amortization expense			17,227	$ 17,953	34,498	35,881
Depreciation expense					15,000	15,400
Allowance for doubtful accounts receivable	1,492	1,446	1,492		1,492		1,446
Provision related to current period sales					200	500
Equity-based compensation expense					$ 11,500	15,800
Number of reportable segments \| Segment					2
Reduction in revenue from transfer of intellectual property and other			(263,685)	(292,601)	$ (518,598)	(558,981)
Accumulated deficit	$ 1,081,397	$ 1,036,959	1,081,397		1,081,397		1,036,959
Increase in contract liabilities					$ (30,812)	(31,122)
Minimum
Summary of Significant Accounting Policies [Line Items]
Intangible assets, estimated useful lives					3 years
Maximum
Summary of Significant Accounting Policies [Line Items]
Intangible assets, estimated useful lives					20 years
Government Contracts Concentration Risk \| Accounts Receivable
Summary of Significant Accounting Policies [Line Items]
Concentration percentage	17.40%	15.80%
Customer Concentration Risk \| Accounts Receivable
Summary of Significant Accounting Policies [Line Items]
Concentration percentage	2.60%	3.20%
Software
Summary of Significant Accounting Policies [Line Items]
Property, plant and equipment, estimated useful lives					3 years
Machinery, Medical and Other Equipment \| Minimum
Summary of Significant Accounting Policies [Line Items]
Property, plant and equipment, estimated useful lives					5 years
Machinery, Medical and Other Equipment \| Maximum
Summary of Significant Accounting Policies [Line Items]
Property, plant and equipment, estimated useful lives					8 years
Furniture and Fixtures \| Minimum
Summary of Significant Accounting Policies [Line Items]
Property, plant and equipment, estimated useful lives					5 years
Furniture and Fixtures \| Maximum
Summary of Significant Accounting Policies [Line Items]
Property, plant and equipment, estimated useful lives					12 years
Buildings and Improvements \| Minimum
Summary of Significant Accounting Policies [Line Items]
Property, plant and equipment, estimated useful lives					10 years
Buildings and Improvements \| Maximum
Summary of Significant Accounting Policies [Line Items]
Property, plant and equipment, estimated useful lives					40 years
Automobiles and Aircraft \| Minimum
Summary of Significant Accounting Policies [Line Items]
Property, plant and equipment, estimated useful lives					3 years
Automobiles and Aircraft \| Maximum
Summary of Significant Accounting Policies [Line Items]
Property, plant and equipment, estimated useful lives					5 years
Accumulated Deficit \| Accounting Standards Update 2016-01
Summary of Significant Accounting Policies [Line Items]
Cumulative effect of new accounting update								$ 4,900
Effect of change \| Accounting Standards Update 2014-09
Summary of Significant Accounting Policies [Line Items]
Reduction in revenue from transfer of intellectual property and other							29,800
Accumulated deficit		$ 29,800					29,800
Increase in contract liabilities						2,896	$ 29,800
Transfer of intellectual property and other
Summary of Significant Accounting Policies [Line Items]
Reduction in revenue from transfer of intellectual property and other			$ (19,107)	(29,723)	$ (34,855)	(45,328)
Transfer of intellectual property and other \| Effect of change \| Accounting Standards Update 2014-09
Summary of Significant Accounting Policies [Line Items]
Reduction in revenue from transfer of intellectual property and other				$ (1,147)		1,826
Transferred over Time \| Transfer of intellectual property and other \| Effect of change \| Accounting Standards Update 2014-09
Summary of Significant Accounting Policies [Line Items]
Reduction in revenue from transfer of intellectual property and other						$ 2,900

XML 47 R35.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies - Schedule of Topic 606 Impact (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017	Dec. 31, 2017
Condensed Consolidated Statement of Operations
Total revenues	$ 263,685	$ 292,601	$ 518,598	$ 558,981
Selling, general and administrative	87,653	105,579	179,172	215,523
Research and development	29,211	33,128	62,097	59,685
Condensed Consolidated Balance Sheet
Other current assets and prepaid expenses	41,651		41,651		$ 42,513
Accrued expenses	200,992		200,992		230,301
Other long-term liabilities, principally contract liabilities, contingent consideration and line of credit	209,444		209,444		239,955
Accumulated deficit	(1,081,397)		(1,081,397)		(1,036,959)
Condensed Consolidated Statement of Cash Flows
Net loss	(6,201)	(16,916)	(49,315)	(51,419)
Contract liabilities			(30,812)	(31,122)
As originally reported
Condensed Consolidated Statement of Operations
Selling, general and administrative		128,338		265,023
Research and development		32,593		58,615
Condensed Consolidated Balance Sheet
Other current assets and prepaid expenses					37,113
Accrued expenses					215,102
Other long-term liabilities, principally contract liabilities, contingent consideration and line of credit					219,954
Accumulated deficit					(1,007,159)
Condensed Consolidated Statement of Cash Flows
Net loss				(48,523)
Contract liabilities				(34,018)
Accounting Standards Update 2014-09 \| Effect of change
Condensed Consolidated Statement of Operations
Total revenues					(29,800)
Selling, general and administrative		(22,759)		(49,500)
Research and development		535		1,070
Condensed Consolidated Balance Sheet
Other current assets and prepaid expenses					5,400
Accrued expenses					15,199
Other long-term liabilities, principally contract liabilities, contingent consideration and line of credit					20,001
Accumulated deficit					(29,800)
Condensed Consolidated Statement of Cash Flows
Net loss				(2,896)
Contract liabilities				2,896	$ 29,800
Services
Condensed Consolidated Statement of Operations
Total revenues	216,055	233,912	427,369	462,456
Services \| As originally reported
Condensed Consolidated Statement of Operations
Total revenues		256,671		511,956
Services \| Accounting Standards Update 2014-09 \| Effect of change
Condensed Consolidated Statement of Operations
Total revenues		(22,759)		(49,500)
Transfer of intellectual property and other
Condensed Consolidated Statement of Operations
Total revenues	$ 19,107	29,723	$ 34,855	45,328
Transfer of intellectual property and other \| As originally reported
Condensed Consolidated Statement of Operations
Total revenues		28,576		47,154
Transfer of intellectual property and other \| Accounting Standards Update 2014-09 \| Effect of change
Condensed Consolidated Statement of Operations
Total revenues		$ 1,147		$ (1,826)

XML 48 R36.htm IDEA: XBRL DOCUMENT

Earnings (Loss) Per Share - Schedule of Earnings (Loss) Per Share, Basic and Diluted (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Net loss, basic	$ (6,201,000)	$ (16,916,000)	$ (49,315,000)	$ (51,419,000)
Add: Interest on 2033 Senior Notes	0	652,000	0	1,291,000
Change in FV of embedded derivative income	0	(5,069,000)	0	(10,014,000)
Net loss, diluted	$ (6,201,000)	$ (21,333,000)	$ (49,315,000)	$ (60,142,000)
Weighted average common shares outstanding, basic	559,541,253	559,347,540	559,507,732	558,892,375
Dilutive potential shares	0	4,816,000	0	4,725,000
Weighted average common shares outstanding, diluted	559,541,253	564,163,808	559,507,732	563,617,274
Loss per share, basic (in dollars per share)	$ (0.01)	$ (0.03)	$ (0.09)	$ (0.09)
Loss per share, diluted (in dollars per share)	$ (0.01)	$ (0.04)	$ (0.09)	$ (0.11)
Stock options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Dilutive potential shares	0	0	0	0
Warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Dilutive potential shares	0	0	0	0
2033 Senior Notes
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Dilutive potential shares	0	4,816,000	0	4,725,000

XML 49 R37.htm IDEA: XBRL DOCUMENT

Earnings (Loss) Per Share - Narrative (Details) - shares	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Number of common stock warrant and common stock options exercised (in shares)	332,000	539,500	332,000	1,646,372
Number of common stock issued for stock warrant and stock options exercised (in shares)	145,677	351,625	145,677	1,373,515
Shares surrendered in lieu of cash payment (in shares)	186,323	187,875	186,323	272,857
Common Stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Dilutive potential shares	16,520,314		16,545,495

XML 50 R38.htm IDEA: XBRL DOCUMENT

Composition of Certain Financial Statement Captions (Details) - USD ($) $ in Thousands	Jun. 30, 2018	Dec. 31, 2017
Accounts receivable, net:
Accounts receivable	$ 154,269	$ 166,962
Less: allowance for doubtful accounts	(1,492)	(1,446)
Accounts receivable, net	152,777	165,516
Inventories, net:
Consumable supplies	24,986	21,546
Finished products	16,783	21,012
Work in-process	3,910	5,873
Raw materials	5,800	7,467
Less: inventory reserve	(4,726)	(6,565)
Inventory, net	46,753	49,333
Other current assets and prepaid expenses:
Taxes recoverable	21,319	18,138
Other receivables	2,031	8,798
Prepaid supplies	10,278	8,207
Prepaid insurance	3,259	3,532
Other	4,764	3,838
Other current assets and prepaid expenses	41,651	42,513
Intangible assets, net:
Less: accumulated amortization	(231,996)	(198,935)
Intangible assets, net	648,541	683,835
Accrued expenses:
Contract liabilities	61,846	61,388
Employee benefits	46,621	50,377
Clinical trials	11,598	12,191
Taxes payable	3,604	4,609
Contingent consideration	2,042	11,750
Capital leases short-term	3,166	3,399
Milestone payment	4,967	4,868
Professional fees	1,727	2,355
Other	65,421	79,364
Accrued expenses	200,992	230,301
Other long-term liabilities:
Contract liabilities	47,720	78,990
Line of credit	105,539	104,152
Contingent consideration	25,712	29,603
Mortgages and other debts payable	1,704	1,567
Capital leases long-term	6,638	7,786
Other	22,131	17,857
Other long-term liabilities	209,444	239,955
Customer relationships
Intangible assets, net:
Intangible assets	447,225	448,345
Technologies
Intangible assets, net:
Intangible assets	340,815	340,921
Trade names
Intangible assets, net:
Intangible assets	50,494	50,553
Licenses
Intangible assets, net:
Intangible assets	10,246	10,305
Covenants not to compete
Intangible assets, net:
Intangible assets	16,367	16,372
Product registrations
Intangible assets, net:
Intangible assets	9,694	10,475
Other
Intangible assets, net:
Intangible assets	$ 5,696	$ 5,799

XML 51 R39.htm IDEA: XBRL DOCUMENT

Composition of Certain Financial Statement Captions - Changes in Goodwill (Details) $ in Thousands	6 Months Ended
	Jun. 30, 2018 USD ($)
Goodwill [Roll Forward]
Beginning balance	$ 717,099
Foreign exchange and other	(2,865)
Ending balance	714,234
BioReference
Goodwill [Roll Forward]
Ending balance	401,800
Pharmaceutical \| CURNA
Goodwill [Roll Forward]
Beginning balance	4,827
Foreign exchange and other	0
Ending balance	4,827
Pharmaceutical \| EirGen
Goodwill [Roll Forward]
Beginning balance	89,226
Foreign exchange and other	(2,201)
Ending balance	87,025
Pharmaceutical \| FineTech
Goodwill [Roll Forward]
Beginning balance	11,698
Foreign exchange and other	0
Ending balance	11,698
Pharmaceutical \| OPKO Chile
Goodwill [Roll Forward]
Beginning balance	5,203
Foreign exchange and other	(307)
Ending balance	4,896
Pharmaceutical \| OPKO Biologics
Goodwill [Roll Forward]
Beginning balance	139,784
Foreign exchange and other	0
Ending balance	139,784
Pharmaceutical \| OPKO Health Europe
Goodwill [Roll Forward]
Beginning balance	7,898
Foreign exchange and other	(197)
Ending balance	7,701
Pharmaceutical \| OPKO Renal
Goodwill [Roll Forward]
Beginning balance	2,069
Foreign exchange and other	0
Ending balance	2,069
Pharmaceutical \| Transition Therapeutics
Goodwill [Roll Forward]
Beginning balance	3,608
Foreign exchange and other	(160)
Ending balance	3,448
Diagnostics \| BioReference
Goodwill [Roll Forward]
Beginning balance	401,821
Foreign exchange and other	0
Ending balance	401,821
Diagnostics \| OPKO Diagnostics
Goodwill [Roll Forward]
Beginning balance	17,977
Foreign exchange and other	0
Ending balance	17,977
Diagnostics \| OPKO Lab
Goodwill [Roll Forward]
Beginning balance	32,988
Foreign exchange and other	0
Ending balance	$ 32,988

XML 52 R40.htm IDEA: XBRL DOCUMENT

Acquisitions, Investments and Licenses - Summary of Investments (Details) - USD ($) $ in Thousands	Jun. 30, 2018	Dec. 31, 2017
Business Combinations [Abstract]
Equity method investments	$ 19,703
Variable interest entity, equity method	706
Equity securities	22,350
Equity securities with no readily determinable fair value	939
Warrants and options	1,799
Total carrying value of investments	45,497	$ 40,642
Equity method investment, underlying equity in net assets	$ 15,547

XML 53 R41.htm IDEA: XBRL DOCUMENT

Acquisitions, Investments and Licenses - Equity and Cost Method Investments Narrative (Details) $ in Millions	6 Months Ended
	Jun. 30, 2018 USD ($)
Schedule of Equity Method Investments [Line Items]
Total assets of equity method investees	$ 363.3
Total (liabilities) of equity method investees	(174.6)
Net (losses) of equity method investees	(143.5)
Market value	$ 40.1
Pharmsynthez
Schedule of Equity Method Investments [Line Items]
Ownership percentage, equity method	9.00%
Cocrystal
Schedule of Equity Method Investments [Line Items]
Ownership percentage, equity method	9.00%
Non-Invasive Monitoring Systems, Inc.
Schedule of Equity Method Investments [Line Items]
Ownership percentage, equity method	1.00%
Neovasc
Schedule of Equity Method Investments [Line Items]
Ownership percentage, equity method	6.00%
VBI Vaccines Inc
Schedule of Equity Method Investments [Line Items]
Ownership percentage, equity method	10.00%
InCellDx, Inc
Schedule of Equity Method Investments [Line Items]
Ownership percentage, equity method	29.00%
BioCardia, Inc.
Schedule of Equity Method Investments [Line Items]
Ownership percentage, equity method	5.00%
Xenetic Biosciences, Inc.
Schedule of Equity Method Investments [Line Items]
Ownership percentage, equity method	5.00%

XML 54 R42.htm IDEA: XBRL DOCUMENT

Acquisitions, Investments and Licenses - Available for Sale Investments, Sale of Investments and Warrants and Options Narrative (Details) shares in Thousands	Jun. 30, 2018 shares
Rxi Pharmaceuticals Corporation
Investment [Line Items]
Ownership percentage	1.00%
ChromaDex
Investment [Line Items]
Ownership percentage	0.00%
MabVax
Investment [Line Items]
Ownership percentage	2.00%
Eloxx Pharmaceuticals
Investment [Line Items]
Ownership percentage	4.00%
Xenetic Biosciences, Inc.
Investment [Line Items]
Number of shares into which warrants may be converted (in shares)	500
Neovasc
Investment [Line Items]
Number of shares into which warrants may be converted (in shares)	2,900
BioCardia, Inc.
Investment [Line Items]
Ownership percentage	5.00%
Number of shares into which warrants may be converted (in shares)	400
Investment options, vested (in shares)	100
Cocrystal
Investment [Line Items]
Number of shares into which warrants may be converted (in shares)	33
InCellDx, Inc
Investment [Line Items]
Number of shares into which warrants may be converted (in shares)	700
Rxi
Investment [Line Items]
Number of shares into which warrants may be converted (in shares)	22

XML 55 R43.htm IDEA: XBRL DOCUMENT

Acquisitions, Investments and Licenses - Schedule of Net Gains and Losses on Equity Securities (Details) $ in Thousands	6 Months Ended
	Jun. 30, 2018 USD ($)
Business Combinations [Abstract]
Net gains recognized during the period on equity securities	$ 11,289
Less: Net losses realized during the period on equity securities sold during the period	(113)
Unrealized net gains and losses recognized during the period on equity securities still held at the reporting date	$ 11,402

XML 56 R44.htm IDEA: XBRL DOCUMENT

Acquisitions, Investments and Licenses - Variable Interest Entities Narrative (Details) - Zebra	6 Months Ended
	Jun. 30, 2018 shares
Variable Interest Entity [Line Items]
Ownership percentage, equity method	29.00%
Series A-2 Preferred Stock
Variable Interest Entity [Line Items]
Investment owned (in shares)	1,260,000
Restricted Stock
Variable Interest Entity [Line Items]
Shares received as a gift (in shares)	900,000

XML 57 R45.htm IDEA: XBRL DOCUMENT

Debt - Narrative (Details)		1 Months Ended			3 Months Ended		6 Months Ended		48 Months Ended
Debt - Narrative (Details)	Jan. 30, 2013 USD ($) d $ / shares	Feb. 28, 2018 USD ($) $ / shares	Nov. 30, 2015 USD ($)	Apr. 30, 2015 d conversion_right $ / shares	Jun. 30, 2018 USD ($) institution	Jun. 30, 2017 USD ($)	Jun. 30, 2018 USD ($) institution	Jun. 30, 2017 USD ($)	Dec. 31, 2016 USD ($) shares	Dec. 31, 2017 USD ($) institution
Debt Instrument [Line Items]
Change in FV of embedded derivative income					$ 0	$ 5,069,000	$ 0	$ 10,014,000
Credit line capacity					196,900,000		196,900,000
Goodwill					$ 714,234,000		$ 714,234,000			$ 717,099,000
Number of financial institutions \| institution					11		11			11
BioReference
Debt Instrument [Line Items]
Net assets					$ 1,000,000,000		$ 1,000,000,000
Goodwill					401,800,000		401,800,000
Intangible assets					$ 425,400,000		$ 425,400,000
OPKO Health Europe
Debt Instrument [Line Items]
Weighted average interest rate					3.00%		3.00%			3.00%
Minimum \| OPKO Health Europe
Debt Instrument [Line Items]
Variable interest rates					1.80%		1.80%
Maximum \| OPKO Health Europe
Debt Instrument [Line Items]
Variable interest rates					6.30%		6.30%
Senior Notes \| Notes Due February 1, 2033
Debt Instrument [Line Items]
Interest rate on notes payable	3.00%
Debt face amount	$ 175,000,000.0
Equivalent redemption price	100.00%
Notes \| Notes Due February 1, 2033
Debt Instrument [Line Items]
Conversion price per share (in dollars per share) \| $ / shares	$ 7.07			$ 7.07
Conversion rate	0.14148			0.1414827
Equivalent redemption price	100.00%
Convertible debt, threshold percentage of stock price trigger	130.00%			130.00%
Number of trading days \| d				20
Number of consecutive trading days applicable conversion price \| d				30
Common stock trigger price (in dollars per share) \| $ / shares				$ 9.19
Conversion right triggered \| conversion_right				1
Notes \| Notes Due February 1, 2033 \| Minimum
Debt Instrument [Line Items]
Number of trading days \| d	20
Notes \| Notes Due February 1, 2033 \| Maximum
Debt Instrument [Line Items]
Number of consecutive trading days applicable conversion price \| d	30
Notes \| Notes Due February 1, 2033 \| On or after February 1, 2017 and before February 1, 2019
Debt Instrument [Line Items]
Equivalent redemption price	100.00%
Notes \| Notes Due February 1, 2033 \| On or after February 1, 2019
Debt Instrument [Line Items]
Equivalent redemption price	100.00%
Convertible Debt \| 5% Convertible Notes
Debt Instrument [Line Items]
Interest rate on notes payable		5.00%
Debt face amount		$ 55,000,000.0
Maturity duration		5 years
Par value per converted share (in dollars per share) \| $ / shares		$ 0.01
Conversion price per share (in dollars per share) \| $ / shares		$ 5.00
Minimum conversion notice		30 days
Maximum conversion notice		60 days
Convertible Debt \| Notes Due February 1, 2033
Debt Instrument [Line Items]
Converted debt amount									$ 143,200,000.0
Line of Credit
Debt Instrument [Line Items]
Weighted average interest rate					4.70%		4.70%			4.20%
Revolving Credit Facility \| Line of Credit \| New Credit Agreement
Debt Instrument [Line Items]
Credit line capacity			$ 175,000,000.0
Higher borrowing capacity option			$ 275,000,000.0
Remaining borrowing capacity					$ 0		$ 0
Commitment fee percentage			0.50%
Swingline \| Line of Credit \| New Credit Agreement
Debt Instrument [Line Items]
Credit line capacity			$ 20,000,000.0
Letter of Credit \| Line of Credit \| New Credit Agreement
Debt Instrument [Line Items]
Credit line capacity			$ 20,000,000.0
LIBOR \| Revolving Credit Facility \| Line of Credit \| New Credit Agreement
Debt Instrument [Line Items]
Basis spread on variable rate			2.50%
LIBOR, First 12 Months \| Revolving Credit Facility \| Line of Credit \| New Credit Agreement
Debt Instrument [Line Items]
Basis spread on variable rate			0.35%
LIBOR Thereafter \| Revolving Credit Facility \| Line of Credit \| New Credit Agreement
Debt Instrument [Line Items]
Basis spread on variable rate			0.50%
LIBOR, First 12 Months, Adjusted for Eurocurrency Liabilities \| Revolving Credit Facility \| Line of Credit \| New Credit Agreement
Debt Instrument [Line Items]
Basis spread on variable rate			1.35%
LIBOR, Thereafter, Adjusted for Eurocurrency Liabilities \| Revolving Credit Facility \| Line of Credit \| New Credit Agreement
Debt Instrument [Line Items]
Basis spread on variable rate			1.50%
Common Stock \| Convertible Debt \| Notes Due February 1, 2033
Debt Instrument [Line Items]
Shares issued on converted debt (in shares) \| shares									21,539,873

XML 58 R46.htm IDEA: XBRL DOCUMENT

Debt - Notes (Details) - USD ($) $ in Thousands	6 Months Ended
Debt - Notes (Details) - USD ($) $ in Thousands	Jun. 30, 2018	Jun. 30, 2017
Debt Instrument [Roll Forward]
Amortization of debt issuance costs	$ 99	$ 112
Senior Notes
Debt Instrument [Roll Forward]
2033 Senior Notes, beginning balance	31,850
Discount, beginning balance	(2,565)
Debt issuance cost, beginning balance	(125)
Total, beginning balance	29,160
Amortization of debt discount	1,109
Amortization of debt issuance costs	74
Amortization of debt discount and debt issuance costs	1,183
2033 Senior Notes, ending balance	31,850
Discount, ending balance	(1,456)
Debt issuance cost, ending balance	(51)
Total, ending balance	$ 30,343

XML 59 R47.htm IDEA: XBRL DOCUMENT

Debt - Lines Of Credit (Details) - USD ($)	Jun. 30, 2018	Dec. 31, 2017
Line of Credit Facility [Line Items]
Credit line capacity	$ 196,900,000
Balance Outstanding	$ 109,496,000	$ 114,664,000
JPMorgan Chase
Line of Credit Facility [Line Items]
Interest rate on borrowings at June 30, 2018	4.01%
Credit line capacity	$ 175,000,000
Balance Outstanding	$ 105,539,000	104,152,000
Itau Bank
Line of Credit Facility [Line Items]
Interest rate on borrowings at June 30, 2018	5.50%
Credit line capacity	$ 1,810,000
Balance Outstanding	$ 1,179,000	446,000
Bank of Chile
Line of Credit Facility [Line Items]
Interest rate on borrowings at June 30, 2018	6.60%
Credit line capacity	$ 3,800,000
Balance Outstanding	$ 502,000	1,598,000
BICE Bank
Line of Credit Facility [Line Items]
Interest rate on borrowings at June 30, 2018	5.50%
Credit line capacity	$ 2,500,000
Balance Outstanding	$ 798,000	1,819,000
BBVA Bank
Line of Credit Facility [Line Items]
Interest rate on borrowings at June 30, 2018	5.50%
Credit line capacity	$ 3,250,000
Balance Outstanding	$ 250,000	1,665,000
Security Bank
Line of Credit Facility [Line Items]
Interest rate on borrowings at June 30, 2018	5.50%
Credit line capacity	$ 98,000
Balance Outstanding	$ 98,000	501,000
Estado Bank
Line of Credit Facility [Line Items]
Interest rate on borrowings at June 30, 2018	5.50%
Credit line capacity	$ 3,500,000
Balance Outstanding	$ 757,000	2,111,000
Santander Bank
Line of Credit Facility [Line Items]
Interest rate on borrowings at June 30, 2018	5.50%
Credit line capacity	$ 4,500,000
Balance Outstanding	$ 262,000	1,988,000
Scotiabank
Line of Credit Facility [Line Items]
Interest rate on borrowings at June 30, 2018	5.00%
Credit line capacity	$ 1,800,000
Balance Outstanding	$ 9,000	384,000
Banco Bilbao Vizcaya
Line of Credit Facility [Line Items]
Interest rate on borrowings at June 30, 2018	2.90%
Credit line capacity	$ 292,000
Balance Outstanding	$ 0	0
Santander Bank
Line of Credit Facility [Line Items]
Interest rate on borrowings at June 30, 2018	2.67%
Credit line capacity	$ 350,000
Balance Outstanding	$ 102,000	$ 0

XML 60 R48.htm IDEA: XBRL DOCUMENT

Debt - Mortgage Notes And Other Debt (Details) - USD ($) $ in Thousands	Jun. 30, 2018	Dec. 31, 2017
Mortgage notes and other debt payables
Other long-term liabilities	$ 1,704	$ 1,567
EirGen Pharma Limited, OPKO Europe and Bio Reference
Mortgage notes and other debt payables
Current portion of notes payable	2,821	1,632
Other long-term liabilities	6,469	2,011
Total	$ 9,290	$ 3,643

XML 61 R49.htm IDEA: XBRL DOCUMENT

Accumulated Other Comprehensive Income (Loss) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Accumulated Other Comprehensive Income (Loss), Net [Rollforward]
Beginning balance			$ 1,855,578
Reclassification adjustment due to adoption of ASU 2016-01	$ 0	$ 0	(4,876)	$ 0
Ending Balance	1,810,496		1,810,496
Foreign currency
Accumulated Other Comprehensive Income (Loss), Net [Rollforward]
Beginning balance			(5,404)
Other comprehensive loss before reclassifications			(7,600)
Reclassification adjustment due to adoption of ASU 2016-01			0
Net other comprehensive loss			(7,600)
Ending Balance	(13,004)		(13,004)
Unrealized gain (loss) in Accumulated OCI
Accumulated Other Comprehensive Income (Loss), Net [Rollforward]
Beginning balance			4,876
Other comprehensive loss before reclassifications			0
Reclassification adjustment due to adoption of ASU 2016-01			(4,876)
Net other comprehensive loss			(4,876)
Ending Balance	0		0
AOCI Attributable to Parent
Accumulated Other Comprehensive Income (Loss), Net [Rollforward]
Beginning balance			(528)
Other comprehensive loss before reclassifications			(7,600)
Reclassification adjustment due to adoption of ASU 2016-01			(4,876)
Net other comprehensive loss			(12,476)
Ending Balance	$ (13,004)		$ (13,004)

XML 62 R50.htm IDEA: XBRL DOCUMENT

Fair Value Measurements - Assets And Liabilities Measured At Fair Value (Details) - USD ($) $ in Thousands	Jun. 30, 2018	Dec. 31, 2017
Assets:
Equity securities	$ 22,350
Fair Value, Measurements, Recurring
Assets:
Equity securities	22,350	$ 12,461
Common stock options/warrants	1,799	3,333
Total assets	24,172	15,901
Liabilities:
Total liabilities	27,754	41,670
Fair Value, Measurements, Recurring \| Quoted prices in active markets for identical assets (Level 1)
Assets:
Equity securities	22,350	12,461
Common stock options/warrants	0	0
Total assets	22,350	12,568
Liabilities:
Total liabilities	0	0
Fair Value, Measurements, Recurring \| Significant other observable inputs (Level 2)
Assets:
Equity securities	0	0
Common stock options/warrants	1,799	3,333
Total assets	1,822	3,333
Liabilities:
Total liabilities	0	317
Fair Value, Measurements, Recurring \| Significant unobservable inputs (Level 3)
Assets:
Equity securities	0	0
Common stock options/warrants	0	0
Total assets	0	0
Liabilities:
Total liabilities	27,754	41,353
Fair Value, Measurements, Recurring \| Forward contracts
Liabilities:
Total liabilities		317
Fair Value, Measurements, Recurring \| Forward contracts \| Quoted prices in active markets for identical assets (Level 1)
Liabilities:
Total liabilities		0
Fair Value, Measurements, Recurring \| Forward contracts \| Significant other observable inputs (Level 2)
Liabilities:
Total liabilities		317
Fair Value, Measurements, Recurring \| Forward contracts \| Significant unobservable inputs (Level 3)
Liabilities:
Total liabilities		0
Fair Value, Measurements, Recurring \| Contingent consideration
Liabilities:
Total liabilities	27,754	41,353
Fair Value, Measurements, Recurring \| Contingent consideration \| Quoted prices in active markets for identical assets (Level 1)
Liabilities:
Total liabilities	0	0
Fair Value, Measurements, Recurring \| Contingent consideration \| Significant other observable inputs (Level 2)
Liabilities:
Total liabilities	0	0
Fair Value, Measurements, Recurring \| Contingent consideration \| Significant unobservable inputs (Level 3)
Liabilities:
Total liabilities	27,754	41,353
Money market funds \| Fair Value, Measurements, Recurring
Assets:
Money market funds		107
Money market funds \| Fair Value, Measurements, Recurring \| Quoted prices in active markets for identical assets (Level 1)
Assets:
Money market funds		107
Money market funds \| Fair Value, Measurements, Recurring \| Significant other observable inputs (Level 2)
Assets:
Money market funds		0
Money market funds \| Fair Value, Measurements, Recurring \| Significant unobservable inputs (Level 3)
Assets:
Money market funds		$ 0
Forward contracts \| Fair Value, Measurements, Recurring
Assets:
Derivative Asset	23
Forward contracts \| Fair Value, Measurements, Recurring \| Quoted prices in active markets for identical assets (Level 1)
Assets:
Derivative Asset	0
Forward contracts \| Fair Value, Measurements, Recurring \| Significant other observable inputs (Level 2)
Assets:
Derivative Asset	23
Forward contracts \| Fair Value, Measurements, Recurring \| Significant unobservable inputs (Level 3)
Assets:
Derivative Asset	$ 0

XML 63 R51.htm IDEA: XBRL DOCUMENT

Fair Value Measurements - Level 3 Reconciliation (Details) - Contingent consideration $ in Thousands	6 Months Ended
	Jun. 30, 2018 USD ($)
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning Balance	$ 41,353
Included in results of operations	(13,599)
Ending Balance	$ 27,754

XML 64 R52.htm IDEA: XBRL DOCUMENT

Fair Value Measurements - Narrative (Details) - USD ($) $ in Millions	6 Months Ended
	Jun. 30, 2018	Dec. 31, 2017
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Percentage of decrease in future sales	10.00%
Decrease of estimated future sales in amount	$ 1.7
Contingent consideration	27.7	$ 41.4
Accrued Expenses
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration	2.0	11.8
Other Noncurrent Liabilities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration	$ 25.7	$ 29.6

XML 65 R53.htm IDEA: XBRL DOCUMENT

Derivative Contracts - Balance Sheet Component (Details) - Not Designated as Hedging Instrument - USD ($) $ in Thousands	Jun. 30, 2018	Dec. 31, 2017
Common Stock options/warrants \| Investments, net
Derivatives, Fair Value [Line Items]
Common stock options/warrants	$ 1,799	$ 3,333
Forward contracts \| Unrealized gains on forward contracts are recorded in Other current assets and prepaid expenses. Unrealized (losses) on forward contracts are recorded in Accrued expenses.
Derivatives, Fair Value [Line Items]
Derivative liability, fair value	$ 23	$ (317)

XML 66 R54.htm IDEA: XBRL DOCUMENT

Derivative Contracts - Derivative Gains (Losses) (Details) - Not Designated as Hedging Instrument - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Derivative Instruments, Gain (Loss) [Line Items]
Derivative gain (loss)	$ 2,248	$ 5,482	$ 3,644	$ 9,519
Common Stock options/warrants
Derivative Instruments, Gain (Loss) [Line Items]
Derivative gain (loss)	1,916	444	3,587	(512)
Notes
Derivative Instruments, Gain (Loss) [Line Items]
Derivative gain (loss)	0	5,069	0	10,014
Forward contracts
Derivative Instruments, Gain (Loss) [Line Items]
Derivative gain (loss)	$ 332	$ (31)	$ 57	$ 17

XML 67 R55.htm IDEA: XBRL DOCUMENT

Related Party Transactions (Details)	1 Months Ended									3 Months Ended		6 Months Ended
Related Party Transactions (Details)	May 31, 2018 shares	Apr. 30, 2018 shares	Feb. 28, 2018 USD ($)	Nov. 30, 2017 USD ($) shares	Jul. 31, 2017 USD ($) shares	May 31, 2017 USD ($) shares	Apr. 30, 2017 USD ($) shares	Nov. 30, 2016 USD ($)	Aug. 31, 2016 USD ($) shares	Jun. 30, 2018 USD ($) shares	Jun. 30, 2017 USD ($)	Jun. 30, 2018 USD ($) shares	Jun. 30, 2017 USD ($)	Jan. 01, 2017 USD ($) ft²
Related Party Transaction [Line Items]
Payments to acquire investments \| $												$ 1,000,000	$ 3,000,000
Zebra
Related Party Transaction [Line Items]
Stock ownership percentage												29.00%
Equity method investment, ownership percentage										29.00%		29.00%
Neovasc
Related Party Transaction [Line Items]
Equity method investment, ownership percentage										6.00%		6.00%
Additional investment in equity method investment \| $				$ 3,000,000
Number of shares into which warrants may be converted (in shares)										2,900,000		2,900,000
ChromaDex Corporation
Related Party Transaction [Line Items]
Ownership percentage										0.00%		0.00%
MabVax
Related Party Transaction [Line Items]
Ownership percentage										2.00%		2.00%
Payments to acquire investments \| $					$ 100,000	$ 500,000
COCP
Related Party Transaction [Line Items]
Equity method investment, ownership percentage										9.00%		9.00%
Additional investment in equity method investment \| $							$ 1,000,000		$ 2,000,000
Number of shares into which warrants may be converted (in shares)										33,000		33,000
NIMS
Related Party Transaction [Line Items]
Ownership percentage										1.00%		1.00%
BioCardia, Inc.
Related Party Transaction [Line Items]
Equity method investment, ownership percentage										5.00%		5.00%
Ownership percentage										5.00%		5.00%
Number of shares into which warrants may be converted (in shares)										400,000		400,000
InCellDx, Inc
Related Party Transaction [Line Items]
Equity method investment, ownership percentage										29.00%		29.00%
Number of shares into which warrants may be converted (in shares)										700,000		700,000
Frost Real Estate Holdings LLC
Related Party Transaction [Line Items]
Area of real estate property (in square feet) \| ft²														29,500
Lease payments per month in first year \| $														$ 81,000
Lease payments per month in third year \| $														$ 86,000
Reimbursement Of Travel Expense \| Dr Frost
Related Party Transaction [Line Items]
Reimbursement paid to related party for travel \| $										$ 61,000	$ 121,000	$ 140,000	$ 141,000
Common Stock \| Neovasc
Related Party Transaction [Line Items]
Equity method investment, additional investment in period (in shares)				2,054,794
Common Stock \| COCP
Related Party Transaction [Line Items]
Equity method investment, additional investment in period (in shares)							138,889		162,602
Series G Preferred Stock \| MabVax
Related Party Transaction [Line Items]
Available-for-sale investment, additional investment in period (in shares)					50,714
Series L Preferred Stock \| MabVax
Related Party Transaction [Line Items]
Available-for-sale investment, additional investment in period (in shares)						1,667
Series I Preferred Stock \| MabVax
Related Party Transaction [Line Items]
Available-for-sale investment, additional investment in period (in shares)						107,607
Museum of Science, Inc \| Dr Frost and Mr Pfenniger
Related Party Transaction [Line Items]
Related party future contribution \| $								$ 1,000,000
Related party future contribution term								4 years
Convertible Debt \| COCP
Related Party Transaction [Line Items]
Additional investment in equity method investment \| $			$ 1,000,000
Convertible Debt \| Common Stock \| COCP
Related Party Transaction [Line Items]
Shares received after conversion (in shares)	538,544
5% Convertible Notes \| Convertible Debt
Related Party Transaction [Line Items]
Debt face amount \| $			$ 55,000,000.0
Series A Warrant \| Neovasc
Related Party Transaction [Line Items]
Number of shares into which warrants may be converted (in shares)				2,054,794
Series B Warrant \| Neovasc
Related Party Transaction [Line Items]
Number of shares into which warrants may be converted (in shares)				2,054,794
Shares received upon exercise of warrant (in shares)		106,909,044
Series C Warrant \| Neovasc
Related Party Transaction [Line Items]
Number of shares into which warrants may be converted (in shares)				822,192

XML 68 R56.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies (Details) - USD ($)	1 Months Ended	6 Months Ended
Commitments and Contingencies (Details) - USD ($)	Aug. 31, 2017	Jun. 30, 2018	Dec. 31, 2017
Business Acquisition, Contingent Consideration
Contingent consideration		$ 27,700,000	$ 41,400,000
Membership interest contingent on successful bid		15.00%
Credit line capacity		$ 196,900,000
Purchase obligation		84,400,000
Accrued Liabilities
Business Acquisition, Contingent Consideration
Contingent consideration		2,000,000	11,800,000
Other Noncurrent Liabilities
Business Acquisition, Contingent Consideration
Contingent consideration		$ 25,700,000	$ 29,600,000
Line of Credit \| Veterans Accountable Care Group LLC
Business Acquisition, Contingent Consideration
Credit line capacity	$ 50,000,000.0
Line of credit maturity term	5 years
Interest rate on credit facility	6.50%

XML 69 R57.htm IDEA: XBRL DOCUMENT

Revenue Recognition - Schedule of Disaggregation of Revenue (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Disaggregation of Revenue [Line Items]
Total gross Rayaldee sales	$ 263,685	$ 292,601	$ 518,598	$ 558,981
Healthcare insurers
Disaggregation of Revenue [Line Items]
Total gross Rayaldee sales	92,033	104,366	192,986	217,062
Government payers
Disaggregation of Revenue [Line Items]
Total gross Rayaldee sales	72,459	80,037	139,595	157,090
Client payers
Disaggregation of Revenue [Line Items]
Total gross Rayaldee sales	45,828	42,961	83,357	76,900
Patients
Disaggregation of Revenue [Line Items]
Total gross Rayaldee sales	5,735	6,548	11,431	11,404
Services
Disaggregation of Revenue [Line Items]
Total gross Rayaldee sales	$ 216,055	$ 233,912	$ 427,369	$ 462,456

XML 70 R58.htm IDEA: XBRL DOCUMENT

Revenue Recognition - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017	Dec. 31, 2017
Disaggregation of Revenue [Line Items]
Total revenues	$ 263,685	$ 292,601	$ 518,598	$ 558,981
Contract liability	109,600		109,600		$ 140,400
Rayaldee
Disaggregation of Revenue [Line Items]
Revenue recognized	4,800		8,500
Total revenues			13,582
Transfer of intellectual property and other
Disaggregation of Revenue [Line Items]
Total revenues	19,107	29,723	34,855	45,328
Pfizer \| Collaborative Arrangement, Product
Disaggregation of Revenue [Line Items]
Contract liability	100,100		100,100
Pfizer \| Collaborative Arrangement, Product \| Transfer of intellectual property and other
Disaggregation of Revenue [Line Items]
Total revenues	$ 16,300	$ 18,300	$ 31,000	$ 32,400

XML 71 R59.htm IDEA: XBRL DOCUMENT

Revenue Recognition - Schedule of Product Sales Allowances and Accruals (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Allowance for Doubtful Accounts Receivable [Roll Forward]
Provision related to current period sales			$ 200	$ 500
Total gross Rayaldee sales	$ 263,685	$ 292,601	518,598	$ 558,981
Rayaldee
Allowance for Doubtful Accounts Receivable [Roll Forward]
Beginning balance			1,018
Provision related to current period sales			5,124
Credits or payments made			(4,565)
Ending balance	1,577		1,577
Total gross Rayaldee sales			$ 13,582
Provision for Rayaldee sales allowances and accruals as a percentage of gross Rayaldee sales			38.00%
Chargebacks, discounts, rebates and fees \| Rayaldee
Allowance for Doubtful Accounts Receivable [Roll Forward]
Beginning balance			$ 233
Provision related to current period sales			2,188
Credits or payments made			(1,697)
Ending balance	724		724
Governmental \| Rayaldee
Allowance for Doubtful Accounts Receivable [Roll Forward]
Beginning balance			348
Provision related to current period sales			2,936
Credits or payments made			(2,557)
Ending balance	727		727
Returns \| Rayaldee
Allowance for Doubtful Accounts Receivable [Roll Forward]
Beginning balance			437
Provision related to current period sales			0
Credits or payments made			(311)
Ending balance	$ 126		$ 126

XML 72 R60.htm IDEA: XBRL DOCUMENT

Strategic Alliances (Details) - USD ($)		1 Months Ended			6 Months Ended		9 Months Ended	26 Months Ended	42 Months Ended	91 Months Ended
Strategic Alliances (Details) - USD ($)	Oct. 12, 2017	May 31, 2016	Jan. 31, 2015	Dec. 31, 2010	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2018	Jun. 30, 2018	Jun. 30, 2018	Dec. 31, 2017	Mar. 31, 2013
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Upfront payment from development and license agreement	$ 6,000,000
Milestone revenue recognized							$ 0
Contract liability					$ 109,600,000		109,600,000	$ 109,600,000	$ 109,600,000	$ 109,600,000	$ 140,400,000
Contract liabilities					61,846,000		61,846,000	61,846,000	61,846,000	61,846,000	61,388,000
Contract liabilities					47,720,000		47,720,000	47,720,000	47,720,000	47,720,000	$ 78,990,000
VFMCRP
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Milestone revenue recognized								0
VFMCRP \| Development and License Agreement
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
License revenue, initial payment		$ 50,000,000
VFMCRP \| Regulatory Milestones
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Additional milestone payment to be received		37,000,000
VFMCRP \| Launch and Sales-based Milestones
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Additional milestone payment to be received		195,000,000
VFMCRP \| Exclusive Option
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Additional milestone payment to be received		$ 555,000,000
Pfizer \| Collaborative Arrangement, Product
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Milestone revenue recognized									0
Additional milestone payment to be received			$ 275,000,000.0
Non-refundable and non-creditable upfront payment			295,000,000
Contract liability					100,100,000		100,100,000	100,100,000	100,100,000	100,100,000
Tesaro
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Milestone revenue recognized					0	$ 0
Upfront payment under license agreements				$ 6,000,000.0
Milestone payment received										30,000,000
Additional milestone payment				$ 85,000,000
Period from first commercial sale				12 years
Written termination threshold				3 months
Accrued Expenses \| Pfizer \| Collaborative Arrangement, Product
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Contract liabilities					58,800,000		58,800,000	58,800,000	58,800,000	58,800,000
Other Noncurrent Liabilities \| Pfizer \| Collaborative Arrangement, Product
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Contract liabilities					$ 41,300,000		$ 41,300,000	$ 41,300,000	$ 41,300,000	$ 41,300,000
Minimum \| Pfizer \| Collaborative Arrangement, Product
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Each milestone payment			20,000,000.0
Maximum \| Pfizer \| Collaborative Arrangement, Product
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Each milestone payment			$ 90,000,000.0
Pharmsynthez
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Ownership percentage, equity method					9.00%		9.00%	9.00%	9.00%	9.00%
Rxi Pharmaceuticals Corporation
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Maximum milestone payments to be received												$ 50,000,000.0
Phase Two Initiation
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Milestone payment from development and license agreement	6,000,000
Regulatory And Development
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Milestone payment from development and license agreement	31,000,000
Sales Revenue
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Milestone payment from development and license agreement	$ 75,000,000

XML 73 R61.htm IDEA: XBRL DOCUMENT

Segments - Narrative (Details)			3 Months Ended	6 Months Ended
Segments - Narrative (Details)	Jun. 30, 2018	Dec. 31, 2017	Jun. 30, 2018	Jun. 30, 2018 USD ($) Segment	Jun. 30, 2017
Segment Reporting Information [Line Items]
Number of reportable segments \| Segment				2
Customer Concentration Risk \| Accounts Receivable
Segment Reporting Information [Line Items]
Concentration percentage	2.60%	3.20%
Intersegment Elimination
Segment Reporting Information [Line Items]
Inter-segment sales				$ 0
Inter-segment allocation of interest expense				$ 0
Customer 1 \| Customer Concentration Risk \| Sales Revenue, Net
Segment Reporting Information [Line Items]
Concentration percentage			10.00%		10.00%
Customer 1 \| Customer Concentration Risk \| Accounts Receivable
Segment Reporting Information [Line Items]
Concentration percentage				10.00%
Customer 2 \| Customer Concentration Risk \| Sales Revenue, Net
Segment Reporting Information [Line Items]
Concentration percentage				10.00%

XML 74 R62.htm IDEA: XBRL DOCUMENT

Segments - Operations and Assets Information (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017	Dec. 31, 2017
Segment Reporting Information [Line Items]
Total revenues	$ 263,685	$ 292,601	$ 518,598	$ 558,981
Operating loss	(5,108)	(25,831)	(47,719)	(71,047)
Depreciation and amortization	24,762	25,551	49,518	51,281
Net income (loss) from investment in investees	(7,213)	(5,628)	(9,669)	(7,758)
Assets	2,530,950		2,530,950		$ 2,589,956
Goodwill	714,234		714,234		717,099
United States
Segment Reporting Information [Line Items]
Total revenues	222,535	244,650	437,845	474,084
Ireland
Segment Reporting Information [Line Items]
Total revenues	20,778	22,525	38,060	39,734
Chile
Segment Reporting Information [Line Items]
Total revenues	11,937	11,899	23,670	22,020
Spain
Segment Reporting Information [Line Items]
Total revenues	4,592	5,118	10,125	9,623
Israel
Segment Reporting Information [Line Items]
Total revenues	2,526	7,654	6,141	11,872
Mexico
Segment Reporting Information [Line Items]
Total revenues	1,302	724	2,723	1,589
Other
Segment Reporting Information [Line Items]
Total revenues	15	31	34	59
Corporate
Segment Reporting Information [Line Items]
Operating loss	(8,748)	(12,878)	(20,393)	(28,849)
Depreciation and amortization	21	30	51	60
Net income (loss) from investment in investees	0	0	0	0
Assets	55,201		55,201		60,604
Goodwill	0		0		0
Pharmaceutical \| Operating Segments
Segment Reporting Information [Line Items]
Operating loss	2,165	(8,009)	(20,783)	(34,154)
Depreciation and amortization	6,752	6,694	13,492	13,469
Net income (loss) from investment in investees	(6,942)	(5,309)	(9,114)	(7,123)
Assets	1,258,293		1,258,293		1,287,964
Goodwill	261,447		261,447		264,313
Diagnostics \| Operating Segments
Segment Reporting Information [Line Items]
Operating loss	1,475	(4,944)	(6,543)	(8,044)
Depreciation and amortization	17,989	18,827	35,975	37,752
Net income (loss) from investment in investees	(271)	(319)	(555)	(635)
Assets	1,217,456		1,217,456		1,241,388
Goodwill	452,787		452,787		$ 452,786
Services
Segment Reporting Information [Line Items]
Total revenues	216,055	233,912	427,369	462,456
Services \| Corporate
Segment Reporting Information [Line Items]
Total revenues	0	0	0	0
Services \| Pharmaceutical \| Operating Segments
Segment Reporting Information [Line Items]
Total revenues	0	0	0	0
Services \| Diagnostics \| Operating Segments
Segment Reporting Information [Line Items]
Total revenues	216,055	233,912	427,369	462,456
Products
Segment Reporting Information [Line Items]
Total revenues	28,523	28,966	56,374	51,197
Products \| Pharmaceutical \| Operating Segments
Segment Reporting Information [Line Items]
Total revenues	28,523	28,966	56,374	51,197
Transfer of intellectual property and other
Segment Reporting Information [Line Items]
Total revenues	19,107	29,723	34,855	45,328
Transfer of intellectual property and other \| Corporate
Segment Reporting Information [Line Items]
Total revenues	0	0	0	0
Transfer of intellectual property and other \| Pharmaceutical \| Operating Segments
Segment Reporting Information [Line Items]
Total revenues	19,107	29,723	34,855	45,328
Transfer of intellectual property and other \| Diagnostics \| Operating Segments
Segment Reporting Information [Line Items]
Total revenues	$ 0	$ 0	$ 0	$ 0

EXCEL 75 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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�\*57+)B)AL).5'0:J$SH3TWJD"BYHYI^1SJ\D,:#Z MCVW)QE\MZTD*#]-+M ;)N6F:48'/65[8N6MP( 9X,WQ!LV:!Y: M75@V6'@".26<"JN"@H3^%Y\08!^KVWMCP7/SZN*U=@6M? MSU8K?+HPR0B\DTFSH:JHH-,QAY/D<>BTBSO!K(-Z;N0C=&'[P8I\ M"B"C*K]:!$]#XKC'U3ELJ]NJ@,&;W#5@Z\2:KO!ZIJ03CY8PJ-NUV6/)\W\.KG8S+86#>V6X)^<&E0DEJA4
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end XML 76 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 77 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 79 FilingSummary.xml IDEA: XBRL DOCUMENT 3.10.0.1 html 417 309 1 false 156 0 false 10 false false R1.htm 0001000 - Document - Document and Entity Information Sheet http://www.opko.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 1001000 - Statement - Condensed Consolidated Balance Sheets Sheet http://www.opko.com/role/CondensedConsolidatedBalanceSheets Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 1001501 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://www.opko.com/role/CondensedConsolidatedBalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 1002000 - Statement - Condensed Consolidated Statements of Operations Sheet http://www.opko.com/role/CondensedConsolidatedStatementsOfOperations Condensed Consolidated Statements of Operations Statements 4 false false R5.htm 1003000 - Statement - Condensed Consolidated Statements of Comprehensive Loss Sheet http://www.opko.com/role/CondensedConsolidatedStatementsOfComprehensiveLoss Condensed Consolidated Statements of Comprehensive Loss Statements 5 false false R6.htm 1005000 - Statement - Condensed Consolidated Statements of Cash Flows Sheet http://www.opko.com/role/CondensedConsolidatedStatementsOfCashFlows Condensed Consolidated Statements of Cash Flows Statements 6 false false R7.htm 2101100 - Disclosure - Business and Organization Sheet http://www.opko.com/role/BusinessAndOrganization Business and Organization Notes 7 false false R8.htm 2102100 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.opko.com/role/SummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 8 false false R9.htm 2103100 - Disclosure - Earnings (Loss) Per Share Sheet http://www.opko.com/role/EarningsLossPerShare Earnings (Loss) Per Share Notes 9 false false R10.htm 2104100 - Disclosure - Composition of Certain Financial Statement Captions Sheet http://www.opko.com/role/CompositionOfCertainFinancialStatementCaptions Composition of Certain Financial Statement Captions Notes 10 false false R11.htm 2105100 - Disclosure - Acquisitions, Investments and Licenses Sheet http://www.opko.com/role/AcquisitionsInvestmentsAndLicenses Acquisitions, Investments and Licenses Notes 11 false false R12.htm 2106100 - Disclosure - Debt Sheet http://www.opko.com/role/Debt Debt Notes 12 false false R13.htm 2107100 - Disclosure - Accumulated Other Comprehensive Income (Loss) Sheet http://www.opko.com/role/AccumulatedOtherComprehensiveIncomeLoss Accumulated Other Comprehensive Income (Loss) Notes 13 false false R14.htm 2108100 - Disclosure - Fair Value Measurements Sheet http://www.opko.com/role/FairValueMeasurements Fair Value Measurements Notes 14 false false R15.htm 2109100 - Disclosure - Derivative Contracts Sheet http://www.opko.com/role/DerivativeContracts Derivative Contracts Notes 15 false false R16.htm 2110100 - Disclosure - Related Party Transactions Sheet http://www.opko.com/role/RelatedPartyTransactions Related Party Transactions Notes 16 false false R17.htm 2111100 - Disclosure - Commitments and Contingencies Sheet http://www.opko.com/role/CommitmentsAndContingencies Commitments and Contingencies Notes 17 false false R18.htm 2112100 - Disclosure - Revenue Recognition Sheet http://www.opko.com/role/RevenueRecognition Revenue Recognition Notes 18 false false R19.htm 2114100 - Disclosure - Strategic Alliances Sheet http://www.opko.com/role/StrategicAlliances Strategic Alliances Notes 19 false false R20.htm 2115100 - Disclosure - Segments Sheet http://www.opko.com/role/Segments Segments Notes 20 false false R21.htm 2116100 - Disclosure - Subsequent Events Sheet http://www.opko.com/role/SubsequentEvents Subsequent Events Notes 21 false false R22.htm 2202201 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://www.opko.com/role/SummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://www.opko.com/role/SummaryOfSignificantAccountingPolicies 22 false false R23.htm 2302302 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://www.opko.com/role/SummaryOfSignificantAccountingPoliciesTables Summary of Significant Accounting Policies (Tables) Tables http://www.opko.com/role/SummaryOfSignificantAccountingPolicies 23 false false R24.htm 2303301 - Disclosure - Earnings (Loss) Per Share (Tables) Sheet http://www.opko.com/role/EarningsLossPerShareTables Earnings (Loss) Per Share (Tables) Tables http://www.opko.com/role/EarningsLossPerShare 24 false false R25.htm 2304301 - Disclosure - Composition of Certain Financial Statement Captions (Tables) Sheet http://www.opko.com/role/CompositionOfCertainFinancialStatementCaptionsTables Composition of Certain Financial Statement Captions (Tables) Tables http://www.opko.com/role/CompositionOfCertainFinancialStatementCaptions 25 false false R26.htm 2305301 - Disclosure - Acquisitions, Investments and Licenses (Tables) Sheet http://www.opko.com/role/AcquisitionsInvestmentsAndLicensesTables Acquisitions, Investments and Licenses (Tables) Tables http://www.opko.com/role/AcquisitionsInvestmentsAndLicenses 26 false false R27.htm 2306301 - Disclosure - Debt (Tables) Sheet http://www.opko.com/role/DebtTables Debt (Tables) Tables http://www.opko.com/role/Debt 27 false false R28.htm 2307301 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Tables) Sheet http://www.opko.com/role/AccumulatedOtherComprehensiveIncomeLossTables Accumulated Other Comprehensive Income (Loss) (Tables) Tables http://www.opko.com/role/AccumulatedOtherComprehensiveIncomeLoss 28 false false R29.htm 2308301 - Disclosure - Fair Value Measurements (Tables) Sheet http://www.opko.com/role/FairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://www.opko.com/role/FairValueMeasurements 29 false false R30.htm 2309301 - Disclosure - Derivative Contracts (Tables) Sheet http://www.opko.com/role/DerivativeContractsTables Derivative Contracts (Tables) Tables http://www.opko.com/role/DerivativeContracts 30 false false R31.htm 2312301 - Disclosure - Revenue Recognition (Tables) Sheet http://www.opko.com/role/RevenueRecognitionTables Revenue Recognition (Tables) Tables http://www.opko.com/role/RevenueRecognition 31 false false R32.htm 2315301 - Disclosure - Segments (Tables) Sheet http://www.opko.com/role/SegmentsTables Segments (Tables) Tables http://www.opko.com/role/Segments 32 false false R33.htm 2401401 - Disclosure - Business and Organization (Details) Sheet http://www.opko.com/role/BusinessAndOrganizationDetails Business and Organization (Details) Details http://www.opko.com/role/BusinessAndOrganization 33 false false R34.htm 2402403 - Disclosure - Summary of Significant Accounting Policies (Details) Sheet http://www.opko.com/role/SummaryOfSignificantAccountingPoliciesDetails Summary of Significant Accounting Policies (Details) Details http://www.opko.com/role/SummaryOfSignificantAccountingPoliciesTables 34 false false R35.htm 2402404 - Disclosure - Summary of Significant Accounting Policies - Schedule of Topic 606 Impact (Details) Sheet http://www.opko.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfTopic606ImpactDetails Summary of Significant Accounting Policies - Schedule of Topic 606 Impact (Details) Details 35 false false R36.htm 2403402 - Disclosure - Earnings (Loss) Per Share - Schedule of Earnings (Loss) Per Share, Basic and Diluted (Details) Sheet http://www.opko.com/role/EarningsLossPerShareScheduleOfEarningsLossPerShareBasicAndDilutedDetails Earnings (Loss) Per Share - Schedule of Earnings (Loss) Per Share, Basic and Diluted (Details) Details http://www.opko.com/role/EarningsLossPerShareTables 36 false false R37.htm 2403403 - Disclosure - Earnings (Loss) Per Share - Narrative (Details) Sheet http://www.opko.com/role/EarningsLossPerShareNarrativeDetails Earnings (Loss) Per Share - Narrative (Details) Details http://www.opko.com/role/EarningsLossPerShareTables 37 false false R38.htm 2404402 - Disclosure - Composition of Certain Financial Statement Captions (Details) Sheet http://www.opko.com/role/CompositionOfCertainFinancialStatementCaptionsDetails Composition of Certain Financial Statement Captions (Details) Details http://www.opko.com/role/CompositionOfCertainFinancialStatementCaptionsTables 38 false false R39.htm 2404403 - Disclosure - Composition of Certain Financial Statement Captions - Changes in Goodwill (Details) Sheet http://www.opko.com/role/CompositionOfCertainFinancialStatementCaptionsChangesInGoodwillDetails Composition of Certain Financial Statement Captions - Changes in Goodwill (Details) Details 39 false false R40.htm 2405402 - Disclosure - Acquisitions, Investments and Licenses - Summary of Investments (Details) Sheet http://www.opko.com/role/AcquisitionsInvestmentsAndLicensesSummaryOfInvestmentsDetails Acquisitions, Investments and Licenses - Summary of Investments (Details) Details 40 false false R41.htm 2405403 - Disclosure - Acquisitions, Investments and Licenses - Equity and Cost Method Investments Narrative (Details) Sheet http://www.opko.com/role/AcquisitionsInvestmentsAndLicensesEquityAndCostMethodInvestmentsNarrativeDetails Acquisitions, Investments and Licenses - Equity and Cost Method Investments Narrative (Details) Details 41 false false R42.htm 2405404 - Disclosure - Acquisitions, Investments and Licenses - Available for Sale Investments, Sale of Investments and Warrants and Options Narrative (Details) Sheet http://www.opko.com/role/AcquisitionsInvestmentsAndLicensesAvailableForSaleInvestmentsSaleOfInvestmentsAndWarrantsAndOptionsNarrativeDetails Acquisitions, Investments and Licenses - Available for Sale Investments, Sale of Investments and Warrants and Options Narrative (Details) Details 42 false false R43.htm 2405405 - Disclosure - Acquisitions, Investments and Licenses - Schedule of Net Gains and Losses on Equity Securities (Details) Sheet http://www.opko.com/role/AcquisitionsInvestmentsAndLicensesScheduleOfNetGainsAndLossesOnEquitySecuritiesDetails Acquisitions, Investments and Licenses - Schedule of Net Gains and Losses on Equity Securities (Details) Details 43 false false R44.htm 2405406 - Disclosure - Acquisitions, Investments and Licenses - Variable Interest Entities Narrative (Details) Sheet http://www.opko.com/role/AcquisitionsInvestmentsAndLicensesVariableInterestEntitiesNarrativeDetails Acquisitions, Investments and Licenses - Variable Interest Entities Narrative (Details) Details 44 false false R45.htm 2406402 - Disclosure - Debt - Narrative (Details) Sheet http://www.opko.com/role/DebtNarrativeDetails Debt - Narrative (Details) Details 45 false false R46.htm 2406403 - Disclosure - Debt - Notes (Details) Notes http://www.opko.com/role/DebtNotesDetails Debt - Notes (Details) Details 46 false false R47.htm 2406404 - Disclosure - Debt - Lines Of Credit (Details) Sheet http://www.opko.com/role/DebtLinesOfCreditDetails Debt - Lines Of Credit (Details) Details 47 false false R48.htm 2406405 - Disclosure - Debt - Mortgage Notes And Other Debt (Details) Notes http://www.opko.com/role/DebtMortgageNotesAndOtherDebtDetails Debt - Mortgage Notes And Other Debt (Details) Details 48 false false R49.htm 2407402 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Details) Sheet http://www.opko.com/role/AccumulatedOtherComprehensiveIncomeLossDetails Accumulated Other Comprehensive Income (Loss) (Details) Details http://www.opko.com/role/AccumulatedOtherComprehensiveIncomeLossTables 49 false false R50.htm 2408402 - Disclosure - Fair Value Measurements - Assets And Liabilities Measured At Fair Value (Details) Sheet http://www.opko.com/role/FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueDetails Fair Value Measurements - Assets And Liabilities Measured At Fair Value (Details) Details 50 false false R51.htm 2408403 - Disclosure - Fair Value Measurements - Level 3 Reconciliation (Details) Sheet http://www.opko.com/role/FairValueMeasurementsLevel3ReconciliationDetails Fair Value Measurements - Level 3 Reconciliation (Details) Details 51 false false R52.htm 2408404 - Disclosure - Fair Value Measurements - Narrative (Details) Sheet http://www.opko.com/role/FairValueMeasurementsNarrativeDetails Fair Value Measurements - Narrative (Details) Details 52 false false R53.htm 2409402 - Disclosure - Derivative Contracts - Balance Sheet Component (Details) Sheet http://www.opko.com/role/DerivativeContractsBalanceSheetComponentDetails Derivative Contracts - Balance Sheet Component (Details) Details 53 false false R54.htm 2409403 - Disclosure - Derivative Contracts - Derivative Gains (Losses) (Details) Sheet http://www.opko.com/role/DerivativeContractsDerivativeGainsLossesDetails Derivative Contracts - Derivative Gains (Losses) (Details) Details 54 false false R55.htm 2410401 - Disclosure - Related Party Transactions (Details) Sheet http://www.opko.com/role/RelatedPartyTransactionsDetails Related Party Transactions (Details) Details http://www.opko.com/role/RelatedPartyTransactions 55 false false R56.htm 2411401 - Disclosure - Commitments and Contingencies (Details) Sheet http://www.opko.com/role/CommitmentsAndContingenciesDetails Commitments and Contingencies (Details) Details http://www.opko.com/role/CommitmentsAndContingencies 56 false false R57.htm 2412402 - Disclosure - Revenue Recognition - Schedule of Disaggregation of Revenue (Details) Sheet http://www.opko.com/role/RevenueRecognitionScheduleOfDisaggregationOfRevenueDetails Revenue Recognition - Schedule of Disaggregation of Revenue (Details) Details 57 false false R58.htm 2412403 - Disclosure - Revenue Recognition - Narrative (Details) Sheet http://www.opko.com/role/RevenueRecognitionNarrativeDetails Revenue Recognition - Narrative (Details) Details 58 false false R59.htm 2412404 - Disclosure - Revenue Recognition - Schedule of Product Sales Allowances and Accruals (Details) Sheet http://www.opko.com/role/RevenueRecognitionScheduleOfProductSalesAllowancesAndAccrualsDetails Revenue Recognition - Schedule of Product Sales Allowances and Accruals (Details) Details 59 false false R60.htm 2414401 - Disclosure - Strategic Alliances (Details) Sheet http://www.opko.com/role/StrategicAlliancesDetails Strategic Alliances (Details) Details http://www.opko.com/role/StrategicAlliances 60 false false R61.htm 2415402 - Disclosure - Segments - Narrative (Details) Sheet http://www.opko.com/role/SegmentsNarrativeDetails Segments - Narrative (Details) Details 61 false false R62.htm 2415403 - Disclosure - Segments - Operations and Assets Information (Details) Sheet http://www.opko.com/role/SegmentsOperationsAndAssetsInformationDetails Segments - Operations and Assets Information (Details) Details 62 false false All Reports Book All Reports opk-20180630.xml opk-20180630.xsd opk-20180630_cal.xml opk-20180630_def.xml opk-20180630_lab.xml opk-20180630_pre.xml http://xbrl.sec.gov/country/2017-01-31 http://xbrl.sec.gov/invest/2013-01-31 http://fasb.org/srt/2018-01-31 http://xbrl.sec.gov/dei/2018-01-31 http://fasb.org/us-gaap/2018-01-31 true true ZIP 81 0000944809-18-000035-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000944809-18-000035-xbrl.zip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Š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end